

- Aaron, A, 756(ab)
Aarsvold, JA, 760(ab)
Abadal, L, 1893
Abbeele, ADVD, 923(ab)
Abbott, GL, 773(ab), 920(ab)
Abbott, J, 744(ab), 941(ab)
Abdel-Dayem, H, 982(ab)
Abdel-Dayem, HM, 130, 750(ab), 752(ab), 814(ab), 838(ab), 868(ab), 971(ab), 980(ab), 985(ab), 986(ab)
Abdel-Nabi, H, 812(ab), 898(ab), 978(ab)
Abe, M, 886(ab)
Abe, R, 805(ab)
Abedl-Dayem, H, 320
Abdel, W, 921(ab)
Aboul-Enein, HY, 427
Aboutaleb, AS, 862(ab)
Abrams, P, 897(ab)
Abrams, PG, 39, 834(ab)
Abreu, SH, 764(ab), 780(ab)
Abubacker, KC, 320
Aburano, T, 750(ab), 812(ab), 827(ab), 857(ab), 895(ab)
Ackerman, RH, 821(ab), 836(ab), 920(ab)
Ackermann, RJ, 743(ab), 861(ab), 928(ab)
Ackery, DM, 549, 763(ab), 971(ab), 986(ab), 1153
Adam, MJ, 926(ab)
Adam, WE, 744(ab), 818(ab), 946(ab)
Adams, GK, III, 1057
Adams, GP, 217, 888(ab), 899(ab), 922(ab)
Adams, HR, 772(ab)
Adams, R, 976(ab)
Adatepe, MFH, 2022
Adatepe, MH, 900(ab)
Adcock, DM, 1462
Adcock, KA, 1462
Adelstein, SJ, 923(ab)
Adhikesavulu, D, 800(ab)
Adler, S, 879(ab)
Adzamlı, IK, 847(ab)
Agner, T, 820(ab)
Agostini, D, 841(ab), 842(ab), 872(ab)
Agostini, M, 762(ab)
Agranoff, BW, 784(ab), 808(ab)
Ahmad, M, 843(ab), 887(ab), 902(ab)
Ahmann, FR, 896(ab)
Ahmann, ME, 896(ab)
Ahonen, A, 1521
Aiache, JM, 129
Ajmani, AK, 911(ab)
Akagi, N, 781(ab), 782(ab)
Akers, MS, 805(ab)
Akıns, EW, 972(ab)
Alavi, A, 132, 747(ab), 751(ab), 758(ab), 759(ab), 777(ab), 788(ab), 817(ab), 825(ab), 830(ab), 836(ab), 852(ab), 857(ab), 883(ab), 910(ab), 915(ab), 935(ab), 1015
Alazraki, N, 329, 939(ab), 941(ab)
Alazraki, NP, 793(ab), 910(ab), 944(ab), 1860
Alderson, PO, 168, 764(ab), 855(ab), 925(ab), 1710, 1748
Aledort, LM, 787(ab)
Alger, E, 846(ab)
Alger, EA, 761(ab)
Ali, SA, 835(ab)
Alijani, MR, 1364
Alivisatos, B, 631
Allard, CD, 876(ab), 878(ab)
Allen, JL, 897(ab)
Allen, ML, 942(ab), 982(ab)
Allen, MO, 897(ab)
Allen, S, 898(ab)
Allo, MD, 110
Allred, JF, 835(ab), 929(ab)
Allwright, SJ, 763(ab), 780(ab)
Al-Malki, A, 971(ab)
Al-Nahas, A, 147
Al-Nahas, AM, 850(ab)
Alpert, NM, 773(ab), 821(ab), 832(ab), 836(ab), 876(ab), 920(ab)
Al-Rasheed, A, 320
Alspaugh, JP, 825(ab)
Altschuler, L, 821(ab), 839(ab)
Alvarez, V, 901(ab)
Alvarez, VL, 815(ab)
Alves, W, 830(ab), 910(ab)
Alves, WM, 852(ab)
Al-Wafai, I, 980(ab)
Alyea, K, 766(ab)
Amano, M, 878(ab)
Amartey, J, 908(ab)
Amemiya, H, 802(ab)
Ames, IH, 83
Ammar, IA, 494, 745(ab), 746(ab)
Amox, DG, 812(ab), 893(ab)
Amyotte, GA, 775(ab)
Andersen, AR, 1464
Anderson, GH, 849(ab)
Anderson, JW, 473
Anderson, LD, 835(ab)
Ando, T, 741(ab)
Andreaco, M, 832(ab)
Andreae, G, 769(ab)
Andrew, M, 892(ab)
Andrews, J, 836(ab)
Angelberger, P, 794(ab)
Angello, DA, 952(ab), 1943
Anghileri, LJ, 663, 2020
Anson, CP, 867(ab), 871(ab), 876(ab)
Anthony, G, 908(ab)
Antich, P, 890(ab)
Antico, V, 850(ab)
Antunes, ML, 942(ab)
Aoyama, Y, 985(ab)
Apicella, A, 852(ab)
Apostolides, DL, 888(ab)
Apparu, M, 1230
Appelbaum, F, 757(ab)
Araki, Y, 741(ab)
Arano, Y, 928(ab), 934(ab)
Araujo, L, 241, 783(ab)
Aravantinos, G, 1910
Arbeille, B, 893(ab)
Arcangioli, O, 1790
Archibald, MB, 984(ab)
Areed, J, 741(ab), 770(ab), 861(ab), 951(ab)
Armbrecht, J, 782(ab), 808(ab), 937(ab)
Armstrong, C, 348
Armstrong, PW, 768(ab), 945(ab)
Arnaud, SB, 883(ab), 973(ab)
Arnett, CD, 933(ab)
Aronen, H, 899(ab), 1194
Arora, G, 1875
Arrichiello, P, 1786
Arsenault, A, 864(ab)
Arzoumanian, A, 1498
Asano, Y, 931(ab)
Ash, JM, 791(ab), 792(ab)
Ashburn, WL, 765(ab)
Askienazy, S, 946(ab)
Aslı, IN, 1724
Assey, ME, 955(ab)
Atcher, R, 858(ab)
Atcher, RW, 576, 1810
Atkins, HL, 886(ab), 1697
Attas, L, 898(ab)
Attie, JN, 974(ab)
Aumont, MC, 808(ab)
Awano, N, 954(ab)
Ayers, JWT, 1644
Baas, J, 806(ab)
Babich, JW, 1526
Bacharach, SL, 385, 772(ab), 775(ab)
Baconnet, B, 793(ab), 952(ab)
Badger, CC, 757(ab), 835(ab)
Badimon, JJ, 1237
Bading, JR, 902(ab), 904(ab)
Badosa, F, 1776
Baer, JD, 980(ab)
Bahn, MM, 809(ab), 865(ab), 866(ab)
Bai, L-Q, 933(ab)
Baidoo, KE, 789(ab)
Bailey, DL, 593
Baird, F, 766(ab)
Bairey, CN, 741(ab)
Baker, K, 411
Baker, T, 908(ab), 1189
Balch, CM, 854(ab)
Baldwin, RM, 122, 929(ab)
Baldwin, RW, 761(ab)
Ball, ME, 293, 976(ab), 1526
Ballance, C, 846(ab)
Ballester, M, 1893
Balliet, R, 822(ab)
Ballinger, JR, 572, 902(ab), 919(ab), 978(ab), 984(ab), 985(ab), 1998
Ban, T, 817(ab)
Bandyopadhyay, D, 657
Banket, WJ, 902(ab)
Banner, H, 829(ab)
Baran, GA, 779(ab)
Baranczuk, RA, 853(ab), 979(ab)
Barber, DC, 791(ab)
Barber, HB, 878(ab), 1101
Barclay, AB, 876(ab), 878(ab)
Barden, HS, 882(ab)
Barest, G, 803(ab)
Barkan, AL, 1644
Barker, WW, 852(ab), 912(ab)
Barnes, WE, 974(ab)
Baron, JC, 822(ab), 919(ab)
Barrett, HB, 1101
Barrett, HH, 760(ab), 878(ab)
Barrett, J, 889(ab), 900(ab)
Barrio, JR, 809(ab), 866(ab), 950(ab)
Bartenstein, P, 902(ab)
Barthel, L, 854(ab)
Bartholomew, RM, 812(ab), 893(ab), 895(ab), 1688
Bartlett, J, 789(ab)
Bartzokis, G, 821(ab), 839(ab)
Bascom, MJ, 742(ab), 916(ab)
Bašić, M, 1152
Batjer, HH, 911(ab)
Battersby, TR, 835(ab)
Baulieu, F, 885(ab), 911(ab), 2008
Baulieu, J-L, 885(ab), 893(ab), 911(ab)
Baulieu, JL, 2008
Baum, RP, 834(ab)
Baumgartner, WA, 980(ab)
Baxter, KG, 983(ab), 984(ab)
Baxter, LR, 853(ab)
Bazin, JP, 861(ab)
Beach, R, 829(ab)
Beagle, A, 971(ab)
Beal, WH, 753(ab)
Beasley, CW, 874(ab), 1307
Beatty, BG, 103, 926(ab)
Beatty, JD, 926(ab)
Beaumer, P, 815(ab)
Beaumier, PA, 777(ab), 929(ab)
Beck, T, 873(ab)
Becker, DV, 753(ab)
Becker, LC, 441, 819(ab), 938(ab), 1539
Becker, V, 832(ab)
Beckers, C, 311, 1826
Beckett, ML, 898(ab)
Beekhuis, H, 907(ab), 908(ab)
Beers, B, 1304
Behrendt, H, 791(ab)
Beihn, R, 877(ab)
Beil, C, 866(ab), 915(ab)
Bekerman, C, 756(ab)
Belani, N, 982(ab)
Beller, G, 804(ab)
Beller, GA, 819(ab), 850(ab), 955(ab)
Belletire, J, 801(ab)
Bellil, D, 768(ab)
Bellina, CR, 1833
Bello, A, 816(ab)
Belzberg, ASB, 726
Benamor, M, 898(ab)
Bendriem, B, 879(ab)
Benedetto, AR, 1114, 1610
Benko, H, 423
Benua, RS, 904(ab)
Berent, S, 913(ab)
Berg, G, 852(ab), 867(ab)
Berg, J, 643
Berger, H, 746(ab), 805(ab), 806(ab), 825(ab), 851(ab), 905(ab), 923(ab)
Berger, HJ, 745(ab), 746(ab)
Bergmann, SR, 807(ab), 818(ab), 848(ab), 1223, 2018
Berkopec, JM, 875(ab)
Berman, C, 817(ab)
Berman, D, 741(ab), 755(ab), 768(ab), 770(ab), 793(ab), 802(ab), 804(ab), 8619(ab), 891(ab), 942(ab), 948(ab), 949(ab), 951(ab)
Berná, L, 573, 1893
Berninger, R, 815(ab)
Bernstein, I, 757(ab)
Bernstein, R, 982(ab)
Bernstein, T, 749(ab), 786(ab), 870(ab)
Bert, C, 842(ab), 872(ab)
Bertelli, P, 907(ab)
Berti, A, 1507
Bertrand, A, N1883, 793(ab), 952(ab)

Page numbers followed by (ab) indicate abstracts.

Page numbers followed by (le) indicate letters.

N preceding a page number indicates an article appearing in *Newsline*.

- Besett, J, 760(ab)
 Besnard, JC, 2008
 Besnard, J-C, 893(ab), 911(ab)
 Betebenner, DA, 926(ab)
 Betocchi, S, 1786
 Bettinardi, V, 749(ab), 1971
 Betz, AL, 784(ab)
 Beydon, L, 764(ab)
 Beyer, RW, 817(ab)
 Bhadkamkar, VA, 854(ab)
 Bhargava, KK, 937(ab)
 Bianco, JA, 810(ab)
 Bice, AN, 866(ab), 867(ab), 871(ab), 876(ab), 1207
 Bidaut, L, 771(ab), 867(ab)
 Biersack, HJ, 426, 728, 813(ab), 829(ab), 891(ab), 896(ab), 911(ab), 936(ab)
 Bigler, RE, 803(ab), 845(ab), 858(ab), 874(ab)
 Bigner, DD, 835(ab), 897(ab)
 Bihl, H, 899(ab)
 Bijvoet, OLM, 884(ab)
 Bilaniuk, L, 852(ab)
 Bilezikian, JP, 855(ab)
 Billard, C, 792(ab)
 Billerica, N, 858(ab)
 Billick, S, 921(ab)
 Billings, J, 758(ab), 759(ab), 777(ab)
 Billings, JJ, 788(ab)
 Billington, CJ, 751(ab)
 Billmann, P, 827(ab)
 Biltz, H, 896(ab)
 Bingham, CO, III, 806(ab)
 Binney, G, 854(ab)
 Birdwell, CR, 1688
 Bischof-Delaloye, A, 811(ab)
 Bischoff, PG, 255
 Bitter, F, 744(ab), 818(ab)
 Black, RR, 766(ab)
 Blahd, WH, 804(ab), 817(ab), 831(ab), 855(ab), 903(ab), 944(ab), 980(ab)
 Blake, A, 901(ab)
 Blake, D, 887(ab)
 Blake, GM, 549, 763(ab), 971(ab), 986(ab), 1153
 Blake, GP, 1498
 Blake, JS, 882(ab)
 Blanchette, MA, 788(ab)
 Blankenship, JC, 948(ab)
 Blaquièrre, RM, 549
 Blasberg, R, 796(ab), 897(ab)
 Blasberg, RG, 759(ab), 796(ab), 822(ab), 939(ab)
 Blaufox, MD, 849(ab), 937(ab)
 Blend, MJ, 756(ab), 823(ab), 1810
 Block, P, 806(ab)
 Blomquist, G, 820(ab)
 Blomqvist, G, 754(ab)
 Blood, DK, 841(ab)
 Blood, KMT, 822(ab)
 Blue, PW, 407
 Blumenthal, R, 758(ab), 890(ab)
 Blumhardt, R, 885(ab), 1368
 Bochet, J, 952(ab)
 Bockisch, A, 813(ab), 829(ab), 891(ab), 896(ab), 911(ab)
 Bodenheimer, M, 819(ab), 832(ab)
 Boivin, MJ, 913(ab)
 Bok, B, 981(ab), 1118
 Bol, A, 866(ab), 914(ab), 1633, 1826
 Bolman, RM, III, 1223
 Bolomey, L, 1526
 Bolton, WK, 816(ab)
 Bomanji, J, 147, 850(ab), 1031
 Bonaduce, D, 1786
 Boniface, GR, 815(ab)
 Bonow, RO, 385, 772(ab), 775(ab)
 Bonsib, S, 779(ab)
 Bonte, FJ, 760(ab), 911(ab), 912(ab), 1875
 Bookman, M, 833(ab)
 Boothe, T, 852(ab)
 Bormans, G, 909(ab)
 Börner, W, 1748
 Bornstein, NM, 914(ab)
 Bosslet, K, 925(ab)
 Bossuyt, A, 806(ab), 848(ab)
 Bossuyt Piron, C, 848(ab)
 Botez, MI, 844(ab)
 Botstein, P, N1472
 Böttger, IG, 902(ab)
 Bottini, G, 1507
 Botvinick, E, 840(ab)
 Botvinick, EH, 302, 744(ab), 781(ab), 941(ab), 942(ab), 943(ab)
 Boucher, CA, 769(ab), 805(ab), 945(ab)
 Boudreau, RJ, 974(ab)
 Bourdoiseau, M, 919(ab)
 Bourgeois, P, 807(ab), 954(ab)
 Bourgoignie, JJ, 909(ab)
 Bourguignon, M, 743(ab), 744(ab), 793(ab), 842(ab), 869(ab), 919(ab), 952(ab)
 Bourguignon, MH, 841(ab), 872(ab)
 Bowden, DH, 1607
 Bowen, B, 975(ab)
 Bowen, RD, 973(ab)
 Boxen, I, 1606
 Boyce, TM, 293, 755(ab)
 Boyd, GS, 1411
 Brachman, MB, 753(ab), 854(ab)
 Brack, J, 760(ab)
 Bracops, CHJ, 807(ab), 954(ab)
 Brady, LW, 847(ab)
 Brady, TJ, 836(ab)
 Braganza, F, 908(ab)
 Brameld, JM, 1301
 Brandau, W, 906(ab)
 Brateman, L, 972(ab)
 Braun, A, 822(ab)
 Braun, AR, 772(ab)
 Braunstein, G, 753(ab)
 Brechbiel, MW, 1810
 Breindl, L, 798(ab)
 Breisblatt, WM, 770(ab), 838(ab)
 Breitz, H, 830(ab)
 Brem, H, 784(ab)
 Brendel, AJ, 914(ab), 1515
 Brennan, KM, 785(ab), 916(ab), 942(ab)
 Brennan, MF, 902(ab)
 Bretille, J, 946(ab)
 Brewer, LA, III, 799(ab)
 Briandet, P, 744(ab)
 Bricker, JA, 813(ab), 1169
 Briggs, WS, 810(ab)
 Brihaye, C, 841(ab), 927(ab)
 Brill, AB, 846(ab), 861(ab), 1697
 Brill, DR, 268, 427
 Brinker, J, 756(ab)
 Bristol, KS, 785(ab)
 Bristow, D, 879(ab)
 Britton, KE, 147, 599, 850(ab), 899(ab), 1031, 1878
 Brock, M, 902(ab)
 Brodack, JW, 768(ab), 795(ab)
 Broder, S, 852(ab)
 Brodie, JD, 774(ab)
 Bronca, G, 1200
 Brookeman, VA, 955(ab)
 Brooks, K, 844(ab)
 Brooks, KM, 895(ab)
 Brooks, RA, 421, 1603
 Broussard, W, 894(ab)
 Broussolle, EP, 911(ab)
 Brouwers, JRB, 1302
 Brown, BA, 823(ab)
 Brown, GS, 861(ab)
 Brown, JM, 851(ab), 1810
 Brown, KA, 781(ab)
 Brown, M, 855(ab)
 Brown, MA, 818(ab)
 Brown, ML, 856(ab)
 Brown, PH, 623, 909(ab)
 Brown, S, 757(ab)
 Brown, SG, 1443
 Brownell, A-L, 899(ab)
 Bru, C, 1916
 Bruch, PM, 676
 Bruecke, T, 759(ab), 820(ab)
 Brugera, M, 1916
 Bruix, J, 1916
 Brunetti, A, 181, 852(ab), 939(ab)
 Brunetti, JC, 794(ab)
 Brunham, RC, 1607
 Brunken, RC, 818(ab), 827(ab), 942(ab)
 Brunner, JB, 840(ab)
 Brunot, B, 26
 Brunotte, F, 663
 Brush, JE, 772(ab)
 Bryant, G, 1022
 Bryant, GJ, 897(ab), 901(ab)
 Bubeck, B, 906(ab)
 Buchbinder, S, 797(ab)
 Buchegger, F, 811(ab)
 Buchsbaum, DJ, 835(ab)
 Budinger, TF, 743(ab), 760(ab), 773(ab), 784(ab), 785(ab), 916(ab), 942(ab)
 Buell, U, 756(ab)
 Bugaj, J, 801(ab), 934(ab), 935(ab)
 Büll, U, 426
 Bunke, J, 785(ab)
 Bunker, SR, 780(ab), 943(ab)
 Buonanno, FS, 836(ab), 920(ab)
 Burbank, K, 749(ab)
 Burckhardt, DD, 903(ab)
 Burgess, BA, 758(ab)
 Burgess, C, 953(ab)
 Burgiss, SG, 880(ab)
 Burke, JF, 789(ab), 934(ab)
 Burke, TS, 411
 Burnett, KG, 1688
 Burns, HD, 73
 Burns, MJ, 838(ab)
 Burrows, L, 862(ab)
 Burt, RW, 23, 840(ab), 1651
 Bush, V, 765(ab)
 Bushnell, DL, 886(ab), 974(ab), 977(ab)
 Bussy, E, 869(ab)
 Butler, SP, 593, 764(ab), 925(ab)
 Buxton, DB, 782(ab), 808(ab), 937(ab), 941(ab)
 Buxton, RB, 773(ab), 821(ab), 836(ab)
 Byrd, BL, 925(ab)
 Cagle, L, 1200
 Caillet, M, 893(ab)
 Calcano-Perez, JA, 836(ab)
 Caldwell, J, 807(ab)
 Caldwell, JH, 783(ab)
 Calhoun, J, 813(ab)
 Callaghan, JJ, 764(ab), 780(ab)
 Callahan, AP, 927(ab)
 Callahan, R, 651, 1268
 Callahan, RJ, 830(ab), 872(ab), 887(ab), 902(ab)
 Callcott, F, 571
 Calvet, X, 1916
 Camargo, EE, 805(ab)
 Camerini, E, 907(ab)
 Camerman, A, 800(ab)
 Camin, L, 804(ab), 942(ab), 950(ab)
 Campbell, DA, 790(ab)
 Canade, AB, 757(ab)
 Cannon, JM, 819(ab)
 Cannon, PJ, 841(ab)
 Cantineau, R, 747(ab)
 Cappa, S, 1507
 Cardot, JC, 951(ab), 1486
 Caride, VJ, 114
 Carlo, DJ, 1688
 Carlsen, O, 400
 Carlson, KE, 768(ab)
 Carlson, RL, 881(ab)
 Carlson, W, 91
 Carmann, H, 759(ab)
 Carney, PL, 824(ab), 924(ab), 926(ab)
 Carpentier, WR, 1451
 Carrasquillo, JA, 39, 758(ab), 833(ab), 897(ab), 901(ab), 1022
 Carrier, L, 17, 424, 860(ab)
 Carrió, I, 573, 1893
 Carroll, RG, 812(ab), 896(ab)
 Carroll, TR, 814(ab), 934(ab)
 Carson, B, 784(ab)
 Carson, RE, 759(ab), 772(ab), 775(ab), 796(ab), 822(ab), 867(ab), 1558
 Caruana, V, 2004
 Cascella, NG, 840(ab), 911(ab)
 Casset-Senon, D, 771(ab)
 Cassidy, MM, 943(ab)
 Castle, V, 892(ab)
 Castro, R, 950(ab)
 Castronovo, FP, Jr, 1152
 Catz, Z, 894(ab), 895(ab)
 Cedarholm, JC, 938(ab), 945(ab)
 Cerqueira, M, 807(ab)
 Cerqueira, MD, 1393
 Chabot, J, 757(ab)
 Chalou, S, 911(ab)
 Chaly, T, 370, 784(ab)
 Chamberlain, M, 983(ab)
 Chamberlayne, D, 752(ab)
 Chambers, CE, 781(ab)
 Chambon, C, 2008
 Chan, P, 943(ab)
 Chandra, R, 778(ab)
 Chandramouly, B, 870(ab), 953(ab)
 Chang, AE, 181
 Chang, JY, 852(ab), 912(ab)
 Chang, W, 676, 760(ab)
 Channing, M, 796(ab)
 Chao, KY, 863(ab)
 Chaovapong, W, 226
 Chapman, NJ, 856(ab)
 Charalel, J, 826(ab)
 Charkes, ND, 862(ab), 884(ab), 895(ab)
 Charlier, A, 1826
 Chartrand, R, 17, 424, 860(ab)
 Charuvastra, VC, 980(ab)
 Charuzi, Y, 802(ab), 891(ab)
 Chase, C, 746(ab)
 Chatal, JF, 806(ab), 811(ab), 847(ab)
 Chatelain, P, 1088
 Chatterjee, K, 781(ab)
 Chaudhuri, TK, 753(ab)
 Chawluk, J, 910(ab), 915(ab)
 Chawluk, JB, 132, 836(ab)
 Chawluk, JC, 852(ab)
 Chayes, ZW, 826(ab)
 Checchi, H, 805(ab)
 Cheesman, EH, 788(ab)
 Chehabi, H, 883(ab)
 Chehabi, HH, 944(ab)
 Chen, A, 1688
 Chen, AW, 812(ab), 893(ab), 925(ab)
 Chen, CC, 863(ab), 1272
 Chen, C-T, 839(ab), 868(ab), 875(ab), 912(ab), 977(ab)
 Chen, D, 869(ab)
 Chen, IW, 766(ab)
 Chen, J, 742(ab)
 Chen, JC, 760(ab)
 Chen, JJS, 110, 779(ab), 873(ab)
 Chen, L, 776(ab)
 Chen, WL, 863(ab)
 Chen, YT, 863(ab)
 Cherian, G, 838(ab)
 Cherry, S, 877(ab)
 Chervu, LR, 928(ab), 937(ab)
 Chesis, PL, 754(ab), 930(ab)
 Chesler, D, 805(ab)
 Cheung, NK, 846(ab)

- Chiao, P, 760(ab)
 Chiariello, M, 1786
 Chien, D, 836(ab)
 Chien, S, 1710
 Chikamori, T, 781(ab), 782(ab)
 Chilton, HM, 857(ab), 981(ab)
 Chin, H, 769(ab)
 Chin, M, 840(ab)
 Chin, O, 869(ab)
 Chinol, M, 846(ab), 1428
 Chiou, PF, 863(ab), 936(ab)
 Chiou, RK, 872(ab)
 Chirakal, R, 363
 Chiron, C, 743(ab), 792(ab), 869(ab), 892(ab)
 Chisholm, RJ, 768(ab), 945(ab)
 Chiu, KW, 789(ab)
 Chiueh, CC, 759(ab), 820(ab)
 Chou, J-S, 868(ab)
 Choy, DH-L, 701
 Christensen, RC, 742(ab)
 Christian, P, 329
 Christian, PE, 130, 574, 616, 751(ab)
 Christiansen, C, 248
 Christie, MJ, 1347
 Chu, YK, 826(ab)
 Chugani, HT, 772(ab), 831(ab)
 Chui, C, 803(ab)
 Chun, S, 937(ab)
 Chung, J, 903(ab)
 Chung, J-K, 745(ab)
 Churchod, S, 811(ab)
 Churchwell, A, 91
 Churchwell, AL, 1901
 Cicogna, R, 946(ab)
 Cierny, G, III, 763(ab), 883(ab)
 Ciliax, BJ, 767(ab), 930(ab)
 Cinotti, L, 764(ab), 861(ab)
 Civelek, AC, 756(ab), 799(ab), 873(ab), 944(ab)
 Cladellas, M, 1893
 Clanton, JA, 981(ab)
 Claringbold, PG, 762(ab)
 Clark, O, 885(ab)
 Clark, RV, 859(ab)
 Clarke, G, 801(ab)
 Clarke, K, 826(ab)
 Clarke, LP, 810(ab), 863(ab), 876(ab)
 Clarke, SEM, 33, 1747
 Clausen, M, 744(ab), 756(ab), 799(ab), 818(ab), 946(ab)
 Clements, JP, 977(ab)
 Cleynhens, B, 909(ab)
 Clinthorne, N, 917(ab)
 Clinthorne, NH, 195, 760(ab), 785(ab), 797(ab)
 Cloninger, K, 91, 1901
 Clorius, JH, 751(ab), 776(ab)
 Clothier, J, 852(ab)
 Coakham, HB, 897(ab)
 Coates, G, 824(ab), 892(ab)
 Cochavi, S, 870(ab)
 Coenen, HH, 754(ab), 755(ab), 821(ab), 911(ab)
 Cogneau, M, 914(ab), 1633, 1826
 Cohen, BL, 268
 Cohen, I, 770(ab), 951(ab)
 Cohen, MB, 869(ab), 1200
 Cohen, RM, 759(ab), 796(ab), 820(ab), 852(ab)
 Colapinto, EV, 835(ab)
 Colas-Linhart, N, 981(ab), 1118
 Colcher, D, 1022
 Cole, P, 742(ab), 799(ab), 873(ab), 916(ab), 944(ab)
 Coleman, P, 695
 Coleman, R, 871(ab)
 Coleman, RE, 786(ab), 897(ab), 1045, 1354, 1398
 Collea, JV, 1364
 Collen, MJ, 752(ab)
 Collier, BS, 825(ab)
 Collier, BD, 856(ab), 868(ab), 976(ab), 1761
 Collins, C, 834(ab)
 Collins, L, 850(ab)
 Colombo, F, 801(ab), 934(ab)
 Combs, MJ, 886(ab)
 Combs, R, 933(ab)
 Comerata, A, 844(ab)
 Comet, M, 951(ab), 1230, 1486
 Comunale, JP, 973(ab)
 Condon, BR, 132
 Conforti, G, 1786
 Conlon, KC, 902(ab)
 Connell, JMC, 1746
 Connett, JM, 814(ab), 835(ab)
 Connolly, BT, 473
 Connolly, P, 835(ab)
 Conrad, GR, 813(ab), 1169
 Constantinesco, A, 26
 Constantiniades, C, 838(ab), 982(ab), 985(ab)
 Conti, PS, 903(ab), 904(ab)
 Conway, T, 1957
 Cook, L, 853(ab), 979(ab)
 Cook, N, 62
 Cooke, CD, 810(ab)
 Cooper, AJL, 931(ab)
 Cooper, JA, 1842
 Cooper, MD, 839(ab), 840(ab), 912(ab), 932(ab), 977(ab)
 Cooper, RA, 763(ab), 780(ab)
 Copeland, JG, 742(ab)
 Coptcoat, MJ, 779(ab)
 Corbally, MT, 902(ab)
 Corbett, JR, 760(ab), 805(ab), 841(ab), 944(ab), 948(ab)
 Corday, E, 783(ab)
 Cordes, M, 977(ab)
 Corlija, M, 977(ab), 981(ab), 1568
 Corpuz, S, 795(ab)
 Correia, JA, 773(ab), 821(ab), 836(ab), 872(ab), 920(ab)
 Corstens, F, 860(ab), 1360
 Corwin, LA, Jr, 903(ab)
 Cosnay, P, 771(ab)
 Costa, DC, 912(ab)
 Cottrill, CM, 765(ab), 980(ab)
 Couch, MW, 356, 803(ab), 1668
 Counsell, RE, 503
 Coupal, JJ, 765(ab), 904(ab), 905(ab), 980(ab)
 Coveney, JR, 801(ab), 906(ab), 908(ab)
 Cowan, RA, 485
 Cowan, RC, 857(ab)
 Cox, JL, 1223
 Cox, PH, 851(ab)
 Coyle, JJ, 817(ab)
 Coyle, JJ, Jr, 944(ab)
 Craddock, TD, 684
 Crisp, S, 914(ab)
 Croft, BY, N1871, 717, 816(ab), N1475, N1477
 Crone-Escayne, M-C, 663
 Cronin, B, 752(ab)
 Crook, JE, 925(ab)
 Crosser, M, 921(ab)
 Crossley, R, 873(ab)
 Crouse, DA, 901(ab), 979(ab)
 Crouzel, C, 808(ab), 828(ab), 940(ab)
 Crouzel, M, 808(ab), 828(ab), 940(ab)
 Crowther, D, 485
 Crowther, M, 599
 Cruces, J, 891(ab)
 Cruces, J, III, 802(ab)
 Cuchet, P, 1230
 Cuckler, JM, 883(ab)
 Cull, R, 971(ab), 975(ab), 983(ab)
 Cullom, SJ, 810(ab), 863(ab), 876(ab)
 Culver, CM, 873(ab)
 Cumming, SA, 934(ab)
 Cummings, DD, 776(ab)
 Cummings, J, 821(ab), 839(ab)
 Cuocolo, A, 772(ab), 775(ab)
 Curtet, C, 811(ab)
 Custer, T, 872(ab)
 Dacie, JE, 850(ab)
 Daddona, PE, 898(ab)
 Dae, M, 744(ab), 840(ab), 941(ab)
 Dae, MW, 302, 781(ab), 942(ab)
 Daghigian, F, 832(ab)
 Dahlbom, M, 241
 Daily, V, 833(ab)
 D'Aleo, C, 901(ab)
 Daley, N, 948(ab)
 D'Amour, P, 860(ab)
 Danais, S, 743(ab), 843(ab)
 Danforth, J, 781(ab)
 Dannals, JW, 943(ab)
 Danilov, SM, 1951
 Dann, R, 132
 Dannals, R, 784(ab)
 Dannals, RF, 796(ab), 809(ab), 820(ab), 840(ab), 852(ab), 853(ab), 911(ab), 921(ab), 1207
 Dapogny, M, 129
 Darcourt, J, 159
 D'Argenio, DZ, 908(ab)
 Das, DK, 657
 Das Gupta, TK, 1810
 Datz, FL, 130, 329, 574, 751(ab)
 Daube-Witherspoon, ME., 385
 Daube-Witherspoon, ME, 867(ab), 1558
 Daugherty, A, 848(ab)
 Dauth, J, 759(ab)
 David, GS, 1688
 Davidson, JK, 1587
 Davis, MJ, 953(ab), 1662
 Davis, PS, 263
 Davison, A, 55, 820(ab)
 Deakin, DP, 485
 Dean, R, 905(ab)
 Dean, RT, 745(ab), 746(ab), 851(ab), 923(ab)
 Decorah, MA, 980(ab)
 Deecker, L, 920(ab)
 DeFilippi, VJ, 764(ab)
 DeGalan, MR, 503
 De Geeter, F, 806(ab)
 DeGeorges, M, 828(ab)
 DeGrado, TR, 808(ab), 822(ab), 939(ab)
 Deisenhammer, E, 759(ab)
 DeJager, R, 846(ab)
 de Jesus, OJ, 932(ab)
 de Jong, BM, 927(ab)
 de Jong, PE, 908(ab)
 de Kraker, J, 791(ab), 798(ab)
 Delaloye, B, 804(ab), 811(ab)
 Deland, FH, 980(ab)
 de Lange, MJ, 778(ab), 983(ab)
 de Launoit, Y, 837(ab)
 Delbeke, D, 763(ab), 1454
 Delecluse, F, 911(ab)
 Delforge, J, 863(ab)
 Delling, G, 882(ab)
 Dellis, CJ, 1761
 Dell'Italia, LJ, 1368
 Del Vecchio, S, 833(ab), 897(ab)
 Demaison, L, 1230
 Demangeat, J-L, 26
 Demer, LL, 973(ab)
 De Moerloose, P, 1107
 Demonceau, G, 747(ab), 758(ab)
 DeNardo, GL, 203, 217, 824(ab), 845(ab), 847(ab), 871(ab), 872(ab), 888(ab), 899(ab), 922(ab), 1795
 DeNardo, SJ, 203, 217, 824(ab), 845(ab), 847(ab), 871(ab), 872(ab), 888(ab), 899(ab), 922(ab)
 Denays, R, 893(ab)
 Dence, CS, 807(ab)
 den Hartog Jager, FCA, 798(ab)
 Depaepe, A, 954(ab)
 DePuey, EG, 793(ab), 859(ab), 944(ab), 950(ab), 951(ab), 1479
 Derbekyan, V, 1050
 Derenzo, SE, 760(ab)
 De Roo, M, 747(ab), 752(ab), 758(ab), 909(ab)
 DeRuzzo, ST, 896(ab)
 Desai, A, 985(ab)
 Desai, AG, 263
 DeSantis, M, 819(ab)
 Deshpande, SV, 217, 824(ab), 888(ab), 922(ab)
 DeSisto, W, 874(ab)
 DeSouza, M, 791(ab)
 De Spiegeleer, B, 1107
 Deussen, A, 755(ab)
 Deutsch, E, 801(ab), 847(ab), 934(ab), 935(ab)
 Deutsch, EA, 776(ab)
 DeVito, RP, 798(ab), 845(ab)
 De Volder, AG, 914(ab)
 Devos, P, 752(ab), 909(ab)
 Devous, MD, Sr, 760(ab), 911(ab), 912(ab), 1875
 DeVries, DJ, 845(ab)
 Dewanjee, M, 897(ab)
 Dewanjee, MK, 794(ab)
 Dewes, W, 891(ab)
 Dewey, SL, 767(ab), 933(ab)
 Dewez, S, 927(ab)
 de Wit, H, 840(ab)
 Dey, HM, 945(ab)
 de Zeeuw, D, 907(ab), 908(ab)
 Dhawan, V, 839(ab)
 Dhekne, RD, 766(ab), 982(ab)
 Diamond, G, 949(ab)
 Diamond, M, 839(ab)
 Diaz, P, 760(ab)
 Dibos, PE, 972(ab)
 DiChiro, G, 421, 852(ab), 1603
 Diebler, C, 792(ab)
 Dietemeyer, JA, 794(ab)
 Dietz, G, 684
 Dietz, H, 853(ab)
 Digby, W, 832(ab)
 Digby, WM, 983(ab)
 Diksic, M, 370, 422, 631, 784(ab), 915(ab), 930(ab), 1957
 Dillon, M, 905(ab)
 Dilsizian, V, 769(ab), 945(ab)
 Ding, Y, 760(ab)
 Di Paola, R, 861(ab)
 Di Piero, V, 1507
 DiResta, E, 904(ab)
 DiSciascio, G, 1283
 Di Simone, RN, 725
 DiSisto, W, 948(ab)
 Doctor, DG, 764(ab)
 Doerr, R, 898(ab)
 Doherty, MD, 876(ab)
 Doherty, PD, 846(ab)
 Doherty, PW, 1428
 Doi, Y, 781(ab), 782(ab)
 Domino, EF, 767(ab)
 Donohoe, K, 133, 980(ab)
 Donohoe, KJ, 882(ab)
 Dörken, B, 899(ab)
 Dorsey, D, 853(ab)
 Doudet, D, 820(ab)
 Douzenard, JM, 747(ab), 844(ab)
 Douglass, K, 784(ab)
 Douglass, KH, 796(ab)
 Dowd, M, 839(ab)
 Dowd, MT, 912(ab)
 Dragotakes, S, 872(ab)
 Drayson, M, 485

- Drew, H, 789(ab), 873(ab)
Drew, HH, 1927
Driedger, AA, 684, 947(ab)
Driscoll, JS, 837(ab)
Drost, DJ, 880(ab)
Drury, JK, 783(ab)
Duara, R, 852(ab), 912(ab)
Dubinett, SM, 902(ab)
Duboc, D, 828(ab)
Dubois, F, 1230
Dubovsky, E, 255, 1189
Dubovsky, EV, 908(ab),
1730, 1931
duCret, RP, 974(ab)
Duda, RB, 103
Dudczak, R, 794(ab),
850(ab)
Dufresne, F, 17
Dulac, O, 743(ab), 792(ab),
869(ab), 892(ab)
Dumont, A, 17
Dumont, M, 906(ab)
Duncan, R, 1675
Dunn, D, 91, 756(ab),
938(ab), 945(ab)
Dunn, DW, 1901
Dunn, EK, 561
Dunn, W, 855(ab)
Dunn, WL, 881(ab)
Dupras, G, 781(ab), 793(ab),
864(ab)
Duroux, P, 824(ab)
Durrant, L, 761(ab)
Durski, K, 756(ab), 799(ab),
944(ab)
Dutta, A, 777(ab)
Duwel, CMB, 851(ab), 1934
Dworkin, HJ, 753(ab),
873(ab)
Dydek, GJ, 407
- Eakin, DA, 893(ab)
Eakin, DE, 812(ab)
Eary, JF, 757(ab), 834(ab),
835(ab)
Eaton, S, 891(ab)
Eckelman, WC, 891(ab)
Eckerman, KF, 859(ab)
Eden, PJ, 851(ab)
Edery, S, 861(ab)
Eenige van, MJ, 1934
Efange, SMN, 777(ab)
Eftekhari, M, 1724
Egdell, RG, 789(ab)
Eggl, DF, 752(ab), 892(ab)
Ehrhardt, GJ, 923(ab)
Ehrhardt, JC, 348, 676
Eichling, JO, 874(ab), 1961
Eidelberg, D, 839(ab)
Einhorn, TA, 787(ab)
Eisdorfer, C, 829(ab)
Eisen, HJ, 1223, 2018
Eisenberg, B, 883(ab)
Eisenhut, M, 906(ab)
Eisner, R, 91
Eisner, RL, 756(ab), 938(ab),
945(ab), 1466, 1901
Eklund, A, 905(ab)
Elam, DA, 799(ab)
El-Dadah, M, 971(ab)
Elgazzar, AH, 814(ab)
Elgazzar, AH, 971(ab)
Elkanovitch, R, 1150
Ell, PJ, 912(ab)
- Elliott, AT, 1096
Elliott, AT, 1587
Ellison, D, 62
Elmaleh, DE, 68
Elmaleh, DR, 935(ab)
El-sayed, M, 814(ab)
El-Sayed, M, 971(ab)
Elsinga, PH, 524, 1419
Elson, MK, 856(ab), 875(ab),
882(ab), 897(ab)
El-Tahtawy, A, 837(ab)
Embree, L, 807(ab)
Emran, AM, 1881
Emrich, D, 761(ab)
Endo, K, 235, 766(ab),
837(ab), 889(ab), 890(ab),
1130, 1436
Endo, M, 838(ab), 866(ab),
941(ab)
Endres, JA, 943(ab)
Engelbretson, D, 816(ab)
Engelsman, EE, 798(ab)
Engelstad, B, 795(ab)
Engelstad, BL, 913(ab),
982(ab)
Engenhardt, R, 751(ab)
Englert, J, 39
English, D, 1246
Entine, G, 880(ab)
Epenetos, AA, 762(ab), 1910
Epperly, MW, 900(ab)
Epps, L, 905(ab)
Epps, LA, 745(ab), 746(ab)
Epstein, AL, 847(ab),
888(ab)
Eriksson, L, 820(ab), 984(ab)
Erlandsson, K, 1719
Erman, J, 1853
Erturk, E, 849(ab)
Eshima, D, 616, 669,
907(ab), 909(ab), 936(ab)
Esmaili, J, 1724
Essandoh, LK, 945(ab)
Esser, PD, 168, 717, 1748
Essiambre, R, 793(ab),
804(ab)
Esteban, J, 1022
Esteban, JM, 926(ab)
Esterhai, JL, 1015
Estorch, M, 573, 1893
Etani, H, 1264
Evans, AC, 422, 866(ab),
915(ab)
Evans, H, 816(ab)
Even-Sapir, E, 187
Eyre, H, 329
Ezquerria, NF, 810(ab)
- Faßbender, D, 940(ab)
Faber, TL, 805(ab)
Fagnani, RL, 893(ab)
Fagret, C, 951(ab)
Fagret, D, 1486
Fahey, FH, 752(ab), 1364
Fairbank, JT, 977(ab)
Fajman, WA, 825(ab),
910(ab)
Fanwick, PE, 927(ab)
Farcot, J-M, 26
Farde, L, 754(ab), 767(ab),
820(ab)
Farhangi, M, 775(ab)
Farkas, R, 1022
Faus, R, 1916
- Faversham, JL, 944(ab)
Fawcett, H, 813(ab)
Fawcett, HD, 1745
Fawdry, R, 765(ab), 850(ab)
Fawwaz, RA, 757(ab),
925(ab)
Fay, J, 118
Fayad, F, 909(ab)
Fazekas, F, 836(ab), 852(ab),
910(ab), 915(ab)
Fazio, F, 749(ab), 801(ab),
934(ab), 1507, 1971
Feduska, NJ, 795(ab)
Feiglin, D, 836(ab)
Feindel, W, 422
Feinendegen, LE, 832(ab),
851(ab), 877(ab), 938(ab),
1582
Feinsod, M, 881(ab)
Feinsod, M, 187
Feld, T, 800(ab)
Feldkamp, MJ, 942(ab)
Feldman, M, 852(ab)
Felix, R, 977(ab)
Fer, MF, 834(ab)
Feremans, W, 807(ab)
Fernandez, JA, 909(ab)
Fernandez-Ulloa, M, 1744
Ferrant, A, 1633, 1826
Ferroni, P, 1022
Fetissou, F, 893(ab)
Fetterman, R, 804(ab)
Fettich, J, 147
Feun, L, 897(ab)
Ficken, VJ, 864(ab)
Fielding, SL, 798(ab)
Figuera, J, 1776
Filc-DeRiccio, S, 931(ab)
Filice, D, 791(ab)
Fill, H, 1382
Findley, DO, 875(ab)
Findley, SL, 385
Fine, DR, 549
Fink-Bennett, D, 826(ab),
887(ab)
Fink-Bennett, DM, 753(ab),
873(ab)
Finn, R, 772(ab), 820(ab)
Finn, RD, 181, 772(ab),
796(ab), 822(ab), 852(ab),
939(ab)
Firmau, G, 363
Fischer, M, 778(ab)
Fischman, AJ, 830(ab),
843(ab), 887(ab)
Fish, MB, 1596
Fisher, D, 757(ab)
Fisher, RS, 796(ab)
Fisher, SK, 933(ab)
Fissekis, J, 903(ab), 904(ab)
Fitz, R, 765(ab)
Fitzpatrick, DA, 873(ab)
Fjälling, M, 1638
Fleming, JS, 1153
Fleming, RM, 803(ab)
Fletcher, MA, 829(ab)
Fleuren, GJ, 1078
Flor, WG, 927(ab)
Flower, MA, 752(ab),
798(ab), 877(ab)
Floyd, C, 871(ab)
Floyd, CE, 786(ab), 869(ab)
Floyd, CE, Jr, 797(ab)
Fogelman, I, 1045, 1354
- Folks, RD, 793(ab), 859(ab)
Folland, E, 947(ab)
Folstein, M, 916(ab)
Folstein, S, 916(ab)
Fommei, E, 907(ab)
Foon, KA, 39
Ford, E, 846(ab)
Ford, EH, 757(ab), 761(ab),
833(ab), 898(ab)
Fordyce-Baum, MA, 829(ab)
Forell, BW, 875(ab)
Forrest, I, 884(ab)
Forstrom, LA, 838(ab)
Foster, NL, 743(ab), 915(ab)
Fotiou, S, 1910
Fouchard, J, 828(ab)
Foucher, G, 26
Fournier, D, 808(ab),
940(ab)
Fowler, JS, 767(ab), 933(ab)
Fox, LM, 769(ab)
Fox, MR, 800(ab)
Fox, SM, 769(ab)
Franceschi, D, 819(ab), 1539
Franceschi, M, 851(ab)
Franceschini, M, 933(ab)
Francis, BE, 772(ab)
Frank, G, 1150
Frank, R, 809(ab)
Frank, TL, 441, 938(ab),
1539
Frater, SI, 695
Fratkin, MJ, 411, 888(ab),
1283
Frederiksen, PB, 479
Freeman, I, 819(ab)
Freeman, MR, 768(ab),
871(ab), 945(ab)
Freitas, JE, 859(ab)
French, WJ, 159
Frenkel, A, 187, 879(ab),
881(ab), 1341
Frey, KA, 808(ab), 932(ab)
Friden, A, 897(ab)
Fridrich, R, 804(ab)
Friedland, RP, 867(ab)
Friedman, DM, 893(ab),
895(ab), 925(ab)
Friedman, HS, 835(ab)
Friedman, J, 741(ab),
793(ab), 802(ab), 891(ab)
Friedman, R, 571
Friend, K, 908(ab)
Frincke, JM, 835(ab),
893(ab)
Frischauf, H, 575
Fritzberg, A, 847(ab),
935(ab)
Fritzberg, AR, 777(ab),
800(ab), 815(ab), 834(ab),
929(ab)
Froelich, JW, 1714
Front, A, 879(ab)
Front, D, 187, 879(ab),
881(ab), 1341
Frost, JJ, 796(ab), 809(ab),
921(ab), 1207
Frühling, J, 837(ab)
Fuccello, AJ, 851(ab)
Fuchs, H, 786(ab)
Fudemoto, Y, 1738
Fudo, T, 827(ab), 828(ab),
1181
Fujibayashi, Y, 778(ab),
- 826(ab), 930(ab)
Fujino, A, 954(ab)
Fujisue, R, 451
Fujita, H, 915(ab), 919(ab)
Fujita, T, 802(ab), 843(ab),
844(ab), 877(ab), 918(ab),
922(ab), 1130
Fukuchi, M, 906(ab)
Fukuda, H, 809(ab), 838(ab),
941(ab)
Fukuda, N, 838(ab), 941(ab)
Fukuda, T, 883(ab)
Fukunaga, M, 1448, 1460
Fukuyama, H, 843(ab),
844(ab), 918(ab)
Funch-Rosenberg, H,
905(ab)
Furlan, AJ, 913(ab)
Furukawa, T, 1448
Fuster, V, 1237
Futatsuya, R, 780(ab)
- Gaab, MR, 853(ab)
Gachon, P, 48, 939(ab)
Gadodia, G, 756(ab)
Gagne, GM, 83
Gagnon, A, 804(ab), 844(ab)
Gagnon, D, 864(ab)
Gagnon, M, 17
Gainey, MA, 689
Gal, R, 745(ab)
Galante, M, 885(ab)
Gale, DR, 118
Galinsky, R, 907(ab)
Gallagher, K, 938(ab)
Gallagher, R, 862(ab)
Galle, P, 824(ab)
Galt, JR, 797(ab)
Gambhir, SS, 828(ab),
862(ab)
Gambino, JJ, 903(ab)
Gan, M, 1200
Gandevia, B, 701
Gandsman, EJ, 798(ab)
Ganey, MV, 788(ab)
Gansow, OA, 1810
Ganti, G, 774(ab)
Ganz, SS, 887(ab)
Ganz, W, 909(ab)
Ganz, WI, 887(ab)
Garan, H, 769(ab)
Garcia, AM, 83
Garcia, E, 951(ab)
Garcia, EV, 793(ab),
797(ab), 810(ab), 944(ab)
Garg, PK, 834(ab), 835(ab)
Garibian, G, 742(ab),
943(ab)
Garrett, ES, 363
Garrett, K, 913(ab)
Garrity, ST, 788(ab)
Garty, I, 750(ab)
Garvin, PJ, 779(ab)
Garza, D, 951(ab)
Gasthuisberg, UZ, 752(ab)
Gates, GF, 1467
Gatley, SJ, 828(ab), 930(ab),
1443
Gay, TA, 794(ab)
Geatti, O, 900(ab), 1304
Geckle, WJ, 441
Gee, D, 1943
Gelbard, AS, 902(ab),
931(ab)

- Geldenhuys, EN, 538
 Gelfand, MJ, 892(ab)
 Geltman, EM, 818(ab)
 Generali, T, 910(ab)
 Genna, S, 786(ab)
 Gennarelli, T, 830(ab), 910(ab)
 Gensburg, RS, 1279
 George, EA, 779(ab)
 Georgi, B, 779(ab)
 Georgi, P, 817(ab), 906(ab)
 Georgiou, E, 881(ab)
 Gerard, P, 911(ab)
 Gerli, A, 936(ab)
 Germano, G, 983(ab)
 Gerson, B, 902(ab)
 Gerstenbrand, F, 1382
 Gerundini, P, 801(ab), 934(ab), 1507
 Geuting, B, 851(ab), 938(ab)
 Geyer, AB, 760(ab)
 Ghione, S, 907(ab)
 Gibbons, RJ, 838(ab), 945(ab)
 Gibson, RE, 922(ab), 927(ab)
 Gibson, RW, 293
 Gilardi, MC, 878(ab), 1971
 Gilbert, S, 766(ab), 825(ab)
 Gilday, DL, 791(ab), 792(ab)
 Gildersleeve, DL, 930(ab)
 Gilgien, W, 811(ab)
 Gilland, DR, 643, 748(ab), 749(ab), 786(ab), 870(ab)
 Gillen, GJ, 1096, 1587
 Gillet, P, 792(ab)
 Gillis, E, 1107
 Gillispie, SB, 867(ab), 871(ab)
 Gilman, S, 913(ab)
 Gini, A, 977(ab)
 Ginjaume, M, 1893
 Ginsberg HN, 1237
 Giombetti, R, 913(ab)
 Gionet, M, 762(ab), 846(ab), 1428
 Giordani, B, 913(ab)
 Giorgi, MCP, 805(ab)
 Giubbini, R, 946(ab)
 Givel, JC, 811(ab)
 Given, B, 977(ab)
 Gjedde, A, 809(ab), 820(ab), 915(ab)
 Glass, EC, 944(ab), 1154
 Gleichmann, U, 940(ab)
 Glick, S, 868(ab)
 Glick, SJ, 748(ab), 749(ab), 864(ab), 870(ab), 1980
 Glickman, S, 1768
 Gloor, P, 920(ab)
 Glover, DK, 792(ab)
 Glowniak, JV, 842(ab), 1156
 Go, RT, 913(ab), 946(ab)
 Gober, A, 938(ab), 945(ab)
 Gober, AM, 1901
 Goeckeler, WF, 903(ab)
 Goeldel, NH, 949(ab)
 Goethals, P, 1107
 Goffinet, AM, 914(ab)
 Golazeski, T, 742(ab)
 Gold, HK, 825(ab), 851(ab)
 Goldenberg, DM, 757(ab), 761(ab), 833(ab), 846(ab), 858(ab), 874(ab), 890(ab), 898(ab)
 Goldenberg, H, 757(ab), 833(ab)
 Goldenberg, DM, 758(ab)
 Goldfarb, CR, 707, 1150
 Goldfarb, H, 789(ab)
 Goldfarb, HW, 73
 Goldfogel, G, 812(ab)
 Goldie, J, 975(ab)
 Goldman, S, 852(ab), 911(ab)
 Goldman-Leikin, R, 174, 901(ab)
 Goldsmith, SJ, 764(ab), 787(ab), 814(ab), 862(ab), 921(ab), 1237, 1878
 Goldstein, HA, 1364
 Goldstein, RA, 973(ab)
 Gole, DJ, 767(ab)
 Goll, S, 1015
 Gona, J, 898(ab)
 Gonzalez, A, 921(ab)
 Good, S, 363
 Goodgold, HM, 779(ab), 978(ab)
 Goodman, MM, 777(ab), 843(ab), 1697
 Goodwin, DA, 226
 Gordon, L, 571, 954(ab), 955(ab)
 Goris, ML, 946(ab)
 Goris, MM, 717
 Gose, EE, 974(ab)
 Gotfredsen, A, 248
 Gottschalk, A, 893(ab)
 Gotzamani-Psarrakos, A., 1152
 Gould, KL, 774(ab), 879(ab), 951(ab), 973(ab)
 Gould, LK, 839(ab)
 Goutay, E, 129
 Govelitz, GF, 375
 Grabnic, M, 760(ab)
 Grady, CL, 867(ab)
 Grady, PJ, 903(ab)
 Graeff, RW, 787(ab)
 Grafman, J, 852(ab)
 Graham, AR, 742(ab)
 Graham, CC Jr, 1083
 Graham, LS, 267, 869(ab), 1200
 Graham, M, 783(ab), 830(ab)
 Graham, MM, 717, 773(ab), 879(ab), 920(ab), 933(ab)
 Granowska, M, 599, 899(ab), 1031
 Grant, R, 132
 Graveline, R, 843(ab)
 Gravelle, D, 684
 Gray, LL, 842(ab)
 Grdina, D, 858(ab)
 Greager, JA, 1810
 Green, CE, 769(ab)
 Green, MA, 417, 848(ab), 927(ab), 1549
 Green, MV, 385, 772(ab), 775(ab), 1558
 Green, SL, 897(ab), 901(ab)
 Greenberg, E, 751(ab)
 Greenberg, JH, 747(ab)
 Greene, R, 938(ab), 945(ab)
 Greenspan, F, 885(ab)
 Greenspan, RL, 764(ab)
 Greenwell, K, 1200
 Greer, DM, 356, 803(ab), 1668
 Greer, K, 871(ab)
 Greer, KL, 1398
 Grégoire, J, 781(ab), 793(ab), 804(ab)
 Gregoire, M, 744(ab)
 Grenier, RP, 745(ab)
 Gress, D, 836(ab), 920(ab)
 Greyson, ND, 768(ab), 945(ab)
 Grierson, JR, 926(ab)
 Griffin, JC, 744(ab)
 Griffin, T, 846(ab), 1428
 Griffith, MH, 1795
 Griffith, MH, Jr, 872(ab)
 Griffiths, D, 893(ab)
 Grimmond, HE, 375
 Grochow, L, 799(ab)
 Großmann, K, 851(ab), 938(ab)
 Gronka, ML, 783(ab)
 Gronka, R, 830(ab)
 Gross, M, 503, 796(ab), 859(ab)
 Gross, MD, 744(ab), 859(ab), 917(ab), 918(ab), 1368, 1644
 Grossman, M, 915(ab)
 Grossman, ZD, 1212
 Groth, S, 904(ab), 905(ab)
 Grothe, RA Jr, 530
 Grover-McKay, M, 241
 Grubb, RL, Jr, 831(ab)
 Gruenewald, S, 765(ab)
 Gruenewald, SM, 850(ab)
 Grunwald, AM, 819(ab)
 Grünwald, F, 896(ab), 936(ab)
 Gu, XM, 832(ab), 984(ab)
 Guérin, F, 828(ab)
 Guerra, UP, 946(ab)
 Guerrant, RL, 790(ab)
 Guerreau, D, 847(ab)
 Guertler-Krawczynska, E, 1479, 1860
 Guibourg, H, 938(ab)
 Guillaume, M, 841(ab), 927(ab)
 Guilloteau, D, 885(ab), 893(ab), 911(ab), 2008
 Gulenchyn, KY, 572, 902(ab), 919(ab), 978(ab), 984(ab), 985(ab), 1998
 Gullberg, GT, 749(ab), 786(ab), 870(ab)
 Gungon, RL, 73
 Guo, Y-Z, 777(ab), 788(ab), 935(ab)
 Gupta, N, 825(ab)
 Gupta, S, 977(ab)
 Gur, RC, 830(ab), 910(ab)
 Gur, RE, 830(ab)
 Gusella, J, 853(ab)
 Gustavson, L, 935(ab)
 Gutelius, CA, 980(ab)
 Guth-Touglides, B, 854(ab)
 Guyot, M, 914(ab), 1515
 Guzzardi, R, 1833
 Gyobu, T, 558, 917(ab)
 Haber, E, 746(ab), 939(ab)
 Habibian, MR, 973(ab)
 Hack, SN, 1842
 Hackney, D, 852(ab)
 Hadeishi, H, 915(ab)
 Haden, HT, 1781
 Hadley, SW, 777(ab), 929(ab)
 Hagan, P, 329
 Hagan, PL, 812(ab), 893(ab), 895(ab), 925(ab), 1688
 Hagge, RJ, 864(ab)
 Hagijs, JT, 786(ab)
 Haka, MS, 767(ab)
 Hakim, AM, 866(ab), 915(ab), 920(ab)
 Hakki, A-H, 742(ab)
 Hakki, H, 943(ab)
 Halders, S, 885(ab)
 Hales, CA, 1268
 Halgren, E, 831(ab)
 Halker, R, 320
 Hall, H, 767(ab)
 Hall, J, 972(ab)
 Hall, KM, 747(ab)
 Hall, T, 846(ab)
 Hall, TC, 761(ab), 898(ab)
 Hall, TR, 862(ab)
 Halldin, C, 754(ab), 767(ab), 931(ab)
 Halperin, JL, 787(ab)
 Halpern, SE, 812(ab), 893(ab), 895(ab), 925(ab), 1688
 Ham, HR, 893(ab), 2020
 Hamacher, K, 755(ab)
 Hamada, S, 1868
 Hamamoto, K, 765(ab), 791(ab), 829(ab), 888(ab)
 Hamashige, N, 781(ab), 782(ab)
 Hamill, JJ, 798(ab), 845(ab)
 Hamilton, D, 485
 Hamilton, DR, 797(ab)
 Hammes, RJ, 980(ab)
 Hanada, J, 909(ab)
 Handa, S, 950(ab)
 Handmaker, H, 780(ab)
 Hanna, MG, Jr, 833(ab)
 Hanna, R, 729
 Hannelin, M, 873(ab)
 Hansen, C, 841(ab)
 Hansen, HJ, 757(ab), 898(ab)
 Hansen, L, 616, 907(ab)
 Hansen, WP, 651
 Hanson, RN, 68
 Hanson, WA, 982(ab)
 Hara, T, 921(ab)
 Harby, K, N283, N287, N429, N431, N583, N586, N588, N1003, N1011, N1159, N1162, N1469, N1611, N1751, N1889
 Harcke, HT, 881(ab)
 Hardy, M, 757(ab)
 Harp, GD, 1393
 Harpen, MD, 1750
 Harper, PV, 803(ab)
 Harris, BA, 883(ab), 973(ab)
 Harris, JR, 473
 Harrison, RC, 940(ab)
 Harrison, RL, 867(ab), 871(ab)
 Hartig, PR, 809(ab)
 Hartling, OJ, 1155
 Hartmann, A, 936(ab)
 Hartsough, NE, 878(ab)
 Hartwig, QL, 424
 Hartwig, W, 932(ab)
 Hartz, RK, 879(ab)
 Harwood, SJ, 896(ab)
 Hasegawa, BH, 267, 1466
 Hasegawa, Y, 1738
 Hashimoto, S, 762(ab), 950(ab), 1126
 Hashimoto, T, 827(ab), 828(ab), 1181
 Hasikawa, K, 1264
 Haspel, MV, 833(ab)
 Hassall, EG, 979(ab)
 Hassan, IM, 838(ab), 982(ab), 985(ab)
 Hassine, H, 129
 Hata, M, 883(ab)
 Hatano, K, 931(ab)
 Hatano, M, 741(ab)
 Hatazawa, J, 931(ab)
 Hattner, R, 795(ab), 883(ab)
 Hattner, RS, 302, 913(ab)
 Hauck-Newman, A, 796(ab)
 Haumont, D, 893(ab)
 Hausen, D, 791(ab)
 Hawk, TC, 821(ab)
 Hawkins, LA, 147
 Hawkins, RA, 809(ab), 839(ab), 862(ab), 866(ab), 1768
 Hawkins, WG, 868(ab)
 Hay, RV, 803(ab)
 Hayashi, H, 900(ab)
 Hayashida, K, 914(ab), 1868
 Haydock, C, 858(ab)
 Hayes, G, 884(ab)
 Haynie, MP, 973(ab)
 Haynie, TP, 125, 787(ab), 854(ab), 894(ab), 1921, 2014
 Haynor, DR, 748(ab), 871(ab)
 Hays, MT, 822(ab)
 Haze, K, 802(ab)
 Heacock, C, 901(ab)
 Heal, A, 897(ab), 1675
 Heal, AV, 777(ab)
 Healy, SA, 766(ab)
 Heather, JD, 878(ab)
 Hebold, I, 821(ab)
 Hecht, HS, 769(ab)
 Hefti, F, 777(ab)
 Hegyaljai, T, 894(ab)
 Heiba, S, 712, 887(ab)
 Heidendal, GAK, 885(ab)
 Heindel, ND, 873(ab)
 Heindel, W, 785(ab)
 Heiss, W-D, 785(ab), 821(ab)
 Heistad, D, 348
 Helfrich, GB, 1364
 Hellman, RS, 776(ab), 976(ab)
 Hellman, RS, 1761
 Hellwig, B, 509, 1577
 Hellwig, D, 744(ab), 818(ab)
 Helus, F, 208, 751(ab), 776(ab), 817(ab)
 Heminger, LA, 766(ab)
 Hendee, WR, 267, 1466
 Henderson, EB, 841(ab)
 Hendricks, PJ, 263
 Hendrix, GH, 954(ab)

- 955(ab)
Hendrix, T, 789(ab)
Henkes, H, 977(ab)
Henkin, RE, 927(ab)
Henry, LA, 865(ab)
Henry, RE, 896(ab)
Hensley, KS, 984(ab)
Henze, E, 744(ab), 818(ab), 946(ab)
Heo, J, 742(ab), 943(ab)
Herholz, K, 785(ab)
Herman, PG, 974(ab)
Herman, T, 799(ab)
Hermann, G, 943(ab)
Hermansen, F, 904(ab)
Hernandez, J, 789(ab)
Herning, RI, 840(ab)
Hero, AO, 785(ab)
Heros, RC, 920(ab)
Herranz, R, 1916
Herre, J, 840(ab)
Herscovitch, P, 772(ab), 822(ab), 874(ab), 1961
Herzog, H, 877(ab), 1582
Hesslewood, SR, 1301
Hester, JP, 787(ab)
Hetherington, EL, 762(ab)
Hibbein, J, 948(ab)
Hichwa, RD, 784(ab), 808(ab)
Hickernell, TS, 1101
Hickingbotham, NB, 608
Hicks, KW, 774(ab)
Higano, S, 915(ab), 919(ab)
Higashi, S, 844(ab), 917(ab), 1724
Higazi, E, 814(ab)
Higgins, WL, 266
Higley, B, 934(ab)
Hildebrand, P, 744(ab)
Hilditch, TE, 1096, 1587, 1746
Hill, RD, 973(ab)
Hill, TC, 876(ab)
Hill, VA, 980(ab)
Hilson, AJW, 779(ab)
Hiltunen, J, 873(ab)
Himelman, R, 942(ab)
Himi, T, 838(ab), 941(ab)
Himmelsbach, M, 923(ab)
Hindie, E, 981(ab), 1118
Hines, J, 858(ab)
Hinton, PJ, 752(ab), 798(ab)
Hiramori, K, 802(ab)
Hirano, Y, 1460
Hirata, K, 817(ab)
Hironaka, FH, 805(ab)
Hirose, Y, 878(ab)
Hirsch, JI, 801(ab), 888(ab)
Hirth, W, 800(ab)
Hisada, K, 558, 750(ab), 812(ab), 827(ab), 844(ab), 857(ab), 895(ab), 917(ab), 1724
Hitchens, RE, 879(ab)
Hnatowich, DJ, 762(ab), 846(ab), 889(ab), 1428
Hoeftagel, CA, 791(ab), 798(ab)
Hoekstra, A, 1259
Hoell, K, 759(ab)
Hoffer, PB, 863(ab), 893(ab)
Hoffman, EJ, 241, 832(ab), 837(ab), 950(ab), 983(ab)
Hoffman, JM, 809(ab), 821(ab), 832(ab), 866(ab)
Hoffman, RF, 762(ab)
Hoffman, RG, 1761
Hoffmann, JM, 853(ab)
Hoffpauir, J, 933(ab)
Högberg, T, 767(ab)
Holberg, BL, 270
Holbert, BL, 2022
Holcomb, HH, 853(ab)
Holden, JE, 808(ab), 822(ab), 939(ab)
Holland, G, 910(ab)
Holland, MJ, 933(ab)
Hollenberg, NK, 948(ab)
Hollingsworth, J, 975(ab)
Hollins, WJ, 955(ab)
Holman, BL, 55, N289, 567, 820(ab), 851(ab), 874(ab), N1006, 1704
Holman, LB, 948(ab)
Holmes, RA, 775(ab), 832(ab), 903(ab), 935(ab), 977(ab), 981(ab), 984(ab), 1568
Holt, AR, 921(ab)
Holt, JA, 853(ab), 979(ab)
Holt, S, 975(ab), 983(ab)
Holte, S, 877(ab), 984(ab)
Homra, L, 1347
Honda, N, 745(ab), 879(ab)
Honda, T, 873(ab)
Honma, H, 802(ab), 891(ab)
Hood, TW, 854(ab)
Hooker, G, 1910
Hooper, HR, 895(ab)
Hooper, R, 894(ab)
Hoory, S, 657, 819(ab)
Hopkins, JM, 903(ab)
Hopkins, K, 973(ab)
Hör, G, 834(ab)
Horgan, JG, 907(ab), 1656
Horiuchi, K, 928(ab), 934(ab)
Hornykiewicz, O, 920(ab)
Horowitz, J, 858(ab), 874(ab)
Horowitz, JA, 761(ab), 846(ab), 898(ab)
Horowitz, M, 39
Horwitz, B, 392
Höschl, R, 701
Hosenpud, JD, 842(ab)
Hoshi, H, 1627
Hosoba, M, 745(ab), 879(ab), 883(ab)
Hosoi, S, 235
Hostetler, D, 897(ab)
Hottenrott, C, 834(ab)
Hotze, A, 813(ab), 829(ab), 891(ab), 896(ab)
Houle, S, 884(ab)
Houston, FM, 815(ab)
Hovda, DA, 772(ab)
Hoving, J, 1302
Howell, RW, 375
Howman-Giles, R, 133
Howse, D, 874(ab), 1961
Hu, HB, 748(ab), 749(ab), 786(ab), 870(ab)
Huang, SC, 241, 782(ab), 809(ab), 818(ab), 828(ab), 832(ab), 837(ab), 862(ab), 865(ab), 866(ab), 940(ab), 941(ab), 950(ab), 983(ab)
Huberty, J, 795(ab), 840(ab), 883(ab)
Huberty, JP, 913(ab)
Huesman, RH, 760(ab), 773(ab), 916(ab)
Huffman, JC, 417
Hughes, J, 904(ab)
Huguet, F, 911(ab)
Huisman, RM, 907(ab)
Hull, JE, 825(ab)
Hull, R, 824(ab)
Humphries, LL, 882(ab)
Hundeshagen, H, 853(ab)
Hung, CY, 981(ab)
Hung, JC, 747(ab), 935(ab), 981(ab), 1568
Hungerford, JL, 1031
Hunt, R, 975(ab)
Hunter, R, 846(ab), 1428
Huntley, TE, 856(ab), 882(ab)
Hupf, HB, 270
Hurford, WE, 947(ab)
Hurtig, HI, 836(ab), 852(ab)
Hurwitz, GA, 947(ab)
Hutchins, GD, 774(ab), 783(ab), 807(ab), 904(ab), 938(ab)
Huyghens, L, 806(ab)
Huysmans, D, 1360
Huysmans, D, 860(ab)
Hwang, D-R, 750(ab), 776(ab), 807(ab)
Hwang, PA, 792(ab)
Hylarides, MD, 777(ab), 929(ab)
Iber, F, 974(ab)
Ichise, M, 914(ab)
Ichiya, Y, 916(ab)
Ido, T, 931(ab)
Ihara, H, 780(ab)
Ii, M, 558, 917(ab)
Iida, H, 783(ab), 867(ab), 878(ab), 894(ab), 915(ab), 919(ab)
Iinuma, T, 838(ab), 866(ab), 941(ab)
Iio, A, 765(ab), 888(ab)
Iio, M, 741(ab), 743(ab), 748(ab), 865(ab), 890(ab), 917(ab), 921(ab)
Ikeda, H, 883(ab)
Ikeoka, N, 460
Imai, K, 741(ab), 844(ab), 917(ab), 1724
Imai, S, 1460
Imazumi, M, 1264
Imakita, S, 914(ab)
Inagaki, Y, 838(ab), 941(ab)
Inao, G, 917(ab)
Ing, SJ, 799(ab)
Inglese, E, 804(ab)
Inoue, K, 1130
Inoue, O, 809(ab)
Inoue, S, 877(ab)
Inoue, Y, 883(ab)
Intenzo, C, 985(ab)
Interrante, VL, 786(ab)
Inugami, A, 915(ab), 919(ab), 920(ab)
Iosilevsky, G, 187, 879(ab), 881(ab)
Ireton, R, 978(ab)
Irie, T, 809(ab)
Isaka, Y, 1264
Ishida, Y, 949(ab)
Ishii, R, 1460
Ishikawa, M, 843(ab), 844(ab), 918(ab), 1126
Ishimura, J, 906(ab)
Ishiwata, K, 524, 931(ab), 1419
Isitman, AT, 1761
Iskandrian, A, 742(ab), 943(ab)
Iskandrian, AS, 742(ab)
Isobe, M, 746(ab)
Ison, KT, 779(ab)
Israel, O, 187, 879(ab), 881(ab), 1341
Ito, S, 923(ab)
Ito, T, 809(ab)
Itoh, H, 829(ab), 888(ab)
Itoh, J, 918(ab)
Itoh, K, 985(ab)
Itoh, M, 890(ab), 931(ab)
Itti, R, 771(ab), 793(ab), 885(ab), 911(ab)
Iwanaga, S, 950(ab)
Iwasaki, T, 451
Iwata, K, 1990
Iyo, M, 809(ab)
Izard, ME, 815(ab)
Jabir, AM, 829(ab), 986(ab)
Jackson, JA, 1451
Jacobs, M, 836(ab)
Jacobsen, J, 839(ab)
Jacobson, AF, 947(ab)
Jacobsson, L, 1638
Jaffe, JH, 840(ab), 911(ab)
Jafri, RA, 147, 1878
Jagust, WJ, 743(ab), 773(ab), 916(ab)
Jahan, S, 814(ab)
Jain, R, 907(ab), 1656
Jalali, S, 975(ab)
Jambaque, I, 892(ab)
Jamieson, DG, 836(ab), 852(ab)
Jan, K-M, 1710
Janicek, M, 948(ab)
Jankel, W, 852(ab)
Jansen, DE, 841(ab)
Jansson, S, 1638
Jara, BJ, 689
Jarkewicz, G, 760(ab)
Jass, JR, 899(ab)
Jaszczak, R, 871(ab)
Jaszczak, RJ, 786(ab), 797(ab), 798(ab), 869(ab), 1398
Jatlow, A, 825(ab)
Jaurrieta, E, 1776
Jay, M, 903(ab), 904(ab)
Jazmati, B, 947(ab)
Jeandot, R, 914(ab), 1515
Jeffers, LJ, 712
Jeghers, O, 2020
Jennings, CA, 473
Jerushalmi, J, 881(ab), 1341
Jewell, WR, 853(ab), 979(ab)
Jewett, DM, 754(ab), 755(ab), 768(ab), 808(ab), 931(ab), 932(ab)
Jhingran, S, 816(ab)
Jinnouchi, S, 1627
Jivan, S, 926(ab)
Jochelson, M, 799(ab)
Johansen, KL, 928(ab)
John, E, 927(ab)
Johnes, J, 851(ab)
Johnson, DK, 824(ab), 924(ab), 926(ab)
Johnson, J, 542, 812(ab)
Johnson, JA, 1347
Johnson, L, 825(ab)
Johnson, LL, 806(ab), 841(ab), 942(ab)
Johnson, S, 834(ab)
Johnson, TK, 267, 1466
Jolly, D, 930(ab)
Jonas, U, 1078
Jones, AG, 55, 820(ab)
Jones, GS, 935(ab)
Jones, GS Jr, 68
Jones, MT, 938(ab), 945(ab)
Jones, PL, 823(ab)
Jones, RH, 1492
Jones, T, 878(ab)
Jonker, GJ, 907(ab)
Josephson, MA, 817(ab), 944(ab)
Joshi, SS, 979(ab)
Jouve, B, 841(ab), 842(ab)
Jovkar, S, 821(ab)
Joyce, JM, 587(ab), 980(ab)
Jukić, S, 1152
Junck, L, 913(ab)
Jungwittanaporn, P, 935(ab)
Juni, J, 770(ab)
Juni, JE, 259, 623, 790(ab), 948(ab)
Juni J, 1272
Juri, PN, 800(ab)
Jurisson, S, 800(ab)
Kabalka, GW, 777(ab)
Kaden, T, 924(ab)
Kadmon, D, 750(ab)
Kagaya, A, 838(ab), 941(ab)
Kahan, A, 828(ab)
Kahn, D, 795(ab)
Kahn, E, 861(ab)
Kahn, JK, 805(ab), 948(ab), 1605
Kairemo, KJA, 899(ab)
Kairento, AL, 842(ab)
Kaiser, KP, 851(ab), 938(ab)
Kaizu, H, 745(ab), 879(ab)
Kajihara, Y, 1460
Kakishita, M, 780(ab)
Kälble, T, 906(ab)
Kaldany, A, 923(ab)
Kalir, A, 767(ab)
Kaltovich, F, 789(ab)
Kamada, T, 949(ab), 1264
Kamata, R, 741(ab)
Kambara, H, 801(ab), 827(ab), 828(ab), 1181
Kamei, T, 780(ab)
Kaminski, MS, 904(ab)
Kanclerz, A, 1252
Kander, N, 770(ab)
Kang, H, 816(ab)
Kanke, M, 954(ab)
Kanno, I, 783(ab), 867(ab), 878(ab), 894(ab), 915(ab), 919(ab), 920(ab)

- Kanwar, N. 871(ab)
Kaplan, E. 886(ab), 974(ab), 977(ab)
Kaplan, EH. 174, 757(ab), 901(ab)
Kaplan, IL. 974(ab)
Kaplan, P. 851(ab)
Kaplan, WD. 324, 473, 799(ab), 1745
Kapoor, R. 773(ab), 920(ab)
Kapp, M. 817(ab)
Kar, S. 783(ab)
Karatzas, ND. 1675
Karcher, G. 793(ab), 952(ab)
Karczewski, DA. 800(ab)
Karesh, SM. 927(ab)
Kariya, K. 890(ab)
Kariyone, S. 954(ab)
Karlsson, U. 847(ab)
Karonen, S.-L. 899(ab), 1194
Karreman, AJP. 1934
Karsch, KR. 952(ab)
Kasabali, B. 756(ab), 823(ab)
Kasal, B. 1152
Kase, KR. 846(ab), 1428
Kashab, M. 911(ab)
Kasi, LP. 787(ab), 888(ab), 1921
Kasina, S. 800(ab), 815(ab)
Kasliwal, R. 759(ab), 777(ab)
Kasper, W. 949(ab)
Kassis, AI. 923(ab), 948(ab)
Kataoka, M. 765(ab), 829(ab), 888(ab)
Katz, BP. 788(ab)
Katz, PG. 1781
Katzenellenbogen, JA. 768(ab), 795(ab)
Kaufman, L. 943(ab)
Kaufman, PN. 857(ab)
Kavula, M. 939(ab)
Kawabata, S. 750(ab), 827(ab), 857(ab), 895(ab)
Kawai, C. 801(ab), 827(ab), 828(ab), 1181
Kawai, K. 778(ab)
Kawai, R. 796(ab)
Kawakatsu, S. 1621
Kawakobo, K. 741(ab)
Kawamura, M. 765(ab), 829(ab)
Kawamura, Y. 766(ab), 837(ab), 889(ab), 890(ab), 1436
Kawamura, M. 888(ab)
Kawanaka, M. 906(ab)
Kawashima, Akira. 1279
Kawashima, K. 931(ab)
Kayden, DS. 1865
Kaye, JJ. 1347
Kaye, MP. 794(ab)
Kazerooni, E. 859(ab)
Kazikiewicz, JM. 174, 757(ab), 901(ab)
Kedar, A. 750(ab)
Kee, L. 943(ab)
Keech, F. 830(ab), 843(ab), 947(ab)
Keeling, PWN. 466
Keenan, AM. 39, 1022
Kelbaek, H. 1155
Keller, AM. 806(ab)
Keller, FS. 1730
Kelley, M. 825(ab)
Kelly, KA. 856(ab)
Kelly, RF. 901(ab), 979(ab)
Kelso, T. 935(ab)
Kemerink, G. 885(ab)
Kera, M. 1621
Kern, KA. 181
Kern, RZ. 792(ab)
Keshavarzian, A. 886(ab)
Ketchum, LE. N1, N7, N137, 577
Ketrung, AR. 903(ab)
Kewan, Y. 838(ab)
Keyes, JW, Jr. 769(ab)
Keyeux, A. 311, 1826
Khafagi, FA. 593
Khan, A. 974(ab)
Khare, SS. 903(ab)
Khaw, B-A. 651
Khaw, BA. 746(ab), 825(ab), 830(ab), 851(ab), 887(ab), 905(ab), 939(ab)
Khawli, LA. 923(ab)
Kiat, H. 768(ab), 770(ab), 793(ab), 861(ab), 942(ab), 948(ab), 949(ab), 951(ab)
Kijewski, MF. 1704
Kikuchi, H. 843(ab)
Kilbourn, MR. 112(ab), 754(ab), 755(ab), 767(ab), 768(ab), 931(ab), 932(ab)
Kim, BH. 949(ab)
Kim, CK., 1878
Kim, CK. 764(ab), 862(ab)
Kim, EE. 731, 854(ab), 894(ab)
Kim, HJ. 889(ab)
Kim, S. 985(ab)
Kimball, DA. 1169
Kimmig, B. 751(ab)
Kimsey, P. 793(ab)
Kimura, K. 949(ab), 1264
Kimura, Y. 765(ab)
King, JL. 946(ab)
King, M. 684, 868(ab), 983(ab)
King, MA. 717, 748(ab), 749(ab), 863(ab), 864(ab), 870(ab), 1980
King, T. 765(ab)
Kinney, B. 894(ab)
Kinoshita, F. 982(ab), 986(ab)
Kinoshita, K. 1627
Kinsey, BM. 923(ab)
Kinuya, S. 750(ab), 812(ab), 827(ab), 857(ab), 895(ab)
Kipper, SL. 794(ab)
Kirch, DL. 267, 1466
Kirchner, P. 771(ab), 779(ab), 953(ab)
Kirchner, PT. 348, 676, 760(ab)
Kirchner, R. 952(ab)
Kirkeedie, RL. 973(ab)
Kirsch, C-M. 856(ab), 949(ab)
Kirsch, G. 848(ab), 928(ab)
Kirsh, JC. 914(ab)
Kiss, R. 837(ab)
Kistler, JP. 836(ab), 920(ab)
Kitabatake, A. 949(ab)
Kitz, W. 920(ab)
Kjellström, R. 976(ab)
Klein, H. 852(ab)
Klein, HA. 1848
Klein, JL. 810(ab)
Klein, L. 951(ab)
Klepper, C. 782(ab), 953(ab)
Kletter, K. 575, 794(ab), 816(ab), 805(ab)
Klibanov, AL. 1951
Kline, SJ. 926(ab)
Kling, P. 754(ab)
Klinger, M. 898(ab)
Klippenstein, DL. 1549
Kloppenborg, P. 1360
Kloppenborg, P. 860(ab)
Kluin, KJ. 913(ab)
Knapik, G. 747(ab)
Knapp, FF. 841(ab), 842(ab), 891(ab)
Knapp, FF, Jr. 777(ab), 829(ab), 835(ab), 843(ab), 848(ab), 927(ab), 928(ab), 1697
Knapp, WH. 208, 817(ab), 940(ab)
Knaus, EE. 1252
Knesaurek, K. 749(ab), 868(ab)
Knesewitsch, P. 856(ab), 949(ab)
Knezevic, S. 773(ab)
Knight, LC. 494, 745(ab), 746(ab)
Knittel, BL. 916(ab)
Knop, J. 882(ab)
Knopp, R. 813(ab), 829(ab)
Knust, EJ. 940(ab)
Kobayashi, H. 802(ab)
Kobayashi, K. 460
Kobayashi, T. 1738
Kobayashi, H. 1066
Kodama, Y. 985(ab)
Koeppel, RA. 774(ab), 784(ab), 808(ab), 913(ab), 915(ab), 930(ab)
Koh, C-S. 745(ab)
Kohlen, S. 842(ab)
Koide, H. 1181
Koizumi, K. 750(ab)
Koizumi, M. 235, 766(ab), 837(ab), 889(ab), 890(ab), 1130, 1436
Koizumi, T. 883(ab)
Kojima, S. 516
Kolkmeier, J. 842(ab)
Koller, DW. 1057
Kolodny, GM. 879(ab), 881(ab)
Kolodny, GM. 187
Komatani, A. 1621
Kondo, Y. 920(ab)
Kondos, G. 771(ab)
Konerding, KF. 1781
Konishi, J. 766(ab), 778(ab), 801(ab), 817(ab), 826(ab), 827(ab), 828(ab), 837(ab), 843(ab), 844(ab), 870(ab), 877(ab), 886(ab), 889(ab), 890(ab), 918(ab), 922(ab), 930(ab), 1130, 1181, 1436
Konishi, Y. 817(ab)
Konka, S. 782(ab)
Kootstra, G. 885(ab)
Kopecky, RT. 509, 849(ab)
Koprowski, H. 847(ab)
Koral, KF. 195, 542, 760(ab), 797(ab), 861(ab)
Korkotsidis, A. 881(ab)
Kornguth, ML. 808(ab), 939(ab)
Kosaka, N. 741(ab), 743(ab), 748(ab), 865(ab), 917(ab)
Koster, K. 804(ab)
Kosuda, S. 1126
Kothari, P. 912(ab)
Kotler, J. 897(ab)
Kotler, T. 949(ab), 951(ab)
Kotoura, Y. 235
Kottou, S. 827(ab), 942(ab)
Kouris, K. 868(ab), 982(ab)
Koutoulidis, K. 1910
Kowalsky, WP. 921(ab)
Kozuka, T. 949(ab), 1264
Kradin, RL. 902(ab)
Krahwinkel, W. 1582
Krajewski, A. 914(ab)
Kramer, E. 785(ab)
Kramer, EL. 829(ab), 1607
Kramer, M. 857(ab)
Krasnow, AZ. 1761
Krause, Th. 949(ab)
Krawczynska, E. 941(ab)
Krawczynska, EG. 950(ab)
Kremer Hovinga, TK. 908(ab)
Krepshaw, JD. 98
Kriegel, H. 900(ab)
Krishnamurthy, GT. 623, 825(ab), 1144
Krishnamurthy, S. 825(ab), 1144
Krishnan, L. 853(ab), 979(ab)
Krivokapich, J. 782(ab), 818(ab), 837(ab), 867(ab), 940(ab), 950(ab)
Krohn, K. 757(ab), 807(ab)
Krohn, KA. 773(ab), 783(ab), 835(ab), 920(ab), 933(ab)
Kroiss, A. 423
Kronauge, JF. 55, 820(ab)
Kroop, S. 898(ab)
Kropp, J. 936(ab)
Kubasic, H. 814(ab)
Kübler, W. 776(ab), 817(ab)
Kubo, A. 762(ab), 950(ab), 1126
Kubo, S. 826(ab), 844(ab), 886(ab), 918(ab)
Kubo, Y. 900(ab)
Kubota, K. 843(ab), 1697
Kuczynski, BL. 800(ab)
Kudryk, BJ. 1212
Kuhl, D. 767(ab)
Kuhl, DE. 743(ab), 768(ab), 770(ab), 783(ab), 807(ab), 808(ab), 915(ab), 917(ab), 918, 928(ab), 932(ab)
Kuhlmann, L. 823(ab), 875(ab), 925(ab)
Kuikka, JT. 842(ab)
Kulkarni, PV. 841(ab), 890(ab)
Kumamoto, M. 877(ab)
Kumar, AJ. 742(ab), 916(ab)
Kung, FH. 765(ab), 905(ab)
Kung, H. 777(ab)
Kung, HF. 758(ab), 759(ab), 777(ab), 788(ab), 789(ab), 916(ab), 935(ab), 980(ab), 1675
Kung, HK. 913(ab)
Kung, MP. 758(ab), 759(ab)
Kuni, CC. 974(ab)
Kunieda, E. 950(ab)
Kunimatsu, M. 235
Kuperus, J. 913(ab)
Kupfer, S. 862(ab)
Kurai, O. 860
Kuroki, T. 460, 2021
Kuschnir, E. 942(ab), 950(ab)
Kushner, B. 846(ab)
Kushner, M. 747(ab), 910(ab), 915(ab)
Kushner, MJ. 852(ab)
Kradin, RL. 902(ab)
Kusubov, N. 784(ab)
Kuten, A. 1341
Kuwabara, H. 866(ab), 915(ab)
Kuwabara, Y. 916(ab)
Kuzume, O. 781(ab), 782(ab)
Kwai, AH. 324
Kwiatkowski, M. 847(ab)
Kwong, KK. 773(ab), 836(ab), 920(ab)
Labar, D. 1633
La Canna, G. 946(ab)
Lack, E. 181
Lacy, JL. 293, 976(ab), 1526
Ladwig, EJ. 982(ab)
Laffin, SM. 473
Laflamme, L. 781(ab), 793(ab), 804(ab)
LaFrance, N. 784(ab)
LaFrance, ND. 110, 742(ab), 745(ab), 779(ab), 789(ab), 873(ab), 916(ab), 1057, 1927
Lagunas-Solar, MC. 842(ab)
Lahiri, A. 62, 805(ab)
Lai, KH. 826(ab)
Lai, YL. 905(ab), 980(ab)
Lake, RR. 869(ab), 1200
Lambert, B. 914(ab)
Lambert, R. 792(ab)
Lambrecht, RM. N1758
Lamki, LM. 731, 787(ab), 833(ab), 834(ab), 854(ab), 886(ab), 888(ab), 894(ab), 1921
Lamki, N. 579
Lamoureux, F. 743(ab), 843(ab)
Lamoureux, J. 743(ab), 843(ab)
Lan, JA. 928(ab)
Landesman, AL. 760(ab)
Lang, L. 750(ab)
Lang, W. 920(ab)
Langan, J. 873(ab)
Lange, PH. 875(ab)
Langfitt, T. 910(ab)
Långström, B. 976(ab)
Lanka, VK. 375
Lannoye, GS. 776(ab)
Lanto, AB. 853(ab)
Lanza, RC. 845(ab)
Lapeyre, AC. 838(ab)
Lapeyre, AC. III. 945(ab)

- Lappe, F, 875(ab)
 Laragh, J, 908(ab)
 LaRaia, P, 805(ab)
 Laroche, B, 906(ab)
 Larson, SM, 39, 181, 385, 758(ab), 796(ab), 833(ab), 852(ab), 897(ab), 901(ab), 939(ab), 1022
 Larsson, K, 905(ab)
 Laschinger, JC, 1223
 Laska, E, 774(ab)
 Lassen, N, 869(ab), 919(ab)
 Lassen, NA, 916(ab), 1464
 Lastoria, S, 897(ab)
 Laterre, C, 311
 Latham, IA, 789(ab)
 Lathrop, KA, 803(ab)
 Lattimer, JC, 903(ab)
 Laube, BL, 1057
 Laughlin, JS, 904(ab)
 Laurin, NR, 947(ab)
 Lauterbach, K, 742(ab)
 Lauterbach, KW, 832(ab)
 Laven, D, 896(ab)
 Laven, DL, 981(ab)
 Lavender, JP, 940(ab)
 Laxer, KD, 913(ab)
 Layer, K, 208
 Lazarus, CR, 33
 Lazarus, R, 1747
 Lazzari, S, 762(ab)
 Le, N-A, 1237
 Lear, JL, 907(ab), 1387, 1656
 LeBlanc, A, 816(ab)
 LeBlanc, AD, 1526
 Leclerc, JR, 1498
 Lee, HB, 849(ab)
 Lee, HK, 905(ab)
 Lee, J, 978(ab)
 Lee, JT, 799(ab)
 Lee, KH, 869(ab)
 Lee, MC, 745(ab), 1207
 Lee, RE, 757(ab), 761(ab), 833(ab), 858(ab), 874(ab), 898(ab)
 Lee, W, 781(ab)
 Lee, Y-CC, 925(ab)
 Lefebvre, B, 844(ab)
 Le Floch, OL, 2008
 Lefort, G, 1515
 Le Guludec, D, 744(ab), 808(ab), 841(ab), 842(ab), 872(ab)
 Lehner, B, 751(ab), 776(ab)
 Lehtinen, S, 913(ab)
 Leichner, PK, 868(ab)
 Leinbach, RC, 851(ab)
 Leisure, GP, 880(ab)
 Leitha, T, 794(ab), 850(ab)
 Lemaire, F, 764(ab)
 Leners, N, 1826
 Lenkinski, R, 910(ab)
 Lenzi, GL, 1507
 Leppo, J, 805(ab)
 Leppo, JA, 746(ab), 819(ab), 972(ab)
 Lerario, L, 897(ab), 901(ab)
 Lerch, RA, 1088
 Lesley, TM, 834(ab)
 Leunissen, K, 885(ab)
 Levasseur, M, 822(ab)
 Levatter, R, 948(ab)
 Léveillé, J, 747(ab), 758(ab), 781(ab), 793(ab), 804(ab), 844(ab)
 Lever, J, 796(ab), 921(ab)
 Lever, SZ, 73, 789(ab), 1465
 Levin, HS, 913(ab)
 Levine, AS, 751(ab)
 Levy, AV, 774(ab)
 Levy, DE, 839(ab)
 Levy, LM, 974(ab)
 Levy, R, 757(ab)
 Lew, A, 768(ab)
 Lewellen, BL, 879(ab)
 Lewellen, TK, 717, 866(ab), 867(ab), 871(ab), 876(ab)
 Lewis, CA, 779(ab)
 Lewis, CJ, 943(ab)
 Li, JP, 832(ab), 984(ab)
 Li, Q-S, 1539
 Li, QS, 819(ab), 938(ab)
 Li, S, 676, 760(ab)
 Liang, Z, 871(ab)
 Liberman, H, 91
 Libson, KF, 776(ab)
 Lich, L, 747(ab)
 Lichtenberg, GS, 973(ab)
 Lieberman, DA, 623
 Liebert, M, 900(ab), 1304
 Liewendahl, K, 899(ab), 1194
 Lim, E, 781(ab)
 Lin, LC, 896(ab)
 Lin, TH, 929(ab)
 Lin, W-C, 868(ab)
 Lindbäck, S, 976(ab)
 Lindberg, S, 1638
 Linder, K, 800(ab)
 Linder, KE, 800(ab), 935(ab)
 Lindgren, J, 1194
 Line, BR, 1842
 Ling, M, 885(ab)
 Lingen van, A, 1934
 Link, JM, 783(ab)
 Links, J, 784(ab), 840(ab), 852(ab), 853(ab), 911(ab), 944(ab)
 Links, JM, 441, 717, 796(ab), 820(ab), 832(ab), 1057
 Lipszyc, H, 921(ab)
 Lipton, JJ, 941(ab)
 Lisbona, R, 1050
 Lister-James, J, 55, 923(ab)
 Little, JR, 913(ab)
 Litton, J, 984(ab)
 Litton, JE, 916(ab)
 Liu, B-L, 789(ab)
 Liu, RS, 826(ab), 863(ab), 936(ab)
 Livni, E, 68
 Llaurado, JG, 799(ab)
 Lloyd, LK, 255
 Loats, H, 852(ab)
 Loats, HL, 853(ab)
 Loats, P, 852(ab)
 Loc'h, C, 828(ab)
 Locke, E, 887(ab), 939(ab)
 Loeffler, W, 759(ab)
 Loesse, B, 832(ab)
 Loewenstein, DA, 852(ab), 912(ab)
 Logan, J, 767(ab)
 Logan, KW, 797(ab), 832(ab), 984(ab)
 Logus, JW, 894(ab)
 Loisel, ML, 792(ab)
 Lollo, C, 893(ab)
 Lomangino, L, 921(ab)
 Lomas, F, 729
 Lomeña, F, 1916
 London, ED, 840(ab), 911(ab)
 Long, SE, 766(ab), 982(ab)
 Longino, MA, 503
 Longmore, D, 891(ab)
 Longo, D, 833(ab)
 Loo, C-Y, 1406
 Loos, U, 891(ab)
 Lora, ME, 758(ab)
 Lorenz, M, 834(ab)
 Lorenz, WJ, 776(ab)
 Losse, B, 851(ab)
 Lötter, MG, 538
 Lotze, MT, 758(ab), 897(ab), 901(ab)
 Lowe, S, 835(ab)
 Löwenhielm, P, 1719
 Lowenstein, E, 947(ab)
 Lucignani, G, 862(ab)
 Luck, D, 921(ab)
 Luettgen, J, 788(ab)
 Luger, RC, 972(ab)
 Lui, D, 912(ab)
 Lukash, F, 971(ab)
 Luke, RG, 1730
 Luna, E, 951(ab)
 Lundeen, B, 771(ab), 816(ab)
 Lüthy, P, 1088
 Luxen, A, 937(ab)
 Lynch, K, 947(ab)
 Lynn, F, 889(ab)
 Lyon, IW, 980(ab)
 Lyons, E, 742(ab), 943(ab)
 MacDonald, AC, 947(ab)
 Macey, DJ, 203, 845(ab), 847(ab), 871(ab), 872(ab)
 MacGregor, RR, 767(ab)
 Mach, JP, 811(ab)
 Mach, RH, 777(ab), 788(ab), 935(ab)
 Machac, J, 787(ab)
 Machida, K, 745(ab), 879(ab)
 Machulla, H-J, 940(ab)
 MacIntyre, WJ, 913(ab), 946(ab)
 Mackay, BC, 821(ab), 836(ab)
 MacKay, DR, 815(ab)
 Mackenson, D, 835(ab)
 Mackey, ST, 794(ab)
 MacLean, J, 951(ab)
 MacMathuna, P, 466
 Maddahi, J, 755(ab), 768(ab), 770(ab), 793(ab), 802(ab), 804(ab), 805(ab), 861(ab), 891(ab), 942(ab), 948(ab), 949(ab), 951(ab)
 Madden, JA, 810(ab)
 Mader, J, 813(ab)
 Mader, J. T., 763(ab), 883(ab)
 Maderazo, EG, 608
 Madsen, JL, 857(ab)
 Madsen, MT, 845(ab), 1038
 Maecke, H, 894(ab), 924(ab)
 Maeda, T, 781(ab), 782(ab), 900(ab)
 Magata, Y, 928(ab)
 Maher, R, 849(ab)
 Maheu, LJ, 788(ab), 814(ab), 934(ab)
 Mahmarian, JJ, 755(ab)
 Mahmood, A, 789(ab)
 Mahmoud, A, 814(ab)
 Mahmoud, AR, 985(ab)
 Mahmoud, S, 971(ab)
 Maire, JP, 914(ab)
 Maiscy, MN, 33, 952(ab), 1747
 Majd, M, 778(ab)
 Maki, A, 1130
 Makino, N, 919(ab), 985(ab)
 Makler, T, 805(ab)
 Maksuda, J, 787(ab)
 Makuch, J, 747(ab)
 Malamitsi, J, 1910
 Malawer, M, 181
 Malessa, S, 920(ab)
 Malki, AA, 814(ab)
 Malko, JA, 1466, 1901
 Mallette, S, 812(ab)
 Maloney, PJ, 901(ab)
 Maltais, F, 769(ab)
 Maltese, A, 853(ab)
 Mamiya, T, 745(ab), 879(ab)
 Manabe, T, 1436
 Manciet, G, 1515
 Mandelii, J, 862(ab)
 Mandelkern, M, 831(ab)
 Mandelkern, MA, 817(ab)
 Mandell, GA, 881(ab), 1015
 Maneval, DC, 908(ab)
 Manglos, SH, 869(ab)
 Mangner, TJ, 783(ab), 784(ab), 932(ab)
 Mann, S, 908(ab)
 Mann, SL, 979(ab)
 Mantil, J, 836(ab)
 Mantovanelli, A, 907(ab)
 Mäntylä, M, 899(ab), 1194
 Mar, BM, 929(ab)
 Marani, S, 774(ab)
 March, DE, 263
 Marchand, L, 906(ab)
 Marciano, D, 1768
 Marcus, AJ, 850(ab)
 Marcus, CS, N142, N1477
 Marcus, M, 771(ab), 953(ab)
 Marder, S, 839(ab)
 Marder, SM, 821(ab)
 Margouleff, D, 898(ab)
 Mariani, G, 923(ab)
 Marin-Grez, M, 751(ab)
 Markel, DS, 913(ab)
 Marks, R, 777(ab)
 Markwell, R, 811(ab), 870(ab)
 Marquez, VE, 837(ab)
 Marrett, S, 866(ab)
 Marsden, PK, 877(ab)
 Marsh, JD, 820(ab)
 Marsh, JI, 726
 Marsh, JL, 813(ab)
 Marshall, BJ, 11, 790(ab)
 Marshall, S, 39
 Marshall, TP, 1683
 Martell, AE, 814(ab)
 Martiat, Ph, 1633
 Martin, CC, 810(ab), 932(ab)
 Martin, G, 807(ab)
 Martin, GV, 783(ab)
 Martin, LJ, 976(ab)
 Martin, NL, 763(ab), 853(ab), 971(ab), 979(ab), 982(ab), 983(ab), 986(ab)
 Martin, SE, 938(ab), 945(ab)
 Martin-Comin, J, 1776
 Martindale, AA, 762(ab)
 Marty, J, 940(ab)
 Martynov, AV, 1951
 Marzilli, L, 936(ab)
 Mash, D, 777(ab)
 Mashiter, G, 1354
 Massardo, T, 745(ab)
 Masterson, ME, 803(ab)
 Masuda, K, 916(ab)
 Masuda, Y, 838(ab), 866(ab), 941(ab)
 Masuoka, LS, 1083
 Matarrese, M, 801(ab), 934(ab)
 Mather, SJ, 599, 899(ab)
 Mathes, SJ, 787(ab)
 Mathias, CJ, 747(ab), 750(ab), 768(ab), 795(ab), 814(ab), 835(ab), 848(ab), 929(ab)
 Mathieu, E, 793(ab)
 Mathieu, J-P, 1230
 Mathis, CA, 773(ab), 916(ab)
 Matsuda, H, 558, 844(ab), 917(ab), 1724
 Matsuda, T, 801(ab)
 Matsueda, GR, 825(ab), 905(ab)
 Matsumoto, K, 930(ab)
 Matsumoto, S, 791(ab)
 Matsumoto, T, 895(ab)
 Matsuoka, D, 1393
 Matsushima, H, 934(ab)
 Mattar, AG, 947(ab)
 Mattered, J, 804(ab), 954(ab)
 Mattered, JA, 1865
 Mattis, JA, 494, 923(ab)
 Matzku, S, 899(ab)
 Maublant, J, 793(ab)
 Maublant, JC, 48, 129, 939(ab), 951(ab), 1486
 Maurer, AH, 494, 745(ab), 746(ab), 844(ab)
 Mausner, LF, 849(ab), 924(ab)
 Mavroudakakis, N, 911(ab)
 Mavroy, R, 975(ab), 983(ab)
 Maxon, HR, 766(ab), 776(ab)
 Mayberg, H, 852(ab)
 Mayberg, HS, 796(ab)
 Mayne, B, 887(ab)
 Maze, M, 940(ab)
 Mazess, RB, 131, 882(ab)
 Mazière, B, 828(ab)
 Mazoyer, B, 743(ab)
 Mazoyer, BM, 822(ab), 863(ab), 869(ab), 919(ab)
 Mazziotto, JC, 809(ab), 821(ab), 831(ab), 839(ab), 853(ab), 983(ab)
 Mazziotto, JM, 866(ab)
 McAfee, JG, 83, 509, 800(ab), 849(ab), 1212, 1577
 McAfee, JG, 134
 McArthur, J, 742(ab)

- McCabe, R, 833(ab)
 McCabe, RP, 889(ab)
 McCall, MJ, 217, 226, 824(ab), 888(ab), 922(ab)
 McCallum, RW, 790(ab), 886(ab)
 McCann, B, 823(ab)
 McCarthy, K, 1015
 McCarthy, MS, 742(ab)
 McCartney, WH, 643, 749(ab), 786(ab), 870(ab)
 McClanahan, T, 938(ab)
 McClellan, C, 759(ab)
 McCormick, CA, 473
 McCready, VR, 752(ab), 877(ab)
 McDonald, A, 916(ab)
 McElhany, K, 915(ab)
 McElvany, K, 616
 McEwan, AG, 763(ab), 971(ab), 986(ab)
 McEwan, AJ, 549, 895(ab)
 McEwan, AJB, 775(ab), 894(ab)
 McFarland, WC, 984(ab)
 McFarland, WD, 797(ab), 832(ab), 984(ab)
 McGahan, JP, 847(ab)
 McGrath, PW, 783(ab)
 McGuire, A, 971(ab), 975(ab), 983(ab)
 McGuire, AH, 795(ab)
 McKeever, PE, 854(ab)
 McKenzie, AT, 927(ab)
 McKillop, JH, 750(ab), 1587
 McKnight, R, 858(ab)
 McKusick, K, 1268
 McKusick, KA, 769(ab), 1714
 McLaughlin, AF, 593
 McLean, JR, 838(ab)
 McLellan, AR, 1746
 McLellan, CA, 820(ab)
 McNamara, D, 743(ab), 860(ab)
 McNeil, G, 972(ab)
 McNeill, GC, 742(ab)
 McPherson, D, 933(ab)
 McQuitty, A, 934(ab)
 McTigue M, 226
 Meares, CF, 217, 226, 824(ab), 888(ab), 922(ab)
 Mease, RC, 924(ab)
 Meehin, GK, 1608
 Meerdink, DJ, 746(ab), 819(ab), 972(ab)
 Mehta, RC, 414
 Meignan, M, 824(ab)
 Meijer, S, 778(ab)
 Meinertz, Th, 949(ab)
 Meinken, GE, 924(ab)
 Melin, J, 866(ab)
 Melin, JA, 770(ab), 1826
 Melograna, JM, 927(ab)
 Meltzer, RS, 973(ab)
 Mena, I, 159, 913(ab)
 Meneguetti, JC, 805(ab)
 Mensch, J, 824(ab)
 Merchant, B, 833(ab), 1688
 Merchant, EB, 812(ab), 893(ab)
 Merchant, SL, 972(ab)
 Merhige, ME, 951(ab)
 Merino, MJ, 860(ab)
 Merion, RM, 259, 790(ab)
 Merlet, P, 744(ab), 841(ab), 842(ab), 872(ab)
 Merlii, G, 985(ab)
 Mertens, J, 848(ab)
 Mertz, H, 789(ab)
 Merz, R, 793(ab)
 Messa, C, 1507
 Metman, E, 885(ab)
 Metra, M, 946(ab)
 Metter, EJ, 869(ab)
 Metz, J, 839(ab)
 Meyer, DL, 835(ab)
 Meyer, E, 422, 866(ab), 915(ab), 917(ab)
 Meyer, G-J, 853(ab)
 Meyers, L, 859(ab)
 Meyers, LJ, 861(ab)
 Miale, A, Jr, 975(ab)
 Michaux, JL, 1633
 Michel, C, 1633, 1826
 Michel, Ch, 866(ab), 914(ab)
 Michigishi, T, 827(ab)
 Mietling, SW, 972(ab)
 Milanese, L, 1971
 Miller, JH, 2001
 Miller, MB, 114
 Miller, R, 757(ab)
 Miller, RJ, 932(ab)
 Miller, SF, 1454
 Miller, SJ, 788(ab), 814(ab), 934(ab)
 Miller, TR, 530, 864(ab)
 Milligan, F, 789(ab)
 Millon, C, 829(ab)
 Mills, BG, 1083
 Mills, SL, 847(ab)
 Milroy, R, 750(ab)
 Milster, TD, 760(ab)
 Milton, W, 329
 Minami, S, 801(ab)
 Mineura, K, 919(ab)
 Minn, H, 1521
 Minnaar, PC, 538
 Mintun, MA, 773(ab), 795(ab)
 Mintz, G, 805(ab)
 Miraldi, F, 775(ab), 833(ab)
 Miraldi, FD, 880(ab)
 Mirell, SG, 804(ab), 855(ab)
 Mirzadeh, S, 849(ab)
 Mishkin, S, 1050
 Missala, K, 784(ab)
 Mitsuka, S, 866(ab)
 Mitta, A, 950(ab)
 Mittal, R, 974(ab)
 Miura, S, 783(ab), 867(ab), 878(ab), 894(ab), 915(ab), 919(ab)
 Miyagawa, M, 765(ab), 791(ab)
 Miyagawa, N, 765(ab), 791(ab)
 Miyake, H, 820(ab)
 Miyake, Y, 916(ab)
 Miyao, NP, 899(ab)
 Miyaoka, RS, 871(ab)
 Miyazaki, A, 783(ab)
 Mlcoch, A, 977(ab)
 Mobarak, AL, 985(ab)
 Mochizuki, T, 791(ab)
 Mock, BH, 23, 729, 840(ab), 1246, 1651
 Modell, H, 830(ab)
 Modesto, RR, 787(ab)
 Moeller, JR, 839(ab)
 Moerlein, SM, 776(ab), 835(ab), 848(ab), 929(ab)
 Mogami, H, 829(ab), 888(ab)
 Mohammed, MMJ, 838(ab)
 Mohan, R, 803(ab)
 Mohr, G, 743(ab)
 Moi, MK, 217
 Moins, N, 48, 939(ab)
 Moldenhauer, G, 899(ab)
 Möllenstädt, S, 900(ab)
 Momose, T, 741(ab), 743(ab), 748(ab), 865(ab), 917(ab)
 Monks, R, 1411
 Monna, T, 460
 Monroe, L, 766(ab)
 Monroe, LA, 766(ab)
 Monteiro, K, 948(ab)
 Montgomery, DG, 1368
 Montgomery, JL, 1451
 Moore, JG, 574, 751(ab)
 Moore, MM, 695
 Moore, R, 832(ab)
 Moore, RH, 1714
 Moore, SC, 845(ab), 1704
 Moore, WH, 766(ab), 874(ab), 982(ab), 1157, 1467
 Mora, J, 1776
 Moretti, JL, 793(ab), 952(ab)
 Morgan, AC, 39
 Morgan, RA, 758(ab), 788(ab)
 Morgano, G, 1786
 Morguet, AJ, 952(ab)
 Mori, K, 1130
 Moriconi, L, 907(ab)
 Morimoto, I, 269
 Morin, R, 855(ab)
 Morita, K, 1448, 1460
 Morita, R, 1448, 1460
 Morris, JD, 91
 Morris, P, 780(ab)
 Morris, TA, 1268
 Morrisson, M, 871(ab)
 Morrissey, GJ, 684
 Mortelmans, L, 752(ab)
 Morten, B, 774(ab)
 Mortensen, J, 905(ab)
 Morton, DL, 1200
 Morton, KA, 751(ab)
 Moscatelli, G, 762(ab)
 Moseley, R, 897(ab)
 Moser, E, 856(ab), 949(ab)
 Moses, WW, 760(ab)
 Mosimann, F, 811(ab)
 Moskowitz, GW, 971(ab), 974(ab), 975(ab)
 Moss, DW, 1354
 Motte, G, 744(ab)
 Moulton, JS, 776(ab)
 Mountz, JM, 743(ab), 854(ab), 917(ab), 918(ab), 928(ab), 1644
 Mourino, M, 785(ab)
 Mousa, S, 814(ab), 934(ab), 942(ab)
 Moyes, JS, 798(ab)
 Mueller, SP, 854(ab)
 Mueller-Brand, J, 894(ab)
 Mukai, M, 1126
 Mukai, T, 817(ab), 827(ab), 843(ab), 844(ab), 870(ab), 877(ab), 918(ab), 922(ab)
 Mukherjee, J, 932(ab)
 Mulholland, GK, 754(ab), 768(ab), 808(ab), 931(ab), 932(ab), 933(ab)
 Mullani, N, 839(ab)
 Mullani, NA, 774(ab), 879(ab)
 Müller, C, 920(ab)
 Müller, SP, 1704
 Müller-Schauenburg, W, 952(ab)
 Mumper, RJ, 903(ab)
 Munck, O, 1155
 Munhoz, ACL, 805(ab)
 Munoz, L, 840(ab)
 Munz, DL, 761(ab)
 Murakami, M, 783(ab), 867(ab), 894(ab), 906(ab), 915(ab), 919(ab)
 Muramatsu, M, 745(ab), 879(ab)
 Muranaka, A, 1448
 Murase, K, 791(ab), 888(ab)
 Murphy, GJP, 940(ab)
 Murphy, KC, 726
 Murphy, PH, 874(ab), 982(ab), 1307, 1881
 Murphy, SN, 932(ab)
 Murphy, WD, 725
 Murray, JL, 833(ab), 834(ab)
 Murray, K, 852(ab)
 Murray, LJ, 886(ab)
 Murray, T, 1746
 Murray, W, 883(ab)
 Musa, A, 868(ab)
 Muschel, MJ, 841(ab)
 Musset, D, 824(ab)
 Mustonen, J, 842(ab)
 Muswick, GJ, 775(ab), 833(ab), 880(ab)
 Mut, F, 1768
 Muzi, M, 773(ab), 920(ab)
 Muzic, RF, Jr, 833(ab)
 Muzykantov, VR, 1951
 Myers, HJ, 982(ab)
 Mylavarapu, VB, 375
 Myler, RK, 769(ab)
 Nadel, HR, 979(ab)
 Nagahiro, H, 784(ab)
 Nagai, K, 1448, 1460
 Nagano, Y, 801(ab)
 Nagata, K, 920(ab)
 Nagata, Y, 886(ab)
 Nahmias, C, 363
 Nair, M, 838(ab), 982(ab), 985(ab)
 Najm, YC, 952(ab)
 Nakagawara, J, 880(ab)
 Nakajima, K, 827(ab)
 Nakajima, S, 900(ab)
 Nakajo, M, 1066
 Nakamura, K, 762(ab)
 Nakamura, T, 889(ab)
 Nakano, S, 1627, 1738
 Nakano, Y, 801(ab), 1130
 Nakashima, T, 235, 766(ab)
 Nakatsuka, I, 922(ab)
 Nally, JV, 849(ab)
 Nally, JV Jr, 576
 Narcisse, G, 911(ab)
 Narra, RK, 800(ab)
 Narra, V, 891(ab)
 Naruki, Y, 901(ab)
 Nash, P, 763(ab)
 Nason, T, 823(ab)
 Natale, R, 812(ab)
 Natarajan, TK, 852(ab), 921(ab)
 Naul, LG, 1451
 Nauta, H, 852(ab)
 Navratil, DL, 838(ab)
 Neacy, WP, 858(ab), 1795
 Neal, C, 971(ab), 975(ab), 983(ab)
 Nedelman, M, 651
 Nedelman, MA, 746(ab)
 Needle, LB, 814(ab)
 Neely, H, 766(ab)
 Neils, EW, 1744
 Nelles, MJ, 651
 Nelp, W, 757(ab)
 Nelp, WB, 834(ab), 835(ab)
 Nelson, AD, 775(ab), 833(ab), 880(ab)
 Nelson, CW, 952(ab)
 Nepola, JV, 813(ab)
 Neumann, FJ, 817(ab)
 Neumann, G, 798(ab)
 Neumann, RD, 860(ab), 897(ab)
 Neumayr, A, 423
 Newman, ES, 757(ab)
 Ng, CK, 808(ab), 822(ab), 939(ab)
 Nguyen, Q, 908(ab)
 Nichols, K, 741(ab), 861(ab)
 Nickles, RJ, 810(ab), 822(ab), 880(ab), 932(ab)
 Nicol, PD, 939(ab)
 Nielsen, CM, 903(ab), 904(ab)
 Nielsen, V-AH, 248
 Niemi, M, 977(ab)
 Nienaber, C, 241, 827(ab), 867(ab)
 Nienaber, CA, 771(ab), 782(ab), 783(ab), 818(ab), 828(ab), 937(ab), 940(ab)
 Nierhaus, A, 936(ab)
 Niino, M, 791(ab)
 Nikkinen, P, 1194
 Nikula, T, 873(ab)
 Nilas, L, 131, 248
 Nimmon, CC, 147, 599, 1031, 1878
 Nishikawa, J, 741(ab), 743(ab), 748(ab), 865(ab), 890(ab), 917(ab)
 Nishimura, T, 802(ab), 914(ab), 1868
 Nishio, M, 809(ab)
 Nishishita, S, 1460
 Nishiyama, H, 766(ab)
 Nishizawa, S, 843(ab), 844(ab), 870(ab), 877(ab), 918(ab), 922(ab)
 Nitsch, J, 842(ab)
 Nizze, A, 1200
 Noël, P, 893(ab)
 Noever, T, 91
 Noland, L, 816(ab)
 Nolibé, D, 847(ab)
 Nonaka, M, 921(ab)
 Nordahl, T, 796(ab)
 Nørgaard, H, 248

- Norman, JEdeB, 780(ab)
 Norman, PS, 1057
 Norris, JW, 914(ab)
 Northover, JMA, 899(ab)
 Norton, JA, 181, 860(ab)
 Nosco, DL, 801(ab), 908(ab)
 Noska, MA, 835(ab)
 Nossiff, ND, 746(ab), 825(ab), 887(ab), 905(ab)
 Notardonato, H, 794(ab), 921(ab)
 Notivol, R, 573
 Noto, RB, 883(ab)
 Notohamiprodjo, G, 940(ab)
 Novales-Diaz, JA, 1050
 Nowak, D, 91, 756(ab)
 Nowotnik, DP, 934(ab)
 Noz, M, 785(ab)
 Ntalles, K, 881(ab)
 Nuechterlein, P, 826(ab)
 Nunn, AD, 800(ab), 935(ab)
 Nürnberger, N, 816(ab)
 Nusynowitz, ML, 1114
 Nutt, R, 832(ab)
 Nuttall, PM, 485
- Oates, E, 118, 780(ab), 1122, 1607, 1871
 Oates, J, 91
 Oates, JA, 1901
 Oba, H, 844(ab), 917(ab), 1724
 Obata, Y, 919(ab)
 Obrador, D, 1893
 O'Byrne, GT, 783(ab)
 Ochi, H, 460, 883(ab), 2021
 Ochs, R, 920(ab)
 O'Connell, JW, 941(ab), 982(ab)
 O'Connell, RA, 921(ab)
 O'Connell, W, 840(ab)
 O'Connell, WJ, 302
 O'Conner, W, 765(ab), 980(ab)
 O'Connor, MJ, 830(ab)
 O'Connor, MK, 466, 1747, 1856
 O'Connor, RN, 1607
 Odano, I, 918(ab)
 Odawara, H, 781(ab), 782(ab)
 O'Donnell, CJ, 940(ab)
 O'Donnell, JK, 913(ab), 946(ab)
 O'Donnell, SM, 905(ab)
 Oeff, M, 744(ab)
 Oehr, P, 728, 896(ab)
 Ogihara-Umeda, I, 516
 O'Grady, LF, 847(ab)
 Ogunmekan, AD, 792(ab)
 Ohara, Y, 802(ab)
 Ohgushi, A, 877(ab)
 Ohmomo, Y, 928(ab)
 Ohno, K, 745(ab)
 Ohshio, G, 1436
 Ohta, H, 1130
 Ohtake, T, 741(ab), 743(ab), 748(ab), 865(ab), 917(ab)
 Ohtsuka, R, 1460
 Ohumi, T, 1460
 Ohyanagi, M, 451
 Okada, RD, 792(ab)
 Okamura, T, 883(ab)
 Okerlund, M, 795(ab), 883(ab), 885(ab)
- Okerlund, MD, 795(ab), 913(ab)
 Oldendorf, WH, 855(ab)
 Oldman RK, 39
 Olea, E, 771(ab), 816(ab), 846(ab)
 Olewole, S, 757(ab)
 Olofsson, S, 779(ab)
 Omar, YT, 985(ab)
 O'Meara, JR, 781(ab)
 O'Neil, W, 948(ab)
 O'Neill, WW, 770(ab)
 Ongseng, F, 707, 1150
 Ono, Y, 783(ab)
 Ono S, 1448, 1460
 Onoyama, Y, 883(ab)
 Oomura, M, 883(ab)
 Oosterwijk, E, 1078
 Oppel, F, 902(ab)
 Oppenheim, BE, 98
 O'Rear, J, 869(ab)
 Orenstein, SR, 1848
 Origitano, TC, 927(ab)
 Ortman-Nabi, J, 812(ab), 978(ab)
 Osaka, G, 908(ab)
 Oshima, M, 919(ab), 985(ab)
 Oster, ZH, 843(ab), 886(ab), 1154, 1697
 Ostertag, H, 208
 Ostrzega, E, 802(ab), 891(ab), 948(ab)
 Oswald, SG, 764(ab), 780(ab)
 Oswald, WM, 1856
 O'Toole, JJ, 747(ab)
 Otsuka, M, 916(ab)
 Otsuka, N, 1448, 1460
 Otsuka, S, 901(ab)
 Otsuki, H, 939(ab)
 Ott, RJ, 752(ab), 877(ab)
 Ott, SM, 1853
 Otto, CA, 768(ab), 932(ab), 933(ab)
 O'Tuama, L, 784(ab)
 Outwater, E, 1122, 1871
 Overall, JE, 839(ab)
 Owada, K, 954(ab)
 Owunwanne, A, 130, 320, 752(ab), 971(ab), 980(ab), 986(ab)
 Ozawa, K, 1130
 Ozawa, T, 781(ab), 782(ab)
 Ozawa, Y, 741(ab)
- Paans, AMJ, 1419
 Pabst, HW, 900(ab)
 Packer, MJ, 772(ab)
 Paganelli, G, 762(ab)
 Pahl, JJ, 821(ab), 839(ab), 853(ab)
 Paidi, M, 1237
 Paik, CH, 889(ab), 901(ab)
 Pak, KY, 923(ab)
 Palac, RT, 842(ab), 952(ab), 953(ab)
 Palacios, IF, 945(ab)
 Palechak, J, 909(ab)
 Palestro, C, 764(ab), 787(ab), 814(ab)
 Palevsky, H, 825(ab)
 Palka, JC, 753(ab)
 Palla, L, 907(ab)
- Palme, DF, 875(ab)
 Palmer, DW, 776(ab), 976(ab), 1302, 1761
 Palmer, EL, 769(ab)
 Palmer, MR, 773(ab)
 Palombo, C, 907(ab)
 Pan, S, 758(ab), 759(ab), 777(ab)
 Pannek, HW, 902(ab)
 Panzer, M, 208
 Paoni, RA, 1842
 Papageorgiou, I, 1088
 Papakostas, P, 1910
 Papapoulos, SE, 884(ab)
 Paplanus, SH, 742(ab)
 Pappas, D, 1675
 Paras, P, N145, 753(ab)
 Paris, E, 833(ab)
 Park, BJ, 972(ab)
 Park, C, 985(ab)
 Park, CH, 263, 799(ab), 1038
 Park, H-M, 23
 Park, HM, 1651
 Parker, JA, 947(ab)
 Parkey, RW, 890(ab)
 Parkin, A, 1747
 Parks, PF, Jr, 1347
 Parmentier, C, 1790
 Partain, CL, 135, 763(ab)
 Pascal, O, 872(ab)
 Pascal, S, 852(ab)
 Passafiume, D, 1507
 Patel, B, 816(ab)
 Patel, BR, 979(ab)
 Patel, J, 985(ab)
 Patel, MM, 977(ab)
 Patel, SR, 769(ab)
 Patlak, CS, 759(ab)
 Patt, NL, 768(ab), 945(ab)
 Patt, YZ, 833(ab), 834(ab), 886(ab)
 Patterson, J, 132
 Patterson, R, 91
 Patterson, RE, 756(ab), 938(ab), 945(ab), 1901
 Patton, D, 972(ab)
 Patton, DD, 742(ab), 760(ab)
 Paty, PB, 787(ab)
 Paul, R, 1521
 Pauley, F, 816(ab)
 Pauly, MP, 790(ab)
 Pauwels, EKJ, 884(ab), 1078
 Pavel, DG, 771(ab), 816(ab), 846(ab)
 Pavlik, E, 853(ab), 979(ab)
 Pawlik, G, 821(ab)
 Pawlyk, D, 846(ab)
 Pawlyk, DA, 858(ab), 874(ab)
 Paxton, RJ, 103, 926(ab)
 Peacock, WJ, 831(ab)
 Pearson, G, 742(ab), 820(ab), 911(ab), 916(ab)
 Peck, DC, 1761
 Peck, GE, 986(ab)
 Pecora, M, 939(ab)
 Pedersen, NT, 479
 Peifer, JW, 810(ab)
 Peltier, P, 806(ab), 811(ab)
 Pencke, MD, 876(ab)
 Penney, BC, 748(ab), 864(ab), 870(ab), 1980
- Penney, JB, 774(ab)
 Penninckx, F, 752(ab)
 Pepino, P, 757(ab)
 Perani, D, 1507
 Perentesis, P, 39, 833(ab), 1022
 Perentesis, PJ, 897(ab), 901(ab)
 Perez Balino, N, 942(ab), 950(ab)
 Perkins, AC, 761(ab)
 Perlman, SB, 414, 822(ab), 980(ab)
 Perimutter, JS, 773(ab), 795(ab)
 Perimutter, NS, 953(ab)
 Perry, JR, 643, 748(ab), 749(ab), 786(ab), 870(ab)
 Perry, SE, 933(ab)
 Persson, A, 931(ab)
 Pert, C, 796(ab)
 Peters, AM, 791(ab), 940(ab)
 Petiet, A, 981(ab), 1118
 Petretta, M, 1786
 Petronis, J, 2018
 Petry, N, 859(ab)
 Petry, NA, 743(ab), 812(ab), 928(ab)
 Pettavel, J, 811(ab)
 Pettigrew, RI, 825(ab)
 Peycelon, P, 951(ab), 952(ab), 1486
 Pezzullo, JC, 695
 Pfaff, A, 893(ab), 895(ab), 925(ab)
 Pham, D, 791(ab)
 Phaneuf, DC, 781(ab), 793(ab), 804(ab)
 Phelps, ME, 771(ab), 772(ab), 782(ab), 808(ab), 809(ab), 818(ab), 821(ab), 827, 831(ab), 832(ab), 837(ab), 839(ab), 853(ab), 862(ab), 865(ab), 866(ab), 867(ab), 937(ab), 941(ab), 942(ab), 950(ab), 983(ab)
 Philippe, EA, 879(ab)
 Philippe, L, 159, 771(ab), 952(ab)
 Phillips, P, 784(ab)
 Phillips, PC, 839(ab)
 Phillips, WT, 885(ab)
 Philpott, GW, 814(ab), 835(ab)
 Picard, D, 17, 424, 860(ab)
 Picard, M, 424, 851(ab), 874(ab)
 Pickering, T, 908(ab)
 Picon, L, 885(ab)
 Piekarski, JD, 1790
 Piepsz, A, 893(ab)
 Piers, DA, 778(ab), 907(ab), 908(ab)
 Pierson, GL, 856(ab)
 Pilcher, GD, 908(ab)
 Pileggi, F, 805(ab)
 Pimm, MV, 761(ab)
 Pinsky, S, 756(ab)
 Piotrowski, B, 854(ab)
 Piper, IM, 934(ab)
 Pipes, DW, 801(ab)
 Pippin, JJ, 841(ab), 948(ab)
 Pirat, J-L, 930(ab)
 Piwnica-Worms, D, 55,
- 820(ab)
 Pizer, SM, 786(ab)
 Pizo, P, 852(ab)
 PJ Maloney, 758(ab)
 Plamchon, B, 806(ab)
 Plankey, MW, 790(ab), 886(ab)
 Poans, AMJ, 524
 Pochaczewsky, R, 975(ab)
 Pödenphant, J, 248
 Podoloff, DA, 854(ab), 888(ab), 894(ab)
 Podreka, I, 920(ab)
 Poggenburg, K, 1688
 Pohl, J, 778(ab)
 Pohl, P, 1382
 Pohost, G, 942(ab)
 Poliner, RB, 1750, 2022
 Pollycove, M, N1477
 Polonsky, K, 977(ab)
 Pomper, MG, 768(ab)
 Pons, F, 1916
 Ponto, JA, 1169
 Port, R, 776(ab)
 Port, S, 745(ab)
 Porter, AT, 775(ab)
 Poston, JW, 875(ab)
 Potvin, WJ, 576
 Pouleur, H, 1826
 Pourcelot, I, 893(ab)
 Pourcelot, L, 911(ab), 2008
 Powe, J, 910(ab)
 Powe, JE, 947(ab)
 Powers, J, 825(ab)
 Powers, TA, 763(ab), 973(ab)
 Powers, WJ, 831(ab), 874(ab), 1961
 Prato, FS, 880(ab), 1683
 Pratt, B, 752(ab)
 Preiss, S, 873(ab)
 Prenant, C, 808(ab), 822(ab)
 Preslar, J, 771(ab)
 Press, O, 757(ab)
 Press, OW, 835(ab)
 Preston, DF, 763(ab), 853(ab), 942(ab), 971(ab), 979(ab), 982(ab), 983(ab), 984(ab), 986(ab)
 Pretorius, HT, 794(ab)
 Price, D, 795(ab)
 Price, DC, 787(ab)
 Price, J, 784(ab)
 Pride, B, 869(ab)
 Prigent, F, 891(ab)
 Prince, JR, 864(ab)
 Printz, G, 767(ab)
 Proffitt, RT, 103
 Prough, DS, 880(ab)
 Proukakis, C, 881(ab)
 Proulx, A, 902(ab)
 Psarrakos, K, 1152
 Puchal, R, 1776
 Pulmano, C, 905(ab)
 Purut, CM, 1492
- Quadri, SM, 889(ab), 901(ab)
 Quaife, MA, 901(ab), 979(ab)
 Quinr., DA, 1264
- Rab, ST, 941(ab), 1860
 Rackover, M, 847(ab)

- Rademacher, P, 764(ab)
Raff, U, 907(ab), 1656
Raffel, DM, 808(ab), 822(ab), 939(ab)
Ragazzini, A, 907(ab)
Rahier, J, 1826
Raichle, ME, 747(ab), 773(ab), 831(ab)
Raiszadeh, M, 799(ab)
Ramanna, L, 753(ab), 854(ab)
Ramirez, JAF, 805(ab)
Ramos, M, 1776
Ramos-Gabatin, A, 885(ab)
Rancurel, G, 919(ab)
Ranganath, MV, 774(ab)
Rango, M, 830(ab)
Rao, DV, 375
Rao, SA, 776(ab), 1302, 1761
Rao, TN, 800(ab), 815(ab)
Rapoport, SI, 392, 867(ab)
Rasciti, L, 762(ab)
Rasey, J, 807(ab)
Rashid, F, 975(ab)
Raskob, G, 824(ab)
Rasmussen, JW, 479
Ratib, O, 771(ab), 782(ab), 818(ab), 827(ab), 837(ab), 867(ab), 937(ab)
Rauws, EAJ, 790(ab)
Ravert, H, 784(ab), 820(ab), 853(ab), 921(ab)
Ravert, HT, 796(ab), 852(ab)
Ravich, W, 789(ab)
Raymond, PA, 854(ab)
Raynaud, C, 743(ab), 792(ab), 842(ab), 869(ab), 872(ab), 919(ab)
Raynaud, D, 892(ab)
Razzak, SA, 814(ab)
Reba, RC, 753(ab), 766(ab), 889(ab), 901(ab), 922(ab), 927(ab)
Recht, A, 473
Reddy, KR, 712
Redies, C, 866(ab)
Redoté, R, 841(ab)
Reed, BR, 743(ab)
Reed, NS, 1746
Reese, L, 880(ab)
Rehm, PK, 913(ab), 946(ab)
Rehr, RB, 801(ab)
Rehr, RR, 1283
Reichman, OH, 927(ab)
Reichmann, K, 911(ab), 936(ab)
Reid, RH, 572, 902(ab), 919(ab), 978(ab), 984(ab), 985(ab), 1998
Reilly, J, 758(ab), 759(ab)
Reilly, RM, 1303
Reiners, C, 854(ab)
Reisman, S, 782(ab), 953(ab)
Reisner, T, 920(ab)
Reivich, M, 747(ab), 830(ab), 836(ab), 852(ab), 910(ab), 915(ab)
Remley, K, 130
Renkin, J, 770(ab)
Renooui, W, 1259
Reske, SN, 756(ab), 842(ab)
Resnick, S, 830(ab)
Resser, K, 770(ab), 793(ab), 951(ab)
Reynolds, JC, 39, 751(ab), 758(ab), 833(ab), 897(ab), 901(ab), 1022
Rezai, K, 348, 771(ab), 779(ab), 953(ab), 1876
Rhine, JK, 779(ab)
Ricard, S, 919(ab)
Rice, DE, 927(ab)
Rice, K, 796(ab)
Richalet, JP, 841(ab), 842(ab)
Richard, MD, 788(ab), 1817
Richelle, F, 770(ab)
Richman, P, 899(ab)
Richter, JE, 857(ab)
Richter, P, 818(ab), 946(ab)
Riddell, R, 975(ab)
Riege, WH, 853(ab)
Riesen, A, 924(ab)
Riggs, B, 855(ab)
Rigo, P, 134, 747(ab), 758(ab)
Rimanic, AL, 979(ab)
Rimkus, DS, 765(ab)
Rippin, R, 110
Ritchie, JL, 1393
Ritter, W, 924(ab)
Ritter-Hrnčirik, CA, 1212
Riva, P, 762(ab)
Robbins, MS, 801(ab), 906(ab), 908(ab)
Robbins, W, 909(ab), 951(ab)
Robbins, WL, 793(ab), 1479
Robert, A, 1826
Robert, G, 906(ab)
Robert, J, 663
Roberts, JW, 1451
Roberts, R, 293, 755(ab), 1526
Robeson, W, 898(ab)
Robilotta, CC, 805(ab)
Robin, B, 819(ab)
Robinson, K, 939(ab)
Robinson, PJ, 1747
Robinson, RG, 763(ab), 853(ab), 942(ab), 971(ab), 979(ab), 982(ab), 983(ab), 984(ab), 986(ab)
Robles, RM, 812(ab)
Rocco, T, 769(ab)
Rocco, TP, 769(ab), 945(ab)
Rodes, J, 1916
Roelants, V, 770(ab)
Rogers, LW, 917(ab)
Rogers, PE, 824(ab), 924(ab)
Rogers, WL, 195, 760(ab), 785(ab), 797(ab)
Roland, W, 898(ab)
Romhilt, DW, 1283
Romyn, A, 977(ab)
Roney, TJ, 760(ab)
Rooholamini, M, 771(ab)
Roos, JP, 851(ab), 1934
Roos, MS, 785(ab)
Roosjen, HN, 1302
Ropchan, J, 831(ab)
Rosebrough, SF, 1212
Roseman, H, 805(ab)
Rosen, BR, 836(ab)
Rosen, G, 749(ab), 854(ab)
Rosen, JM, 925(ab)
Rosen, M, 852(ab)
Rosen, ST, 174, 757(ab), 901(ab)
Rosenbaum, EM, 473
Rosenberg, SA, 181
Rosenbloom, M, 1223
Rosenblum, M, 834(ab)
Rosen-Levin, E, 795(ab), 883(ab)
Rosenspire, KC, 783(ab), 784(ab), 807(ab), 938(ab)
Rosenthal, MS, 865(ab), 1848
Rosenthal, L, 1498
Roskopf, M, 509, 1577
Ross, C, 809(ab), 820(ab)
Ross, FK, 923(ab)
Rossen, J, 953(ab)
Rossing, N, 904(ab), 905(ab)
Rössler, H, 1382
Rosso, J, 824(ab)
Rota, E, 877(ab)
Roth, JC, 1462
Roth, SC, 898(ab)
Rothley, JM, 807(ab), 915(ab)
Rotman, M, 833(ab)
Rotmensch, J, 858(ab)
Rottenberg, DA, 839(ab)
Roubin, G, 939(ab)
Rowe, B, 822(ab)
Rowe, BR, 980(ab)
Rowe, RK, 760(ab)
Rowe, RW, 774(ab), 951(ab)
Rowell, KL, 255
Rowlinson, G, 762(ab)
Roy, A, 1050
Roy, L, 793(ab)
Royal, HD, 1157
Rozanski, A, 741(ab), 770(ab)
Rubens, RD, 1045, 1354
Rubin, RH, 651, 830(ab), 887(ab)
Rubinstein, M, 893(ab)
Ruhlmann, J, 891(ab)
Rumancik, W, 974(ab)
Ruotsi, A, 873(ab)
Rusckowski, M, 762(ab), 846(ab), 889(ab)
Rushton, HG, 778(ab)
Rusinek, H, 785(ab)
Ruskin, JN, 769(ab)
Russell, CD, 255, 908(ab), 1189, 1730, 1931
Russell, JAG, 774(ab)
Rüther, M, 813(ab), 829(ab)
Ryan, JW, 803(ab)
Ryman, JC, 859(ab)
Ryo, UY, 765(ab), 877(ab), 882(ab), 903(ab), 904(ab), 905(ab), 980(ab)
Rzeczniak, JA, 900(ab)
Saari, M, 804(ab)
Saccavini, JC, 847(ab)
Sacchi, T, 782(ab)
Sachs, S, 971(ab)
Sacker, DF, 843(ab), 886(ab)
Sackett, JF, 822(ab)
Sada, M, 802(ab)
Sadek, S, 752(ab), 980(ab), 986(ab)
Sadzot, B, 796(ab)
Sadzot, BL, 796(ab), 809(ab)
Saenger, EL, 753(ab)
Saffitz, JE, 1223
Saga, T, 766(ab), 837(ab), 889(ab), 890(ab), 1436
Sagoh, C, 801(ab)
Saha, GB, 913(ab)
Sahweil, A, 814(ab), 985(ab)
Sahweil, AM, 750(ab)
Saiga, A, 922(ab)
Saito, S, 741(ab)
Saito, T, 825(ab), 843(ab), 851(ab), 905(ab)
Saji, H, 778(ab), 801(ab), 817(ab), 826(ab), 827(ab), 828(ab), 843(ab), 844(ab), 877(ab), 886(ab), 918(ab), 922(ab), 928(ab), 1181
Sakahara, H, 235, 758(ab), 889(ab), 890(ab), 897(ab), 901(ab), 1436
Sakai, K, 918(ab)
Sakata, H, 1066
Sakharov, IY, 1951
Sakuma, S, 919(ab), 985(ab)
Sakurai, T, 801(ab)
Salama, A, 809(ab)
Salgado, A, 913(ab)
Salimi, Z, 779(ab)
Salvatore, M, 1786
Samejima, N, 900(ab)
Sampathkumaran, KS, 864(ab)
Sampson, C, 33, 1747
Samson, DS, 911(ab)
Samson, Y, 822(ab), 919(ab)
Samuels, LD, 779(ab), 971(ab), 976(ab), 978(ab)
Sanders, L, 1050
Sanderson, RA, 2001
Sandler, CM, 270, 1279
Sandler, M, 750(ab)
Sandler, MP, 763(ab), 1347, 1454, 1457
Sandrock, D, 860(ab)
Sands, H, 823(ab)
Sanger, J, 785(ab)
Sanger, JJ, 829(ab)
Sanken, LJ, 833(ab)
Sano, M, 840(ab)
Sargent, T, III, 784(ab), 916(ab)
Sargent, TS, III, 773(ab)
Sarkar, S, 908(ab)
Sarno, RC, 118, 1871
Sarti, G, 762(ab)
Sasaki, H, 783(ab), 802(ab), 894(ab), 915(ab), 919(ab)
Sasaki, Y., 982(ab), 986(ab)
Sastry, KSR, 375, 858(ab)
Satoh, K, 880(ab)
Satoyoshi, E, 921(ab)
Satter, MR, 810(ab), 932(ab)
Satyamarthy, N, 809(ab), 866(ab)
Sauris, E, 780(ab)
Savage, S, 746(ab), 819(ab), 972(ab)
Savory, CG, 764(ab), 780(ab)
Sawada, Y, 759(ab)
Sax, FL, 772(ab)
Saxton, RE, 1200
Sayama, I, 915(ab)
Sayle, B, 813(ab)
Sayle, BA, 763(ab), 883(ab)
Sazaki, S, 883(ab)
Scarlato, G, 1507
Schabel, SI, 571
Schaefer, F, 742(ab)
Schaible, T, 806(ab)
Schaible, TF, 746(ab)
Schauwecker, DS, 23, 788(ab), 813(ab), 1246, 1651
Schlechtmann, NM, 302
Scheffel, U, 73, 789(ab), 809(ab), 1465, 2019
Scheiber, C, 837(ab)
Scheinman, ED, 941(ab)
Scheinman, M, 744(ab)
Scheinman, MM, 941(ab)
Schelbert, H, 241
Schelbert, HR, 771(ab), 782(ab), 783(ab), 808(ab), 818(ab), 827(ab), 828(ab), 837(ab), 867(ab), 937(ab), 940(ab), 941(ab), 942(ab), 950(ab)
Schicha, H, 426
Schiepers, CWJ, 869(ab)
Schiff, ER, 712
Schiller, NB, 943(ab)
Schitteck, M, 832(ab)
Schlag, P, 751(ab), 776(ab)
Schlom, J, 1022
Schlumberger, M, 1790
Schlyer, DJ, 767(ab)
Schmelter, RF, 111206
Schmid, A, 877(ab)
Schmid, P, 900(ab)
Schmidbauer, M, 920(ab)
Schmidlin, P, 751(ab), 776(ab)
Schmidt, A, 818(ab), 946(ab)
Schmidt, DH, 745(ab)
Schmidt, E, 827(ab)
Schmidt, K, 862(ab)
Schmidt, KG, 479
Schmidt, RP, 895(ab)
Schmidt, WP, 780(ab), 943(ab)
Schmoliner, R, 794(ab)
Schneider, P, 1748
Schneider, RF, 800(ab)
Schneider, V, 816(ab)
Schnobrich, KE, 924(ab)
Schnur, W, 855(ab)
Schoer, O, 426, 853(ab)
Schoelmerich, J, 827(ab)
Schoeps, K-O, 754(ab)
Scholz, A, 977(ab)
Schorlemmer, HU, 925(ab)
Schradler, J, 785(ab)
Schray, KJ, 873(ab)
Schroder, LE, 776(ab)
Schroff, RW, 39, 834(ab)
Scheingart, DE, 1644
Schubert, SF, 867(ab), 871(ab)
Schubiger, A, 759(ab), 1088
Schuermichen, C, 827(ab), 949(ab)
Schwaiger, M, 770(ab), 782(ab), 783(ab), 807(ab), 818(ab), 827(ab), 837(ab), 938, 950(ab)
Schwartzkopff, B, 832(ab)
Schwartz, AN, 812(ab)
Schwartz, JA, 917(ab)

- 918(ab)
Schwartz, RG, 973(ab)
Schwarz, A, 823(ab),
834(ab), 875(ab), 925(ab)
Schweighardt, SA, 812(ab),
893(ab)
Schwendner, SW, 503
Scofield, AK, 984(ab)
Scott, EA, 972(ab)
Seab, JP, 743(ab), 773(ab),
916(ab)
Seabold, JE, 813(ab), 1169
Seacat, RH, III, 760(ab)
Sease, D, 951(ab)
Sebag, C, 744(ab)
Secchi, V, 885(ab)
Sedvall, G, 754(ab), 767(ab),
931(ab)
See, WA, 978(ab)
Segal, B, 742(ab), 943(ab)
Segal, BL, 742(ab)
Segall, GM, 953(ab), 1662
Seki, H, 844(ab), 895(ab),
917(ab), 1724
Seldin, DW, 168, 806(ab),
841(ab), 855(ab), 942(ab),
1710, 1748
Selhorst, J, 978(ab)
Sell, TL, 1492
Senda, M, 801(ab), 817(ab),
821(ab), 827(ab), 828(ab),
877(ab), 920(ab), 1181
Senekowitsch, R, 900(ab)
Serafini, A, 1675
Serafini, AN, 712, 887(ab),
897(ab)
Servano, P, 742(ab)
Servis, KL, 579, 837(ab)
Sessler, MJ, 761(ab)
Seto, H, 780(ab)
Seto, K, 827(ab)
Seto, M, 940(ab)
Sette, G, 822(ab)
Severson, AR, 856(ab),
882(ab)
Sfakianaki, ED, 1287
Sfakianakis, G, 794(ab),
1287
Sfakianakis, GN, 829(ab),
909(ab), 986(ab), 1675
Sgammmini, H, 950(ab)
Sgouros, G, 803(ab),
845(ab), 858(ab), 874(ab)
Sgoutas, S, 859(ab)
Shafer, RB, 751(ab), 897(ab)
Shafer, RE, 856(ab), 882(ab)
Shaff, MI, 1454
Shafique, I, 756(ab)
Shah, A, 884(ab)
Shah, P, 768(ab)
Shah, SA, 823(ab)
Shah, VO, 886(ab)
Shanes, J, 771(ab)
Shanken, LJ, 834(ab),
886(ab)
Shao, L, 760(ab), 785(ab)
Shapiro, B, 542, 859(ab),
1644
Shapiro, BJ, 914(ab)
Shapiro, T, 977(ab)
Sharkey, CA, 881(ab)
Sharkey, RM, 757(ab),
758(ab), 761(ab), 846(ab),
858(ab), 874(ab), 890(ab),
898(ab)
Sharma, HL, 485
Sharp, JG, 901(ab), 979(ab)
Shaw, LE, 783(ab)
Shaw, SM, 986(ab)
Shealy, D, 923(ab)
Shealy, DJ, 494
Shearer, DR, 695
Sheffield, C, 772(ab), 775(ab)
Sheldon, PE, 943(ab)
Shelton, ME, 807(ab),
848(ab)
Shepard, JH, 599
Sherman, D, 893(ab)
Sherman, DL, 932(ab)
Sherman, PS, 768(ab),
932(ab), 933(ab)
Shewmon, DA, 831(ab)
Shiba, K, 922(ab)
Shibata, N, 1738
Shibata, T, 826(ab), 844(ab),
886(ab), 918(ab)
Shields, WD, 831(ab)
Shih, WJ, 765(ab), 905(ab),
980(ab)
Shiire, Y, 827(ab)
Shimabukuro, K, 1066
Shimonishi, Y, 883(ab)
Shinohara, M, 1621
Shinohara, S, 1066
Shinotoh, H, 809(ab)
Shiomi, S, 460, 2021
Shirono, K, 1066
Shishido, F, 783(ab),
915(ab), 919(ab), 920(ab)
Shiue, CY, 767(ab), 933(ab)
Shively, JE, 103, 926(ab)
Shochat, D, 898(ab)
Shonkoff, D, 1901
Shreeve, WW, 787(ab)
Shreve, P, 1304
Shryock, M, 765(ab)
Shuke, N, 750(ab), 827(ab),
895(ab)
Shuler, S, 766(ab)
Shulkin, BL, 542, 892(ab)
Shusterman, N, 817(ab)
Shutter, B, 780(ab)
Sia, BST, 851(ab)
Siccardi, A, 762(ab)
Siddon, RL, 473, 1745
Sidney Yu, WK, 986(ab)
Sidtis, JS, 839(ab)
Siebecker, D, 762(ab),
846(ab)
Siebecker, DA, 1428
Siegel, J, 846(ab)
Siegel, JA, 689, 803(ab),
844(ab), 858(ab), 862(ab),
874(ab)
Siegel, ME, 869(ab)
Siegel, R, 802(ab)
Sigler, CJ, 769(ab)
Sila, C, 913(ab)
Silberstein, EB, 776(ab),
855(ab)
Silbiger, ML, 876(ab)
Silver, BB, 883(ab), 973(ab)
Silverberg, SJ, 855(ab)
Silverstein, EA, 174, 810(ab),
811(ab), 865(ab), 870(ab),
884(ab), 901(ab)
Simchon, S, 1710
Simmons, G, 877(ab)
Simoen, JP, 847(ab)
Simon, EJ, 933(ab)
Simon, HJ, 756(ab)
Simon, J, 903(ab)
Simon, JD, 1470
Simonetti, I, 953(ab)
Simonović, I, 1152
Simonson, RB, 815(ab)
Simpson, DE, 1022
Simpson, N, 796(ab)
Singer, FR, 1083
Singer, H, 820(ab)
Singhaniyom, W, 759(ab)
Sinn, H-J, 208
Sinusas, AJ, 819(ab),
850(ab), 955(ab)
Sisson, J, 859(ab)
Sisson, JC, 542, 1605
Sitzmann, J, 799(ab)
Skarlos, D, 1910
Skarzynski, JJ, 905(ab)
Skelton, JP, 810(ab)
Skinner, RWS, 503
Sklar, J, 267, 1466
Slade, S, 834(ab)
Slater, JL, 981(ab)
Slater, JM, 799(ab)
Slauson, M, 825(ab)
Sledge, G, 896(ab)
Slegers, G, 1107
Slevin, ML, 599
Slinkin, MA, 1951
Slusarcick, A, 853(ab)
Smart, HL, 791(ab)
Smergel, EM, 689
Smirnov, MD, 1951
Smith, AJ, 882(ab)
Smith, AP, 786(ab)
Smith, GE, 725
Smith, GT, 940(ab)
Smith, JW, 833(ab)
Smith, KF, 806(ab), 841(ab)
Smith, WH, 850(ab), 955(ab)
Snook, D, 762(ab), 1910
Snyder, D, 758(ab), 890(ab)
Snyder, M, 971(ab), 975(ab),
983(ab)
Soares, J, Jr, 805(ab)
Sobel, BE, 818(ab), 1223,
2018
Sobnack, R, 899(ab)
Sokal, G, 1633
Sokoloff, L, 862(ab)
Solanki, K, 147, 1031
Soldano, M, 776(ab)
Sole, MJ, 1697
Solin, O, 767(ab)
Solis, E, 794(ab)
Solomon, H, 852(ab)
Solomon, RW, 764(ab)
Solot, G, 819(ab), 938(ab)
Som, P, 843(ab), 886(ab),
1697
Sonnemaker, R, 766(ab)
Sonoda, T, 1066
Soper, NJ, 856(ab)
Sorby, P, 762(ab), 815(ab)
Sordillo, PP, 903(ab),
904(ab)
Sos, T, 908(ab)
Soucy, JP, 743(ab), 843(ab),
919(ab)
Soufer, R, 954(ab)
Sourkes, TL, 784(ab)
Sournac, M, 129
Sowton, E, 952(ab)
Soya, T, 780(ab)
Spaccavento, LJ, 770(ab),
838(ab)
Spaulding, M, 898(ab)
Spaventi, S, 753(ab)
Specht, HD, 909(ab), 1154
Speed, NM, 917(ab), 918(ab)
Spence, AM, 773(ab),
920(ab)
Spencer, RP, 1463
Sperling, M, 910(ab)
Sperling, MI, 766(ab)
Sperling, MR, 830(ab)
Spicer, JA, 763(ab), 853(ab),
971(ab), 979(ab), 982(ab),
986(ab)
Spicer, KM, 955(ab)
Spielman, G, 910(ab)
Spies, SM, 174, 757(ab),
810(ab), 811(ab), 865(ab),
870(ab), 884(ab), 901(ab)
Spies, WG, 810(ab), 811(ab),
865(ab), 870(ab), 884(ab)
Spinks, TJ, 878(ab), 1833
Spire, JP, 839(ab)
Sporn, V, 942(ab), 950(ab)
Squicciarini, SA, 1368
Sramek, JJ, 980(ab)
Srinivasan, A, 815(ab),
847(ab)
Srivastava, PC, 835(ab),
929(ab)
Srivastava, SC, 787(ab),
849(ab), 924(ab)
Stabin, M, 874(ab), 1526,
1961
Stabin, MG, 803(ab),
859(ab), 874(ab), 875(ab)
Stacy, TM, 135
Stadalnik, RC, 790(ab),
933(ab), 936(ab)
Stafford-Schuck, KA,
743(ab), 854(ab), 918(ab)
Stamos, JA, 760(ab)
Stanford, W, 771(ab)
Stanisavljevic, S, 887(ab)
Stanton, MS, 840(ab)
Stapleton, J, 903(ab)
Stark, C, 771(ab)
Stark, V, 828(ab)
Stark, VJ, 803(ab)
Starling, MR, 744(ab), 1368
Starren, JB, 530
Stauch, M, 946(ab)
Staudinger, K, 780(ab)
Steele, PP, 267, 1466
Stegen, M, 954(ab)
Stein, S, 772(ab)
Stein, SD, 772(ab)
Steinberg, H, 657
Steinberg, KK, 859(ab)
Steinbrenner, L, 898(ab)
Steinstraße, A, 823(ab),
875(ab), 925(ab)
Steis, RG, 833(ab)
Stephens, FO, 593
Steplewski, Z, 847(ab),
924(ab), 925(ab)
Stepniak-Biniakiewicz, D,
801(ab)
Stevens, A, 909(ab)
Stewart, R, 744(ab), 770(ab),
923(ab)
St. George Hyslop, P,
853(ab)
Stirner, H, 756(ab)
Stiteler, W, 83
Stöcklin, G, 754(ab),
755(ab), 821(ab), 911(ab)
Stoddort, HF, 876(ab)
Stokely, EM, 1875
Stomper, P, 799(ab)
Stomper, PC, 324
Stone, CK, 973(ab)
Stone, G, 741(ab)
Stone-Elander, S, 754(ab),
767(ab), 931(ab)
Storch-Becker, A, 851(ab)
Storkey, AE, 789(ab)
Stowe, NT, 849(ab)
Stowe, S, 846(ab)
Stowens, DW, 892(ab)
Strand, G-E, 1719
Strane, TR, 981(ab)
Strashun, AM, 561
Stratbucker, RA, 901(ab),
979(ab)
Stratton, H, 1842
Straub, RF, 787(ab)
Strauss, A, 803(ab), 845(ab)
Strauss, HW, 68, 651,
746(ab), 769(ab), 805(ab),
825(ab), 830(ab), 832(ab),
843(ab), 851(ab), 872(ab),
887(ab), 902(ab), 905(ab),
935(ab), 939(ab), 945(ab),
947(ab), 1714
Strauss, J, 909(ab)
Strauss, L, 784(ab)
Strauss, LG, 751(ab),
776(ab)
Strauss, W, 862(ab)
Strimbu, LM, 760(ab)
Stringham, L, 903(ab)
Stritzke, P, 862(ab), 921(ab),
1878
Strnat, MAP, 889(ab)
Strother, SC, 631, 839(ab),
876(ab), 878(ab)
Stubbs, J, 886(ab)
Studer, A, 811(ab)
Stump, DA, 880(ab)
Stumpf, M, 852(ab)
Stunkard, A, 857(ab)
Stuttler, AWJ, 940(ab)
Stutzman, M, 908(ab), 1189,
1931
Sty, JR, 1750
Subramanian, G, 800(ab),
1212, 1577
Subramanian, K, 908(ab)
Subramanian, R, 889(ab)
Sudora, EJ, 893(ab), 895(ab),
925(ab)
Suess, E, 920(ab)
Sugai, Y, 1621
Sugarbaker, P, 1022
Sugis, JA, 929(ab)
Sugimoto, T, 741(ab)
Suh, JH, 799(ab)
Sukalac, R, 760(ab)
Suki, W, 816(ab)
Sullivan, M, 846(ab)
Sullivan, P, 729
Sumida, R, 821(ab), 832(ab)
Sumiya, H, 844(ab), 917(ab)

1724

Summerfelt, A, 853(ab)
 Sun, S-Y, 789(ab)
 Sun, TTH, 925(ab)
 Sun, Y, 814(ab)
 Sunderland, JJ, 810(ab), 822(ab), 880(ab), 932(ab)
 Surveyor, I, 11
 Susskind, H, 861(ab)
 Susskind, S, 861(ab)
 Sutorik, A, 783(ab)
 Suyenaga, K, 741(ab)
 Suzuki, K, 809(ab)
 Suzuki, N, 890(ab)
 Swailem, FM, 797(ab)
 Swartz, BE, 831(ab)
 Swayne, LC, 974(ab), 2004
 Swett, HA, 863(ab)
 Sychra, JJ, 846(ab)
 Syrota, A, 743(ab), 744(ab), 792(ab), 808(ab), 822(ab), 828(ab), 841(ab), 842, 863(ab), 869(ab), 872(ab), 892(ab), 919(ab), 940(ab)
 Syun, M, 741(ab)
 Szapocznik, J, 829(ab)
 Szeles, C, 756(ab)
 Sziklas, JJ, 608
 Szymendera, J, 39

Taal, BG, 798(ab)
 Tabuchi, A, 1448
 Tachibana, K, 906(ab)
 Tadokoro, M, 919(ab), 985(ab)
 Taguchi, M, 1066
 Taha, B, 868(ab)
 Taher, MA, 268, 1608
 Taillefer, A, 747(ab)
 Taillefer, R, 758(ab), 781(ab), 793(ab), 804(ab), 844(ab)
 Takahashi, A, 783(ab)
 Takahashi, K, 783(ab), 867(ab), 894(ab), 915(ab), 919(ab)
 Takahashi, T, 745(ab), 879(ab)
 Takamiya, M, 802(ab)
 Takanashi, T, 1621
 Takayama, T, 895(ab)
 Taki, J, 851(ab)
 Taki, K, 780(ab)
 Takishima, T, 745(ab), 879(ab)
 Talman, C, 953(ab)
 Tamaki, N, 801(ab), 817(ab), 826(ab), 827(ab), 828(ab), 844(ab), 870(ab), 877, 886(ab), 918(ab), 922(ab), 1181
 Tamas, M, 938(ab), 945(ab)
 Tamas, MJ, 1901
 Tamminga, C, 853(ab)
 Tamura, K, 1126
 Tanada, S, 791(ab), 829(ab), 844(ab), 852(ab), 888(ab), 921(ab), 1207
 Tanaka, H, 235
 Tanasescu, D, 753(ab)
 Tanasescu, DE, 749(ab), 854(ab)
 Tani, A, 949(ab)
 Tanton, E, 895(ab)

Tarburton, JP, 812(ab), 895(ab), 925(ab)
 Tateno, Y, 809(ab), 838(ab), 866(ab), 941(ab)
 Tatsch, K, 856(ab)
 Tatum, JL, 411, 801(ab), 888(ab), 1882
 Tatum JL, 1283
 Taylor, A, 907(ab), 909(ab), 936(ab)
 Taylor, A Jr, 329, 616, 669
 Taylor, RC, 982(ab)
 Taylor-Papadimitriou, J, 1910
 Teates, CD, 816(ab)
 Tefaucal, P, 806(ab)
 Tempel, LW, 831(ab)
 Tempero, MA, 979(ab)
 Tenenbaum, N, 971(ab)
 Teng, R-R, 933(ab)
 Tennison, JR, 1549
 Terada, H, 844(ab), 917(ab), 1724
 Ter Haar Romeny, BM., 1259
 Terriere, D, 848(ab)
 Terzi, A, 946(ab)
 Teule, GJJ, 885(ab)
 Tewson, TJ, 933(ab)
 Thabet, M, 906(ab)
 Thakur, ML, 788(ab), 1038, 1817
 Thedrez, P, 811(ab), 847(ab)
 Thekkumthala, J, 803(ab)
 Thomas, FD, 134, 509, 849(ab), 1577
 Thomas, J, 803(ab)
 Thomas, KD, 803(ab), 1668
 Thomas, M, 886(ab)
 Thomas, SR, 776(ab), 875(ab)
 Thompson, BT, 1268
 Thompson, CM, 1443
 Thompson, NK, 859(ab)
 Thompson, P, 780(ab)
 Thonoor, CM, 356, 803(ab), 1668
 Thorell, J-O, 754(ab), 931(ab)
 Thornback, JR, 1301
 Thorstad, B, 908(ab), 1189
 Thorstad, BL, 1730, 1931
 Thouvenot, P, 663
 Thunberg, S, 905(ab)
 Thurber, M, 746(ab), 819(ab), 972(ab)
 Tiernan, T, 880(ab)
 Tikofsky, RS, 976(ab)
 Tillapaugh-Fay, G, 1212
 Tillmanns, H, 817(ab)
 Timmis, AD, 952(ab)
 Tindale, WB, 791(ab)
 Tisell, L-E, 1638
 Tiu, S, 829(ab)
 Tobc, R, 1436
 Tobin, J, 862(ab)
 Tobolski, MM, 23
 Toda, I, 741(ab)
 Todd-Pokropek, A, 811(ab), 864(ab), 1971
 Todo, Y, 451
 Tomar, RH, 83
 Tomomitsu, T, 1448
 Tomura, N, 915(ab), 919(ab)

Tonami, N, 750(ab), 812(ab), 827(ab), 857(ab), 895(ab)
 Toorongian, SA, 931(ab)
 Toorongian, SA, 754(ab)
 Topol, E, 770(ab), 948(ab)
 Torchilin, VP, 1951
 Torizuka, K, 235, 766(ab), 801(ab), 817(ab), 828(ab), 843(ab), 870(ab), 877(ab), 922(ab)
 Torre, DM, 780(ab), 943(ab)
 Torregrosa, J, 822(ab)
 Toung, JKT, 840(ab)
 Toung, T, 852(ab)
 Touze, M, 806(ab)
 Tow, DE, 947(ab)
 Toyama, S, 235, 889(ab)
 Traylor, JV, 984(ab)
 Treffert, JD, 798(ab)
 Treher, EN, 800(ab)
 Trembath, L-A, 1761
 Trembath, LA, 776(ab)
 Trepashko, DW, 766(ab)
 Triger, DR, 791(ab)
 Troillo, A, 950(ab)
 Trudeau, WL, 790(ab)
 Truelove, S, 777(ab)
 Trujillo, G, 875(ab)
 Tsai, DS, 826(ab)
 Tsai, YF, 759(ab)
 Tsan, M-F, 2019
 Tsuchiya, T, 918(ab)
 Tsuda, Y, 936(ab)
 Tsui, BMW, 643, 748(ab), 749(ab), 786(ab), 797(ab), 870(ab)
 Tsuji, S, 844(ab), 917(ab), 1724
 Tsutsui, J, 1448
 Tu, YK, 920(ab)
 Tubiana, M, 1790
 Tuji, S, 827(ab)
 Tulchinsky, M, 766(ab)
 Tuli, MM, 840(ab)
 Tumeh, SS, 948(ab)
 Tune, L, 820(ab)
 Turek, J, 742(ab), 916(ab), 944(ab)
 Turner, FE, 842(ab)
 Turner, JH, 762(ab), 815(ab)
 Turpin, TA, 923(ab)
 Turski, PA, 822(ab)
 Tuten, TU, 825(ab)
 Tweedle, MF, 891(ab)
 Twitchell, JA, 942(ab)
 Tyler, JL, 422, 631, 920(ab)
 Tyson, IB, 810(ab)
 Tzourio, N, 743(ab), 792(ab), 869(ab), 892(ab), 919(ab)
 Uchida, T, 954(ab)
 Uchiyama, N, 1066
 Uebis, R, 756(ab)
 Uehara, A, 1264
 Uehara, T, 914(ab), 1868
 Uemura, K, 783(ab), 867(ab), 894(ab), 915(ab), 919(ab), 920(ab)
 Ugolini, V, 841(ab)
 Uksik, P, 1683
 Ultee, ME, 815(ab)
 Underwood, DA, 946(ab)

Underwood, R, 891(ab)
 Unger, EF, 772(ab), 775(ab)
 Unger, M, 329, 896(ab)
 Unger, MW, 812(ab), 834(ab), 886(ab), 893(ab)
 Unger, S, 935(ab)
 Ungersböck, K, 920(ab)
 Upas, B, 806(ab)
 U'Prichard, D, 809(ab)
 Urbain, D, 2020
 Urbain, JL, 752(ab)
 Uren, RF, 133
 Urrutia, E, 1212
 Urtasun, R, 894(ab)
 Uusitupa, M, 842(ab)
 Vaalburg, W, 524, 1419
 Vacek, JL, 942(ab)
 Vaghaiwalla Mody, F, 782(ab), 818(ab), 828(ab)
 Vaknine, R, 862(ab), 921(ab)
 Valentino, F, 760(ab)
 Valette, H, 744(ab), 841(ab), 842(ab), 872(ab)
 Valk, PE, 760(ab)
 Valkema, R, 884(ab)
 Vallabhajosula, S, 787(ab), 814(ab), 862(ab), 921(ab), 1237
 Vallar, G, 1507
 Vallgren, S, 980(ab)
 Vallois, JM, 940(ab)
 Valvano, M, 1842
 Vanchiere, JA, 849(ab)
 Vancutsem, E, 752(ab)
 Vandecruys, A, 909(ab)
 Van den Abbeele, AD, 948(ab)
 Vandendorre, Ph, 752(ab)
 Van den Bossche, W, 1107
 Vandenmaegdenbergh, V, 752(ab)
 van der Hem, GK, 908(ab)
 Vanderheyden, J-L, 800(ab), 815(ab), 847(ab), 935(ab)
 van der Schoot, JB, 806(ab)
 VanderWerf, R, 983(ab)
 van Dijk, J, 1078
 Van Dort, ME, 767(ab), 930(ab)
 van Eenige, MJ, 851(ab)
 Van Gysel, JP, 807(ab)
 Van Heertum, RL, 794(ab), 921(ab)
 van Hooff, J, 885(ab)
 van Kaick, G, 751(ab)
 van Kroonenburgh, MJPG, 1078
 van Lingen, A, 885(ab)
 van Luijk, WHJ, 778(ab)
 vanMullekom, AP, 909(ab)
 Van Nostrand, D, 764(ab), 780(ab)
 Vannoy, SD, 867(ab), 876(ab)
 VanPachterbeke, Th, 893(ab)
 Van Roermund, PM, 1259
 van Royen, EA, 790(ab), 806(ab), 927(ab)
 Van Train, K, 755(ab), 770(ab), 861(ab), 948(ab), 951(ab)
 van Vlies, B, 806(ab)

VanZanten, S, 975(ab)
 Vaquer, RA, 561
 Varga, D, 846(ab)
 Varma, VM, 753(ab)
 Varney, D, 832(ab)
 Vassilarou, D, 1910
 Vasudeva, R, 975(ab), 983(ab)
 Vaugeois, JC, 782(ab), 953(ab)
 Vaughan, M, 973(ab)
 Vazquez, R, 118
 Velchik, MG, 751(ab), 817(ab), 857(ab), 1015
 Venkateshan, CN, 923(ab)
 Venner, PM, 775(ab)
 Ventureraya, ECG, 919(ab), 985(ab)
 Vera, DR, 790(ab), 933(ab), 936(ab)
 Verani, MS, 293, 755(ab), 1526
 Verbruggen, A, 909(ab)
 Verdenet, J, 1486
 Verdonet, J, 951(ab)
 Verhest, J, 911(ab)
 Vernant, P, 841(ab)
 Verrey, B, 822(ab), 869(ab)
 Vessella, RL, 875(ab)
 Vester, E, 832(ab), 851(ab)
 Veyre, A, 129
 Viavoda, D, 954(ab)
 Vidal, M, 1230
 Videen, TO, 773(ab)
 Vilani, JW, 896(ab)
 Villardell, F, 573
 Villablanca, JR, 772(ab)
 Villanueva, J, 913(ab)
 Villemagne, V, 820(ab), 852(ab), 853(ab), 921(ab)
 Villemure, J-G, 422
 Vinciguerra, V, 898(ab)
 Vinik, AI, 1605
 Virji, N, 940(ab)
 Virtanen, KS, 842(ab)
 Vismans, F-JFE, 884(ab)
 Visser, CA, 806(ab)
 Visser, FC, 851(ab), 1934
 Vitti, RA, 844(ab), 884(ab), 895(ab)
 Voelker, WH, 833(ab)
 Vogl, G, 1382
 Volkert, WA, 747(ab), 903(ab), 935(ab), 977(ab), 981(ab), 1568
 Volkow, N, 767(ab)
 Volkow, ND, 774(ab), 839(ab)
 Volterrani, D, 907(ab)
 Von Moll, LK, 259
 Votaw, JR, 810(ab), 932(ab)
 Voûte, PA, 791(ab), 798(ab)
 Vyska, K, 940(ab)
 Wackers, F, 954(ab)
 Wackers, FJ, 804(ab)
 Wackers, FJTh, 1865
 Wade, KR, 929(ab)
 Wagner, H, Jr, 784(ab)
 Wagner, HN, Jr, 742(ab), 756(ab), 779(ab), 789(ab), 796(ab), 799(ab), 809(ab), 819(ab), 820(ab), 832(ab), 840(ab), 852(ab), 853(ab)

- 873(ab), 911(ab), 916(ab),
921(ab), 938(ab), 944(ab),
1057, 1207, N1329, 1465
Wagner, HN Jr, 73, 110
Wagner, JG, 889(ab),
900(ab)
Wagner, Jr, HN., 1539
Wagstaff, J, 485
Wahl, RL, 812(ab), 889(ab),
900(ab), 904(ab), 923(ab),
1304
Wahner, H, 855(ab)
Wahner, HW, 881(ab)
Wakasugi, S, 1738
Walker, JV, 1596
Walker, KZ, 815(ab)
Walker, PM, 884(ab)
Wall, RM, 806(ab), 841(ab),
942(ab)
Waller, DG, 1153
Wallis, JW, 864(ab)
Walovitch, R, 747(ab)
Walovitch, RC, 747(ab),
758(ab), 788(ab)
Walsler, M, 1927
Walsh, MN, 818(ab)
Walsh, RA, 1368
Walters, GL, 954(ab)
Wang, SJ, 826(ab), 863(ab),
936(ab)
Wang, TF, 927(ab)
Wang, TST, 757(ab), 925(ab)
Wang, X, 195, 542, 797(ab)
Wang, YL, 936(ab)
Wani, H, 883(ab)
Wanjura, D, 744(ab)
Warber-Matich, SL, 790(ab)
Ware, RW, 753(ab), 885(ab)
Warmelink, CA, 873(ab)
Warnaar, SO, 1078
Warner Stevenson, L,
818(ab)
Warren, SD, 835(ab)
Washburn, LC, 578, 925(ab)
Watanabe, A, 1460
Watanabe, I, 741(ab)
Watanabe, K, 1627
Watanabe, N, 750(ab),
895(ab), 954(ab)
Watanabe, T, 741(ab),
743(ab), 748(ab), 865(ab),
917(ab)
Watanabe, Y, 235, 766(ab),
837(ab), 889(ab), 890(ab),
895(ab), 1436
Watkins, GL, 755(ab),
931(ab)
Watson, AD, 747(ab),
788(ab)
Watson, DD, 804(ab),
819(ab), 850(ab), 955(ab)
Watson, EE, 427
Waxman, A, 770(ab)
Waxman, AD, 749(ab),
753(ab), 854(ab), 1083
Waxman, S, 854(ab)
Webb, S, 877(ab)
Webbon, P, 62
Weber, DA, 843(ab), 886(ab)
Weber, K, 887(ab)
- Webster, EW, 425
Webster, W, 896(ab)
Wedebye, IM, 479
Wedeking, PW, 891(ab)
Wegst, AV, 763(ab), 853(ab),
971(ab), 979(ab), 986(ab)
Wei, Y, 789(ab)
Weigle, JB, 849(ab)
Weiland, FL, 753(ab),
770(ab), 838(ab)
Weinberg, I, 782(ab)
Weinberg, IN, 832(ab)
Weiner, R, 896(ab)
Weingarten, M, 810(ab)
Weingerg, IN, 241
Weinheimer, CJ, 818(ab)
Weir, J, 887(ab)
Weise, S, 872(ab), 920(ab)
Weise, SB, 821(ab)
Weiselberg, L, 898(ab)
Weiss, J, 756(ab)
Weiss, R, 771(ab)
Weiss, W, 423
Welch, MJ, 747(ab), 750(ab),
754(ab), 768(ab), 776(ab),
795(ab), 807(ab), 814(ab),
835(ab), 848(ab), 929(ab),
930(ab)
Weller, R, 744(ab), 818(ab),
946(ab)
Wellman, HN, 23, 840(ab),
896(ab), 1246, 1651, 1742
Wells, TM, 769(ab)
Wendt, RE, III, 1610
Wesolowski, CA, 676
Wessels, BW, 872(ab),
875(ab), 1795
Wester, D, 800(ab)
Westermann, J, 728
Wetzel, E, 751(ab)
Wexler, J, 862(ab)
Wheichel, JD, 950(ab)
Whitaker, KB, 1354
White, C, 953(ab)
White, DW, 913(ab)
White, FW, III, 1817
White, J, 844(ab)
White, JK, 955(ab)
White, RD, 943(ab)
Wichman, A, 852(ab)
Wickham, JEA, 779(ab)
Widén, L, 754(ab)
Wiebe, LI, 1252
Wieland, DM, 767(ab),
807(ab), 930(ab), 932(ab),
938(ab)
Wienhard, K, 821(ab)
Wierzbinski, B, 905(ab),
980(ab)
Wigger, B, 954(ab)
Wijns, W, 770(ab), 866(ab),
1826
Wilbur, DS, 777(ab), 929(ab)
Wilbur, S, 901(ab)
Wiles, HB, 1526
Wilkening, D, 815(ab)
Wilkins, K, 880(ab)
Wilkinson, R, 651, 830(ab),
843(ab), 887(ab), 902(ab)
Williams, AE, 768(ab)
- Williams, BA, 941(ab)
Williams, CC, 776(ab)
Williams, CM, 356, 803(ab),
972(ab), 1668
Williams, H, 936(ab)
Williams, JJ, 676, 760(ab)
Williams, KA, 803(ab),
828(ab)
Williams, L, 873(ab)
Williams, LE, 103, 859(ab),
875(ab), 926(ab), 1464
Williams, S, 747(ab)
Williams, SJ, 747(ab),
788(ab), 814(ab), 934(ab)
Williams, W, 972(ab)
Williams, WH, 947(ab)
Wilson, A, 784(ab), 820(ab),
853(ab), 921(ab)
Wilson, AA, 796(ab),
852(ab)
Wilson, B, 900(ab), 1304
Wilson, CR, 856(ab)
Wilson, D, 947(ab)
Wilson, E, 898(ab)
Wilson, GA, 973(ab)
Wilson, M, 414
Wilson, MA, 822(ab),
980(ab)
Wilson, MW, 918(ab)
Wilson, R, 953(ab)
Wilson, RA, 952(ab),
953(ab), 1943
Windham, JP, 576
Winge, S, N6
Winkler, K, 882(ab)
Winniford, M, 953(ab)
Winston, MA, 855(ab)
Wisenberg, G, 1683
Witanowski, LS, 1212
Witherspoon, L, 766(ab)
Witte, C, 972(ab)
Witte, M, 972(ab)
Wolber, G, 751(ab)
Woldring, MG, 524, 1419
Wolf, AP, 767(ab), 774(ab),
876(ab), 933(ab)
Wolf, BH, 725
Wolf, W, 837(ab), 908(ab)
Wolfe, C, 781(ab)
Wolfson, C, 1498
Wolkoff, AW, 928(ab)
Wolverson, MK, 779(ab)
Wong, C, 948(ab)
Wong, D, 784(ab)
Wong, DF, N2, 717,
809(ab), 820(ab), 840(ab),
852(ab), 911(ab)
Wong, JYC, 103, 875(ab),
926(ab)
Wong, STS, 785(ab)
Wong, W-H, 338
Wong, WH, 761(ab),
877(ab), 879(ab)
Wong, X, 195
Woo, DV, 847(ab), 873(ab)
Woodard, HQ, 803(ab)
Woodard, ML, 756(ab)
Woodbury, MC, 1644
Woodhouse, CS, 39
Woodle, ES, 936(ab)
- Woods, SD, 748(ab), 867(ab)
Woodson, M, 872(ab)
Woolfenden, JM, 878(ab),
1101
Woolley, G, 62
Wooten, WW, 616
Woronick, CL, 608
Worsley, K, 920(ab)
Worsley, KJ, 631
Wortzman, G, 914(ab)
Wright, P, 33, 1747
Wright, GL, 898(ab)
Wu, CC, 826(ab)
Wu, F, 329
Wu, J-L, 122
Wu, JL, 929(ab)
Wu, LC, 863(ab)
Wyper, DJ, 132
- Yabuki, M, 934(ab)
Yacoub, T, 752(ab), 980(ab),
986(ab)
Yagi, K, 890(ab)
Yamada, LS, 1200
Yamada, N, 802(ab)
Yamagishi, H, 880(ab)
Yamaguchi, K, 1621
Yamamoto, K, 817(ab),
826(ab), 844(ab), 877(ab),
886(ab), 918(ab), 922(ab)
Yamamoto, S, 878(ab)
Yamamoto, YL, 422, 631
Yamamuro, T, 235, 889(ab)
Yamaoka, N, 880(ab)
Yamasaki, T, 809(ab),
838(ab), 941(ab)
Yamashita, K, 801(ab),
817(ab), 827(ab), 828(ab),
1181
Yamazaki, K, 900(ab)
Yanagimoto, S, 1448
Yang, C, 781(ab)
Yang, DJ, 767(ab), 930(ab)
Yang, L, 741(ab), 948(ab)
Yang, NC, 868(ab)
Yano, Y, 942(ab)
Yarchoan, R, 852(ab)
Yardley, J, 789(ab)
Yasillo, N, 839(ab)
Yasillo, NJ, 977(ab)
Yasuda, T, 825(ab), 851(ab),
905(ab), 939(ab)
Yegelwel, E, 886(ab)
Yeh, SDJ, 846(ab)
Yeh, SH, 826(ab), 863(ab),
936(ab)
Yester, MV, 908(ab), 1189,
1931
Yim, D, 778(ab)
Yip, T-CK, 884(ab)
Yoganandan, N, 856(ab)
Yohannes, P, 936(ab)
Yokoi, F, 921(ab)
Yokoyama, A, 778(ab),
922(ab), 928(ab), 930(ab),
934(ab)
Yokoyama, K, 750(ab),
812(ab), 827(ab), 857(ab),
895(ab), 1022
Yoneda, S, 1264
- Yonekura, Y, 801(ab),
817(ab), 826(ab), 827(ab),
828(ab), 843(ab), 844(ab),
870(ab), 877(ab), 886(ab),
918(ab), 922(ab), 1181
Yonezawa, Y, 781(ab),
782(ab)
Yonts, S, 877(ab)
Yoo, HS, 799(ab)
Yorke, ED, 1795
Yoshida, K, 838(ab),
866(ab), 941(ab)
Yoshida, S, 781(ab), 782(ab)
Yoshii, F, 852(ab)
Yoshikawa, K, 890(ab)
Yoshitake, A, 922(ab)
Young, AB, 767(ab),
774(ab), 930(ab)
Young, J, 832(ab)
Young, KA, 788(ab), 1246
Young, LS, 651
Yu, P, 23
Yuan, J, 810(ab)
Yudd, AP, 794(ab)
Yumikura, S, 741(ab)
Yutami, C, 802(ab)
- Zabel, P, 1683
Zalutsky, MR, 834(ab),
835(ab), 897(ab)
Zamora, PO, 886(ab)
Zanelli, GD, 62
Zangerle, R, 1382
Zanzi, I, 898(ab)
Zanzonico, PB, 803(ab),
845(ab), 858(ab), 874(ab)
Zapf-Longo C, 1212
Zapol, WM, 947(ab)
Zaret, B, 954(ab)
Zaret, BL, 1865
Zatorre, RJ, 631
Zeeberg, BR, 922(ab),
927(ab)
Zeller, JA, 766(ab)
Zhang, CG, 871(ab), 872(ab)
Zhang, J, 845(ab)
Zhang, Z, 937(ab)
Zhu, J, 871(ab)
Zhu, YY, 781(ab)
Zicot, M, 841(ab)
Ziessman, HA, 752(ab),
769(ab), 1364, 1608
Ziffer, J, 909(ab)
Ziffer, JA, 825(ab), 910(ab)
Zimmer, AM, 174, 757(ab),
810(ab), 811(ab), 865(ab),
870(ab), 884(ab), 901(ab)
Zimmer, M, 823(ab)
Zimmerman, R, 830(ab),
910(ab)
Zimmerman, RA, 836(ab),
852(ab)
Zimmerman, RE, 845(ab),
874(ab), 1745
Zimmermann, R, 817(ab)
Zipes, DP, 840(ab)
Zivanovic, MA, 549
Zohgbi, S, 954(ab)
Zuckier, LS, 707
Zwas, ST, 1150

A

Abscess

- abdominal sepsis, value of SPECT, In-111 leukocytes, 794(ab)
- diagnostic pattern of Ga-67 uptake, lymphocytic interstitial pneumonitis, 887(ab)
- experimental, localization with In-111 neutrophils in rabbits, 733(ab)
- Fisher immunotype 1 *Pseudomonas aeruginosa*, I-125 monoclonal antibody, 651
- imaging potential, Tc-99m multilamellar liposomes, 888(ab)
- imaging with In-111 biotin, streptavidin-conjugated monoclonal antibodies, 889(ab)
- In-111 white blood cell scintigraphy, febrile ICU patients, 795(ab)
- occult infection, accuracy of Ga-67, 608
- preparation of Tc-99m SnF₂ colloid kit, leukocyte labeling, 888(ab)
- quantification of PMN granulocyte infiltration, gore-tex graft, abdominal aorta, 794(ab)
- salmonella costochondritis, 2004
- Tc-99m anti-SSEA-1 as tracer, human neutrophils, 788(ab)

Absorptiometry

- dual photon: See Dual-photon absorptiometry
- medicare coverage, HFCA, N1620

Acquired immunodeficiency syndrome (AIDS)

- asymptomatic HIV seropositive persons, SPECT imaging, I-123 isopropyl amphetamine, 742(ab)
- biodistribution of 5-fluoro-2',3'-dideoxycytidine, NMR spectroscopy, 837(ab)
- dementia complex
 - PET-FDG studies, azidothymidine, 852(ab)
 - SPECT in, 1382
- diagnostic pattern of Ga-67 uptake, lymphocytic interstitial pneumonitis, 887(ab)
- Ga-67 renal hyperactivity, 909(ab)
- pulmonary Ga-67 uptake, pediatric patient, 707
- variable presentation of PCP, Ga-67 scans, HIV-positive persons, 829(ab)

Adrenal glands

- adenoma, benign, Ga-67 uptake, 1451
- imaging update, 2026(ab)
- increase in I-131 NP-59 uptake, adrenalectomy, 859(ab)
- low-density lipoprotein biodistribution, 1237
- NP-59 scintigraphy utility, disease diagnosis, 859(ab)

Adrenal medulla

- I-131 MIBG imaging, methodology and dosimetry, 1638
- tumor, nuclear imaging, 276(ab)

Adrenergic receptors

- beta, halothane, C-11 CGP 12177, 940(ab)
- I-125 HEAT, binding in rat brain, 356
- synthesis of C-11 prazosin, 930(ab)

Adriamycin, cardiomyopathy, earlier detection, ventriculography, 949(ab)**Aerosol, Tc-99m DTPA, utility of inhalation**

scans, artificial ventilation, 764(ab)

Aging

- effects of, Tc-99m MAG₃ clearances, kidney, 906(ab)
- sensitivity of cerebral glucose metabolism, cerebrovascular risk factors, 852(ab)
- seventy years old and greater, dipyrindamole thallium imaging, 953(ab)

AIDS dementia complex. See Acquired immunodeficiency syndrome**Alcohol**

- cerebral glucose utilization, relation to brain structure, polydrug abusers, 911(ab)
- effects on regional cerebral metabolic rate, normal subjects, 840(ab)
- intoxication, regional cerebral blood flow, 839(ab)

Algorithms

- circular harmonic transform, quantitative SPECT, 868(ab)
- computer processing, *in vitro* evaluation, 862(ab)
- direct scatter compensation, photopeak distribution analysis, 797(ab)
- edge detection, emission computed tomography, 868(ab)
- method for receptor pharmacology, non-linear models, variable radioactivities, 822(ab)
- multi-grid maximum likelihood image reconstruction, PET, real data, 774(ab)
- planar Tl-201, quantification, degree of reversibility, 861(ab)
- radiopharmaceutical organ uptake, measurement, improved method, 861(ab)
- Tl-201 SPECT, estimation, left ventricular mass, 945(ab)

N-Alkylation, comparison of bromo vs. iodoalkyl triflates, F-18 radiolabeling, secondary amines, 754(ab)**Aluminum, systemic, Tc-99m MDP distribution, 856(ab)****Alzheimer's disease**

- cerebral perfusion in, Tc-99m HM-PAO SPECT study, 1507
- cortical signal abnormalities, MRI study, 836(ab)
- differential diagnosis of non-vascular dementia, SPECT, 743(ab)
- left hemisphere dysfunction, FDG/PET scans, 912(ab)
- relationships, SPECT findings, clinical features, 743(ab)

Ambulatory cardiac monitoring device

- detection of silent myocardial ischemia, 741(ab)
- dipyridimole SPECT thallium imaging and, chest pain syndrome, normal coronary arteriograms, 742(ab)
- left ventricular function, radionuclide monitoring, patient outcome, 838(ab)
- nuclear monitoring, post-prandial changes, coronary artery disease, 742(ab)
- ventricular function monitor validation, exercise left ventricular ejection fraction, 741(ab)

American Board of Nuclear Medicine, Inc.,

recertification examination for nuclear medicine physicians in 1988, N146

Amino acids

- brain transport studies, new radioiodinated radiopharmaceutical, 778(ab)
- imaging studies using C-11 AIB, malignant melanoma, 904(ab)
- neutral, accumulation, maturation in brain, 784(ab)
- N-13 glutamine transport, cancer cachexia, skeletal muscle, 902(ab)
- Aminobisphosphate, osteoporosis treatment, dual-photon absorptiometry, 884(ab)**
- Aminocarboxylic acid, rare earth complex, skeletal uptake of, 280(ab)**
- Aminophosphonic acid, rare earth complex, skeletal uptake of, 280(ab)**
- Amyotrophic lateral sclerosis, normal cerebral glucose utilization, 821(ab)**

Aneurysm

- "black hole" sign, Tl-201 SPECT images, 756(ab)
- ruptured intracranial, Tc-99m HM-PAO SPECT, 844(ab)

Angiocardigraphy, radionuclide, first-pass,

correlation of ejection fraction and volume measurements, 1114

Angiography, radionuclide

- assessment of renal perfusion, insensitive indicator, renal allografts, 779(ab)
- compared to renal scintigraphy, chronic glomerulonephritis, 907(ab)
- detection of regional wall motion abnormalities
 - biplane contrast, factor analysis, 771(ab)
 - improved probabilistic image, 863(ab)
- diastolic function, myocardial infarction, 1786
- factor analysis of, valvular regurgitation, 159
- first-pass, multiwire gamma camera and tantalum-178, 293
- gating mode effects, analysis of left ventricular function, 1272
- hepatic perfusion in cancer patients, parameters, 894(ab)
- I-123 HIPDM metabolic lung imaging, pulmonary hypertension, 765(ab)
- left ventricular maximum time-varying elastance calculation, 1368
- left ventricular pressure-volume loops, determination in clinical setting, 1492
- left ventricular volume calculation, 745(ab)
- new tracer Ir-191m, arterioscintigraphy, 841(ab)
- quantitative assessment of blood flow, renal transplants, pediatrics, 791(ab)
- removal of Ir-192 from reactor-produced Os-191, 927(ab)
- repeat, stress testing, Tl-201 scintigraphy, 770(ab)
- Tc-99m MIBI and Tl-201 SPECT, coronary artery disease, 952(ab)
- Tc-99m pertechnetate, rectal portal scintigraphy, 460
- triple mode evaluation, subarachnoid hemorrhage, vasospasm, 743(ab)
- ventilation-perfusion and digital subtraction,

Page numbers followed by (ab) indicate abstracts.

Page numbers followed by (le) indicate letters.

N preceding a page number indicates an article appearing in *Newsline*.

- compared value, pulmonary embolism, 824(ab)
- Angioplasty**
 coronary, TI-201 SPECT, indications for referral, 946(ab)
 predictive value of thallium SPECT, myocardial infarction, 770(ab)
 stress testing and TI-201 scintigraphy, patient selection, repeat angiography, 770(ab)
 stress TI-201 imaging, restenoses, recurrent symptoms, 770(ab)
- Angiotensin converting enzyme**
 inhibition in renal artery stenosis
 I-123 hippurate renography, 907(ab)
 renography and renal scintigraphy, 908(ab)
- Antibodies**
 bifunctional, optimization of ligand structure, imaging, 835(ab)
 radioimmunotherapy for micrometastases, At-211, 858(ab)
 utility for labeling, meta vs. para substituted *N*-succinimidyl stannyl benzoates, 834(ab)
- Antimyosin**
 first-pass myocardial extraction, effect of reperfusion, 746(ab)
 In-111-labeled
 kinetics in septum, necrosis, 941(ab)
 uptake specificity, myocardial infarction, 746(ab)
- Aortic regurgitation**
 cine NMR quantification, 802(ab)
 left ventricular ejection fraction, exercise response, 744(ab)
- Arteriosclerigraphy**, new tracer Ir-191m, 841(ab)
- Arthroplasty**
 hip
 detection of infection, 887(ab)
 infection evaluation, In-111 leukocytes, 883(ab)
 prostheses evaluation, In-111 granulocytes, 883(ab)
 prosthetic tip, In-111 WBC, 764(ab)
 prosthetic tip, three phase bone scan, 780(ab)
- Aspartame**, effect on human brain C-11 ACHC uptake, 784(ab)
- Astatine-211**, radioimmunotherapy for micrometastases, 858(ab)
- Astatine-211 monoclonal antibodies**, iodine labeling, *N*-succinimidyl-3-(tri-*n*-butylstannyl)benzoate, 835(ab)
- Astrocytoma**, human high grade, microautoradiography localization, TI-201, 854(ab)
- Atherosclerosis**
 I-131 fibronectin imaging, 1264
 plaques, human biodistribution, I-123 and Tc-99m LDL, 803(ab)
- Atomic bomb**
 revised data, radiation exposure risks, N1162
 thyroid cancer in survivors, 268(le)
- Attenuation correction**
 comparison of LAO view with geometric mean, compensation, solid gastric emptying studies, 752(ab)
 detector response and, cardiac SPECT image reconstruction, 870(ab)
 direct scatter compensation, photopeak distribution analysis, 797(ab)
 factor determination, absolute quantitation, radionuclide, 872(ab)
 non-uniform, SPECT, photopeak and Compton spectral windows, 798(ab)
 PET quantitation errors due to headrest, 878(ab)
- SPECT quantitation, inhomogeneous media, transmission scan, 797(ab)
- Autoradiography**
 evaluation of PET feasibility studies, study protocol screening, 774(ab)
 mapping of glutamate receptor channels, 930(ab)
 O-15 water, oxygen inhalation, cerebral blood flow, 915(ab)
 quantitative
 detection of cardiomyopathy, animal model, 1697
 tumor antigen concentration, tissue sections, 897(ab)
- Azidothymidine**, AIDS-related dementia, PET-FDG studies, 852(ab)
- B**
- Barium fluoride (BaF₂) scintillator**, camera performance design evaluation, PET, 338
- B cells**, monoclonal anti-B cell antibodies, localization, human B-lymphoma transplants, 899(ab)
- Benzodiazepine receptors**
 binding of H-3-RO15-4513, 809(ab)
 central type, quantitative analysis, steady-state in living brain, 809(ab)
 C-11 Ro15-1788, PET studies, 931(ab)
 new radioligands for PET studies, 3-[C-11] methoxybenzodiazepines, 755(ab)
 SPECT mapping in brain, 759(ab)
- Bile acid**, malabsorption, 1411
- Binding assay**, In-111 monoclonal antibodies, gastrointestinal tumor, 1436
- Biotin**
 In-111-labeled, streptavidin-conjugated antibody, tumor localization studies, 762(ab)
 potential tumor imaging agents, 729(le)
- Bismuth germanate (BGO) scintillator**, camera performance design evaluation, PET, 338
- Bladder**
 artifact correction, SPECT evaluation, hips, 780(ab), 868(ab)
 urinary, model, radiation dosimetry calculations, 875(ab)
- Blood**, distribution of Gd-153 (DTPA)², pharmacokinetic analysis, 891(ab)
- Blood flow**
 Alzheimer's disease, SPECT findings, clinical features, 743(ab)
 arterial input function, plasma separation, PET oxygen studies, 832(ab)
 cerebral
 alcohol intoxication, 839(ab)
 cache memory system, high resolution PET, 878(ab)
 canine stroke model, PET studies, 920(ab)
 comparison, IMP SPECT, 747(ab)
 dementia, assessment with Xe-133 SPECT, 1621
 dynamic PET technique, 775(ab)
 epilepsy, I-123 iofetamine tomography, 892(ab)
 error analysis in SPECT, children, 869(ab)
 evaluation, 3-headed SPECT system, 912(ab)
 I-123 IMP SPECT redistribution, ischemic cerebral vascular disease, 918(ab)
 linearization of values, Tc-99m HM-PAO, 936(ab)
 maturation in infants, SPECT, 743(ab)
 maturation in newborns, I-123 IMP and SPECT, 893(ab)
 measurement with Tc-99m HM-PAO, 1387
- molecular structure of Cu(PTSM), 927(ab)
 new method, Tc-99m HM-PAO SPECT, 748(ab)
 O-15 steady state method, arterial concentration, 821(ab)
 O-15 water autoradiography and PET, oxygen inhalation, 915(ab)
 oxygen and glucose metabolism, stroke, 852(ab)
 partial epilepsy, childhood, 892(ab)
 PET, copper-labeled radiopharmaceuticals, 1549
 PET, lack of ID for EC/IC bypass, 831(ab)
 PET agent validation, I-122 HIPDM, 916(ab)
 potential imaging agents, Tc-99m NEP-DADT, 73
 radioxenon tomography, 1875(le)
 resting and hypercapnic, carotid artery stenosis and, 311
 side localization by SPECT, temporal lobe epilepsy, 916(ab)
 simultaneous SPECT acquisition, 876(ab)
 single-pass extraction, Tc-99m-D,L-HM-PAO, 747(ab)
 Tc-99m compounds for measurement, 1464(le)
 Tc-99m ECD compared to Tc-99m HM-PAO, 844(ab), 912(ab)
 Tc-99m ECD compared to Xe-133, 913(ab)
 Tc-99m ECD imaging, 758(ab), 788(ab)
 Tc-99m HM-PAO SPECT, during Matas test, 1724
 tracers, copper bis(thio-semicarbazones, 848(ab)
 tumors, Tc-99m HM-PAO uptake, glutathione content, 920(ab)
 uptake of I-125 HIPDM, 1675
 validation studies by radioxenon tomography, 348
 Xe-133 SPECT, compared to PET, 919(ab)
- cerebrovascular disease**
 early and late I-123 IMP SPECT, 844(ab)
 rapid sequential SPECT study, 880(ab)
 congestive heart failure, peripheral hemodynamics and selection of vasodilators, 451
 CO₂ reactivity using I-122 HIPDM, PET study, 773(ab)
 coronary venous retroperfusion, myocardial ischemia, PET, 783(ab)
 density of capillaries, stroke, living human brain, 915(ab)
 dilated and ischemic cardiomyopathy, profile analysis, PET, 818(ab)
 first-pass radionuclide determination, cardiac output, 1154(le)
 graft perfusion in pancreas-spleen transplantation, serial radionuclide determinations, 885(ab)
 hepatic, arterial and portal venous components, 466
 I-123 IMP brain SPECT, clinical study, auditory hallucination, 917(ab)
 liver physiology, non-invasive multiparametric study, cirrhosis, 791(ab)
 liver transplant rejection, scintigraphy, deconvolutional analysis, 790(ab)
 localization of seizure foci, 913(ab)
 medically-treated cerebral ischemia, prognosis, PET, 831(ab)
 metabolism of Tc-99m ECD, normal volunteers, 747(ab)
 mild cerebral ischemia, reverse redistribution, Tc-99m HM-PAO, 914(ab)

Blood pool imaging

- monitoring of arterial positron concentration, gamma detector, 833(ab)
 - myocardial
 - binding characteristics of imaging agents, 55
 - intra-operative regional monitor, 880(ab)
 - molecular structure of Cu(PTSM), 927(ab)
 - N-13 ammonia, noninvasive quantification, 940(ab)
 - N-13 ammonia metabolic fate, human blood, 783(ab)
 - N-13 ammonia PET, 838(ab)
 - myocardial ischemia and leg muscle assessment, stress testing, dipyridamole and exercise, 947(ab)
 - oxygen metabolism and, spinocerebellar degeneration, PET, 920(ab)
 - potential tracers, single-pass studies, copper bis(thio-semicarbazones), 848(ab)
 - quantitative assessment
 - first-pass tracer fractionation, kidney, 907(ab)
 - regional myocardial perfusion, dynamic PET and N-13 ammonia, 782(ab)
 - renal transplants, pediatrics, 791(ab)
 - rapid generation of blood activity curves, multi-slice gated cardiac PET data, 775(ab)
 - rate constant determination, kinetic model, Tc-99m HM-PAO, 917(ab)
 - renal, noninvasive assessment, temporal deconvolution, 862(ab)
 - retention of Tc-99m ECD in brain, *in vivo* metabolism, 747(ab)
 - selection of tracers, experimental procedures, imaging techniques, 862(ab)
 - Tc-99m HM-PAO SPECT
 - compared to I-123 IMP, ischemic lesions, 919(ab)
 - ruptured intracranial aneurysm, 844(ab)
 - Tl-201 renal imaging, stress cardiac imaging, 910(ab)
 - tumor uptake and, 1463(le)
 - vasoreactivity in cerebral arteriosclerosis, without carotid stenosis, 911(ab)
- Blood pool imaging**
- blood volume measurement with C-11 carbon monoxide, carboxyhemoglobin half-life, systemic hematocrit, 894(ab)
 - cell labeling efficiency and, red cell surface charge, 1710
 - compartmental and non-compartmental modeling, HIDA studies, 862(ab)
 - Cu-62 HSA, plasma volume measurement, 930(ab)
 - human testicular carcinoma xenograft, athymic mice, radioimmunoassay, 896(ab)
 - left ventricular maximum time-varying elastance calculation, 1368
 - mechanism of inspiratory reduction, left ventricular stroke volume, function, 949(ab)
 - protein binding studies, Tc-99m, 62
 - scintigraphic appearance, torsion of testicular appendages, 892(ab)
 - Tc-99m DTPA-HSA, initial experience in man, 922(ab)
- Blood volume**, visceral, redistribution in exercise, 1714
- Bone**
- calcium and mineral changes, hemodialysis, 816(ab)
 - cancer-related pain, radionuclide palliation, 2027(ab)
 - cancer therapy, Sn-117m, high specific activity, 849(ab)
 - clinical SPECT studies, optimization, angular sampling frequency, 869(ab)
 - condensing osteitis, clavicle, 1122
 - delayed/non-union fractures, Tc-99m/In-111 leukocyte and Tc-99m/Ga-67 imaging, 813(ab)
 - density
 - comparison from different skeletal sites, 168
 - measurement, different skeletal sites, 1748(le)
 - premenopausal women, hormonal relationship, 859(ab)
 - spine and distal forearm, osteoporosis, 131(le)
 - digitally acquired and displayed radioisotope images, diagnostic consequences, 884(ab)
 - dual energy radiography, mineral analysis of lumbar spine, 855(ab)
 - dual-photon absorptiometry
 - mineral distribution in skeleton, 881(ab)
 - non-hormonal therapy of osteoporosis, 855(ab)
 - osteoporosis, 884(ab)
 - precision of, 880(ab)
 - ectopic, mineralization, MDP effect, 882(ab)
 - frontal and lateral DPA measurements, lumbar spine, strength of vertebral body, 856(ab)
 - healing, lower limb lengthening by distraction epiphysiolysis, 1259
 - imaging, symmetric photon deficiency in femoral heads, 266(le)
 - In-111 chloride imaging
 - diabetic foot, 813(ab)
 - treated osteomyelitis, 763(ab)
 - In-111 granulocytes, complicated hip prostheses, evaluation, 883(ab)
 - In-111 leukocytes, role, diagnosis of fracture and osteomyelitis, 814(ab)
 - In-111 white blood cells
 - localization, non-infected surgery site, 788(ab)
 - osteomyelitis evaluation, 813(ab)
 - lower extremity periostitis, secondary to venous insufficiency, Tc-99m MDP, 1279
 - marrow scintigraphy, compared to magnetic resonance tomography, plasmocytoma, 891(ab)
 - metabolic disease
 - early diagnosis, dual tracer method, 780(ab)
 - hip mineral density measurements, interval changes, 779(ab)
 - metastases, bone scan flare for, 1354
 - mineral content
 - hemodialysis effects, 277(ab)
 - lumbar spine, dual-photon absorptiometry, 248
 - measurement in cats, 280(ab)
 - mineral loss, normal postmenopausal women, 881(ab)
 - osteomyelitis, subperiosteal abscess complicating, In-111 leukocyte scintigraphy, 1871
 - osteomyelitis complicated by pre-existing condition, In-111 WBC in detection, 1015
 - Paget's disease, Ga-67 citrate localization in osteoclast nuclei, 1083
 - painful prostate and breast cancer, Sr-89 chloride, treatment results, 763(ab)
 - pelvic studies, digital filtering of the bladder in, 1587
 - radiolabeled monoclonal antibodies, osteosarcoma, 235
 - radionuclide imaging, calvarial infarction in sickle cell disease, 411
 - red marrow dosimetry, radiolabeled monoclonal antibodies, 858(ab)
 - salmonella costochondritis, Ga-67 detection, 2004
 - scanning
 - baseline, breast cancer, 1045
 - MRI in, 2026(ab)
 - osteoid osteoma, 272(ab)
 - osteosarcoma in Paget's disease, 414
 - prediction of successful therapy for metastases, 1354
 - reflex sympathetic dystrophy of the hand, 26
 - review of sternal disease, 780(ab)
 - scintigraphic sternal lesions, patients with breast cancer, 324
 - symmetric photon deficiency in femoral heads, 266(le)
 - trochanteric bursitis, 763(ab)
 - scintigraphy
 - combined with In-111 leukocyte scans, neuropathic foot disease, 1651
 - detection of obstructive uropathy, 1781
 - emergency use, pediatric, 736(ab)
 - factor analysis, renal osteodystrophy, 883(ab)
 - MRI and, osseous spine metastases, 763(ab)
 - quantitative, 881(ab)
 - stress fractures, 1150(le)
 - Tl-201, soft tissue sarcoma and, 854(ab)
 - skeletal metastases, initial experience, 186-Re(Sn)-HEDP, 776(ab)
 - skeletal muscle necrosis, quantitation, Tc-99m PYP, 884(ab)
 - skeletal radiotherapeutic agent, Ga-72 nitrate, 776(ab)
 - SM-153 EDTMP
 - disseminated skeletal metastasis, dosimetry, 762(ab)
 - metastatic cancer, dose tolerance, 775(ab)
 - tumors, response to therapy, 903(ab)
 - solitary lesions, Tl-201 role, etiologic classification, 814(ab)
 - SPECT
 - comparison with planar scintigraphy, skull, 1341
 - in hyperplasia, mandibular condyle, 780(ab)
 - spinal osteoporosis, diagnostic sensitivity, SPA and DPA, 882(ab)
 - surgical radiation probes, 881(ab)
 - Tc-99m DTPA-HSA, initial experience in man, 922(ab)
 - Tc-99m MDP, adverse reactions, 1302(le)
 - therapy of osseous metastases, marrow toxicity, Sr-89, 776(ab)
 - three phase scan, porous coated hip arthroplasty, prosthetic tip, 780(ab)
 - toddler's fracture, Tc-99m MDP, 2001
 - total joint arthroplasty, occult infection following, Tc-99m HDP and In-111 WBC imaging, 1347
- Bone densitometry**
- mineral content of spine/hip/forearm, primary hyperparathyroidism, 855(ab)
 - osteoporosis in eating disorder patients, 882(ab)
 - X-ray scintillation camera, 855(ab)
- Book reviews**
- Advances in Clinical Cardiology, Vol. III: Regional Myocardial Metabolism by Positron Tomography*, 1157
 - Age-Related Factors in Radionuclide Metabolism and Dosimetry*, 428
 - Basics of Magnetic Resonance Imaging*, 1750
 - Cardiac Nuclear Medicine*, 1157
 - Clinical Arthrography*, 2nd Ed, 2022
 - Diagnostic Imaging of Child Abuse*, 135
 - Diagnostic Ultrasound: Text and Cases*, 579
 - Gamuts in Nuclear Medicine*, 1467
 - Graft-Scientific Plotting/Data Transformation*, 1307

- Magnetic Resonance Annual 1988*, 1610
Magnetic Resonance Imaging, 1882
Mammography, Self Assessment in Radiology and Imaging, 1750
NCRP Report No. 93. Ionizing Radiation Exposure of the Population of the United States, 1881
New Approaches to Tumour Identification. Cancer Surveys; Advances and Prospects in Clinical, Epidemiological and Laboratory Oncology, 731
Noninvasive Imaging of Cardiac Metabolism, 270
Nuclear Magnetic Resonance Imaging in Medicine and Biology, 135
Nuclear Medicine Annual 1987, 731
Nuclear Medicine Applications to Surgery, 2022 Principles of Nuclear Magnetic Resonance in One and Two Dimensions, 579
Quality Assurance and Image Artifacts in Magnetic Resonance Imaging, 1307
Radiation Dose to Patients from Radiopharmaceuticals: ICRP Publication 53, 1610
Radionuclides in Nephrology, 427
Radiopharmaceuticals in Nuclear Medicine Practice, 427
Rational use of Diagnostic Imaging in Paediatrics: Report of a WHO Study Group, 1750
Safety and Efficacy of Radiopharmaceuticals, 1881
The Clinician's Guide to Diagnostic Imaging, 1467
1988 Year Book of Diagnostic Radiology, 2022
1987 Year Book of Diagnostic Radiology, 270
1987 Year Book of Nuclear Medicine, 270
- Boron**, -capped Tc-99m oxime, compared to tin-capped, 935(ab)
- Brain**
- AIDS dementia complex
 PRT-FDG studies, 852(ab)
 SPECT in, 1382
- Alzheimer's disease
 left hemisphere dysfunction, FDG/PET scans, 912(ab)
 normal aging and, CT/MR/PET comparisons, 852(ab)
 Tc-99m HM-PAO SPECT study, 1507
- amino acid transport, radioiodinated radiopharmaceutical, 778(ab)
- benzodiazepine receptors
 central type, quantitative analysis, 809(ab)
 RO15-4513 binding, 809(ab)
 SPECT mapping, 759(ab)
- blood, metabolites of F-18 fluoro-L-dopa, 363
- blood flow. *See* Blood flow, cerebral
- C-11 ACHC uptake, effect, dietary aspartame, 784(ab)
- C-11 diprenorphine and buprenorphine, uptake, PET, 933(ab)
- C-11 diprenorphine and carfentanil, opiate receptor binding, dual detector system, 921(ab)
- C-11 methionine
 amino acid accumulation, maturation, 784(ab)
 human model, kinetics, 822(ab)
- C-11 NMPB, synthesis and regional distribution, 768(ab)
- C-11 l-pyruvate, mitochondrial encephalomyopathy, PET, 921(ab)
- C-11 YM-09151-2, uptake, dopamine D-2 receptors, 931(ab)
- cat, metabolic maturation, 772(ab)
- cerebral infarction
 MRI, proton self-diffusion coefficient, 836(ab)
 Tc-99m HM-PAO scintitography, 843(ab)
- cerebral maturation in first 20 months of life, regional cerebral blood flow, SPECT, 743(ab)
- cerebral oxygen metabolism, effect, O-15 water recirculation, 917(ab)
- collateral circulation, Tc-99m HM-PAO SPECT, during Matas test, 1724
- density of capillaries, stroke, 915(ab)
- determination of flow and rate constants
 I-123 IMP SPECT, 870(ab)
 kinetic model, Tc-99m HM-PAO, 917(ab)
- dopamine receptor binding sites
 kinetic parameters for FESP interactions, PET, 865(ab)
 SPECT, 848(ab)
- F-18 cyclofoxy
 evaluation in rat, 796(ab)
 PET imaging in man, 796(ab)
- F-18 6-L-DOPA imaging, asymptomatic MPTP-lesioned monkeys, 820(ab)
- F-18 fluorodeoxyglucose, high resolution, event requirements, 760(ab)
- F-18 fluorophenylalanine, tumor imaging agent, 919(ab)
- F-18 2-fluorotyrosine, protein synthesis tracer, 754(ab)
- F-18 GBR 13119, synthesis and uptake, dopamine uptake blocker, 767(ab)
- F-18 sex hormone uptake, F-18 ligands, PET, 795(ab)
- glioma, PET-FDG technique, 421(le)
- glucose metabolism
 acute cocaine, human substance abusers, 840(ab)
 cerebellar FDG metabolism, brain trauma, 822(ab)
 normal, amyotrophic lateral sclerosis, 821(ab)
 PET measurement of, 631
 rates, PET, 867(ab)
 sensitivity, age and risk factors, 852(ab)
 structure, polydrug abusers, 911(ab)
- grey and white tissue water content, partition coefficient, labeled water, 773(ab)
- haloperidol, regional and temporal distribution, 767(ab)
- hexokinase Michaels-Menten kinetics, 773(ab)
- hypercapnia, uptake of I-125 HIPDM, 1675
- I-123 HIPDM SPECT, carotid artery occlusion, 913(ab)
- I-123 IMP SPECT
 after cerebral radiation therapy, 914(ab)
 clinical study, auditory hallucination, 917(ab)
 death and coma, clinical study, 917(ab)
 evaluation of major psychosis, 921(ab)
 human newborn maturation, blood flow, 893(ab)
 optimum Butterworth-Wiener filter, data preprocessing, 879(ab)
 O-15 water cerebral blood flow comparison, 747(ab)
 redistribution, ischemic cerebral vascular disease, 918(ab)
 revascularization prediction, carotid endarterectomy, 844(ab)
- I-123 iofetamine tomography, epilepsy, pediatric patients, 892(ab)
- I-125 DHTP, mapping central noradrenergic innervation, 777(ab)
- I-125 MIBG, H-3 NE uptake and release, 911(ab)
- imaging agents
 5-iodo-thienylamphetamine synthesis, 777(ab)
 radioactive iodobenzamide, 777(ab)
- imaging characteristics of MUMPI, cylindrical neuro-SPECT system, 832(ab)
- improved HPLC system, analysis, organic amine radiopharmaceuticals, 926(ab)
- In-111 oxime, labeling, hematoporphyrin derivative, 927(ab)
- metabolic rate for glucose, partial correlation coefficients, 392
- metabolism
 alcohol effects, normal subjects, 840(ab)
 hypometabolism, olivopontocerebellar atrophy, 913(ab)
 patterns of, acute ischemic aphasia, 915(ab)
 patterns of, vegetative subjects, 839(ab)
 progressive supranuclear palsy, PET, 914(ab)
 relationships, condition-dependent changes, 839(ab)
 subcortical alterations, partial epilepsy, 830(ab)
- MRI
 new technique, automated edge detection, 865(ab)
 normal pressure hydrocephalus, radionuclide cisternography, 836(ab)
- multiple region-of-interest capabilities, monitoring, positron-emitting tracers, 832(ab)
- multi-slice, SPECT, position-sensitive bar detector system, 760(ab)
- muscarinic receptors
 C-11 scopolamine, PET, 808(ab)
 radioligand dissociation kinetics, 927(ab)
 N-(3-F-18 fluoropropyl)MK-801, NMDA receptors, 932(ab)
- perfusion
 quantitative SPECT imaging, improved method, 869(ab)
 reserve in cerebrovascular disease, Tc-99m DTPA-HSA, I-123 IMP, 918(ab)
 Tc-99m ECD imaging, 788(ab)
 Tc-99m HM-PAO, pediatric patients, 919(ab)
 Tc-99m HM-PAO and ECD, comparison, 844(ab)
- PET
 canine stroke model, 920(ab)
 cerebral hemodynamics, lack of ID for EC/IC bypass, 831(ab)
 compared to MRI, partial epilepsy, 910(ab)
 compared to MRI and CT, acute head injury, 910(ab)
 correlation with MRS, CNS disorders, 910(ab)
 degenerative disorders, rate constants, 915(ab)
 dementia, I-123 IMP and Tc-99m HM-PAO SPECT, 916(ab)
 dynamic and static, quantitation of uncertainties, 912(ab)
 evaluation of potential agents, mAChR, 933(ab)
 hyperkinetic movement disorders, 839(ab)
 image analysis, metabolic centroid method, 774(ab)
 medically-treated cerebral ischemia, prognosis, 831(ab)
 neuroanatomy localization, coordinate system, 918(ab)
 neuroreceptor binding ligands, kinetic data, 865(ab)
 neuroreceptor quantification, various models, 922(ab)
 oxygen metabolism and blood flow,

Brain death

- spinocerebellar degeneration, 920(ab)
regional correction, atrophy effects, 773(ab)
ROI analysis, MRI-based templates, 866(ab)
role, pediatric epilepsy surgery, 831(ab)
visual cortex hypometabolism, head injury patients, 830(ab)
- PET scanner**
high resolution, double wobbling mode, 877(ab)
performance of machine parameters, metabolic data, 877(ab)
proxy for capillary FDG, limitations, arterial FDG, 822(ab)
radiation dosimetry
I-123 SCH 23982, 1668
radioiodinated SCH23982, biodistribution, 803(ab)
radiochemical purity of Tc-99m HM-PAO, 572(le)
radioiodinated I-125 HEAT, binding, 356
registration of MRI-PET images, procedure, validation, 853(ab)
scan, I-123 IMP, patient with auditory hallucination, 558
seizure foci localization, 913(ab)
serotonin
labeling of uptake sites, 3H-paroxetine, 809(ab)
synthesis, plasma tryptophan, 784(ab)
- SPECT**
cerebrovascular reserve, hemodynamic risk patients, 911(ab)
future directions, 567
I-123 IMT, 911(ab)
phantom evaluation of distortion, 877(ab)
rapid sequential study, cerebrovascular diseases, 880(ab)
ring-geometry instrument for imaging, 760(ab)
temporal lobe epilepsy, side localization, 916(ab)
three-headed system, initial on-site evaluation, 760(ab)
totally digital annular camera, 786(ab)
- Tc-99m-D,L-HM-PAO**
single-pass extraction, 747(ab)
stabilization, gentisic acid, 935(ab)
- Tc-99m dithiosemicarbazone complex**, condensed ring structure, 934(ab)
- Tc-99m ECD SPECT**
kinetics, biodistribution, 921(ab)
metabolism, normal volunteers, 747(ab)
retention of, *in vivo* metabolism, 747(ab)
tomographic imaging, stable perfusion agent, 758(ab)
- Tc-99m HM-PAO SPECT**
cerebral perfusion, middle cerebral artery velocities, 914(ab)
compared to I-123 IMP, ischemic lesions, 919(ab)
cortical peeling and mapping, 914(ab)
decomposition, aqueous media, 1568
evaluation, cerebral perfusion tracer, 843(ab)
evaluation, post-stroke depression, 918(ab)
high resolution imaging, SPRINT, 917(ab)
mild cerebral ischemia, reverse redistribution, 914(ab)
ruptured intracranial aneurysm, 844(ab)
- Tc-99m oxime**
complexed with 3 Schiff base ligands, 936(ab)
tin-capped vs. boron-capped, 935(ab)
- tumors**
Co-57 bleomycin delivery to, SPECT, 187
FDG-PET and image-guided MR spectroscopy, 785(ab)
glutathione content, Tc-99m HM-PAO uptake, 920(ab)
multi-parameter studies, PET, 853(ab)
primary and metastatic, Tc-99m HM-PAO uptake, 895(ab)
rat model, deoxyglucose and glucose transport, 920(ab)
unilateral occlusive disease of internal carotid artery, resting and hypercapnic rCBF, 311
validation studies, radioxenon tomography, 348
vasoreactivity in cerebral arteriosclerosis, without carotid stenosis, 911(ab)
- Xe-133 SPECT imaging**
developmental childhood dysphasia, 792(ab)
Sturge-Weber cerebral angiomas, 792(ab)
- Brain death**, diagnostic options, 2026(ab)
- Breast**
AIDS and, 1607(le)
cancer
baseline bone scan, 1045
ER-positive, I-123 estradiol, 853(ab)
In-111 anti-CEA imaging, subtraction techniques, 899(ab)
mucin-like carcinoma-associated antigen, clinical value, 894(ab)
scintigraphic sternal lesions in, 324
Ga-67 uptake, 1606(le)
patient with hypothalamic granuloma, 118
internal lymph nodes, localization by radionuclide lymphoscintigraphy, 473
internal mammary lymphoscintigraphy, ultrasonic guidance for, 1744(le)
painful metastasis in bone, Sr-89 chloride, treatment results, 763(ab)
synthesis and target tissue uptake, progesterin receptor-based radiotracer, 768(ab)
- Breastfeeding**, internal and external radiation dose, nursing child, Tl-201-exposed mother, 874(ab)
- Breast milk**
excretion of I-131, lactating patient with Grave's disease, 407
In-111 in, 1301(le)
- Bromine-77 bromospiperone**, no-carrier-added synthesis, nucleophilic bromodeiodination, 776(ab)
- Bromoacetylation**, synthesis of para-substituted phenyl glyoxals, 928(ab)
- 3-Bromopropyl triflate**, compared to iodoalkyl triflates, F-18 radiolabeling, secondary amines, 754(ab)
- Brookhaven National Laboratory**
contract with USDOE, N292
Esselen Award for PET research, N440
- Budd-Chiari syndrome**, Xe-133 splenoportography, 423(le)
- Bursitis**, trochanteric, bone scanning, 763(ab)
- C**
- CA125**, recognition by monoclonal antibodies, *in vitro* and *in vivo* use, 766(ab)
- Cachexia**, cancer, N-13 glutamine transport, skeletal muscle, 902(ab)
- Calcitonin**, human serum, evaluation, commercial radioimmunoassay kit, 766(ab)
- Calcium**, unique non-invasive measurement method, tissues, 883(ab)
- Calcium-45**, osteoporosis, eating disorder patients, 882(ab)
- Calcium-47**, early diagnosis of metabolic bone disease, dual tracer method, 780(ab)
- Campylobacter pylori**, gastritis associated with, C-14 urea breath test for, 11
- Campylobacter pyloridis**, C-14 urea breath test, 789(ab), 790(ab)
- Cancer**
see also specific type
anti-antibody enhancement, monoclonal antibody imaging, 757(ab)
bone, Sn-117m therapy, high specific activity, 849(ab)
colonic, radiolabeled monoclonal antibodies, 762(ab)
SM-153 EDTMP
disseminated skeletal metastasis, SPECT, 762(ab)
metastatic bone, dose tolerance, 775(ab)
- Captopril**
abnormal renogram, Tc-99m hippuran analog, 1730
quantitative radionuclide studies, renal artery stenosis, 908(ab)
renal scintigraphic test, angiographic data comparison, glomerulonephritis, 907(ab)
renography
effects, volume depletion, 849(ab)
Goldblatt hypertension, 575(le)
renal artery stenosis, 850(ab)
saralasin comparison, hypertension, 849(ab)
renovascular hypertension, comparison of radioactive agents, rat model, 509
Tc-99m MAG₃, renovascular hypertension, 849(ab)
- Carbon-11 D,L-homocysteine thiolactone**, potential tracer for myocardial ischemia, PET, 755(ab)
- Carbon-11 acetate**
myocardial oxidative metabolism, 808(ab)
clearance, 937(ab)
myocardial infarction, PET, 818(ab)
normal myocardium, 937(ab)
stunned myocardium, dynamic PET, 782(ab)
probe for myocardial metabolism, simple and efficient synthesis, 932(ab)
- Carbon-11 ACHC**, uptake in human brain, effect, dietary aspartame, 784(ab)
- Carbon-11 AIB**, imaging studies, malignant melanoma, 904(ab)
- Carbon-11 buprenorphine**, compared to C-11 diprenorphine, brain uptake, PET, 933(ab)
- Carbon-11 carbon dioxide**, trap for removing oxides of nitrogen, 933(ab)
- Carbon-11 carbon monoxide**, blood volume measurement, carboxyhemoglobin half-life, systemic hematocrit, 894(ab)
- Carbon-11 carfentanil**, C-11 diprenorphine and, opiate receptor binding, dual detector system, 921(ab)
- Carbon-11 CGP 12177**, halothane-induced decrease, myocardial beta adrenoceptor, PET, 940(ab)
- Carbon-11 diprenorphine**
binding to opiate receptors in man, PET, 796(ab)
C-11 buprenorphine and, brain uptake, PET, 933(ab)
C-11 carfentanil and
opiate receptor binding, dual detector system, 921(ab)
opiate receptors in man, PET, 796(ab)
- Carbon-11 DMHDA**, synthesis and biologic evaluation, 68
- Carbon-11 malonate platinum**, PET studies, 1107
- Carbon-11 methionine**
abnormal oxidation, schizophrenia, 784(ab)
cerebral neutral amino acid accumulation, maturation, PET study, 784(ab)

- kinetics model, human brain, 822(ab)
- Carbon-11 3-methoxybenzodiazepines**, new radioligands for PET studies, benzodiazepine receptors, 755(ab)
- Carbon-11 methyl-L-tryptophan**, no-carrier-added, synthesis, 370
- Carbon-11 nisoxetine**, fluoxetine and, syntheses, 932(ab)
- Carbon-11 nitroalkanes**, production, synthesis, D-glucose and β -phenethylamine, 754(ab)
- Carbon-11 NMPB**, synthesis and regional brain distribution, 768(ab)
- Carbon-11 prazosin**, synthesis of, 930(ab)
- Carbon-11 pyruvate**, metabolism in brain and muscle, mitochondrial encephalomyopathy, PET, 921(ab)
- Carbon-11 raclopride**, kinetic analysis, central D-2 dopamine receptors, 820(ab)
- Carbon-11 Ro15-1788**
benzodiazepine receptors
PET studies, 931(ab)
quantitative analysis, living brain, 809(ab)
- Carbon-11 SarCNU**, synthesis, 1957
- Carbon-11 scopolamine**, muscarinic receptor imaging in brain, PET, 808(ab)
- Carbon-11 TRB**, synthesis and preliminary evaluation, ligand, muscarinic receptor, 932(ab)
- Carbon-11 YM-09151-2**, dopamine D-2 specific brain uptake, 931(ab)
- Carbon-14 iodoantipyrine**, kinetic evaluation of 3H-cyclofoxy, rat brain, 796(ab)
- Carbon-14 urea**
breath taste, diagnosis of *Campylobacter pylori* associated gastritis, 11
breath test
Campylobacter pyloridis gastric disorders, 789(ab), 790(ab)
reproducibility, *Campylobacter pyloridis*, 790(ab)
- Carboxyhemoglobin**, correlation with systemic hematocrit, blood volume measurement, C-11 carbon monoxide, 894(ab)
- Carcinoembryonic antigen (CEA)**
circulating antigen levels and molecular size, biodistribution, labeled monoclonal antibodies, 890(ab)
correlation of radiochemical yield, chelator concentration, In-111 labeled antibody-chelator conjugates, 924(ab)
I-131-labeled monoclonal antibodies, radioimmunotherapy, phase I/II trial, 846(ab)
In-111 anti-CEA, unlabeled F(ab')₂ fragment, colorectal cancer, 834(ab)
In-111 anti-CEA monoclonal antibody ZCE 025, detection, colorectal carcinoma, 812(ab)
In-111 Fab', compared to In-111 F(ab')₂ derivative, 812(ab)
In-111-labeled monoclonal antibody detection, occult metastatic cancer, 833(ab)
tumor mass as determining factor, biodistribution, 926(ab)
monoclonal antibodies
cancer imaging, anti-antibody enhancement, 757(ab)
effects of uptake, external beam radiation, 926(ab)
pancreatic oncofetal antigen and, combined assay, digestive system cancer, 906(ab)
-producing tumors
diagnostic value, immunoscintigraphy, 811(ab)
radioimmunodetection, I-123 antibody fragments, 898(ab)
radioimmunopharmaceuticals, intact vs. fragments, tumor model, 893(ab)
radiolabeled antibodies, imaging of pancreatic cancer, 833(ab)
Tc-99m-labeled monoclonal antibody, immunoscintigraphy, colorectal carcinoma, 834(ab)
- Carcinoma, breast**, mucin-like carcinoma-associated antigen, monitoring, clinical value, 894(ab)
- Carcinoma, colon**
imaging, I-131 16-88 monoclonal antibody, 833(ab)
imaging by Tc-99m monoclonal antibody, 834(ab)
multicell spheroids, radioimmunotherapy, 858(ab)
radiolabeled monoclonal antibodies, 762(ab)
- Carcinoma, colorectal**
detection of
In-111 anti-CEA mAb ZCE 025, 812(ab)
SPECT compared to planar imaging, 886(ab)
known and occult, Tc-99m anti-CEA, immunoscintigraphy, 834(ab)
localization, In-111 monoclonal antibody, 898(ab)
presurgical screening, anti-CEA monoclonal antibody, 897(ab)
radioimmunoscintigraphy, In-111 antibody, compared to In-111 anti-CEA, 899(ab)
radiolabeling of monoclonal antibodies, bifunctional chelate, 814(ab)
recurrent tumors, evaluation, PET, 751(ab)
tumor targeting of radiolabeled monoclonal antibody, chemical bond modification, 889(ab)
unlabeled F(ab')₂ fragment, In-111 F(ab')₂, biodistribution, 834(ab)
- Carcinoma, hepatocellular**
massive type, application, I-131 lipiodol, 799(ab)
recurrent, Ga-67 citrate imaging, 712
Tc-99m DISIDA, hepatobiliary agent in diagnosis, 1916
- Carcinoma, lung**
imaging by Tc-99m monoclonal antibody, 834(ab)
In-111 monoclonal antibody, imaging and kinetics, 896(ab)
- Carcinoma, ovarian**, enhanced uptake, radiolabeled monoclonal antibody, 900(ab)
- Carcinoma, pancreatic**, imaging with antibodies to CEA, 833(ab)
- Carcinoma, renal cell**, escalating single and multiple fraction low dose rate, I-131 monoclonal antibodies, 875(ab)
- Carcinoma, squamous cell**, serum TA-4 as marker, lung and other organs, 765(ab)
- Carcinoma, testicular**, radioimmunodetection, human xenograft in athymic mice, 896(ab)
- Carcinoma, thyroid**
criteria for ablation of normal tissue, after surgery, 885(ab)
medullary, MIBG uptake, animal model, 893(ab)
Tc-99m MIBI and Tl-201 uptake, 854(ab)
value of total body scans, I-131 therapy, 885(ab)
- Cardiac output**, first-pass radionuclide determination, gamma camera method, 1154(le)
- Cardiomyopathy**
detection, animal model, quantitative autoradiography, 1697
dilated, myocardial gallium uptake, 274(ab)
dilated and ischemic, profile analysis, PET, 818(ab)
hypertrophic, myocardial glucose metabolism, PET, 828(ab)
hypertrophic obstructive, Tl-201 imaging, 1738
Carotid artery, adherence, In-111 endothelial cells, 939(ab)
Carotid endarterectomy, prediction of successful revascularization, I-123 IMP, 844(ab)
Carotid stenosis, correlation of cerebral perfusion, Tc-99m HM-PAO brain SPECT, 914(ab)
- Catecholamines**, I-125 MIBG compared to H-3 NE uptake and release, different brain regions, 911(ab)
- Catheter ablation**, phase image triangulation of accessory pathways, posteroseptal pathways, 744(ab)
- Catheterization**, cardiac, radionuclide studies and, clinical indications, 2024(ab)
- Cat-scratch disease**, liver lesion with no lymphadenopathy, 1454
- Central nervous system**
F-18 FDG compared to F-18 FDM, PET, 772(ab)
radiation necrosis, PET and NMR, 785(ab)
- Cerebrospinal fluid**, intracranial, quantifying using NMR, 132(le)
- Charcot foot**, scintigraphy of, 280(ab)
- Chelates**
bifunctional, radiolabeled antibodies, 814(ab)
influence of denticity, biodistribution, In-111 B72.3 immunconjugates, 824(ab)
optimization of ligand structure, imaging, bifunctional antibody, 835(ab)
potential metabolizable linkers, In-111 monoclonal antibody, 922(ab)
sulfur-donating, action, Tc-99m renal agents, 801(ab)
Tc-99m antibody labeling, N₃S and N₂S₂ amide mercaptides, 815(ab)
Tc-99m complexes
 α, α -disubstituted, α -hydroxy carboxylic acids, 934(ab)
3 Schiff base/oxime ligands, 936(ab)
- Chemotherapy**
how to avoid complications, intrahepatic arterial infusions, 799(ab)
intra-arterial, SPECT evaluation of, 593
-treated mammary tumor, P-31 NMR 1H-MRI study, 837(ab)
- Chernobyl**
I-131 thyroid uptake, southern Sweden, 1719
plume, biological retention, fission products, 804(ab)
travelers after, I-131 uptake, thyroid, 1152(le)
- Cholecystitis**, acute, In-111 WBC imaging, false positive hepatobiliary scan, 826(ab)
- Cholecystography**, DISIDA, pre- and post-CCK gallbladder sonography, 826(ab)
- Cholescintigraphy**, rim sign in, prognostic value, 1608(le)
- Choletec**, newly approved agent, N287
- Cholic acid**, In-111-labeled, hepatobiliary imaging agent, 926(ab)
- Chromatography**
column, In-111 DTPA protein fractions, monoclonal antibodies, 925(ab)
sizing evaluation, fate of In-111 antibodies, 923(ab)
- Circulation**, portal-systemic, evaluation, Tl-201 and Tc-99m pertechnetate, 827(ab)
- Cisternography**, radionuclide, MRI, normal

Clavicle

- pressure hydrocephalus, 836(ab)
- Clavicle, condensing osteitis, Tc-99m, 1122**
- Cobalt-57 bleomycin, delivery to brain tumors, SPECT, 187**
- Cocaine, regional cerebral glucose utilization, human substance abusers, 840(ab)**
- Collimator**
 - application of count-dependent Metz filter, bremsstrahlung imaging, 863(ab)
 - cone beam, SPECT with, 1398
 - design and manufacturing defects, nonisotropic point spread function, 1096
 - effects of scatter, spatial resolution, 845(ab)
 - gamma camera, new methods of examining, 676
 - general purpose, high resolution and, comparison, 273(ab)
 - maximum-likelihood reconstruction, cone beam SPECT, 869(ab)
 - multiplane SPECT reconstruction, 785(ab)
 - perturbation of image, renal plasma flow measurements, 909(ab)
 - radiopharmaceutical organ uptake, measurement, improved method, 861(ab)
 - rotating slant hole, determination of kidney depth, 276(ab)
 - slant hole, measurement of angle, 1745(le)
 - SPECT center of rotation measurements and, 1393
 - SPECT imaging of bremsstrahlung radiation, energy window, 876(ab)
- Compton-scatter correction**
 - SPECT
 - analysis of energy spectra, 195
 - three boundary detection methods, 203
- Computed tomography**
 - compared to MRI and PET brain imaging, acute head injury, 910(ab)
 - fast, scintigraphic phase maps, ventricular contraction, 941(ab)
 - high dose-delayed Ga-67 scintigraphy and, sarcoma, 749(ab)
 - In-111 WBC scintigraphy, febrile ICU patient, 795(ab)
 - right ventricular ejection fraction determination, three scintigraphic methods, 771(ab)
 - triple mode evaluation, subarachnoid hemorrhage, vasospasm, 743(ab)
- Computers**
 - controlled motion phantom, NMR imaging, 280(ab)
 - detection of regional wall motion abnormalities, improved probabilistic image, 863(ab)
 - instrumentation and, SNM Winter Meeting, N6 nuclear medicine systems, considerations in purchase, 717
 - suitability of microcomputer systems, numerical analysis, medical images, 865(ab)
- Computers, software**
 - alternative formulation, Wiener restoration filter, 845(ab)
 - attenuation and detector response correction, cardiac SPECT image reconstruction, 749(ab)
 - automated quantitative analysis, cardiac PET studies, 867(ab)
 - automatic calculation of LV volumes and EF, gated RP-30 tomograms, 805(ab)
 - bull's eye plot
 - emission cardiac tomography, 267(le)
 - Tl-201 myocardial perfusion scans, 1466(le)
 - cardiac imaging, patient and organ movement in SPECT, 441
 - cardiac SPECT data, evaluation, reconstruction algorithms, 748(ab)
 - compensation for collimator divergence, SPECT, maximum likelihood reconstruction, 786(ab)
 - constrained least-squares Metz filter, 864(ab)
 - correction for partial volume effects, cardiac PET, 774(ab)
 - design of simulation system, emission tomographs, 871(ab)
 - development of PET workstation, personal computer, 867(ab)
 - 3D visualization
 - coronary arterial tree, perfusion distribution, 810(ab)
 - emission and transmission data, SPECT, 786(ab)
 - SPECT image data, stereo pairs, 810(ab)
 - estimation of left ventricular mass, Tl-201 SPECT, bullseye display, 945(ab)
 - expert images, cardiac wall motion abnormalities, 846(ab)
 - expert system shell, quality assurance package, 811(ab)
 - factor analysis of bone scintigraphy, renal osteodystrophy, 883(ab)
 - FDA policy proposals, N588
 - hepatobiliary SPECT, changing radioactivity distribution, 98
 - hypermedia, new method for image analysis, 863(ab)
 - image restoration of SPECT projections, singular value decomposition technique, 749(ab)
 - image spread sheet, manipulation, digital images, 811(ab)
 - interactive digital filtering, gated cardiac studies, cine display, 864(ab)
 - in vitro* evaluation, computer processing algorithms, 862(ab)
 - lung index, Ga-67, 1154(le)
 - MACII as satellite image processing station, 810(ab)
 - maximum-likelihood reconstruction, cone beam SPECT, 869(ab)
 - monoclonal antibody therapy, treatment planning, 3D dosimetry, 803(ab)
 - Monte Carlo simulation, Compton scatter, distributed sources, 865(ab)
 - multicenter trial of Cedars-Sinai method, quantitative analysis, Tl-201 myocardial tomography, 755(ab)
 - multiplane SPECT reconstruction, compensation, collimator response, 785(ab)
 - optimization of data acquisition, SP-3000 time-of-flight PET system, 876(ab)
 - parameter estimation gating models, ventilation studies, 1842
 - parametric color coded images, analysis of Tl-201 washout, 302
 - performance of high-speed ethernet system, image archiving, nuclear medicine, 810(ab)
 - PET brain image analysis, metabolic centroid method, 774(ab)
 - physiological data, simultaneous acquisition of nuclear medicine images, 1848
 - predicting noise energy in SPECT reconstructions, 748(ab)
 - quantitative SPECT
 - empirical threshold method, 879(ab)
 - Tl-201, 756(ab)
 - receptor density and binding rate constants, single tracer injection, 863(ab)
 - registration of MRI-PET images, procedure, validation, 853(ab)
 - right ventricular ejection fraction, first-pass time-activity curves, 1990
 - simulation of collimator scatter effects, spatial resolution, 845(ab)
 - SPECT 3D modulation transfer function, stationarity, averaging opposing projections, 749(ab)
 - three-dimensional display, PET of heart, 530
 - Tl-201 myocardial imaging, correcting for patient motion, 91
 - tumor-incorporating mean absorbed dose calculation, 874(ab)
 - use of resampling methods, precision estimation, emission tomography images, 748(ab)
 - ventricular function, heart rate variation and, gating mode effects on analysis, 1272
- Cone beam reconstruction, iterative maximum likelihood method, 786(ab)**
- Congestive heart failure, radionuclear measurement, peripheral hemodynamics and selection of vasodilators, 451**
- Continuous ambulatory peritoneal dialysis, peritoneal leaks, abdominal wall and diaphragm, 1598**
- Contrast-detail curves**
 - film selection and, 272(ab)
 - logistic function, 273(ab)
- Copper bis(thio-azemcarbazones), cerebral and myocardial blood flow tracers, single-pass studies, 848(ab)**
- Copper-62 HSA, plasma volume measurement, 930(ab)**
- Copper(II) complex, synthesis of para-substituted phenyl glyoxals, bromoacetylation, 928(ab)**
- Copper-67 monoclonal antibody, cancer therapy, 217**
- Coronary artery disease (CAD)**
 - activities in ischemic heart disease patients, evaluation, ambulatory ventricular function monitor, 741(ab)
 - amplitude analysis of Tc-99m RP-30A, 805(ab)
 - antimyosin imaging, patients with ischemic chest pain, 805(ab)
 - assessment with gated magnetic resonance, 943(ab)
 - cardiac stressing, esophageal pacing, 942(ab)
 - correlation of severe obstruction, reversible Tl-201 abnormalities, 953(ab)
 - delayed recovery of myocardial metabolism, successful angioplasty, 817(ab)
 - detection of
 - dobutamine thallium imaging, 955(ab)
 - planar Tc-99m isonitrile exercise imaging, 804(ab)
 - diffuse decreased wash-out, myocardial Tl-201, quality of stress, 945(ab)
 - dipyridamole
 - coronary vasodilation, PET and N-13 ammonia, 818(ab)
 - perfusion scintigraphy, known or suspected angina, 781(ab)
 - perfusion scintigraphy, coronary events in the elderly, 781(ab)
 - serum drug level following, 1662
 - distribution of myocardial perfusion, patients surviving death, 769(ab)
 - 3D visualization of coronary arterial tree, myocardial perfusion distribution, 810(ab)
 - estimation of left ventricular mass, Tl-201, bullseye display, 945(ab)
 - exercise thallium scintigraphy, unstable angina, 945(ab)
 - extent of, lung uptake, Tc-99m MIBI, 952(ab)

- "false" positive pyrophosphate tomoscintigrams, 954(ab)
- left bundle branch block with, Tl-201 SPECT, 1479
- measurement with I-125 cholesteryl iopanoate, 503
- myocardial uptake and redistribution, RP-30 compared to SQ 32014, 819(ab)
- noninvasive detection, vasospastic angina, 782(ab)
- post-prandial changes in left ventricular function, ambulatory nuclear monitoring, 742(ab)
- quantitative methods of myocardial imaging, Tc-99m MIBI, 955(ab)
- regurgitant valvular disease, angiocardiology, 1114
- resting thallium perfusion abnormalities, coronary stenoses, unstable angina, 768(ab)
- reversible rest-redistribution thallium-201 defects, unstable angina, 768(ab)
- SQ30217 and Tl-201 planar myocardial imaging, coronary anatomy comparison, 841(ab)
- stress Tl-201 imaging post angioplasty, restenoses, recurrent symptoms, 770(ab)
- stress Tl-201 myocardial emission assessment, Kawasaki disease, 791(ab)
- Tc-99m MIBI and Tl-201 SPECT, 952(ab)
- Tl-201 SPECT
- abnormal clearance, improved assessment, 948(ab)
 - acceleration of redistribution, ribose, 953(ab)
 - blood levels and myocardial reversible defects, fasting or eating, 952(ab)
 - combined with "bullseye" analysis, 756(ab)
 - compared to Rb-82 PET, 817(ab)
 - compared to Tc-99m MIBI, 793(ab)
 - dipyridamole perfusion, compared to exercise, 838(ab)
 - evaluation, pre-renal transplant patients, 950(ab)
 - improved detection during exercise, 755(ab)
 - patients with LBBB, 279(ab)
 - perfusion studies, delayed 24-hour redistribution, 769(ab)
 - poor predictive values, inferior wall defects, 944(ab)
 - prone vs. supine position, 953(ab)
 - quantitation of, 756(ab)
 - quantitative, community hospital, 943(ab)
 - referrals, subsequent coronary angioplasty, 946(ab)
 - results of exercise/rest, 756(ab)
 - reverse redistribution, 952(ab)
 - unbiased sensitivity, specificity determinations, 946(ab)
 - wash-in and wash-out, redistribution phenomenon, 939(ab)
- Tl-201 washout, from parametric color coded images, 302
- trapping of I-123 OPPA, myocardium, 851(ab)
- triple vessel disease, exercise Tl-201 scintigraphy, benefit from surgery, 949(ab)
- utility of septal thallium perfusion pattern, discrimination, LAD or PDA disease from dual vessel disease, 942(ab)
- validation of quantitative analysis, exercise thallium tomograms, 871(ab)
- Corrections**
- amendment to author line
 - article corrections by Edward A. Deutsch
 - author correction, 1880
 - erratum correction, 1879
- figure captions switched
- residency opening, 577
- typographical error, 1897(le)
- Count rate curves**, NEMA scintillation cameras, 538
- Creutzfeldt-Jakob disease**, differential diagnosis of non-vascular dementia, SPECT, 743(ab)
- Crohn's disease**, assessment of localization and activity, reliability, Tc-99m HM-PAO-labeled leukocytes, 827(ab)
- Crossmatching**, red blood cell compatibility testing, In-111m tropolone RBC, 684
- Cyclofoxy**
- F-18-labeled PET imaging in man, 796(ab)
 - kinetic evaluation in rat brain, 796(ab)
- Cyclosporine**
- monitoring, rapid I-125 radioimmunoassay method, 766(ab)
 - nephrotoxicity, various renal radioactive agents, 1577
- Cyclotron**, 11 MeV proton model, production, other radionuclides, 932(ab)
- Cytokines**, effect of administration on biodistribution, radiolabeled murine lymphocytes, 902(ab)
- D**
- Decay**, radioactive, energetics of, 1156(le)
- Deconvolution**, hepatic blood flow, arterial and portal venous components, 466
- Deiodination**, comparison of antibody conjugates, iodovinyl, para-iodophenyl, 777(ab)
- Dementia**
- AIDS complex
 - PET-FDG studies, 852(ab)
 - SPECT, 1382
 - assessment, Xe-133 SPECT, 1621
 - asymptomatic HIV seropositive persons, SPECT imaging, I-123 isopropyl amphetamine, 742(ab)
 - diamox and HIPDM, 734(ab)
 - Huntington's disease, I-123 IMP brain imaging, 916(ab)
 - I-123 IMP and Tc-99m HM-PAO SPECT compared to PET, 916(ab)
 - left hemisphere dysfunction, FDG/PET scans, Alzheimer's disease, 912(ab)
 - non-vascular, differential diagnosis, SPECT, 743(ab)
- Department of Energy (DOE)**
- applicants for research grants, N1760
 - appropriation for research in nuclear medicine, N1167
 - workshop, improved availability of research isotopes, N1611
- Diabetes**
- autonomic neuropathy, sudden cardiac death in, 1605(le)
 - foot, In-111 chloride, 279(ab)
 - I-123 free fatty acid metabolism, ischemic myocardium, 842(ab)
 - In-111 chloride imaging in foot, 813(ab)
 - Tc-99m DTPA and I-125 iothalamate plasma clearances, 816(ab)
- Dialysis**, continuous ambulatory peritoneal, utility, Tc-SC intraperitoneal scan, 817(ab)
- Diamide dithiolate ligands**, stereochemistry of Tc-99m N₂S₂ complexes, 800(ab)
- Diet**
- effect of caloric content, gastric emptying, 751(ab)
 - effect of dietary fiber, gastric emptying, 751(ab)
 - labeled chicken liver and egg-white as solid markers, gastric emptying studies, 752(ab)
- Dipyridamole**
- lung uptake of Tl-201, global left ventricular dysfunction, 953(ab)
 - myocardial perfusion imaging, coronary vasodilation, 781(ab)
 - noninvasive detection of coronary artery disease, vasospastic angina, 782(ab)
 - perfusion scintigraphy, coronary event prediction, elderly, 781(ab)
 - regional myocardial blood flow, assessment, N-13 ammonia PET, 838(ab)
 - single oral dose, serum drug level following, 1662
 - SPECT Tl-201 perfusion, compared to Tl-201 exercise SPECT, coronary artery disease, 838(ab)
 - Tl-201 imaging
 - ambulatory ventricular function monitor, chest pain, 742(ab)
 - complications predictions, non-cardiac surgery, 838(ab)
 - elderly patients, 953(ab)
 - prediction, in-hospital ischemia, 781(ab)
 - ST segment depression, myocardium, 782(ab) - Tl-201 tomographic scintigraphy, significance, ECG changes, 945(ab)
 - tomographic myocardial perfusion, Tc-99m SQ 30217, 938(ab)
- Distraction epiphysiolysis**, lower limb lengthening, bone healing during, 1259
- Diuresis**
- renography
 - degree of hydronephrosis, renal function, 816(ab)
 - intrapelvic pressure, frusemide, 816(ab)
- Dobutamine**, thallium imaging, detection, coronary artery disease, 955(ab)
- Donner Laboratory**, nuclear medicine innovation, N431
- L-DOPA**, use of phenylalanine dehydrogenase for synthesis, N-13, 931(ab)
- Dopamine**, uptake blocker, F-18 GBR 13119, synthesis and brain uptake, 767(ab)
- Dopamine receptors**
- binding sites in baboon brain, SPECT, 848(ab)
- D-1**
- I-123-IBZP imaging agent, 758(ab)
 - radiation dosimetry, SCH 23982, 803(ab)
 - radioiodinated SCH 23982, SPECT, 929(ab)
- D-2**
- brain uptake, C-11 YM-09151-2, 931(ab)
 - dynamic FESP interactions, PET, 865(ab)
 - (ethyl-F-18)fluororaclopride, PET, 767(ab)
 - I-123-IBZM imaging agent, 759(ab)
 - imaging by SPECT, 922(ab)
 - kinetic analysis, C-11 raclopride, 820(ab)
 - PET investigation, 3-N-(F-18) fluoroethylspiperone, 821(ab)
 - quantification by PET, various models, 922(ab)
 - Tourette's syndrome, manic depressive illness, 820(ab)
 - new analogs of radioactive iodobenzamide, brain imaging agents, 777(ab)
- Dosimetry**
- absorbed fractions for electrons, beta particles, small spheres, 803(ab)
 - biodistribution of In-111 liposomes, normal persons, 873(ab)
 - biodistribution of Tc-99m MIBI, 874(ab)
 - biological retention of fission products, Chernobyl plume, 804(ab)
 - bremstrahlung, component, Y-90 monoclonal antibody therapy, 859(ab)

DTPA complex

- clinical thermoluminescent dosimeter, 872(ab)
extra-articular leakage, radiation synovectomy, dysprosium-165-FHMA, 873(ab)
- I-131 monoclonal antibodies
estimation, absorbed radiation dose, 900(ab)
fractionation of lym-1, radioimmunotherapy, 847(ab)
liver and lung tumors, 874(ab)
- In-111 oxine, children, 689
- In-111 ZCE-025 anti-CEA monoclonal Fab' fragments, biodistribution, 896(ab)
- internal and external radiation dose, nursing child, Tl-201 to mother, 874(ab)
- method for estimating organ brake radiation doses, 875(ab)
- physics protocol for UKCCSG toxicity, I-131 MIBG, resistant neuroblastoma, 798(ab)
- radiation
absorbed dose of I-123, I-131, and Tc-99m DTPA, 400
In-111, human melanoma, 329
thyroid uptake of I-131 after Chernobyl, 1152(le)
treatment of hepatoma, 1038
tumor uptake, as a function of tumor mass, mathematical model, 103
radiation calculations, urinary bladder model, 875(ab)
radioimmunotherapy, patient-specific kinetics and S-values, 2030(ab)
radioimmunotherapy for micrometastases, At-211, 858(ab)
radioiodinated SCH 23982, biological distribution, 803(ab)
red marrow, radiolabeled monoclonal antibody therapy, sacrum, 858(ab)
selection of nuclides, immunoscintigraphy, immunotherapy, 875(ab)
theoretical tumor absorbed doses, radioimmunotherapy, 858(ab)
thermoluminescent, micro, radioimmunotherapy measurement, 1795
tissue-equivalent anthropomorphic phantom, imaging studies, 803(ab)
treatment planning, monoclonal antibody therapy, 803(ab)
treatment planning for monoclonal antibody therapy, quantitative planar imaging, anthropomorphic phantom, 845(ab)
tumor-incorporating mean absorbed dose calculation, 874(ab)
- DTPA complex**, conjugated monoclonal antibodies, cellular characterization, hepatocytes, 823(ab)
- Dual-detector probe**, surgical tumor staging, 1101
- Dual energy acquisition**, correction factors for, 2028(ab)
- Dual-photon absorptiometry (DPA)**
accuracy, excised femurs, 1853
bone density measurements, spine and distal forearm, osteoporosis, 131(le)
bone mineral content
distribution in skeleton, 881(ab)
lumbar spine, 248
spine/hip/forearm, primary hyperparathyroidism, 855(ab)
bone mineral loss, normal postmenopausal women, 881(ab)
frontal and lateral measurements, lumbar spine, vertebral body strength, 856(ab)
hormonal relationship of bone density, premenopausal women, 859(ab)
osteoporosis
aminobisphosphate treatment, 884(ab)
eating disorder patients, 882(ab)
non-hormonal therapy, 855(ab)
spinal, diagnostic sensitivity, 882(ab)
precision of, 880(ab)
- Dual probe positron detector**, duration of occupancy of opiate receptors, naltrexone, 1207
- Duodenal bulb**, chronic ulcer, scintigraphic study, 17
- Duodenal-gastric reflux**, hepatobiliary imaging of, 17
- Dysphasia**, childhood, Xe-133 brain SPECT imaging, 792(ab)
- Dysprosium-165**, activable isotopes of, biodegradable radiotherapeutic microspheres, 903(ab)
- Dysprosium-165 ferric hydroxide macroaggregates**, radiation synovectomy for, 275(ab)
- Dysprosium-165-FHMA**, extra-articular leakage, radiation synovectomy, 873(ab)

E

- Eating disorders**, osteoporosis, 882(ab)
- Echocardiography**, Doppler techniques and, 2024(ab)
- Editorials**
Nuclear hepatology: Where is it heading now?, 1144
Of special note, 125
SPECT of the brain and heart—future directions, 567
- Education and Research Foundation**, student fellowships, N1338
- Ejection fraction**
cardiac
central circulatory function and, multi-probe device, 832(ab)
energy window effects, 385
response to various activities, ischemic heart disease patients, VEST, 741(ab)
cine NMR quantification, aortic regurgitation, 802(ab)
counts-based index, ECG-gated myocardial perfusion scans, 947(ab)
in vitro evaluation, computer processing algorithms, 862(ab)
left ventricular
exercise response, aortic regurgitation, 744(ab)
impaired filling, exercise response, 772(ab)
inspiratory reduction mechanism, stroke volume :949(ab)
measurement, 274(ab)
volume calculation, gated radionuclide angiography, 745(ab)
quantification of infarct size, Tc-99m RP-30A and SPECT, 946(ab)
right ventricular
determination, three scintigraphic methods, 771(ab)
enhanced exercise performance, balloon valvotomy, 945(ab)
first-pass time-activity curves, 1990
noninvasive method for determination, 2029(ab)
- Electrocardiogram (ECG) gating**, gating mode effects, analysis of left ventricular function, 1272
- Electrolytes**, unique non-invasive measurement method, tissues, 883(ab)
- Electron microscopy**, internal conversion, Tc-99m oxidation state measurement, 789(ab)
- Emission computed tomography**
Alzheimer's dementia and normal aging, comparisons, CT and MR, 852(ab)
C-11 acetate, myocardial oxidative metabolism, 808(ab)
compensation for collimator divergence, SPECT, maximum likelihood reconstruction, 786(ab)
design of simulation system, 871(ab)
edge detection, evaluation, various strategies, 868(ab)
FDG, primary visual cortex hypometabolism, head injury, 830(ab)
F-18 uracil accumulation, liver metastases, 776(ab)
high resolution PET scanner, double wobbling mode, 877(ab)
I-123 free fatty acid metabolism, ischemic myocardium, diabetes, 842(ab)
multi-slice brain SPECT, position-sensitive bar detector system, 760(ab)
optimum Butterworth-Wiener filter, I-123 IMP brain SPECT, 879(ab)
persistent Tl-201 defects, significance, metabolic activity, 827(ab)
position-sensitive bar detector system, multi-slice brain SPECT, 760(ab)
quantitative bone scintigraphy, 881(ab)
quantitative SPECT, empirical threshold method, 879(ab)
regional
correction for brain atrophy effects, PET, 773(ab)
left ventricular wall motion assessment, bull's eye display, cardiac blood pool SPECT, 745(ab)
reversibility bullseye polar map, myocardial ischemia, 951(ab)
selection of tracers and experimental procedures, blood flow and metabolism, 862(ab)
simple high resolution PET camera detector design, 761(ab)
stress-induced ischemia, N-13 ammonia, coronary bypass surgery, 817(ab)
subcortical metabolic alterations, partial epilepsy, 830(ab)
three-dimensional cone beam reconstruction, iterative maximum likelihood method, 786(ab)
validation of absolute quantitation, calibration phantom, 871(ab)
workload and sex-related variability, myocardial fatty acid utilization, normals, 841(ab)
- Emphysema**
I-123 HIPDM
lung scintigraphy, 905(ab)
metabolic lung imaging, pulmonary hypertension, 765(ab)
- Endocarditis**, bacterial, In-111 leukocyte scintigraphy, 794(ab)
- Energy window**, cardiac ejection fraction and, 385
- Epidermal growth factor receptor**, glioma radioimmunotherapy, I-125 monoclonal antibody, 847(ab)
- Epilepsy**
children
I-123 iofetamine tomography, 892(ab)
interictal SPECT-HMPAO, 792(ab)
surgery, role of PET, 831(ab)
controlled partial, cerebral blood flow, SPECT, 892(ab)
frontal lobe, F-18 FDG PET scanning, 831(ab)
opiate receptor measurement, C-11 diprenorphine and carfentanil, 796(ab)
partial

- PET compared to MRI, 910(ab)
subcortical metabolic alterations, 830(ab)
registration of MRI-PET images, procedure, validation, 853(ab)
seizure disorders, remote hypometabolic effects, 920(ab)
temporal lobe, side localization, SPECT, 916(ab)
- Esophagus**
Barrett's, Tc-99m pertechnetate scintigraphy, 886(ab)
function study using radiolabeled paté, 885(ab)
imaging probe for tumor detection, 878(ab)
motility disorders, new parametric imaging technique, 856(ab)
pacing, cardiac stressing, 942(ab)
- Esselen Award**, PET research, Brookhaven National Laboratory, N440
- Estrogen**, bone mineral loss, normal postmenopausal women, 881(ab)
- Estrogen receptors**, -positive breast cancer detection, I-123 estradiol, 853(ab)
- European Association of Nuclear Medicine (EANM)**
first congress, N1618
second congress, N1883
SNME and ENMS disband and support EANM, N7
- European Nuclear Medicine Society (ENMS)**, SNME and, formation of European Association of Nuclear Medicine, N7
- Exercise**
changes in myocardial FFA metabolism, I-123 HDA, 851(ab)
detection of coronary artery stenoses, PET, 837(ab)
ejection fraction response, impaired left ventricular filling, 772(ab)
electrocardiography, quantitative TI-201 planar imaging, single vessel disease, 948(ab)
improved detection of coronary artery disease, TI-201 SPECT, 755(ab)
left ventricular ejection fraction, contractile state, aortic regurgitation, 744(ab)
lung uptake of TI-201, global left ventricular dysfunction, 953(ab)
post-, perfusion tracers, distribution behavior, 942(ab)
prediction of coronary events, TI-201 quantitation, jeopardized myocardium, 770(ab)
rest and, N-13 glutamate myocardial uptake, PET, 950(ab)
thallium tomograms, validation, quantitative analysis, 871(ab)
TI-201 scintigraphy, benefit from surgery, triple vessel disease, 949(ab)
TI-201 SPECT
blood levels and myocardial reversible defects, fasting or eating, 952(ab)
compared to dipyridamole, coronary artery disease, 838(ab)
coronary artery disease, 756(ab)
upright, redistribution of visceral blood volume, 1714
- Eye**, radioimmunoscintigraphy, sensitivity and practical considerations, 1031
- F**
- Factor analysis**
biplane contrast angiography and phase images, detection, regional wall motion abnormalities, 771(ab)
bone scintigraphy, renal osteodystrophy, 883(ab)
correction of activity cross-contamination,
myocardium and cardiac cavity, PET, 866(ab)
dynamic renal studies, urology, 816(ab)
- Fatty acids**
C-11, synthesis, myocardial, 68
derivatives of PnAO, tracers, myocardial metabolism, 934(ab)
 β -hydroxy, acylation, "masked" malonic ester, 848(ab)
influx in myocardium, biochemical characteristics, 940(ab)
19-iodo-3,3-dimethyl-18-nonadecenoic acid uptake, myocardium, hypertension, 843(ab)
- metabolism**
ischemic myocardium, diabetes, 842(ab)
I-131 OPPA and PPPA, heart, 938(ab)
methyl-branched, myocardial metabolism of, 1230
preserved I-123 IPPA uptake, reperfused myocardium, 842(ab)
Tc-99m DADS-amido-, myocardial imaging, 935(ab)
Tc-99m diaminodithiol-, myocardial imaging, 935(ab)
Tc-99m-labeled analogs, 935(ab)
utilization in myocardium, workload and sex-related variability, SPECT, 841(ab)
- Femur**, excised, accuracy of dual-photon absorptiometry, 1853
- F-18 fluoropropylputrescine**, potential PET imaging agent, 750(ab)
- Fiber**, dietary, effect on gastric emptying, 751(ab)
- Fibrin**, monoclonal antibodies, uptake by mouse cancer, coagulative properties, 899(ab)
- Fibrinopeptide-A**, measurement in single urine sample, fibrin generation, 766(ab)
- Fibrosarcoma**, paramagnetically-labeled low density lipoproteins, GA-67, 890(ab)
- Film**
selection, lesion detectability curves and, 272(ab)
sensitometry, logistic distribution application to, 273(ab)
- Fluoride ion**, multiphase extraction, nucleophilic radiolabeling reactions, 931(ab)
- Fluorine-18**
Alzheimer's dementia and normal aging, comparisons, CT/MR/PET, 852(ab)
arterial sampling vs. quantitative LV cavity imaging, cardiac PET, 772(ab)
cerebral glucose metabolism, sensitivity to age, risk factors, 852(ab)
comparison of bromo vs. iodoalkyl triflates, radiolabeling, secondary amines, 754(ab)
mapping glutamate receptor channels, MK-801 analogs, 930(ab)
metabolic maturation in cat brain, 772(ab)
N-(3-fluoropropyl)MK-801, NMDA receptors, 932(ab)
- PET**
cerebral glucose metabolism, 631
evaluation of uptake, post-infarct myocardium, 783(ab)
polymer-supported NCA nucleophilic radiofluorination, 754(ab)
regional and temporal haloperidol distribution, brain, 767(ab)
remote hypometabolic effects, seizure disorders, 920(ab)
- Fluorine-18 cyclofoxy**, PET imaging in man, 796(ab)
- Fluorine-18 deoxyglucose**, planar scintigraphy, myocardial glucose metabolism, 828(ab)
- Fluorine-18 6-L-DOPA**, brain imaging,
asymptomatic MPTP-lesioned monkeys, 820(ab)
- Fluorine-18 FENP**, synthesis and target tissue uptake, breast, 768(ab)
- Fluorine-18 FESP**, measurement of serotonin 52 neuroreceptor densities, PET, double-injection method, 809(ab)
- Fluorine-18 fluoride**, multiphase extraction, nucleophilic radiolabeling reactions, 931(ab)
- Fluorine-18 fluoroalkyl diprenorphine**, PET studies of opiate receptors, 930(ab)
- Fluorine-18 fluorodeoxyglucose**
arterial, limitations of, proxy for brain capillary FDG, 822(ab)
cerebellar metabolism, brain trauma, 822(ab)
cerebral metabolic rate, glucose, 392
compared to F-18 FDM, PET, 772(ab)
detection of tumor involvement, lymph nodes, 904(ab)
dynamic and static PET, quantitation of uncertainties, 912(ab)
evaluation of treatment response to radiotherapy, head and neck cancer, 1521
high resolution in human brain, event requirements, 760(ab)
- PET**
coordinate system, neuroanatomy localization, 918(ab)
coronary artery stenoses, exercise, 837(ab)
frontal lobe epilepsies, 831(ab)
left hemisphere dysfunction, Alzheimer's disease, 912(ab)
primary visual cortex hypometabolism, head injury, 830(ab)
quantitative comparison, metabolic rates, 867(ab)
rate constants, degenerative brain disorders, 915(ab)
role, pediatric epilepsy surgery, 831(ab)
therapeutic effects, transarterial embolization to liver tumors, 886(ab)
subcortical indices of hypometabolism, olivopontocerebellar atrophy, 913(ab)
- Fluorine-18 2-fluorodeoxyglucose**
compartmental model, ion-exchange assay, tissue radioactivity, 939(ab)
quality control, hexokinase reaction, 1443
- Fluorine-18 fluorodinitrobenzene**, myocardial glutathione detoxification system, 808(ab)
- Fluorine-18 fluoro-L-dopa**, metabolites, human blood, 363
- Fluorine-18 fluoroethylpiperone**, PET investigation, dopaminergic system, 821(ab)
- Fluorine-18 fluorometaraminol**
evaluation of kinetics, myocardium, PET, 807(ab)
marker of neuronal injury, "stunned" myocardium, 938(ab)
- Fluorine-18 fluoromisonidazole**, potential marker of salvageable myocardium, 807(ab)
- Fluorine-18 fluorophenylalanine**, new imaging agent, brain tumors, 919(ab)
- Fluorine-18 fluororaclopride**, alkylation of desethyl precursor, dopamine D-2 receptors, PET, 767(ab)
- Fluorine-18 fluorotrimethylsilane**, labeling of 16-fluoropalmitic acid, no aqueous evaporation step, 930(ab)
- Fluorine-18 2-fluorotyrosine**, potential tracer, *in vivo* cerebral protein synthesis, 754(ab)
- Fluorine-18 FUDR**, hepatoma heterotransplant uptake, 903(ab)
- Fluorine-18 GBR 13119**, synthesis and regional

Fluorine-18 PCP analogs

brain uptake, 767(ab)

Fluorine-18 PCP analogs, PET study, 767(ab)

Fluorine-18 sex hormones, uptake in mammalian brain, F-18 ligands, PET, 795(ab)

Fluorine-18 uracil, accumulation in liver metastases, 776(ab)

Fluorine-19, NMR spectroscopy, 5-fluoro-2',3'-dideoxycytidine, AIDS virus, 837(ab)

Fluoromisonidazole

enhanced binding, hypoxia, myocytes, 807(ab)
F-18-labeled, marker, salvageable myocardium, 807(ab)

16-Fluoropalmitic acid, labeling of, use, F-18 fluorotrimethylsilane, 930(ab)

Fluoxetine, C-11-labeled, synthesis of, 932(ab)

Food and Drug Administration (FDA)

clarification of policies, commentary, N1472
drugs and biologics in separate centers, N146
limiting physician-sponsored INDs, N137
newly approved agents in 1987, N287
Office of Orphan Product Development, funds underused by nuclear medicine researchers, N1011

policies on radiochemicals and PET products, N142

reclassification of NMR instruments, N592
software policy proposals, N588

Foot, surgical radiation probes, 881(ab)

Fourier mapping, multiharmonic, location of onset, ventricular tachycardia, 744(ab)

Frusamide

diuresis renography
degree of hydronephrosis, 816(ab)
intrapelvic pressure, 816(ab)

Furosemide, renovascular hypertension, comparison of radioactive agents, rat model, 509

G

Gadolinium-153

bone mineral content, dual-photon absorptiometry, 248
bone mineral distribution in skeleton, dual-photon absorptiometry, 881(ab)
frontal and lateral DPA measurements, lumbar spine, vertebral body strength, 856(ab)

Gadolinium-DTPA

gated MRI and, serial assessment, myocardial infarction, 802(ab)
iron compounds as MRI contrast agents, liver, 837(ab)

Gadolinium-153 DTPA

comparison with Tc-99m DTPA, biodistribution, 1683
pharmacokinetic analysis, distribution, dog blood, 891(ab)

Gallbladder, pre- and post-CCK sonography, DISIDA cholecystography, 826(ab)

Gallium-67

accuracy, occult infection, 608
detection of infection, delayed/non-union fractures, 813(ab)
diagnostic pattern of uptake, lymphocytic interstitial pneumonitis, 887(ab)
esophageal imaging probe, tumor detection, 878(ab)
high dose-delayed scintigraphy, sarcoma, compared with CT and MRI, 749(ab)
HIV+ patients, 281(ab)
increased delivery to tumors, serum-stable liposomes, 516
lung index computerization, interstitial pneumonitis, 1154(le)
mechanism of tumor accumulation, 2019(le)

cell membrane permeability and, 663
paramagnetically-labeled low density lipoproteins, fibrosarcoma, 890(ab)
pulmonary activity, tobacco smoking, HIV-positive persons, 829(ab)
renal hyperactivity, AIDS patients, 909(ab)
salmonella costochondritis, 2004
SPECT, chest, 276(ab)
uptake
bilateral breast, 1606(le)
breast, AIDS and, 1607(le)
myocardial, dilated cardiomyopathy, 274(ab)

Gallium-67 citrate

biodistribution, tumor stage and metastasis effects, Lewis lung carcinoma model, 1252
comparison of planar and SPECT images, chest, CT in lymphoma patients, 898(ab)
detection of intracardiac malignant lymphoma, 1868
diagnosis and follow-up of neuroblastoma, 750(ab)
osteoclast nuclei localization, Paget's disease, 1083
radiation pneumonitis
assessment of, lung cancer, 829(ab)
detection of, lung cancer, 888(ab)
recurrent hepatocellular carcinoma, 712
response prediction, therapy, diffuse large-cell lymphoma, 799(ab)

uptake

benign adrenocortical adenoma, 1451
breast, patient with hypothalamic granuloma, 118
pediatric AIDS patient, 707
variable presentation of PCP, HIV-positive persons, 829(ab)

Gallium-68

low cost large area positron camera, physical evaluation, 877(ab)
macromolecular tracer, vascular permeability, 939(ab)

Gallium-68 deferoxamine-galactosyl-neoglycoalbumin, regional measurement, hepatic receptor concentration, 933(ab)

Gallium-68 DTPA-LDL, receptor activity with PET, 848(ab)

Gallium-72 nitrate, skeletal radiotherapeutic agent, 776(ab)

Gamma cameras

acceptance testing, 267(le)
collimator, new methods of examining, 676
determination of weighting coefficients, energy weighted acquisition, 845(ab)
dual-headed digital, dynamic flow studies, 272(ab)
estimation of tumor uptake, I-131 MIBG, 542
handheld low power, design considerations, 832(ab)
I-123 HIPDM lung scintigraphy, chronic obstructive pulmonary disease, 905(ab)
imaging characteristics of MUMPI, cylindrical neuro-SPECT system, 832(ab)
multi-probe device, cardiac and central circulatory function, 832(ab)
multiwire
first-pass radionuclide angiography, 293
high volume clinical applications, 1526
myocardial glucose metabolism, perfusion imaging, F-18 deoxyglucose and TI-201, 828(ab)
performance of high-speed ethernet system, image archiving, nuclear medicine, 810(ab)
planar, radionuclide content, liver or spleen of abdominal phantom, 845(ab)

quantitative planar imaging, treatment planning, monoclonal antibody therapy, 845(ab)
scatter removal, pre- and post-processing techniques, 798(ab)
Tc-99m DTPA clearance, healthy non-smokers, 905(ab)

Gas, inert, Kr-81m/Tc-99m MAA ventilation perfusion ratio, weaning, 764(ab)

Gastric function

Campylobacter pyloridis, C-14 urea breath test, 789(ab), 790(ab)
emptying
body position, 751(ab)
caloric content, 751(ab)
dietary fiber, 751(ab)
distal stomach removal, 752(ab)
Garren-Edwards gastric bubble, 857(ab)
gender-related differences, 573(le)
high resolution scintigraphy, 857(ab)
LAO view, attenuation compensation, 752(ab)
noninvasive determination, antral motility, 862(ab)
small bowel transit and, ileal pouch-anal anastomosis, 856(ab)
solid markers, chicken liver and egg white, 752(ab)
esophageal motility disorders, new parametric imaging technique, 856(ab)
gastrointestinal transit, 857(ab)
GI transcan, upper tract motility, 886(ab)
Tc-99m sulfur colloid sucralfate, ulcer avid agent, 936(ab)

Gastritis, *Campylobacter pylori* associated with, C-14 urea breath test for, 11

Gastroenteropathy, protein-losing, serial abdominal imaging, In-111 transferrin, 857(ab)

Gastrointestinal tract

bleeding
heparin and, Tc-99m RBC imaging, 725(le)
radionuclide detection and localization, 130(le)
Technetium-99m RBC
localization of gastrointestinal bleeding, 130(le)
ultrasonic visualization of tablets, 129(le)

Gastropathy, primary, scintigraphic study, 17

Gated blood-pool studies

cardiac and central circulatory function, multi-probe device, 832(ab)
cardiac stressing, esophageal pacing, 942(ab)
hemodynamic changes, radionuclide ventriculograms, cardiac transplant rejection, 742(ab)
interactive digital filtering, cine display, 864(ab)
mechanism of inspiratory reduction, left ventricular stroke volume, function, 949(ab)
phase image triangulation of accessory pathways, catheter ablation, posteroseptal pathways, 744(ab)
regional left ventricular wall motion assessment, bullseye display, cardiac blood pool SPECT, 745(ab)
regional wall motion abnormalities, left bundle branch block, quantitative phase analysis, 744(ab)

Gated heart studies

ambulatory radionuclide monitoring, left ventricular function, patient outcome, 838(ab)
amplitude analysis of Tc-99m RP-30A, coronary artery disease assessment, 805(ab)
automatic calculation of LV volumes and EF,

- RP-30 tomograms, 805(ab)
 cardiac response to various activities, ischemic heart disease patients, VEST, 741(ab)
 counts-based index, left ventricular "ejection fraction", myocardial perfusion scans, 947(ab)
 expert images, cardiac wall motion abnormalities, 846(ab)
 gated magnetic resonance, 943(ab)
 quantification of infarct size, Tc-99m RP-30A and SPECT, 946(ab)
- Generators, isotope**
 cerebral and myocardial blood flow tracers, copper bis(thio-semicarbazones), 848(ab)
 Cu-62 HSA, plasma volume measurement, 930(ab)
 new tracer Ir-191m, arterioscintigraphy, 841(ab)
 removal of Ir-192 from reactor-produced Os-191, 927(ab)
 Tungsten-178/Tantalum-178 system, high volume clinical applications, 1526
- Gentisic acid**, stabilization of Tc-99m D,L-HM-PAO, 935(ab)
- Glioma**
 monoclonal antibody imaging, 897(ab)
 radioimmunotherapy, I-125 monoclonal antibody, epidermal growth factor receptor, 847(ab)
 rat transplanted brain tumor model, glucose transport, 920(ab)
 therapy-resistant malignant, P-32 therapy, 902(ab)
- Glomerular filtration rate (GFR)**
 measurement with Tc-99m DTPA, plasma clearance techniques, 1152(le)
 radioisotopic measurement, severe chronic renal failure, 1927
- Glomerulonephritis**, chronic, renal scintigraphic test, angiographic data comparison, 907(ab)
- Glucose**
 cerebral blood flow, oxygen metabolism, stroke, 852(ab)
 cerebral utilization, relation to structure, polydrug abusers, 911(ab)
 density of capillaries, stroke, living human brain, 915(ab)
 F-18 FDG compared to F-18 FDM, PET, 772(ab)
 F-18 2-fluoro-deoxyglucose compartmental model, ion-exchange assay, tissue radioactivity, 939(ab)
 hexokinase Michaelis-Menten kinetics, 773(ab)
 hyperkinetic movement disorders, PET, 839(ab)
 interaction to hexokinase, 928(ab)
 myocardial metabolism, hypertrophic cardiomyopathy, PET, 828(ab)
 normal cerebral utilization, amyotrophic lateral sclerosis, 821(ab)
 patterns of regional cerebral metabolism, stimulated/deprived, vegetative subjects, 839(ab)
 performance of machine parameters, PET scanner, 877(ab)
 PET and genetic linkage results, subjects at risk, Huntington's disease, 853(ab)
 PET-FDG studies, AIDS-related dementia, azidothymidine, 852(ab)
 PET studies of motor system, tardive dyskinesia, 821(ab)
 progressive supranuclear palsy, metabolism, cerebral cortex, 914(ab)
 regional cerebral utilization, human substance abusers, acute cocaine, 840(ab)
 transport, transplanted brain tumor model, 920(ab)
 utilization and rate constants, partial volume effect, ischemic myocardium, 783(ab)
- D-Glucose**, synthesis, C-11 nitroalkane production, 754(ab)
- Glutamate receptors**, channel mapping, MK-801 analogs, 930(ab)
- Glutathione**
 content in brain tumors, Tc-99m HM-PAO uptake, 920(ab)
 myocardial detoxification system, assessment, F-18 fluorodinitrobenzene, 808(ab)
 Tc-99m HM-PAO stereoisomer interaction, 1998
- Granulocytes**
 In-111-labeled, imaging of infections, 23
 novel Tc-99m antibody for targeting, 925(ab)
- Grave's disease**, lactating patient, breast milk excretion of I-131, 407
- H**
- Haloperidol**, regional and temporal distribution in brain, 767(ab)
- Halothane**, -induced decrease of C-11 CGP 12177 binding, myocardial beta adrenoceptor, PET, 940(ab)
- Hand**, reflex sympathetic dystrophy, bone scanning in, 26
- Health Care Financing Administration (HFCA)**, Medicare coverage for Absorptiometry, N1620
- Heart**
 Adriamycin cardiomyopathy, earlier detection, ventriculography, 949(ab)
 anatomy, SQ30217 and Tl-201 planar myocardial imaging, 841(ab)
 arterial sampling vs. quantitative LV cavity imaging, PET, 772(ab)
 blood flow, molecular structure of Cu(PTSM), 927(ab)
 blood flow tracers, copper bis(thio-semicarbazones), 848(ab)
 cardiac output, first-pass radionuclide determination, 1154(le)
 changes in myocardial FFA metabolism, exercise, I-123 HDA, 851(ab)
 congestive failure
 MIBG myocardial uptake, 841(ab)
 peripheral hemodynamics and selection of vasodilators, 451
 V/Q pattern, xenon retention, 905(ab)
 detection of regional wall abnormalities, factor analysis, biplane contrast angiography, 771(ab)
 detection of single vessel disease, quantitative Tl-201 planar and tomographic imaging, 948(ab)
 determination of left ventricular mass, cine vs. gated spin NMR imaging, 891(ab)
 diastolic function, myocardial infarction, 1786
 digital acquisition, radioisotope tomographic images, 870(ab)
 effect of metabolic inhibitors, Tc-99m MIBI uptake, 820(ab)
 effect of nifedipine, myocardial perfusion and metabolism, systemic sclerosis, 828(ab)
 ejection fraction, energy window effects, 385
 enhanced binding of fluoromisonidazole, hypoxia, myocytes, 807(ab)
 expert images, wall motion abnormalities, 846(ab)
 fatty acid utilization, workload and sex-related variability, SPECT, 841(ab)
 F-18 2-fluoro-deoxyglucose compartmental model, ion-exchange assay, tissue radioactivity, 939(ab)
 gated PET data, rapid generation, blood activity curves, 775(ab)
 halothane-induced decrease of C-11 CGP 12177, beta adrenoceptor, 940(ab)
 β -hydroxy fatty acids, acylation, "masked" malonic ester, 848(ab)
 imaging, quality control, WHO study of, N440
 In-111 leukocyte scintigraphy, surgical complications, bacterial endocarditis, 794(ab)
 left ventricular maximum time-varying elastance, radionuclide angiographic calculations, 1368
 left ventricular pressure-volume loops, determination in clinical setting, 1492
 left ventricular volumes assessment, gated Tc-99m isonitrite tomography, 771(ab)
 low-density lipoprotein biodistribution, 1237
 malignant lymphoma, Ga-67 citrate and Tl-201 chloride detection, 1868
 metabolism, assessment with I-123 HDA, 1088
 method for receptor pharmacology, non-linear models, variable radioactivities, 822(ab)
 modular scintillation cameras, status and applications, 760(ab)
 muscarinic acetylcholine receptor, hyper- and hypothyroidism, PET, 808(ab)
 myocardial blood flow, N-13 ammonia metabolic fate, human blood, 783(ab)
 myocardial oxidative metabolism, C-11 acetate, 937(ab)
 myocardial perfusion and wall motion, Tc-99m MIBI vs. Tl-201 perfusion, Chagas' cardiomyopathy, 950(ab)
 myocarditis, In-111 antimyosin Fab, 939(ab)
 new high resolution PET scanner, double wobbling mode, 877(ab)
 new technique for automated edge detection, MR images, 865(ab)
 NMR spectroscopy, 2030(ab)
 noninvasive delineation of infarct size, vessel patency, Tc-99m RP-30A, 819(ab)
 non-neuronal uptake of I-123 MIBG, humans, 842(ab)
 orthotopic allografts, detection of rejection with In-111 lymphocytes and gamma scintigraphy, 1223
 peritoneal fluid
 SPECT inferior attenuation, 941(ab)
 SPECT Tl-201 imaging in women, 1860
- PET studies**
 acquired input functions for, 241
 arterial activity concentrations, 941(ab)
 automated quantitative analysis, 867(ab)
 three-dimensional display, 530
 pharmacokinetic analysis of Gd-153 (DTPA)², distribution in blood, 891(ab)
 planar Tc-99m isonitrite exercise imaging detection, coronary artery disease, 804(ab)
 new normal database, modified background correction, 804(ab)
 prolonged muscle flow physiology, distribution behavior, perfusion tracers, 942(ab)
 protective effect of calcium antagonist, In-111-antiacardiac myosin antibody, 745(ab)
 protein binding studies, Tc-99m, 62
 regional ischemic coronary disease, Tl-201 imaging, combined with "bullseye" analysis, 756(ab)
 regional oxidative metabolism, C-11 acetate, dynamic PET, 782(ab)
 regional wall motion abnormalities, left bundle

branch block, quantitative phase analysis, 744(ab)
 regurgitant valvular disease, angiocardigraphy, 1114
 rejection, In-111 antimyosin, 1893
 right ventricular ejection fraction, first-pass time-activity curves, 1990
 SPECT, future directions, 567
 SPECT image reconstruction, attenuation, detector response correction, 870(ab)
 studies with ECATIII, Monte Carlo calculation, spillover corrections, 866(ab)
 Tc-99m DADS-amido-fatty acids, imaging agents, 935(ab)
 Tc-99m dithiosemicarbazone complex, condensed ring structure, 934(ab)
 Tc-99m HEXAMIBI synthesis, pharmacokinetics, 934(ab)
 technetium dioxime complexes, chloro-hydroxy substitution, 800(ab)
 tin-capped vs. boron-capped Tc-99m oxime, 935(ab)
 Tl-201, bull's eye program for, 1466(le)
 Tl-201 imaging
 correcting for patient motion, 91
 elliptical versus circular acquisition, 736(ab)
 patient and organ movement in SPECT, 441
 Tl-201 redistribution, ribose effects, 1943
 Tl-201 SPECT, intraobserver variability, 944(ab)
 transplant rejection
 see also Transplantation
 allograft rejection with In-111 lymphocytes, 2018(le)
 early rejection detection, In-111 monoclonal antimyosin imaging, 745(ab)
 hemodynamic changes, radionuclide ventriculograms, 742(ab)
 sodium NMR imaging, 802(ab)
 valvular/coronary artery and aortic disease, application, cine cardiac MRI, 802(ab)
 valvular regurgitation, evaluation by factor analysis of first-pass angiography, 159
 white blood cell accumulation, reperfusion myocardial injury, 954(ab)
Hematocrit, correlation with half-life of carboxyhemoglobin, blood volume measurement, C-11 carbon monoxide, 894(ab)
Hematoporphyrin derivative, labeling of, In-111 oxime, 927(ab)
Hemodialysis, bone calcium and mineral changes, 816(ab)
Hemodynamics
 captopril renography, renal artery stenosis, 850(ab)
 cerebral, PET, lack of ID for EC/IC bypass, 831(ab)
 medically-treated cerebral ischemia, prognosis, PET, 831(ab)
 patients at risk, SPECT cerebrovascular reserve measurement, 911(ab)
Hemorrhage, subarachnoid, triple mode evaluation, 743(ab)
Heparin
 gastrointestinal bleeding, Tc-99m RBC imaging, 725(le)
 radioimmunoinaging of thrombi, antifibrin and antiplatelet antibodies, 825(ab)
 Tl-201 SPECT infarct size, myocardial infarction, 951(ab)
Hepatobiliary imaging
 accessory hepatic duct leak, following liver transplantation, 259

duodenal-gastric reflux, 17
 dynamic SPECT, changing radioactivity distribution, 98
 false positive, In-111 WBC imaging, acute cholecystitis, 826(ab)
 Ga-67 citrate, recurrent hepatocellular carcinoma, 712
 non-invasive multiparametric study, liver physiology, cirrhosis, 791(ab)
 scintigraphy with deconvolutional analysis, diagnosis, liver transplant rejection, 790(ab)
 Tc-99m IDA time-activity curves, 623
Hepatocytes, uptake of Tc-99m IDAS, 928(ab)
Hepatoma
 application of I-131 lipiodol, 799(ab)
 I-131 lipiodol, biodistribution via hepatic artery, 1066
 uptake of positron emitting biomolecules, heterotransplants, PET feasibility, 903(ab)
Herpes simplex, type 1, In-111 monoclonal antibody binding, 275(ab)
Hevesy Pioneer Award, Seymour S. Kety and Louis Sokoloff, N583
HIDA, compartmental and non-compartmental modeling, 862(ab)
Hip
 arthroplasty, infection detection, 887(ab)
 bladder artifact correction, SPECT evaluation, 780(ab), 868(ab)
 complicated post-operative prostheses, evaluation, In-111 granulocytes, 883(ab)
 porous coated arthroplasty prosthesis, In-111 WBC, 764(ab)
 three phase bone scan, prosthetic tip, 780(ab)
 possibly-infected arthroplasties, evaluation, In-111 leukocytes, 883(ab)
 surgery, deep vein thrombosis, In-111 platelet imaging, 787(ab)
 surgical radiation probes, 881(ab)
Holmium-165, activable isotopes of, biodegradable radiotherapeutic microspheres, 903(ab)
Holospectral imaging, method for scatter correction, energy information, 864(ab)
Human immunodeficiency virus (HIV)
 -positive persons
 Ga-67 and In-111 WBC in, 281(ab)
 Ga-67 pulmonary activity, tobacco smoking, 829(ab)
Huntington's disease
 I-123 IMP brain imaging, 916(ab)
 PET and genetic linkage results, subjects at risk, 853(ab)
Hyperemia, myocardial oxidative metabolism, C-11 acetate clearance, 937(ab)
Hyperparathyroidism, primary, bone mineral content, spine/hip/forearm, 855(ab)
Hyperplasia, mandibular condyle, bone SPECT, 780(ab)
Hypertension
 effects of volume depletion, captopril renography, 849(ab)
 ejection fraction response to exercise, impaired left ventricular filling, 772(ab)
 myocardial uptake, 19-iodo-3,3-dimethyl-18-nonadecenoic acid, verapamil, 843(ab)
 renovascular
 captopril, rat model, 509
 captopril renography, 575(le)
 Tc-99m MAG, clearances, captopril, 849(ab)
 sensitivity of renography and renal scintigraphy, renal artery stenosis, ACE inhibition, 908(ab)
 two-kidney/one-clip, saralasin vs. captopril

renography, 849(ab)
Hyperthyroidism
 postmenopausal woman, 263
 sensitive TSH assay, 766(ab)
 Tl-201 of suppressed thyroid, 1360
Hypoxemia, utility of Tc-99m DTPA aerosol inhalation scans, artificially ventilated patients, 764(ab)
Hypoxia
 altitude, sympathetic activity index, I-123 MIBG myocardial uptake, 842(ab)
 enhanced binding of fluoromisonidazole, adult rat myocytes, 807(ab)

I

Ileum, terminal, high resolution scintigraphy, 857(ab)
Image processing
 alternative formulation, Wiener restoration filter, 845(ab)
 constrained least-squares Metz filter, 864(ab)
 determination of weighting coefficients, energy weighted acquisition, 845(ab)
 high resolution of F-18 fluorodeoxyglucose, human brain, 760(ab)
 holospectral imaging, scatter correction, energy information, 864(ab)
 hypermedia, new method for image analysis, 863(ab)
 image spread sheet, manipulation, digital images, 811(ab)
 MACII as satellite station, 810(ab)
 optimum filter function, SPECT, 643
 PET camera image quality improvement, removeable rings, high atomic number material, 877(ab)
 PET resolution nonuniformity, cylindrical detectors, partial volume effects, 876(ab)
 radioisotope bone images, diagnostic consequences, 884(ab)
 restoration of SPECT projections, singular value decomposition technique, 749(ab)
 ring-geometry SPECT instrument, brain imaging, 760(ab)
 scatter removal, pre- and post-processing techniques, 798(ab)
 suitability of microcomputer systems, numerical analysis, medical images, 865(ab)
 thallium reinjection after delayed imaging, fill-in to regions with "fixed" defects, 769(ab)
Image reconstruction
 Bayesian reconstruction of SPECT, parallel/fan/cone beam geometries, 871(ab)
 factors determining noise character, filtered back-projection SPECT reconstructions, 870(ab)
 multi-grid maximum likelihood, PET, real data, 774(ab)
 multiplane SPECT reconstruction, compensation, collimator response, 785(ab)
 predicting noise energy, SPECT, 748(ab)
Immune complex, formation and clearance, mouse monoclonal antibody, 758(ab)
Immune response, imaging consequences of human anti-mouse antibody, monoclonal antibody, 761(ab)
Immunoglobulin G
 In-111-labeled, compared to Tc-99m WBC, localizing inflammation, 830(ab)
 radiolabeled with In-111/Tc-99m/I-125, compared to albumin, focal sites of infection, 887(ab)
Immunoglobulin M, radioimmunodetection, testicular carcinoma xenograft, athymic

- mice, 896(ab)
- Immunomodulation**, I-131 T101, chronic lymphocytic leukemia, 757(ab)
- Immunoradiometric TSH assay**, clinical performance of, 280(ab)
- Immunoscintigraphy**
- diagnostic accuracy, In-111 OC 125 and I-131 OC 125, 811(ab)
 - diagnostic value, CEA-producing tumors, 811(ab)
 - effect of circulating antigen, monoclonal antibody localization, 762(ab)
 - imaging consequences of human anti-mouse antibody, monoclonal antibody, 761(ab)
 - kinetics and metabolism, labeled monoclonal antibodies, cellular level, 823(ab)
 - native and DTPA conjugated monoclonal antibodies, cellular characterization, hepatocytes, 823(ab)
 - selection of nuclides, 875(ab)
 - Tc-99m anti-CEA, known and occult colorectal carcinoma, 834(ab)
- Indium(III) complexes**, functionalized tetraazamacrocyclic ligands, monoclonal antibody coupling, 924(ab)
- Indium-111**
- antiacidic myosin antibody, protective effect of calcium antagonist, myocardium, 745(ab)
 - attenuation correction factor, absolute quantitation, 872(ab)
 - cytotoxicity, mouse testes, 375
 - intact vs. fragments,
 - radioimmunopharmaceuticals, tumor model, 893(ab)
 - intracavitary use, 1910
 - neutrophil injection, infected wound chambers, 787(ab)
 - platelet survival studies, 564
- Indium-111 9.2.27**, anti-melanoma monoclonal antibody, antibody dose effects on, 39
- Indium-111 albumin**, compared to In-111 non-specific IgG, other radiolabels, focal sites of infection, 887(ab)
- Indium-111 antibodies**, sizing chromatographic evaluation, 923(ab)
- Indium-111 antibody-chelator conjugates**, correlation of radiochemical yield, chelator concentration, 924(ab)
- Indium-111 anti-CEA**
- compared to In-111 antibody, radioimmunoscintigraphy, colorectal carcinoma, 899(ab)
 - detection of occult metastatic cancer, 833(ab)
 - effect of two dose levels, unlabeled antibody, lung tumor uptake, 825(ab)
 - Fab' fragments, biodistribution, 896(ab)
 - imaging, mammary and lung cancer, subtraction techniques, 899(ab)
 - presurgical screening, colorectal carcinoma, 897(ab)
 - SPECT compared to planar imaging, detection, metastatic colorectal cancer, 886(ab)
- Indium-111 anti-fibrin antibody**, imaging vascular thrombi, 494
- Indium-111 antifibrin monoclonal antibody**, venous thrombosis, 746(ab), 806(ab), 807(ab), 825(ab)
- Indium-111 antimyosin**
- early detection, cardiac rejection, 745(ab)
 - inferior left ventricular infarction, right ventricular involvement, 806(ab)
 - kinetics in septum, necrosis, 941(ab)
 - myocardial damage assessment, suspected myocarditis and cardiac rejection, 1893
- patients with ischemic chest pain, 805(ab)
- Q-wave myocardial infarction**
- comparative imaging, thallium and SPECT, 806(ab)
 - size, SPECT, 942(ab)
- scintigraphy**, prediction, extent of akinesis, 851(ab)
- uptake specificity**, myocardial infarction, 746(ab)
- Indium-111 antimyosin Fab**
- myocarditis, 939(ab)
 - regional asynergy, myocardial infarction, 806(ab)
 - tumor of rhabdomyosarcoma, 791(ab)
- Indium-111 antimyosin Fab-DTPA**
- absence of human antimouse antibody response, 851(ab)
 - trace metal ion contamination, 923(ab)
- Indium-111 9B9**, blood clearance, 1951
- Indium-111 benzyl-EDTA monoclonal antibody**, metabolism in mouse liver, 824(ab)
- Indium-111 bifunctional haptens**, pre-targeted immunoscintigraphy, 226
- Indium-111 B72.3 immunconjugates**, biodistribution, influence, chelator denticity, 824(ab)
- Indium-111 biotin**, abscess imaging, streptavidin-conjugated monoclonal antibodies, 889(ab)
- Indium-111 chelates**, optimization of ligand structure, imaging, bifunctional antibody, 835(ab)
- Indium-111 chloride**
- diabetic foot, 279(ab)
 - imaging in diabetic foot, 813(ab)
 - imaging in treated osteomyelitis, 763(ab), 883(ab)
- Indium-111 cholic acid**, hepatobiliary imaging agent, 926(ab)
- Indium-111 citrate**, radiolabeling of monoclonal antibodies, bifunctional chelate, 814(ab)
- Indium-111 DTPA**
- imaging of localized bacterial infections, non-specific antibody fragments, 887(ab)
 - new approaches to radiosensitization, hypoxic tumor cells, 873(ab)
 - separation of protein fractions, column chromatography, monoclonal antibodies, 925(ab)
 - thrombus imaging, radiolabeled Fab' fragments, 940(ab)
- Indium-111 endothelial cells**, adherence to carotid arteries, 939(ab)
- Indium-111 Fab'**
- compared to F(ab)'2 derivative, 812(ab)
 - enhancement of utility, radioimmunodetection, 925(ab)
 - studies using serum from patients, 895(ab)
- Indium-111 granulocytes**
- accumulation, malignant tumors, 479
 - comparison with In-111 mixed leukocytes, imaging of infections, 23
 - evaluation, complicated post-operative hip prostheses, 883(ab)
- Indium-111 IgG**
- clinical experience, 830(ab)
 - compared to radiolabeled albumin, focal sites of infection, 887(ab)
 - compared to Tc-99m WBC, localizing inflammation, 830(ab)
 - imaging of localized bacterial infections, 887(ab)
- Indium-111 leukocytes**
- comparison with In-111 granulocytes, imaging of infections, 23
 - diagnosis of fracture and osteomyelitis, 814(ab)
- evaluation, infected hip arthroplasties, 883(ab)
 - Ga-67 and, HIV+ patients, 281(ab)
 - HM-PAO-labeled leukocytes comparison, Tc-99m-labeled small colloid, osteomyelitis, 813(ab)
 - importance of whole body studies, immunosuppressed organ transplantation, 795(ab)
 - In-111 in breast milk, 1301(le)
 - ischemic myocardium, 1826
 - localization, noninfected neoplasms, 1921
 - lung microvascular injury, 657
 - migratory patterns, thymectomized and control rats, 83
 - neuropathic foot disease, 1651
 - photopenic skeletal defect, Paget's disease, 561
 - potential of imaging abscesses, Tc-99m multilamellar liposomes, 888(ab)
 - scintigraphy of heart, surgical complications, bacterial endocarditis, 794(ab)
 - specificity of imaging, non-inflammatory soft tissue lesions, 795(ab)
 - subperiosteal abscess, complicating osteomyelitis, 1871
 - value of SPECT, abdominal sepsis, 794(ab)
- Indium-111 liposomes**, biodistribution in normal persons, 873(ab)
- Indium-111 lymphocytes**
- detection of allograft rejection, heart, 2018(le)
 - gamma scintigraphy and, detection of orthotopic cardiac allograft rejection, 1223
- Indium-111 monoclonal antibodies**
- absence of intrinsically higher tissue uptake, 924(ab)
 - anti-CEA ZCE 025, detection, colorectal carcinoma, 812(ab)
 - binding of herpes simplex virus type 1, 275(ab)
 - biodistribution differences, 2029(ab)
 - CITC, protein mass effect, hepatic uptake, 888(ab)
 - detection of occult metastases, 893(ab)
 - effect of radiolabeling method, retention, cultured cells, 901(ab)
 - imaging and kinetics, lung carcinoma, 896(ab)
 - internally-labeled, biodistribution, 889(ab)
 - interstitially administered, lymphoscintigraphy, 1303(le)
 - kinetics and metabolism, cellular level, 823(ab)
 - localization of colorectal carcinoma, 898(ab) OC 125
 - biodistribution, ovarian cancer, 847(ab)
 - diagnostic accuracy, immunoscintigraphy, 811(ab)
 - potential metabolizable linkers, 922(ab)
 - radioimmunodetection of human melanoma, 329
 - semiquantitative binding assay, cancer and normal tissues, 1436
 - subcellular kinetics in liver, 812(ab)
 - tissue biodistribution, tumor mass, determining factor, 926(ab)
 - tumor accumulation, bone, 235
 - tumor targeting, chemical bond modification, 889(ab)
- Indium-111 neutrophils**, experimental abscess, gram-positive and gram-negative bacteria, 733(ab)
- Indium-111 oxine**
- dosimetry, children, 689
 - labeling of hematoporphyrin derivative, 927(ab)
 - molecular structure, 417
 - platelet survivals, thrombocytopenic children, 892(ab)
 - radiolabeled murine lymphocytes, cytokine

Indium-111 plastic particles

- administration, biodistribution effect, 902(ab)
- Indium-111 plastic particles**, gastrointestinal transit, 857(ab)
- Indium-111 platelets**
- accuracy of imaging, deep vein thrombosis, hip surgery, 787(ab)
 - diagnosis of deep venous thrombophlebitis, 1169
 - natural history of platelet aggregation, endothelial injury, angiography, 948(ab)
 - survival and sequestration, patients with neoplasms, 787(ab)
- Indium-111 porphyrin**, tumor imaging, 900(ab)
- Indium-111 transferrin**
- macromolecular tracer, vascular permeability, 939(ab)
 - serial abdominal imaging, protein-losing gastroenteropathy, 857(ab)
- Indium-111 tropolonate**, Tc-99m HM-PAO and, kinetics of leukocytes labeled with, 1246
- Indium-111 tropolone**, migratory patterns, thymectomized and control rats, 83
- Indium-111 white blood cells**
- accumulation, reperfusion myocardial injury, 954(ab)
 - closed system, 733(ab)
 - detection of infection
 - delayed/non-union fractures, 813(ab)
 - hip arthroplasty, 887(ab)
 - detection of osteomyelitis, complicated by a pre-existing condition, 1015
 - evaluation of localization, non-infected surgery site, 788(ab)
 - false positive in simple fracture, 571(le)
 - identification of acute cholecystitis, false positive hepatobiliary scan, 826(ab)
 - imaging following porous coated hip arthroplasty, study, prosthetic tip, 764(ab)
 - osteomyelitis evaluation, 813(ab)
 - quantification of PMN granulocyte infiltration, gore-tex graft, abdominal aorta, 794(ab)
 - scintigraphy, febrile ICU patient, 795(ab)
 - Tc-99m HDP comparison, occult infection following total joint arthroplasty, 1347
- Indium-111m tropolone RBC**, red blood cell compatibility testing, 684
- Indium-114m lymphocytes**, autologous, lymphoid cell malignancy and, 485
- Infection imaging**
- hip arthroplasty, Tc-99m sulfur colloid, In-111 WBC, 887(ab)
 - localized bacterial infections, radiolabeled non-specific antibody fragments, 887(ab)
 - Tc-99m/In-111 leukocyte and Tc-99m/Ga-67, delayed/non-union fractures, 813(ab)
- Infection/inflammation**, Ga-67 imaging, 608
- Inflammation**
- localization
 - comparison, In-111 IgG and Tc-99m WBC, 830(ab)
 - In-111 IgG, 830(ab)
 - non-inflammatory soft tissue lesions, specificity, In-111 leukocytes, 795(ab)
- Inflammatory disease**, detection using Tc-99m anti-granulocyte antibody, 829(ab)
- In memoriam**
- Gerald L. Hine, Ph.D., N145
 - Hans Creutzig, M. D., 426
 - Raymond L. Hayes, Ph.D., 578
- Instrumentation**, computer seminars and, SNM Winter Meeting, N6
- Interleukin 1**, reduction, radioantibody-induced myelosuppression, 758(ab)
- Interleukin 2**
- biodistribution of I-131 monoclonal antibody, 897(ab)
 - effect on biodistribution, I-131 monoclonal antibody, 901(ab)
- Intraperitoneal disease**, alpha-emitting radiocolloid treatment, 858(ab)
- Investigational new drug exemptions (INDs)**, physician-sponsored, FDA limiting of, N137
- Iodine-122 HIPDM**
- cerebral blood flow agent for PET, validation of, 916(ab)
 - CO₂ reactivity, blood flow tracer, PET study, 773(ab)
- Iodine-123**
- absorbed fractions for electrons, beta particles, small spheres, 803(ab)
 - factors related to parathyroid imaging, 860(ab)
 - free fatty acid metabolism, ischemic myocardium, diabetes, 842(ab)
 - β -hydroxy fatty acids, acylation, "masked" malonic ester, 848(ab)
 - I-124 contamination of, second dose calibrator, 1302(le)
 - SPECT, thyroid, multinodular goiter, 110
 - Tc-99m and, comparative imaging, thyroid nodules, 753(ab)
- Iodine-123 AMT**, cerebral amino acid transport studies, 778(ab)
- Iodine-123 BGA**, glucose derivative, interaction to hexokinase, 928(ab)
- Iodine-123 estradiol**, ER-positive breast cancer detection, 853(ab)
- Iodine-123 HDA**
- assessment of myocardial metabolism, fatty acid oxidation effects, 1088
 - changes in myocardial FFA metabolism, peak exercise, 851(ab)
- Iodine-123 HIPDM**
- brain SPECT, carotid artery occlusion, 913(ab)
 - clinical evaluation, pancreas scintigraphy, 826(ab)
 - dementia and diamox, 734(ab)
 - lung scintigraphy, chronic obstructive pulmonary disease, 905(ab)
 - metabolic lung imaging, pulmonary hypertension, 765(ab)
 - pre-rectal portal scintigraphy, 2020(le)
- Iodine-123 hippurate**
- renography, angiotensin converting enzyme inhibition, renal artery stenosis, 907(ab)
 - renography and Tc-99m DMSA renal scintigraphy, renal artery stenosis, ACE inhibition, 908(ab)
- Iodine-123 IBZM**
- new analogs, brain imaging agents, 777(ab)
 - potential D-2 dopamine receptor imaging agent, 759(ab)
- Iodine-123 IBZP**, potential D-1 dopamine receptor imaging agent, 758(ab)
- Iodine-123 IMP**
- accumulation, metastatic hepatocellular carcinoma, 1460(le)
 - brain imaging, Huntington's disease, 916(ab)
 - brain maturation in human newborns, 893(ab)
 - brain scan, auditory hallucination, 558
 - brain SPECT
 - after cerebral radiation therapy, 914(ab)
 - clinical study, auditory hallucination, 917(ab)
 - optimum Butterworth-Wiener filter, 879(ab)
 - construction of flow and back diffusion rate images, human brain, dynamic SPECT, 870(ab)
- early and late SPECT, value and limitation, cerebrovascular disease, 844(ab)
 - in vivo chemistry of, 122
 - malignant melanoma detection, 1200
 - ocular melanoma, 1448
 - redistribution patterns, prediction, successful revascularization, 844(ab)
 - regional cerebral perfusion, quantitative SPECT imaging, improved method, 869(ab)
- SPECT**
- assessment, perfusion reserve in CVD, 918(ab)
 - blood flow and redistribution, ischemic CVD, 918(ab)
 - clinical application, brain death and coma, 917(ab)
 - evaluation, major psychosis, 921(ab)
 - meningioma, 1627
 - Tc-99m HM-PAO SPECT and, compared to PET, dementia, 916(ab)
- Iodine-123 IMT**, brain SPECT, 911(ab)
- Iodine-123 iofetamine**, tomography in pediatric patients, epilepsy, 892(ab)
- Iodine-123 IPPA**
- preserved uptake, reperfused myocardium, 842(ab)
 - SPECT imaging, asymptomatic HIV seropositive persons, 742(ab)
 - workload and sex-related variability, fatty acid utilization, SPECT, 841(ab)
- Iodine-123 ISP**, SPECT, dopamine D-2 receptor imaging, 922(ab)
- Iodine-123 LDL**, Tc-99m LDL and, human biodistribution, 803(ab)
- Iodine-123 MIBG**
- comparative SPECT and Tl-201 cardiac imaging, myocardial infarction, 840(ab)
 - myocardial uptake
 - congestive heart failure, 841(ab)
 - sympathetic activity index, altitude hypoxia, 842(ab)
 - non-neuronal cardiac uptake, humans, 842(ab)
- Iodine-123 monoclonal antibodies**, radioimmunodetection, CEA-producing tumors, 898(ab)
- Iodine-123 OIH**
- absorbed radiation dose, 400
 - Tc-99m MAG₃ comparison, patients with renal disorders, 147
- Iodine-123 OPPIA**, trapping of, myocardium, 851(ab)
- Iodine-123 PIP conjugate**, protein labeling, 929(ab)
- Iodine-123 SCH 23982**, biodistribution, radiation dosimetry and, 1668
- Iodine-123 spiperone**, dopamine receptor binding sites, SPECT, baboon brain, 848(ab)
- Iodine-125**
- effect of circulating antigen, monoclonal antibody localization, 762(ab)
 - β -hydroxy fatty acids, acylation, "masked" malonic ester, 848(ab)
 - meta vs. para substituted *N*-succinimidyl stannyl benzoates, utility, antibody labeling, 834(ab)
 - MK-801 analogs, mapping, glutamate receptor channels, 930(ab)
 - rapid radioimmunoassay method, cyclosporine monitoring, 766(ab)
- Iodine-125 albumin**, compared to I-125 non-specific IgG, other radiolabels, focal sites of infection, 887(ab)
- Iodine-125 biotin**, radiolabeled derivative, facile preparation, 923(ab)

- Iodine-125 cholesteryl iopanoate**, measuring atherosclerosis, 503
- Iodine-125 DHTP**, mapping central noradrenergic innervation, 777(ab)
- Iodine-125 HEAT**, radioiodinated, binding in rat brain, 356
- Iodine-125 HIPDM**, uptake, brain, hypercapnia, 1675
- Iodine-125 iodocyanopindolol**, receptor pharmacology, non-linear models, variable radioactivities, 822(ab)
- Iodine-125 lothalamate**
clearance and biodistribution, altered physiologic state effects, 669
plasma clearances, Tc-99m DTPA, diabetic patients, 816(ab)
- Iodine-125 IPM**, radiolabeled monoclonal antibodies, compared to I-125 ICI labeling, tumor uptake, 836(ab)
- Iodine-125 MIBG**, compared to H-3 NE uptake and release, different brain regions, 911(ab)
- Iodine-125 monoclonal antibodies**
absence of intrinsically higher tissue uptake, In-111, 924(ab)
effect of radiolabeling method, retention, cultured cells, 901(ab)
epidermal growth factor receptor, glioma radioimmunotherapy, 847(ab)
fibrin, uptake by mouse cancer, coagulative properties, 899(ab)
Fisher immunotype 1 *Pseudomonas aeruginosa* infection, 651
influence of antibody catabolism, shed antigen, 823(ab)
internalization of monoclonal 3G5-IgM, 923(ab)
internally-labeled, biodistribution, 889(ab)
pharmacokinetics, intraperitoneal injection volume, protein dose, 889(ab)
quantitative autoradiography, tumor antigen concentration, tissue sections, 897(ab)
radioimmunoscintigraphy, colon cancer, 1022
recombinant human-mouse chimeric mAb, immunoreactivity, lymphocytic leukemia, 890(ab)
- Iodine-125 nucleoside**, synthesis and biodistribution, 929(ab)
- Iodine-125 SCH-23982**, mapping cerebral dopamine D-1 receptors, 929(ab)
- Iodine-131**
absorbed fractions for electrons, beta particles, small spheres, 803(ab)
attenuation correction factor, absolute quantitation, 872(ab)
breast milk excretion, lactating patient, 407
collimator perturbation of image, renal plasma flow measurements, 909(ab)
criteria for ablation of normal thyroid tissue, surgery, thyroid cancer, 885(ab)
external exposure rates, guidelines, resuming close contact, 873(ab)
intracavitary use, 1910
location of ovarian dysfunction, 1644
meta vs. para substituted *N*-succinimidyl stannyl benzoates, utility, antibody labeling, 834(ab)
mortality in well-differentiated thyroid cancer, 753(ab)
parotid oncocytoma, 1126
rationale for T1 thyroglobulin screening, 753(ab)
reduction in radioantibody-induced myelosuppression, recombinant interleukin-1, 758(ab)
- thyroid uptake, after Chernobyl, 1152(le)
T101 in patients with chronic lymphocytic leukemia, cellular immunomodulation, 757(ab)
total body scan after, thyroid carcinoma, 279(ab)
uptake
from Chernobyl, southern Sweden, 1719
inflammatory lung disease, 701
value of total body scans, thyroid carcinoma, 885(ab)
- Iodine-131 anti-CEA**
enhancement of tumor imaging and therapy, administration, second antibody, 890(ab)
radioimmunotherapy
colon carcinoma multicell spheroids, 858(ab)
phase I/II trial, 846(ab)
- Iodine-131 ethiodol**, dosimetry, treatment of hepatoma, 1038
- Iodine-131 fibronectin**, atherosclerotic lesion and thrombus, 1264
- Iodine-131 heptadecanoic acid**, time-activity curves, myocardium, 1934
- Iodine-131 hippuran**
compared to Tc-99m MAG₃, dual channel technique, 908(ab)
effect of saralasin vs. captopril renography, two-kidney/one-clip hypertension, 849(ab)
measurement of differential renal function, 134(le)
- Iodine-131 lipiodol**
biodistribution via hepatic artery, liver cancer, 1066
massive type hepatocellular carcinoma, 799(ab)
- Iodine-131 lym-1**, successful radioimmunotherapy, lymphoma, 847(ab)
- Iodine-131 MIBG**
adrenal medullary imaging, methodology and dosimetry, 1638
diagnosis and follow-up of neuroblastoma, 750(ab)
I-131 3F8 and, neuroblastoma imaging, 846(ab)
nonsecreting paraganglioma metastases, 2008
physics protocol for UKCCSG toxicity, resistant neuroblastoma, 798(ab)
side effects, neural crest tumors, 798(ab)
Sipple's syndrome, with liver tumors, 1130
thyroid medullary carcinoma, 33
tumor uptake, gamma camera estimation of, 542
- Iodine-131 monoclonal antibodies**
astatine labeling, *N*-succinimidyl-3-(tri-*n*-butylstannyl)benzoate, 835(ab)
B-cell lymphoma treatment, 757(ab)
effect of interleukin-2 on biodistribution, 897(ab)
biodistribution, 901(ab)
enhanced uptake of OC 125 (Fab')₂, ovarian carcinoma, 900(ab)
escalating single and multiple fraction low dose rate, renal cell carcinoma, 875(ab)
estimation of absorbed radiation dose, tumor and major organs, 900(ab)
imaging of colon cancer, 833(ab)
imaging of gliomas, 897(ab)
kinetics and metabolism, cellular level, 823(ab)
OC 125, diagnostic accuracy, immunoscintigraphy, 811(ab)
organ and tumor dosimetry, liver and lung tumors, 874(ab)
pharmacokinetics, intraperitoneal injection volume, protein dose, 889(ab)
radioimmunoscintigraphy, colon cancer, 1022
radioimmunotherapy of cutaneous T-cell lymphoma, retreatment following plasmapheresis, 174
- Iodine-131 NP-59**
compensatory functional increase in uptake, adrenalectomy, 859(ab)
scintigraphy, accuracy and utility, disease diagnosis, 859(ab)
- Iodine-131 OIH**
absorbed radiation dose, 400
clearance, comparison with Tc-99m MAG₃, 1878(le)
clearance and biodistribution, altered physiologic state effects, 669
compared to Tc-99m MAG₃, kit formulations, 909(ab)
evaluation of Tc-99m D-MAGAG diastereomers, primates, 909(ab)
probenecid inhibition of uptake, kidney, 908(ab)
Tc-99m MAG₃, comparison, patients with renal disorders, 147
- Iodine-131 OPPA and PPPA**, metabolism in heart, 938(ab)
- Iodine-131 PPPA**, metabolism in heart, 938(ab)
- Iodo-antipyrine**, lung water measurements, 275(ab)
- 3-Iodopropyl triflate**, compared to 3-bromopropyl triflate, F-18 radiolabeling, secondary amines, 754(ab)
- Iodovinyl antibody conjugate**, compared with para-iodophenyl conjugate, *in vivo* deiodination, 777(ab)
- Iridium-191m**, new tracer for arterioscintigraphy, 841(ab)
- Iron**, evaluation as MRI contrast agents, liver, 837(ab)
- Iron-59**, macromolecular tracer, vascular permeability, 939(ab)
- Isopropylidodoamphetamine**, SPECT, comparison, O-15 water cerebral blood flow, 747(ab)
- Isotopes**, research, DOE workshop on availability, N1611

K

Kawasaki disease, assessment, stress Tl-201 myocardial emission tomography, 791(ab)

Kidney

accuracy of Tc-99m DMSA renal cortical scintigraphy, pyelonephritis, 778(ab)
action of Tc-99m renal agents, sulfur-donating chelates, 801(ab)
blood flow, noninvasive assessment, temporal deconvolution, 862(ab)
captopril renography
effects, volume depletion, 849(ab)
renal artery stenosis, 850(ab)
chronic failure, hemodialysis, effects on bone mineral, 277(ab)
chronic glomerulonephritis, renal scintigraphic test, angiographic data comparison, 907(ab)
collimator perturbation of image, renal plasma flow measurements, 909(ab)
disorders, Tc-99m MAG₃, I-123 and I-131 OIH comparison, 147
diuresis renography
degree of hydronephrosis, 816(ab)
intrapelvic pressure, frusemide, 816(ab)
diuretic scan, urinary tract obstruction, 133(le)
extracellular fluid volume, Tc-99m DTPA, 255
factor analysis, dynamic renal studies, urology, 816(ab)
failure
severe chronic, glomerular filtration rate in, 1927
Tc-99m MAG₃, kit formulation, 616

Kinetic models

- first-pass tracer fractionation, blood flow, 907(ab)
function
 after extracorporeal shock-wave lithotripsy, radionuclide evaluation, 906(ab)
 quantitation of, 2024(ab)
 quantitation with Tc-99m MAG₃, 1931
- Ga-67 renal hyperactivity, AIDS patients, 909(ab)
- Goldblatt hypertension, captopril renography, 575(le)
- handling of Tc-99m DMSA, 778(ab)
- I-123 hippurate and Tc-99m DTPA renography, Tc-99m DMSA renal scintigraphy, renal artery stenosis with ACE inhibition, 908(ab)
- mean parenchymal transit time, detection, renal artery stenosis, 850(ab)
- measurement of differential function, 134(le)
- osteodystrophy, factor analysis, bone, 883(ab)
- pharmacokinetic analysis of Gd-153 (DTPA)², distribution in blood, 891(ab)
- probenecid inhibition of uptake, Tc-99m MAG₃ and OIH, 908(ab)
- quantitative renography, renal artery stenosis, 850(ab)
- renal antegrade perfusion scintigraphy, study, ureteric function, 779(ab)
- renal function agents, Tc-99m PAH analogs, 937(ab)
- segmental resection of ureter, radionuclide and radiological renal function study, 778(ab)
- Tc-99m complexes, α , α -disubstituted, α -hydroxy carboxylic acids, 934(ab)
- Tc-99m DMSA pharmacokinetics, cold loading, 908(ab)
- Tc-99m DTPA and I-125 iothalamate plasma clearances, diabetic patients, 816(ab)
- Tc-99m DTPA measurement of GFR, plasma clearance techniques, 1152(le)
- Tc-99m MAG₃
 clearance, effects of aging, 906(ab)
 clearance after captopril, renovascular hypertension, 849(ab)
 comparison with I-131 hippuran, simultaneous dual channel technique, 1189
 I-131 hippuran and, dual channel technique, 908(ab)
 pharmacokinetics, 906(ab)
 urinary pH effect, 906(ab)
- Tc-99m MP-600, 735(ab)
- Tl-201 imaging, stress cardiac evaluation, 910(ab)
- transplants
 see also Transplantation
 perfusion after, quantitative measurement of, 1656
 pregnancy and, renal scans in, 1364
 pre-surgical evaluation, Tl-201 cardiac SPECT, 950(ab)
 quantitative assessment, blood flow, 791(ab)
 renal perfusion assessment, 779(ab)
 ultrasound and scintigraphy, assessment, 779(ab)
- tumor-bearing, model for scintigraphic screening for monoclonal antibodies, 1078
- Kinetic models**
 determination of flow and rate constants, Tc-99m HM-PAO, human brain, 917(ab)
 high speed automated discrete blood sampling, PET, 879(ab)
 influence of finite resolution, rate constant estimates, ligand-neuroreceptor binding, 866(ab)
 Tc-99m galactosyl-neoglycoalbumin, sensitivity of, 936(ab)
- Knee**, joint disorders, muscle atrophy, P-31 MR spectroscopy, 890(ab)
- Krypton-81m**
 Tc-99m MAA ventilation perfusion ratio, inert gas and, weaning, 764(ab)
 texture analysis of lung scans, 861(ab)
- L**
- Lactate**, changes in myocardial FFA metabolism, I-123 HDA, 851(ab)
- Lactation**, breast milk excretion of I-131, patient with Grave's disease, 407
- Lactoperoxidase**, radiiodinated tyramine-cellobiose labeling, monoclonal antibodies, 835(ab)
- Lead-203**, new antibody label, radioimmunoimaging, 924(ab)
- Left bundle branch block**
 coronary artery disease, Tl-201 SPECT, 1479
 regional wall motion abnormalities, quantitative phase analysis, 744(ab)
 stress-redistribution Tl-201 scintigraphy, 946(ab)
- Lesion detectability curves**, film selection and, 272(ab)
- Leukemia, lymphocytic**
 chronic
 cellular immunomodulation, I-131 T101, 757(ab)
 radioimmunotherapy, I-131 monoclonal antibody, 901(ab)
 common acute, human-mouse chimeric mAb, immunoreactivity, 890(ab)
- Leukocytes**
 In-111-labeled
 imaging of infections, 23
 migratory patterns, thymectomy and, 83
 In-111 white blood cells, porous coated hip arthroplasty, prosthetic tip, 764(ab)
 kinetics, In-111 tropolonate and Tc-99m HM-PAO, 1246
 labeling kit, preparation, Tc-99m stannous fluoride colloid, 888(ab)
 Tc-99m albumin colloid-labeled, evaluation, 903(ab)
 Tc-99m anti-SSEA-1 as tracer, human neutrophils, 788(ab)
 Tc-99m HM-PAO, reliability, Crohn's disease, 827(ab)
- Levothyroxine**, effect of post dose sampling time, thyroid function indices, 753(ab)
- Ligands**
 F-18, uptake of sex hormones, mammalian brain, 795(ab)
 Tc-99m, synthesis, biodistribution, 788(ab)
- Lipoproteins**
 low density, biodistribution, 1237
 paramagnetically-labeled low density, Ga-67, fibrosarcoma, 890(ab)
- Lipoprotein receptors**, activity, Ga-68 DTPA-LDL, PET, 848(ab)
- Liposomes**, In-111-labeled, biodistribution, normal persons, 873(ab)
- Lithiasis**, intrahepatic, detectability, Tc-99m DISIDA SPECT, 826(ab)
- Lithotripsy**, extracorporeal shock-wave, kidney function, Tc-99m MAG₃, 906(ab)
- Liver**
 avoiding complications, intrahepatic arterial infusions, chemotherapeutic agents, 799(ab)
 blood flow
 arterial and portal venous components, 466
 Tc-99m microcolloids, graft rejection diagnosis, 1776
 chronic disease, rectal portal scintigraphy, 460
 clinical SPECT studies, optimization, angular sampling frequency, 869(ab)
- compartmental and non-compartmental modeling, HIDA studies, 862(ab)
- diagnosis of transplant rejection, scintigraphy, deconvolutional analysis, 790(ab)
- digital acquisition, radioisotope tomographic images, 870(ab)
- fatty, focally abnormal sonograms, scintigraphy in, 1050
- hepatobiliary diseases, Tc-99m IDA time-activity curves, 623
- hepatoma, dosimetry of I-131 Ethiodol, 1038
- hepatoma heterotransplants, uptake of positron emitting biomolecules, 903(ab)
- I-131 lipiodol, biodistribution via hepatic artery, cancer patients, 1066
- In-111 benzyl-EDTA monoclonal antibody, metabolism of, 824(ab)
- In-111 B72.3 immunocjugates, chelator density, biodistribution, 824(ab)
- In-111 cholic acid, hepatobiliary imaging agent, 926(ab)
- In-111 monoclonal antibody
 absence, intrinsically higher tissue uptake, 924(ab)
 potential metabolizable linkers, 922(ab)
 protein mass, hepatic uptake, 888(ab)
 subcellular kinetics, 812(ab)
 lesion, cat-scratch disease, 1454
 low-density lipoprotein biodistribution, 1237
 metastases, F-18 uracil accumulation, 776(ab)
 native and DTPA conjugated monoclonal antibodies, cellular characterization, hepatocytes, 823(ab)
 nuclear hepatology, future of, 1145
 organ and tumor dosimetry, I-131 monoclonal antibodies, 874(ab)
- Pb-203 as new antibody label, radioimmunoimaging, 924(ab)
- Pb compounds as MRI contrast agents, 837(ab)
- perfusion index, 1747(le)
- perfusion parameters, cancer patients, 894(ab)
- physiology in cirrhotic and non-cirrhotic patients, non-invasive multiparametric study, 791(ab)
- planar gamma camera methods, quantitation, radionuclide content, 845(ab)
- regional measurement of receptor concentration, Ga-68 deferoxamine-galactosyl-neoglycoalbumin, 933(ab)
- Tc-99m galactosyl-neoglycoalbumin, kinetic sensitivity, 936(ab)
- Tc-99m IDAS, hepatocyte uptake, 928(ab)
- Tc-99m NGA test of functional mass, 790(ab)
- Tc-99m sulfur colloid, spleen size, planar and transaxial SPECT images, 870(ab)
- Tc-99m sulfur colloid uptake, microautoradiographic study, 1118
- transarterial embolization, therapeutic effects, F-18 FDG PET, 886(ab)
- transplantation
 see also Transplantation
 accessory hepatic duct leak, 259
 uptake of radiolabel, B72.3 and F(ab')₂ fragment, 823(ab)
 volume determination, Tc-99m sulfur colloid SPECT, 1768
- Logistic function**
 contrast-detail curves and, 273(ab)
 film sensitometry and, nuclear medicine, 273(ab)
- Lung**
 accumulation of neutral alkyl-DADT-Tc complexes, structure-biodistribution relationships, 789(ab)
 airway, fine aerosol distribution in, 1057

- cancer
 evaluation, Tl-201 SPECT, 895(ab)
 In-111 anti-CEA imaging, subtraction techniques, 899(ab)
 diagnosis of acute pulmonary embolism, angiography methods, 824(ab)
 emphysema
 I-123 HIPDM lung scintigraphy, emphysema, 905(ab)
 I-123 HIPDM metabolic lung imaging, pulmonary hypertensin, 765(ab)
 increased Ga-67 activity, tobacco smoking, HIV-positive persons, 829(ab)
 increased Tl-201 uptake during exercise, size of perfusion deficit, 943(ab)
 initial experience with Technegas, 765(ab)
 interstitial pneumonitis, Ga-67 lung index computerization, 1154(le)
 Lewis carcinoma model, biodistribution of Ga-67 citrate in, 1252
 lymphocytic interstitial pneumonitis, diagnostic pattern, Ga-67 uptake, 887(ab)
 metastases
 differentiated thyroid carcinoma, I-131 and, 1790
 thyroid carcinoma, I-131 uptake and, 701
 metastatic large cell carcinoma, Tc-99m MDP uptake, 726(le)
 microvascular injury, In-111 leukocytes for detection, 657
 normal perfusion scan, clinical validity, pulmonary embolism, 824(ab)
 organ and tumor dosimetry, I-131 monoclonal antibodies, 874(ab)
 perfusion scanning, diffusing capacity and, 1268
 radiation pneumonitis
 cancer, Ga-67 citrate scans, 829(ab)
 detection of, Ga-67 citrate scans, 888(ab)
 early diagnosis, permeability, 894(ab)
 radioisotopic lobectomy, P-32 resin microspheres, 799(ab)
 Radon reduction, cost-effectiveness, 268(le)
 regional ventilation, compartmental modeling, 861(ab)
 scans, texture analysis, 861(ab)
 squamous cell carcinoma, serum TA-4 as marker, 765(ab)
 Tc-99m carbon particles, ventilation scanning, 765(ab)
 Tc-99m DTPA aerosol
 position effect, ventilation scintigraphy, 764(ab)
 towards normal values for clearance, 904(ab)
 Tc-99m DTPA clearance, gamma camera, nonsmokers, 905(ab)
 Tc-99m HEXAMIBI synthesis, pharmacokinetics, 934(ab)
 Tc-99m MIBI uptake, extent of coronary artery disease, 952(ab)
 thyroid cancer metastases, quantitative analysis, Tl-201 scans, 895(ab)
 Tl-201 uptake, dipyridamole, global left ventricular dysfunction, 953(ab)
 tumor uptake, two dose levels, In-111 anti-CEA monoclonal antibody, 825(ab)
 water measurements, iodo-antipyrine, 275(ab)
 Xe-133 retention, V/Q pattern, congestive heart failure, 905(ab)
Lymph nodes
 detection of tumor involvement, F-18 FDG, 904(ab)
 mammary, measurement of angle in slant hole collimator, 1745(le)
Lymphocytes
 allogenic, Tc-99m MAA, control of allograft rejection, 757(ab)
 In-111 oxine-labeled, cytokine administration, biodistribution effect, 902(ab)
 radiolabeled murine, cytokine administration, biodistribution effect, 902(ab)
Lymphoid cell malignancy, In-114m lymphocyte behavior, 485
Lymphoma
 comparison of GA-67 planar and SPECT images, chest, CT, 898(ab)
 cutaneous T-cell, radiotherapy using I-131 monoclonal antibody, 174
 diffuse large-cell, Ga-67 citrate therapy, response prediction, 799(ab)
 non-Hodgkin's, C-11 thymidine uptake, PET, 1633
Lymphoma, B cell
 localization of transplants, monoclonal anti-B cell antibodies, 899(ab)
 successful radioimmunotherapy, I-131 lym-1 monoclonal antibody, 847(ab)
 treatment, I-131 murine monoclonal antibodies, 757(ab)
Lymphoscintigraphy
 interstitially administered In-111 monoclonal antibodies, 1303(le)
 mammary, Tc-99m antimony colloid, 1744(le)
 measurement of angle, slant hole collimator, 1745(le)
 radionuclide, localization of internal mammary lymph nodes, 473
 Tc-99m SbSc, cutaneous malignant melanoma, 893(ab)
 Tc-99m sulfur colloid, surgical management, melanoma, 854(ab)
- M**
- Magnetic resonance imaging:** See Nuclear magnetic resonance
Mammary tumor, chemotherapy-treated, P-31 NMR and 1H-MRI study, 837(ab)
Mandible, hyperplasia, bone SPECT, 780(ab)
Manic-depressive illness, Tourette's syndrome and, D-2 dopamine receptors, 820(ab)
Medicare, coverage for absorptiometry, HFCA, N1620
Melanoma
 cutaneous malignant
 In-111 9.2.27 anti-melanoma monoclonal antibody, antibody dose effects on, 39
 malignant
 I-123 IMP detection, 1200
 imaging studies, C-11 AIB, 904(ab)
 radioimmunodetection, 896(ab)
 metastatic, detection of, Tc-99m monoclonal antibodies, 897(ab)
 ocular, I-123 IMP visualization of, 1448
 ocular radioimmunoscintigraphy, 1031
 Tc-99m SbSC lymphoscintigraphy, 893(ab)
 surgical management, 854(ab)
Meningioma, I-123 SPECT, 1627
Metaiodobenzylguanidine, expanding role of, 1457
Metal-induced artifacts, MRI and, 279(ab)
Metals
 catalytic effect, radioiodination, *N*-isopropyl-p-iodoamphetamine, 929(ab)
 trace ion contamination, In-111 antimosin Fab-DTPA, 923(ab)
Metastasis
 disseminated skeletal, SM-153 EDTMP therapy dosimetry, SPECT, 762(ab)
 lung carcinoma, In-111 monoclonal antibody, imaging and kinetics, 896(ab)
 occult, detection of, In-111 monoclonal antibodies, 833(ab), 893(ab)
 prostate cancer, Sr-89 for palliation, wide field radiotherapy, 775(ab)
 radioimmunodetection, malignant melanoma, 896(ab)
 therapy of osseous metastases, marrow toxicity, Sr-89, 776(ab)
 thyroid cancer
 lung, Tl-201 scans, 895(ab)
 Tl-201 SPECT, 804(ab)
3-[C-11]Methoxybenzodiazepines, new radioligands for PET studies, benzodiazepine receptors, 755(ab)
***N*-Methyl-D-aspartate receptors**, *N*-(3-F-18 fluoropropyl)MK-801, 932(ab)
 α -Methyl-L-tryptophan, C-11, synthesis, 370
Metz filter, image-dependent, nuclear medicine images, 1980
MIBG, mechanism of uptake in animal model, medullary thyroid carcinoma, 893(ab)
Microautoradiography, Tc-99m sulfur colloid uptake, liver, 1118
Microwave, no-carrier-added synthesis, bromine-77 bromospiperone, 776(ab)
Migratory patterns, In-111 leukocytes, thymectomized and control rats, 83
Milk, internal and external radiation dose, nursing child, Tl-201-exposed mother, 874(ab)
Misonidazole, new approaches to radiosensitization, hypoxic tumor cells, 873(ab)
Mitral valvotomy, enhanced right ventricular exercise performance, 945(ab)
MK-801 analogs
 mapping of glutamate receptor channels, 930(ab)
N-(3-F-18 fluoropropyl)MK-801, NMDA receptors, 932(ab)
Molybdenum-99
 enriched uranium embargo risked supply, N1003 radiopharmaceuticals contaminated with, 695
Monoclonal antibodies
 19-24, improved sarcoma imaging and reduced hepatic activity, 1810
 absorbed fractions for electrons, beta particles, small spheres, 803(ab)
 anti-antibody enhancement of cancer imaging, 757(ab)
 anti-B cell, localization, human B-lymphoma transplants, 899(ab)
 anti-CEA, presurgical screening, colorectal carcinoma, 897(ab)
 antifibrin
 detection, pulmonary emboli and venous thrombi, 905(ab)
 detection, venous thrombosis, 825(ab)
 Tc-99m imaging, venous thrombi, 745(ab)
 antifibrin and antiplatelet, radioimmunoinaging, pulmonary emboli, 825(ab)
 anti-melanoma, In-111 9.2.27, antibody dose effects on, 39
 antimosin radiolabeled fragments, tumor imaging, rhabdomyosarcoma, 791(ab)
 B72.3 and B6.2, antibody catabolism, human tumors, 823(ab)
 comparison of antibody conjugates, iodovinyl, para-iodophenyl, 777(ab)
 correlation of *in vivo* distribution, tissue sampling *in vitro*, metastatic colon carcinoma, 901(ab)
 Cu-67, cancer therapy, 217
 direct radiorhenium labeling, model studies, 847(ab)
 distinct routes of administration, radioimmunodetection of tumor deposits, 761(ab)
 examination of classes and fragments, absorp-

tion, peritoneal cavity, 900(ab)
 fibrin, uptake by mouse cancer, coagulative properties, 899(ab)
 human anti-mouse antibody
 imaging consequences, 761(ab)
 radioimmunotherapy clinical trial, 761(ab)
 response absence, antimyosin Fab-DTPA, 851(ab)
IgM, distribution in murine models, 1688
I-131-labeled
 anti-CEA and anti-AFP, radioimmunotherapy, 846(ab)
 B-cell lymphoma treatment, 757(ab)
 biodistribution, interleukin-2 effect, 897(ab)
 escalating single fraction low dose rate, renal cell carcinoma, 875(ab)
 3F8 and MIBG, neuroblastoma imaging, 846(ab)
 interleukin-2 effect, biodistribution, 901(ab)
 organ and tumor dosimetry, lung and liver, 874(ab)
 radioimmunotherapy, chronic lymphocytic leukemia, 901(ab)
 radioimmunotherapy of cutaneous T-cell lymphoma with, 174
 imaging of gliomas, 897(ab)
 imaging with Tc-99m
 lung and colon carcinoma, 834(ab)
 tumor xenografts, carbohydrate residue label, 815(ab)
In(III)complexes, functionalized tetraazamacrocyclic ligands, 924(ab)
In-111 and I-131, thrombus imaging, 1212
In-111 anti-CEA
 two dose levels, lung tumor uptake, 825(ab)
 unlabeled F(ab')₂ fragment, colorectal cancer, 834(ab)
In-111 antifibrin, imaging venous thrombi, 806(ab)
In-111 bifunctional hapten, pre-targeted immunoscintigraphy, 226
In-111 CITC, protein mass, hepatic uptake, 888(ab)
In-111 fab, studies using serum from patients, 895(ab)
In-111-labeled, subcellular kinetics, liver, 812(ab)
In-111 OC 125, biodistribution, ovarian cancer, 847(ab)
internally-labeled, biodistribution, 889(ab)
labeled
 biodistribution, antigen levels and molecular size, 890(ab)
 kinetics and metabolism, cellular level, 823(ab)
 labeling with iodine and astatine, *N*-succinimidyl-3-(tri-*n*-butylstannyl)benzoate, 835(ab)
 localization, effect, circulating antigen, 762(ab)
 method of labeling, effect on retention, cultured cells, 901(ab)
 mixture of, optimization, tumor targeting, 750(ab)
 mouse, complex formation and clearance, 758(ab)
 native and DTPA conjugated, cellular characterization, hepatocytes, 823(ab)
 novel Tc-99m antibody, targeting of granulocytes, 925(ab)
OC 125, In-111- and I-131-labeled, diagnostic accuracy, 811(ab)
 pharmacokinetics, intraperitoneal injection volume, protein dose, 889(ab)
 platelets, thrombus imaging, radiolabeled Fab' fragments, 940(ab)
 prostate tumor localization, mouse subrenal capsule model, 898(ab)

radioimmunodetection, testicular carcinoma xenograft, athymic mice, 896(ab)
 radioimmunopharmaceuticals, intact vs. fragments, tumor models, 893(ab)
 radioiodinated tyramine-cellobiose labeling, compared to lactoperoxidase, 835(ab)
 radiolabeled
 bifunctional chelate, 814(ab)
 enhanced uptake, ovarian carcinoma, 900(ab)
 intraperitoneal administration, colon cancer, 762(ab)
 red marrow dosimetry, 858(ab)
 tumor accumulation of, bone, 235
 tumor targeting, chemical bond modification, 889(ab)
 radiolabeled with IPM, compared to I-125 ICI labeling, tumor uptake, 836(ab)
 recognition of CA125, *in vitro* and *in vivo* use, 766(ab)
 recombinant human-mouse chimeric, immunoreactivity, lymphocytic leukemia, 890(ab)
 reduction in radioantibody-induced myelosuppression, recombinant interleukin-1, 758(ab)
 selective radiolabeling, neutrophils, 1817
 sensitive TSH assay, 766(ab)
 separation of In-111 DTPA protein fractions, column chromatography, 925(ab)
 Sm-153, production, radioimmunoconjugates, 815(ab)
 streptavidin-conjugated, abscess imaging, In-111 biotin, 889(ab)
 Tc-99m and In-111 labeled antifibrin antibodies, thrombus model, 746(ab)
 Tc-99m anti-CEA, known and occult colorectal carcinoma, 834(ab)
 Tc-99m antiplatelet, diagnosis, mesenteric thrombosis, 886(ab)
 Tc-99m anti-SSEA-1 as tracer, human neutrophils, 788(ab)
 Tc-99m-labeled, detection, metastatic melanoma, 897(ab)
 tissue biodistribution, tumor mass, determining factor, 926(ab)
 treatment planning for therapy
 3D dosimetry, 803(ab)
 quantitative planar imaging, anthropomorphic phantom, 845(ab)
 uptake of radiolabel in liver cells, F(ab')₂ fragment, 823(ab)
Y-90
 therapy, bremsstrahlung dosimetry, 859(ab)
 therapy, human cancer xenografts, 901(ab)
Moynihan's disease, duodenal-gastric reflux in, scintigraphic study, 17
Mucin, -like carcinoma-associated antigen, monitoring, breast cancer patients, 894(ab)
Muscarinic receptors
 C-11 TRB as ligand, synthesis, preliminary evaluation, 932(ab)
 evaluation of potential PET agents, 933(ab)
 hyper- and hypothyroidism, PET investigation, 808(ab)
 imaging in brain, C-11 scopolamine, PET, 808(ab)
 regional quantitation, radioligand dissociation kinetics, 927(ab)
 synthesis and regional brain distribution, C-11 NMPB, 768(ab)
Muscle
 atrophy in knee-joint disorders, P-31 MR spectroscopy, 890(ab)
 C-11 l-pyruvate metabolism, mitochondrial encephalomyopathy, PET, 921(ab)

skeletal, N-13 glutamine transport, cancer cachexia, 902(ab)
Myocardial cells, TI-201 chloride and Tc-99m MIBI uptake and release, 48
Myocardial infarction
 absence of human antimouse antibody response, antimyosin Fab-DTPA monoclonal antibody, 851(ab)
 accumulation of polymorphonuclear leukocytes, 1826
 accumulation of white blood cells, reperfusion myocardial injury, 954(ab)
 acute coronary reperfusion, reverse redistribution, poor early prognosis, 948(ab)
 acute Q-wave infarct size, In-111 antimyosin SPECT, 942(ab)
 ambulatory radionuclide monitoring, left ventricular function, patient outcome, 838(ab)
 apical, electrocardiographic correlation, 2029(ab)
 "black hole" sign of left ventricular aneurysm, TI-201 SPECT images, 756(ab)
 comparative SPECT imaging, thallium and antimyosin, acute Q-wave, 806(ab)
 complications predictions of non-cardiac surgery, dipyridamole thallium tomography, 838(ab)
 defect size, TI-201 SPECT measurement, 1486
 diastolic function in, 1786
 differentiation from ischemia, TI-201 bullseye display, 938(ab)
 exercise TI-201 scintigraphy, assessment of prognosis, 951(ab)
 "false" positive pyrophosphate tomoscintigrams, 954(ab)
 glucose metabolism and perfusion imaging, ischemia detection, planar scintigraphy, 828(ab)
 I-123 MIBG SPECT compared to TI-201 cardiac imaging, 840(ab)
 In-111 antimyosin Fab scintigraphy, regional asynergy, 806(ab)
 inferior left ventricle, right ventricular involvement, antimyosin, 806(ab)
 intravenous dipyridamole-TI-201 imaging, prediction, in-hospital ischemia, 781(ab)
 left ventricular function, gated planar Tc-99m RP-30, contraction fraction, 818(ab)
 noninvasive delineation of size, vessel patency, Tc-99m RP-30A, 819(ab)
 non-invasive detection of reperfusion, TI-201/Tc-99m PPI uptake pattern, 949(ab)
 patients with ischemic chest pain, antimyosin imaging, 805(ab)
 post-, PET evaluation, F-18 uptake, 783(ab)
 posterolateral, TI-201 SPECT, 954(ab)
 prediction of extent of akinesis, acute antimyosin scintigraphy, 851(ab)
 predictive value, thallium SPECT, 770(ab)
 regional oxidative metabolism, PET, C-11 acetate, 818(ab)
 reperfusion after thrombolysis, Tc-99m isonitrite, 1865
 reperfusion effects, Tc-99m RP-30 and TI-201, 819(ab)
 serial assessment, gated MRI and Gd-DTPA, 802(ab)
 tissue glucose metabolism, PET, persistent TI-201 defects, 827(ab)
 TI-201 SPECT infarct size, heparin, fibrinolytic agent, 951(ab)
 uptake specificity, In-111 antimyosin, 746(ab)
Myocardial ischemia
 abnormal clearance of TL-201 during SPECT, assessment, coronary artery disease, 948(ab)
 after attempted reperfusion, TI-201/Tc99m RP-

- 30A disparity, 1283
- ambulatory ventricular function monitor, validation, exercise left ventricular ejection fraction, 741(ab)
- comparison of Tl-201 and Tc-99m RP-30A, quantitative cardiac SPECT, 793(ab)
- coronary bypass surgery, N-13 ammonia, PET, 817(ab)
- coronary venous retroperfusion, PET, 783(ab)
- counts-based index, left ventricular "ejection fraction", ECG-gated perfusion scans, 947(ab)
- defect detection, Tc-99m MIBI vs. Tl-201, 850(ab)
- delayed 24-hour redistribution, SPECT Tl-201 myocardial perfusion studies, 769(ab)
- detection of coronary artery stenoses, exercise, PET, 837(ab)
- differentiation from infarction, Tl-201 bullseye display, 938(ab)
- dipyridamole perfusion scintigraphy, known or suspected angina, 781(ab)
- distribution of perfusion, patients surviving sudden death, 769(ab)
- early Tl-201 redistribution, effect, SPECT imaging, 947(ab)
- effect of nifedipine, perfusion and metabolism, systemic sclerosis, 828(ab)
- effect of reperfusion, first-pass extraction, pyrophosphate and antimyosin, 746(ab)
- enhanced binding of fluoromisonidazole, hypoxia, 807(ab)
- extent of coronary disease in unstable angina, exercise thallium scintigraphy, 945(ab)
- glucose metabolism
- hypertrophic cardiomyopathy, PET, 828(ab)
 - rate constants, partial volume effect, 783(ab)
- I-123 free fatty acid metabolism, diabetes, 842(ab)
- improved detection of coronary artery disease, exercise, Tl-201 SPECT tomography, 755(ab)
- injections of Tc-99m MIBI, myocardial tomographic imaging, 804(ab)
- nitroglycerin response prediction, radionuclide monitoring, left ventricular function, 838(ab)
- oxidative metabolism, C-11 acetate clearance, 937(ab)
- persistent Tl-201 defects, significance, metabolic activity, 827(ab)
- planar Tc-99m isonitrile exercise imaging
- detection, coronary artery disease, 804(ab)
 - new normal database, modified background correction, 804(ab)
- potential tracer using PET, 1-[C-11]-D,L-homocysteine thiolactone, 755(ab)
- protective effect of calcium antagonist, In-111-anticardiac myosin antibody, 745(ab)
- quantification of infarct size, Tc-99m RP-30A and SPECT, 946(ab)
- quantitation of ischemic zone at risk, coronary occlusion, PET, 951(ab)
- regional oxidative metabolism, C-11 acetate, dynamic PET, 782(ab)
- regional wall motion, perfusion and metabolism, PET, 828(ab)
- reperfusion and
- preserved I-123 IPPA uptake, 842(ab)
 - Tc-99m RP-30, 1539
- resting thallium perfusion abnormalities, coronary stenoses, unstable angina, 768(ab)
- reversibility bullseye polar map, 951(ab)
- reversible rest-redistribution thallium-201 defects, unstable angina, 768(ab)
- ribose effects on Tl-201, 1943
- role of 24-hour tomographic Tl-201 myocardial imaging, revascularization, 769(ab)
- scintigraphic assessment, sympathetic nerves, 840(ab)
- significance of regional wall thickening, cardiac MRI imaging, perfusion and PET, 801(ab)
- silent, detection of, ambulatory left ventricular function monitor, 741(ab)
- simultaneous assessment of leg muscle, stress testing, dipyridamole and exercise, 947(ab)
- stress-redistribution Tl-201 scintigraphy, left bundle branch block, 946(ab)
- thallium dobutamine imaging, detection, coronary artery disease, 955(ab)
- Tl-201 perfusion defects, weaning, mechanical ventilator-dependent patients, 947(ab)
- Tl-201 redistribution, ribose, coronary artery disease, 953(ab)
- Tl-201 SPECT
- bullseye, applying standard deviation, 954(ab)
 - value and limitations, 1181
- transient, one and two day protocol, Tc-99m MIBI, 851(ab)
- uptake of Tc-99m MIBI and Tl-201, 819(ab)
- validation of quantitative analysis, exercise thallium tomograms, 871(ab)
- Myocarditis**
- In-111 antimyosin Fab, 939(ab)
 - myocardial damage in, In-111 antimyosin, 1893
- Myocardium**
- assessment of metabolism and function, multi-gated PET, 771(ab)
 - assessment of regional blood flow, N-13 ammonia PET, 838(ab)
 - blood flow, noninvasive quantification, N-13 ammonia, 940(ab)
 - C-11 acetate probe of metabolism, simple and efficient synthesis, 932(ab)
 - cardiac cavity and, correction, activity cross-contamination, 866(ab)
 - C-11 fatty acid synthesis and biologic evaluation, 68
 - congestive heart failure, MIBG myocardial uptake, 841(ab)
 - correction for partial volume effects, PET, 774(ab)
 - damage, myocarditis and cardiac rejection, In-111 antimyosin, 1893
 - determination of left ventricular mass, cine vs. gated spin NMR imaging, 891(ab)
 - differentiation by P-31 NMR, reperfused viable from reperfused infarcted, 801(ab)
 - dipyridamole-induced coronary vasodilation, quantitative assessment, PET and N-13 ammonia, 818(ab)
 - dipyridamole tomographic myocardial perfusion, Tc-99m SQ 30217, 938(ab)
 - emission tomography, bull's eye plot for, 267(1e)
 - estimation of right ventricular pressure overloading, Tl-201 myocardial SPECT, 950(ab)
 - evaluation of F-18 6-fluorometaraminol kinetics, PET, 807(ab)
 - experimentally-induced necrosis, In-111 antimyosin kinetics, septum, 941(ab)
 - glutathione detoxification system, assessment, F-18 fluorodinitrobenzene, 808(ab)
 - β -hydroxy fatty acids, acylation, "masked" malonic ester, 848(ab)
 - hypertrophic obstructive cardiomyopathy, Tl-201 imaging, 1738
 - imaging agent, binding characteristics, 55
 - I-123 MIBG uptake, sympathetic activity index, altitude hypoxia, 842(ab)
 - improved accuracy of imaging, elliptical regions of interest, 944(ab)
 - intra-operative blood flow monitor, 880(ab)
 - jeopardized, ischemia assessment, exercise SPECT Tl-201, 943(ab)
 - left ventricular maximum time-varying elastance, radionuclide angiographic calculations, 1368
 - mechanism of Tl-201 uptake in tumors, 750(ab)
 - metabolism
 - I-131 OPPA and PPPA, 938(ab)
 - radioiodinated methyl-branched fatty acids, 1230
 - Tc-99m fatty acid analogs, 935(ab)
 - tracers, fatty acid derivatives of PnAO, 934(ab) - MRI, computer analysis of, 277(ab)
 - multicenter trial of Cedars-Sinai method, quantitative analysis, Tl-201 myocardial tomography, 755(ab)
 - neutral tris oxime complexes, technetium(III), chemistry, 800(ab)
 - N-13 glutamate uptake, rest and exercise, PET, 950(ab)
 - normal and ischemic, fatty acid influx, biochemical characteristics, 940(ab)
 - novel diaminodithiol-fatty acid complex, synthesis, imaging agent, 935(ab)
 - oxidative metabolism
 - C-11 acetate, 808(ab), 937(ab)
 - C-11 acetate clearance, 937(ab) - perfusion distribution, 3D visualization, coronary arterial tree, 810(ab)
 - perfusion images, end-diastolic versus conventional, 2030(ab)
 - planar Tl-201, quantification, degree of reversibility, 861(ab)
 - potential imaging agents, Tc-99m complexes of aromatic isocyanides, 800(ab)
 - prediction of coronary events, Tl-201 quantitation, 770(ab)
 - quantitative assessment of regional perfusion, N-13 ammonia, dynamic PET, 782(ab)
 - rest and exercise SPECT studies, Tl-201 thallous chloride, Tc-99m isonitrile, 944(ab)
 - salvageable, marker, F-18 fluoromisonidazole, 807(ab)
 - sarcoid heart disease, magnetic resonance imaging, 891(ab)
 - scar size, quantification in SPECT, 872(ab)
 - serial biopsies, time-activity curves, 1934
 - SPECT imaging
 - poor predictive values, inferior wall defects, 944(ab)
 - reconstruction, attenuation, detector response correction, 749(ab) - ST segment depression, intravenous dipyridamole thallium infusion, 782(ab)
 - "stunned", F-18 fluorometaraminol, neuronal injury, 938(ab)
 - Tc-99m MIBI
 - compared to Tc-99m MPIN, imaging in man, 794(ab)
 - compared to Tl-201, coronary artery disease, 793(ab)
 - dosimetry and biodistribution, 874(ab)
 - effect on uptake, metabolic inhibitors, 820(ab)
 - perfusion and wall motion assessment, Chagas' cardiomyopathy, 950(ab)
 - slow infusion, rest and stress studies, 942(ab)
 - Tc-99m RP-30, kinetics, flow and work controlled conditions, 792(ab) - thallium reinjection after delayed imaging, fill-in to regions with "fixed" defects, 769(ab)
 - Tl-201

Naltrexone

- diffuse decreased wash-out, quality of stress, 945(ab)
late redistribution, viability, 948(ab)
reverse redistribution, coronary artery disease, 952(ab)
wash-in and wash-out, redistribution phenomenon, 939(ab)
trapping of I-123 OPPA, 851(ab)
uptake and redistribution, RP-30 compared to SQ 32014, 819(ab)
uptake of 19-iodo-3,3-dimethyl-18-nonadecenoic acid, hypertension, verapamil, 843(ab)
- N**
- Naltrexone**, opiate receptors, duration of occupancy, 1207
National Academy of Sciences (NAS)
Alfred P. Wolf elected, N1014
report on reactor safety, N1760
National Cancer Institute (NCI), cancer near US nuclear plants, N440
National Institutes of Health, consensus panel, MRI judged safe, N291
National Research Council, Committee on Nuclear and Radiochemistry reports, N1338
National Study of Resource-based Relative Value Scales (RVS), submitted to HHS, N1167
NEMA specifications, scintillation cameras, count rate curve determination, 538
Neoplasms, noninfected, In-111 leukocyte localization in, 1921
Nephrology, pediatric, nuclear medicine in, 1287
Nephrotoxicity, cyclosporine, various renal radioactive agents, 1577
Neural crest tumors, side effects of I-131 MIBG, 798(ab)
Neuroblastoma
imaging and target radiotherapy, I-131 3F8 and MIBG, 846(ab)
value of I-131-MIBG/Tc-99m-MDP/Ga-67-citrate, diagnosis and follow-up, 750(ab)
Neuroreceptors
ligand binding, finite resolution, rate constant estimates, 866(ab)
opiate receptor binding, C-11 diprenorphine and carfentanil, dual detector system, 921(ab)
quantification by PET, various models, 922(ab)
selection criteria for binding ligands, kinetic PET data, 865(ab)
Neutrophils
In-111 injection, infected wound chambers, 787(ab)
selective radiolabeling, monoclonal antibodies as agents for, 1817
Tc-99m anti-SSEA-1 as tracer, 788(ab)
Tc-99m-Sn-pyrophosphate localization in, 1406
Newsline
Commentary
FDA clarification of policies, N1472
lines from the President, N289, N1006, N1475, N1891
new managing editor, N10
Nifedipine, regional myocardial blood flow, assessment, N-13 ammonia PET, 838(ab)
Nisoxetine, C-11-labeled, synthesis of, 932(ab)
Nitrogen, trap for removing oxides of, C-11 carbon dioxide, 933(ab)
Nitrogen-13, use of phenylalanine dehydrogenase for synthesis, L-phenylalanine, L-tyrosine and L-DOPA, 931(ab)
Nitrogen-13 ammonia
detection of coronary artery stenoses, PET, exercise, 837(ab)
dynamic PET and, quantitative assessment, regional myocardial perfusion, 782(ab)
myocardial blood flow
metabolic fate in human blood, PET, 783(ab)
noninvasive quantification, PET, 940(ab)
PET and first-pass flow model, 838(ab)
quantitation of ischemic zone at risk, coronary occlusion, PET, 951(ab)
stress-induced ischemia, coronary bypass surgery, 817(ab)
Nitrogen-13 glutamate
delayed recovery of myocardial metabolism, successful angioplasty, 817(ab)
methotrexate effects, Walker-256 carcinoma, 208
myocardial uptake, rest and exercise, PET, 950(ab)
Nitrogen-13 glutamine, transport in skeletal muscle, effect, cancer cachexia, 902(ab)
Nitroglycerin
regional myocardial blood flow, assessment, N-13 ammonia PET, 838(ab)
response prediction, radionuclide monitoring, left ventricular function, 838(ab)
Nitrosourea, C-11, synthesis, 1957
Noise power, SPECT, 1704
Noradrenergic neurons, mapping central noradrenergic innervation, I-125 DHTP, 777(ab)
Nuclear magnetic resonance
Alzheimer's dementia and normal aging, comparisons, CT and PET, 852(ab)
application of cine cardiac MRI, valvular, coronary artery and aortic disease, 802(ab)
-based templates with PET images, inter-observer variability, ROI analysis, 866(ab)
cine imaging, aortic regurgitation, 802(ab)
compared to bone marrow scintigraphy, plasmocytoma, 891(ab)
compared to bone scintigraphy, evaluation, osseous spine metastases, 763(ab)
compared to CT and PET brain imaging, acute head injury, 910(ab)
compared to PET, partial epilepsy, 910(ab)
comparison to radionuclide scintigraphy, parathyroid adenoma and paraganglioma, 277(ab)
computer-controlled motion phantom for, 280(ab)
cortical signal abnormalities, Alzheimer's disease, 836(ab)
evaluation of PET feasibility studies, study protocol screening, 774(ab)
F-19, 5-fluoro-2',3'-dideoxycytidine, AIDS virus, 837(ab)
gated, coronary assessment, 943(ab)
gated MRI and Gd-DTPA, serial assessment, myocardial infarction, 802(ab)
Gd-153 (DTPA)², pharmacokinetic analysis, blood distribution, 891(ab)
grey and white tissue water content, partition coefficient, labeled water, 773(ab)
high dose-delayed Ga-67 scintigraphy and, sarcoma, 749(ab)
imaging of proton self-diffusion coefficient, cerebral infarction, PET correlation, 836(ab)
instruments, FDA reclassification of, N592
iron compounds as contrast agents, liver, 837(ab)
metal-induced artifacts on, 279(ab)
MRI judged by consensus panel of NIH, N291
myocardium differentiation, reperfused viable from reperfused infarcted, 801(ab)
new technique for automated edge detection, 865(ab)
P-31
1H-MRI study, chemotherapy-treated mammary tumor, 837(ab)
muscle atrophy, knee joint disorders, 890(ab)
PET
coordinate system, localization of neuroanatomy, 918(ab)
radiation necrosis, canine CNS, 785(ab)
radionuclide cisternography and, evaluation, normal pressure hydrocephalus, 836(ab)
registration of MRI-PET images, procedure, validation, 853(ab)
sarcoid heart disease, 891(ab)
significance of regional wall thickening, cardiac MRI imaging, 801(ab)
sodium, cardiac rejection, heterotopic heart transplantation, 802(ab)
spectroscopy
compared to FDG-PET, brain tumors, 785(ab)
correlation with PE, CNS disorders, 910(ab)
Nuclear medicine
pediatric urology and nephrology, 1287
recruitment, FDA/SNM/ACNP, N1477
resolution test pattern, 1856
simultaneous acquisition, images and physiological data, 1848
Nuclear medicine images, image-dependent Metz filter, 1980
Nuclear medicine practice
considerations in purchase of computer, 717
FDA software policy proposals, N588
future of, interdisciplinary meeting, N1
how to strengthen, N2
Superconducting Super Collider, 576(le)
Nuclear medicine research
DOE seeks applicants for research grants, N1760
DOE appropriation for, N1167
fraud and, N1470
Hevesy Pioneer Award, Seymour S. Kety and Louis Sokoloff, N583
orphan product program funds, N1011
Nuclear medicine technology
Donner Laboratory, N431
film sensitometry, application of logistic distribution, 273(ab)
how to strengthen, N2
scan trends reflect multiple forces, N1009
Nuclear Medicine Week, 1988, N438
Nuclear pharmacists, recertification, N10
Nuclear plants, US, NCI studies of cancer, N440
Nuclear reactors, safety, National Academy of Sciences report, N1760
Nuclear Regulatory Commission (NRC)
commissioners meet on quality assurance rule proposal, N592
proposed quality assurance regulations, N283
revision of, N1008
proposed training rules, N1159
West Virginia hospital fined, N1007
- O**
- Oak Ridge National Laboratory**, enriched uranium embargo risk supply of Tc-99m/Mo-99, N1003
Opiate receptors
binding
C-11 diprenorphine and carfentanil, 796(ab)
C-11 diprenorphine and carfentanil, dual detector system, 921(ab)
brain uptake, C-11 buprenorphine and diprenorphine, 933(ab)
duration of occupancy, naltrexone, 1207
F-18 fluoroalkyl diprenorphine, PET studies, 930(ab)
kinetic evaluation of ligand, 3H-cyclofoxy, rat brain, 796(ab)
multi-compartmental analysis, C-11 diprenor-

phine binding, PET, 796(ab)

Orphan products development, funds underused by nuclear medicine researchers, N1011

Os-191, reactor-produced, removal of Ir-192, 927(ab)

Osteoid osteoma, bone scan, 272(ab)

Osteomyelitis
 comparison of HM-PAO-labeled leukocytes, Tc-99m small colloid, 813(ab)
 diagnosis of fracture and, role, In-111 leukocytes, 814(ab)
 hematogeneous, failure of Tc-99m MDP bone scintigraphy in, 274(ab)
 In-111 chloride imaging
 diabetic foot, 813(ab)
 treated, 763(ab), 883(ab)
 In-111 leukocytes, possibly-infected hip arthroplasties, 883(ab)
 In-111 WBC
 evaluation, 813(ab)
 localization, non-infected surgery site, 788(ab)
 neuropathic foot disease, In-111 leukocyte scans and bone scintigraphy, 1651

Osteoporosis
 bone mineral loss, normal postmenopausal women, 881(ab)
 eating disorder patients, 882(ab)
 non-hormonal therapy of, dual-photon absorptiometry, 855(ab)
 spinal, diagnostic sensitivity, SPA and DPA, 882(ab)
 spine and distal forearm, bone density measurements in, 131(le)

Osteosarcoma
 calvarium, Paget's disease, 414
 neoadjuvant chemotherapy, scintigraphic evaluation, Tc-99m MDP, 882(ab)

Ovarian cancer
 biodistribution, In-111 OC 125 monoclonal antibody, 847(ab)
 radioimmunoscintigraphy, 599
 recognition of CA125 by monoclonal antibodies, *in vitro* and *in vivo* use, 766(ab)

Ovarian dysfunction, I-131 scintigraphic localization, 1644

Oxygen
 cerebral blood flow, glucose metabolism, stroke, 852(ab)
 metabolism and blood flow, spinocerebellar degeneration, PET, 920(ab)
 metabolism in cerebrovascular disease, early and late I-123 IMP SPECT, 844(ab)

Oxygen-15
 absorbed dose estimates, newborn, 1961
 dynamic PET studies, arterial input function, plasma separation, 832(ab)
 radiation absorbed dose estimate, newborn infants, 874(ab)
 steady state method, correction, arterial concentration, 821(ab)

Oxygen-15 water
 autoradiography and PET, oxygen inhalation, cerebral blood flow, 915(ab)
 direct measurement of distribution volume, PET, 822(ab)
 effect of recirculation, estimation, cerebral oxygen metabolism, 917(ab)
 evaluation of dispersion, input function, dynamic PET, 867(ab)
 high resolution PE, cache memory system, real-time operation, 878(ab)

P

PACS
 high-speed ethernet system, image archiving, nuclear medicine, 810(ab)
 image spread sheet, manipulation, digital images, 811(ab)

Paget's disease
 osteoclast nuclei, Ga-67 citrate localization, 1083
 osteosarcoma in calvarium, 414
 photopenic skeletal defect, In-111 leukocytes, 561

Pancreas
 oncofetal antigen, combined assay, digestive system, 906(ab)
 scintigraphy, evaluation, I-123 HIPDM, 826(ab)
 -spleen transplantation, graft perfusion, serial radionuclide determinations, 885(ab)

Pancreatic cancer, imaging with antibodies to CEA, 833(ab)

Paraganglioma, nonsecreting, metastases, I-131 MIBG effectiveness, 2008

Parathyroid
 adenoma and paraganglioma, radionuclide scintigraphy and MRI, 277(ab)
 factors related to imaging, 860(ab)
 failure of scintigraphy, 860(ab)

Parkinson's disease, metabolites of F-18 fluoro-L-dopa, human blood, 363

Parotid, oncocytoma, I-131 therapy, 1126

3H-Paroxetine, labeling of serotonin uptake sites, 809(ab)

Partial correlation coefficient, interregional relations, cerebral metabolic activity, 392

Paul C. Aebersold Award, achievement in basic science, William C. Eckelman, N586

Pediatric patients
 emergency use of bone scintigraphy, 736(ab)
 In-111 oxine, dosimetry, 689
 lymphocytic interstitial pneumonitis, Ga-67 uptake in AIDS, 707
 nuclear medicine in, 1287
 osteomyelitis, subperiosteal abscess complicating, In-111 leukocyte scintigraphy, 1871

Peptic ulcer, *Campylobacter pylori*, C-14 urea breath test for, 11

Periostitis, lower extremity, secondary to venous insufficiency, 1279

Peristalsis, renal antegrade perfusion scintigraphy, study, ureteric function, 779(ab)

Peritoneal cavity, examination of antibody classes and fragments, absorption, 900(ab)

Peritoneal fluid, SPECT inferior attenuation, 941(ab)

PET: See Positron emission tomography (PET)

Phantom, tissue-equivalent anthropomorphic, radionuclide dosimetry, imaging studies, 803(ab)

Pharmacokinetics, monitoring of positron-emitting tracers, multiple region-of-interest capabilities, 832(ab)

Phencyclidine, F-18 PCP analogs for PET, 767(ab)

β -Phenethylamine, synthesis, C-11 nitroalkane production, 754(ab)

Phenylalanine dehydrogenase, synthesis of L-phenylalanine, L-tyrosine and L-dopa, N-13, 931(ab)

Phenylalkylamines, 5-iodo-thienylamphetamine synthesis, brain imaging agents, 777(ab)

Phenylalkyloxirane carboxy acid, metabolism of I-131 OPPA and PPPA, heart, 938(ab)

Phillips and Picker Medical Systems, joint venture plan, N292, N440

Phosphorus-32, therapy for therapy-resistant malignant glioma, 902(ab)

Phosphorus-32 chromic phosphate, intracavitary

Positron emission tomography (PET)

therapy, 2027(ab)

Phosphorus-31 NMR, myocardium differentiation, reperfused viable from reperfused infarcted, 801(ab)

Phosphorus-32 resin microspheres, radioisotopic lobectomy, vicinal and systemic safety, 799(ab)

Physician training, NRC, medical use of byproduct materials, N1159

Pick disease, differential diagnosis of non-vascular dementia, SPECT, 743(ab)

Planar imaging
 compared to Ga-67 SPECT, chest, CT in lymphoma patients, 898(ab)
 compared to SPECT, detection, metastatic colorectal cancer, 886(ab)
 F-18 deoxyglucose and Tl-201, ischemia detection, post-myocardial infarction, 828(ab)
 gamma camera, radionuclide content, liver or spleen of abdominal phantom, 845(ab)
 SQ30217 and Tl-201, comparison with coronary anatomy, 841(ab)

Plasmapheresis, retreatment of cutaneous T-cell lymphoma following, I-131 monoclonal antibody, 174

Plasminogen activator, radioiodinated recombinant tissue, localization of malignant tumors, 1194

Plasmocytoma, bone marrow scintigraphy, compared to magnetic resonance tomography, 891(ab)

Platelets
 improved kit method for labeling with Tc-99m, 787(ab)
 In-111 endothelial cells, adherence, carotid arteries, 939(ab)
 monoclonal antibody, thrombus imaging, radio-labeled Fab' fragments, 940(ab)
 natural history of aggregation, endothelial injury, angiography, 948(ab)
 survival and sequestration of In-111 donor platelets, patients with neoplasms, 787(ab)
 survival in thrombocytopenic children, In-111 oxine, 892(ab)
 survival studies, In-111, 564

***Pneumocystis carinii* pneumonia**, variable presentation, Ga-67 scans, HIV-positive persons, 829(ab)

Pneumonitis
 lymphocytic interstitial, Ga-67 uptake in pediatric AIDS patient, 707
 radiation
 early detection, Ga-67 citrate scans, 888(ab)
 early diagnosis, lung permeability, 894(ab)

Positron, energetics of decay, 1156(le)

Positron emission tomography (PET)
 acceptance testing of CTI 933/04 ECAT scanner, 880(ab)
 accuracy of neuroreceptor quantification, various models, 922(ab)
 acquired input functions, cardiac studies, 241
 Alzheimer's dementia and normal aging, comparisons, CT and MR, 852(ab)
 arterial sampling vs. quantitative LV cavity imaging, 772(ab)
 assessment of regional wall motion, perfusion, metabolism, 828(ab)
 brain image analysis, metabolic centroid method, 774(ab)
 brain metabolic relationships, condition-dependent changes, 839(ab)
 C-11 acetate
 clearance, myocardial oxidative metabolism, 937(ab)

Positron emission tomography (PET)

- myocardial oxidative metabolism, 937(ab)
regional oxidative metabolism, myocardial infarction, 818(ab)
regional oxidative metabolism, stunned myocardium, 782(ab)
simple and efficient synthesis, myocardial metabolism, 932(ab)
- C-11 diprenorphine compared to carfentanil binding to opiate receptors, man, 796(ab)
brain uptake, 933(ab)
- C-11 malonate platinum, 1107
- C-11 1-pyruvate, brain and muscle metabolism, mitochondrial encephalomyopathy, 921(ab)
- C-11 Ro15-1788, benzodiazepine receptors, 931(ab)
- C-11 scopolamine, muscarinic receptor imaging, brain, 808(ab)
- C-11 thymidine uptake, non-Hodgkin's lymphoma, 1633
- C-11 TRB, ligand, muscarinic receptor, 932(ab)
- C-11 YM-09151-2, brain uptake, dopamine D-2 receptors, 931(ab)
- camera image quality improvement, removeable rings, high atomic number material, 877(ab)
camera performance design evaluation, BGO and BaF₂ scintillators, 338
canine stroke model, 920(ab)
cardiac
arterial activity concentrations, 941(ab)
automated quantitative analysis, 867(ab)
correction, partial volume effects, 774(ab)
cerebellar metabolism of FDG, brain trauma, 822(ab)
cerebral blood flow, oxygen and glucose metabolism, stroke, 852(ab)
cerebral glucose utilization, relation to brain structure, polydrug abusers, 911(ab)
cerebral metabolic rate, glucose, 392
cerebral oxygen metabolism, effect, O-15 water recirculation, 917(ab)
clinical, N1751
clinical center, manpower requirement and work flow organization, 2028(ab)
clinical status in U. S. in 1987, 1136
compared to CT and MRI brain imaging, acute head injury, 910(ab)
compared to early and late I-123 IMP SPECT, cerebrovascular disease, 844(ab)
compared to I-123 IMP and Tc-99m HM-PAO SPECT, dementia, 916(ab)
compared to MRI, partial epilepsy, 910(ab)
compared to Xe-133 SPECT, cerebral blood flow, 919(ab)
comparison of bromo vs. iodoalkyl triflates, F-18 radiolabeling, secondary amines, 754(ab)
comparison of macromolecular tracers, vascular permeability, 939(ab)
coordinate system, localization, neuroanatomy, 918(ab)
copper-labeled radiopharmaceuticals, cerebral and myocardial blood flow evaluation, 1549
CO₂ reactivity using I-122 HIPDM, quantitative blood flow tracer, 773(ab)
coronary artery disease, neurological disorders and, 2028(ab)
coronary venous retroperfusion, myocardial ischemia, 783(ab)
correction for arterial concentration variation, O-15 steady state method, cerebral blood flow, 821(ab)
correction of activity cross-contamination, myocardium and cardiac cavity, factor analysis, 866(ab)
correlation with MRS, CNS disorders, 910(ab)
- Cu-62 HSA, plasma volume measurement, 930(ab)
current generation scanner, performance evaluation, 878(ab)
cyclotron-produced radiopharmaceutical for clinical use, 2030(ab)
delayed recovery of myocardial metabolism, successful angioplasty, 817(ab)
design of simulation system, 871(ab)
detection of coronary artery disease, Rb-82 PET compared to Tl-201 SPECT, 817(ab)
detection of coronary artery stenoses, exercise, 837(ab)
detector design, crystal masking analog positioning, 761(ab)
development of PET workstation, personal computer, 867(ab)
dilated and ischemic cardiomyopathy, visual, circumferential profile analysis, 818(ab)
dipyridamole-induced coronary vasodilation, quantitative assessment, N-13 ammonia, 818(ab)
direct measurement of distribution volume, water, PET, 822(ab)
dopaminergic system, 3-N-(F-18)fluoroethylpiperone, 821(ab)
dual detector system, opiate receptor binding, C-11 diprenorphine and carfentanil, 921(ab)
dynamic and static, quantitation of uncertainties, 912(ab)
dynamic technique, cerebral blood flow evaluation, 775(ab)
enhanced binding of fluoromisonidazole, hypoxia, myocytes, 807(ab)
evaluation of dispersion, peripherally sampled input function, 867(ab)
evaluation of feasibility studies, other modalities, study protocol screening, 774(ab)
evaluation of F-18 6-fluoromecaraminol kinetics, 807(ab)
evaluation of F-18 uptake, post-infarct myocardium, 783(ab)
evaluation of potential agents, mAChR, 933(ab)
evaluation of recurrent colorectal tumors, 751(ab)
evaluation of Tc-99m HM-PAO SPECT, cerebral perfusion tracer, 843(ab)
- FDG
AIDS-related dementia, azidothymidine, 852(ab)
compared to image-guided MR spectroscopy, brain tumors, 785(ab)
left hemisphere dysfunction, Alzheimer's disease, 912(ab)
primary visual cortex hypometabolism, head injury, 830(ab)
rate constants, degenerative brain disorders, 915(ab)
- F-18 cyclofoxy imaging in man, 796(ab)
- F-18 FDG
compared to F-18 FDM, 772(ab)
frontal lobe epilepsy, 831(ab)
hexokinase reaction, 1443
initial clinical experience, 2028(ab)
therapeutic effects, transarterial embolization to liver tumors, 886(ab)
- F-18 fluoromisonidazole, marker, salvageable myocardium, 807(ab)
- F-18 fluorophenylalanine, brain tumors, 919(ab)
- F-18 PCP analogs, 767(ab)
- 6-F-18-L-DOPA brain imaging, asymptomatic MPTP-lesioned monkeys, 820(ab)
- Ga-68 deferoxamine-galactosyl-neoglycoalbumin, regional measurement, receptor concentration, 933(ab)
Ga-68 DTPA-LDL, receptor activity, 848(ab)
genetic linkage results and, subjects at risk, Huntington's disease, 853(ab)
D-glucose and β -phenethylamine synthesis, production, C-11 nitroalkanes, 754(ab)
glucose metabolism, cerebral, 631
glucose utilization and rate constants, partial volume effect, ischemic myocardium, 783(ab)
grey and white tissue water content, partition coefficient, labeled water, 773(ab)
halothane-induced decrease of C-11 CGP 12177, myocardial beta adrenoceptor, 940(ab)
hepatoma heterotransplant uptake, 903(ab)
high resolution, cache memory system, realtime operation, 878(ab)
high speed automated discrete blood sampling, 879(ab)
hyperkinetic movement disorders, 839(ab)
I-122 HIPDM, cerebral blood flow agent, 916(ab)
imaging agent for prostate tumors, 750(ab)
improved HPLC system, analysis, organic amine radiopharmaceuticals, 926(ab)
influence of finite resolution, rate constant estimates, ligand-neuroreceptor binding, 866(ab)
kinetic parameters
FESP-D2 receptor interactions, 865(ab)
selection criteria, neuroreceptor binding ligands, 865(ab)
lack of ID for EC/IC bypass, cerebral hemodynamics, 831(ab)
low cost large area camera, physical evaluation, 877(ab)
maturation of cerebral neutral amino acid accumulation, C-11 methionine, 784(ab)
measurement of protein synthesis rates, tyrosine, 524
medically-treated cerebral ischemia, prognosis of, 831(ab)
metabolic imaging, extremity musculoskeletal tumors, 181
metabolic maturation in cat brain, 772(ab)
metabolites of F-18 fluoro-L-dopa, human blood, 363
3-[C-11]methoxybenzodiazepines, new radioligands, benzodiazepine receptors, 755(ab)
11 MeV proton cyclotron, production, other radionuclides, 932(ab)
MK-801 analogs, mapping, glutamate receptor channels, 930(ab)
model of C-11-L-methionine kinetics, human brain, 822(ab)
monitoring of arterial positron concentration, gamma detector, 833(ab)
monitoring of positron-emitting tracers, multiple region-of-interest capabilities, 832(ab)
Monte Carlo calculation, spillover corrections, cardiac studies, 866(ab)
MRI of proton self-diffusion coefficient, cerebral infarction, 836(ab)
multigated, assessment, myocardial metabolism, 771(ab)
multi-grid expectation maximization algorithm, 278(ab)
multi-grid maximum likelihood image reconstruction algorithm, real data, 774(ab)
multi-parameter studies, brain tumors, 853(ab)
myocardial glucose metabolism, hypertrophic cardiomyopathy, 828(ab)
myocardial muscarinic acetylcholine receptor, hyper- and hypothyroidism, 808(ab)
myocardial perfusion and metabolism, nifedipine effect, systemic sclerosis, 828(ab)

- N-13 ammonia
 assessment, myocardial blood flow, 838(ab)
 metabolic fate, human blood, 783(ab)
 noninvasive quantification, myocardial blood flow, 940(ab)
 quantitative assessment, regional myocardial perfusion, 782(ab)
 new high resolution scanner, double wobbling mode, 877(ab)
N-(3-F-18 fluoropropyl)MK-801, NMDA receptors, 932(ab)
 NMR and, radiation necrosis, canine CNS, 785(ab)
 normal cerebral glucose utilization, amyotrophic lateral sclerosis, 821(ab)
 O-15 water autoradiography and, oxygen inhalation, cerebral blood flow, 915(ab)
 oxygen metabolism and blood flow, spinocerebellar degeneration, 920(ab)
 oxygen-15 radiopharmaceuticals, absorbed dose estimates, newborn, 1961
 oxygen studies, arterial input function, plasma separation, 832(ab)
 patterns of cerebral metabolism, acute ischemic aphasia, 915(ab)
 patterns of regional cerebral metabolism, stimulated/deprived, vegetative subjects, 839(ab)
 payments, N1753
 performance of machine parameters, influence, metabolic data, 877(ab)
 POSICAM 6.5 BGO positron camera, three dimensional volumetric imaging, 879(ab)
 postinjection transmission measurements, rotating source, 1558
 preparation of (ethyl-F-18)fluororaclopride, dopamine D-2 receptors, 767(ab)
 progressive supranuclear palsy, metabolism, cerebral cortex, 914(ab)
 protein synthesis rates, carbon-11 comparisons with, 1419
 quantitation, 1603
 errors, headrest attenuation, 878(ab)
 ischemic zone at risk, coronary occlusion, 951(ab)
 quantitative comparison, glucose metabolic rates, 867(ab)
 radiochemicals and, FDA policies, N142
 rapid generation of blood activity curves, multislice gated cardiac data, 775(ab)
 receptor density and binding rate constants, single tracer injection, 863(ab)
 reduced inter-observer variability, ROI analysis, MRI-based templates, 866(ab)
 regional and temporal haloperidol distribution, brain, 767(ab)
 regional cerebral blood flow, alcohol intoxication, 839(ab)
 regional cerebral metabolic rate, alcohol effects, normal subjects, 840(ab)
 regional correction, effects, brain atrophy, 773(ab)
 registration of MRI-PET images, procedure, validation, 853(ab)
 remote hypometabolic effects, seizure disorders, 920(ab)
 resolution nonuniformity, cylindrical detectors, partial volume effects, 876(ab)
 role in pediatric epilepsy surgery, 831(ab)
 role in thyroid disease treatment, 752(ab)
 sensitivity of cerebral glucose metabolism, age, cerebrovascular risk factors, 852(ab)
 significance of regional wall thickening, cardiac MRI imaging, 801(ab)
 SP-3000
 evaluation and operation, 880(ab)
 optimization, data acquisition, 876(ab)
 stress-induced ischemia, N-13 ammonia, coronary bypass surgery, 817(ab)
 studies of motor system, tardive dyskinesia, 821(ab)
 subcortical indices of hypometabolism, olivopontocerebellar atrophy, 913(ab)
 subcortical metabolic alterations, partial epilepsy, 830(ab)
 synthesis and regional brain distribution, C-11 NMPB, 768(ab)
 synthesis of para-substituted phenyl glyoxals, bromoacetylation, 928(ab)
 three-dimensional display, heart, 530
 tissue glucose metabolism, persistent Tl-201 defects, 827(ab)
 tracer for cerebral protein synthesis, F-18 2-fluorotyrosine, 754(ab)
 tracer for myocardial ischemia, 1-[C-11]-D,L-homocysteine thiolactone, 755(ab)
 uptake of F-18 sex hormones, mammalian brain, 795(ab)
 use of resampling methods, precision estimation, emission tomography images, 748(ab)
 whole-body, performance characteristics, 1833
Pregnancy, transplant patients, renal scans in, 1364
Pressure-volume loops, determination in clinical setting, radionuclide angiography, 1492
Probenecid, inhibition of Tc-99m MAG₃ and OIH uptake, kidney, 908(ab)
Progesterone receptors, synthesis and target tissue uptake, F-18 FENP, 768(ab)
Prostate
 metastatic cancer, Sr-89 for palliation, wide field radiotherapy, 775(ab)
 painful metastasis in bone, Sr-89 chloride, treatment results, 763(ab)
 potential PET imaging agent, 750(ab)
 tumor localization, monoclonal antibody, mouse subrenal capsule model, 898(ab)
Protein
 labeling by triamine complexes of Rh(III), 814(ab)
 labeling with I-123 PIP conjugate, 929(ab)
 -losing gastroenteropathy, serial abdominal imaging, In-111 transferrin, 857(ab)
 mass, In-111 CITC monoclonal antibody, hepatic uptake, 888(ab)
 synthesis in brain, tracer, F-18 2-fluorotyrosine, 754(ab)
 synthesis rates
 measurement with PET, 524
 PET, C-11 comparisons, 1419
Pulmonary embolism
 clinical validity, normal perfusion lung scan, 824(ab)
 compared value of ventilation-perfusion, digital subtraction angiography, 824(ab)
 detection of, comparison, monoclonal antifibrin antibodies, 905(ab)
 detection of venous thrombosis, In-111 antifibrin antibody imaging, 825(ab)
 lung ventilation scanning, Tc-99m carbon particles, 765(ab)
 radioimmunoimaging, monoclonal antifibrin, antiplatelet antibodies, 825(ab)
Pulmonary gating, parameter estimation, ventilation studies, 1842
Pyelonephritis
 radiological imaging, 2025(ab)
 Tc-99m renal cortical scintigraphy, accuracy of, 778(ab)
Pyrophosphate, first-pass myocardial extraction, effect of reperfusion, 746(ab)
- ## Q
- Quality assurance**
 cardiac imaging, WHO study of, N440
 proposed regulations
 NRC, N283, N1008
 NRC commissioners meet, N592
Quality control, fluorine-18 FDG, hexokinase reaction, 1443
Quinuclidinyl benzilate, analysis of receptor-ligand binding, time-activity data, 759(ab)
- ## R
- Radiation dose**
 application of count-dependent Metz filter, bremsstrahlung imaging, 863(ab)
 biological retention of fission products, Chernobyl plume, 804(ab)
 estimates for O-15 tracers, newborn infants, 874(ab)
 estimation, tumor and major organs, I-131 monoclonal antibodies, 900(ab)
 extra-articular leakage, radiation synovectomy, dysprosium-165-FHMA, 873(ab)
 I-131 and I-133 uptake, from Chernobyl, southern Sweden, 1719
 In-111 in breast milk, 1301(le)
 organ brake, method for estimation, 875(ab)
 oxygen-15 radiopharmaceuticals, newborn, 1961
 radioiodinated-SCH 23982, 1668
 removal of Ir-192 from reactor-produced Os-191, 927(ab)
 SPECT imaging of bremsstrahlung radiation, energy window, collimation, 876(ab)
 Tl-201 pharmacokinetics, routine myocardial scintigraphy, 1582
 tumor-incorporating mean absorbed dose calculation, 874(ab)
Radiation necrosis, PET and NMR, canine CNS, 785(ab)
Radiation risk
 detection of pneumonitis in lung cancer patients, Ga-67 citrate scans, 888(ab)
 exposure risks, revised atomic bomb data, N1162
 Ga-67 citrate scan, radiation pneumonitis, lung cancer, 829(ab)
 NCI studies cancer near US nuclear plants, N440
 pneumonitis, early diagnosis, lung permeability, 894(ab)
Radiation sickness, medical treatment, 424(le)
Radioactive agents, comparison, renovascular hypertension, rat model, 509
Radioactive waste
 Appalachian States Low-Level Radioactive Waste Compact, 1167
 low-level disposal, N1889
 New York Academy of Sciences symposium on, N1337, N1889
Radioactivity
 cumulative organ concentrations, Radon-222, following ingestion, 872(ab)
 selection of tracers and experimental procedures, blood flow and metabolism, 862(ab)
Radioaerosol, distribution, human airway, 1057
Radiochemicals, FDA policies, N142
Radiochemistry, β -hydroxy fatty acids, acylation, "masked" malonic ester, 848(ab)
Radiocolloid
 alpha-emitting, treatment, intraperitoneal disease, 858(ab)
 Tc-99m, leukocyte labeling, 729(le)

Radiofluorination

Radiofluorination, polymer-supported NCA nucleophilic, 754(ab)

Radiography, dual energy, bone mineral analysis, lumbar spine, 855(ab)

Radiohalogenation, no-carrier-added synthesis, bromine-77 bromospiperone, 776(ab)

Radioimmunoassay
commercial kit evaluation, human serum calcitonin, 766(ab)
fibrinopeptide-A measurement, single urine sample, 766(ab)
new monoclonal antibodies, recognition, CA125, 766(ab)
pancreatic oncofetal antigen/CA19-9/CEA, cancer of digestive system, 906(ab)
rapid I-125 method, cyclosporine monitoring, 766(ab)

Radioimmunoconjugates, production of, Sm-153, 815(ab)

Radioimmunodetection
anti-antibody enhancement, monoclonal antibody imaging, cancer, 757(ab)
antibody dose effects, In-111 anti-melanoma monoclonal antibody, 39
CEA-producing tumors, I-123 antibody fragments, 898(ab)
In-111 Fab', enhancement of utility, 925(ab)
malignant melanoma, 896(ab)
testicular carcinoma xenograft, 896(ab)
tumor deposits, combination routes, monoclonal antibodies, 761(ab)

Radioimmunoscinigraphy
anti-CEA monoclonal antibodies, presurgical screening, colorectal carcinoma, 897(ab)
In-111 antibody compared to In-111 anti-CEA, colorectal carcinoma, 899(ab)
probability mapping and kinetic analysis, ovarian cancer, 599
Tc-99m monoclonal antibodies, detection, metastatic melanoma, 897(ab)

Radioimmunotherapy
anti-antibody enhancement of tumor imaging, therapy, radiolabeled antibodies, 890(ab)
chronic lymphocytic leukemia treatment, I-131 monoclonal antibody, 901(ab)
escalating single and multiple fraction low dose rate, I-131 monoclonal antibody, renal cell carcinoma, 875(ab)
glioma, I-125 monoclonal antibody, epidermal growth factor receptor, 847(ab)
human colon carcinoma multicell spheroids, 858(ab)
micrometastases, At-211, 858(ab)
micro-TLD measurements for, 1795
monoclonal antibody biokinetics and biodistribution, effect, human anti-mouse antibody, 761(ab)
patients with lymphoma, I-131 lym-1 monoclonal antibody, 847(ab)
selection of nuclides, 875(ab)
theoretical tumor absorbed doses, several radionuclides, 858(ab)
WR-2721 as adjunct, Y-90 monoclonal antibodies, 925(ab)
W-188/Re-188 gel generator, 923(ab)

Radioiodination
N-isopropyl-p-iodoamphetamine, catalytic effect, metals and salts, 929(ab)
Tl01 in patients with chronic lymphocytic leukemia, cellular immunomodulation, 757(ab)
tyramine-cellobiose antibody labeling, compared to lactoperoxidase, 835(ab)

Radioiodine
comparison of antibody conjugates, iodovinyl,

para-iodophenyl, 777(ab)

5-iodo-2-thienylamphetamine synthesis, evaluation, brain imaging agents, 777(ab)

radiopharmaceutical for cerebral amino acid transport, 778(ab)

study in 100 hyper-/hypo-/euthyroid patients, Tc-99m pertechnetate uptake and imaging, 753(ab)

therapy controversies, 2026(ab)

Radioisotopes, production LINAC, commentary, N1758

Radioligands, analysis of receptor-ligand binding, time-activity data, quinuclidinyl benzilate, 759(ab)

Radionuclides
dosimetry and imaging studies, tissue-equivalent anthropomorphic phantom, 803(ab)
production on 11 MeV proton cyclotron, 932(ab)
radiological renal function study, segmental resection of ureter, 778(ab)
theoretical tumor absorbed doses, radioimmunotherapy, 858(ab)
treatment planning for monoclonal antibody therapy, 3D dosimetry, 803(ab)

Radiopharmaceuticals
cerebral blood flow, uptake, neocortex, 927(ab)
contaminated with molybdenum-99, radiation dose, 695
copper-labeled, cerebral and myocardial blood flow with PET, 1549
cytotoxicity, mouse testes, 375
early diagnosis of metabolic bone disease, dual tracer method, 780(ab)
intact vs. fragments, tumor model, 893(ab)
organic amine, improved HPLC system, analysis, 926(ab)
organ uptake, measurement, improved method, 861(ab)
PET, advisory committee for quality assurance, FDA, N137
radioiodination, cerebral amino acid transport, 778(ab)
renal, nephrotoxicity, 1577
sarcosinamide analog of BCNU, 1957
synthesis of C-11 prazosin, 930(ab)
Tc-99m MAA, sedimentation characteristics, 904(ab)
technetium compounds, structure-stability relationship, 789(ab)

Radiosensitization, new approaches, hypoxic tumor cells, 873(ab)

Radiotherapy
evaluation of treatment response with fluorine-18 FDG, head and neck cancer, 1521
wide field, Sr-89 for palliation, metastatic prostate cancer, 775(ab)

Radon, reduction, cost-effectiveness, 268(le)

Radon-222, radioactivity concentrations, following ingestion, 872(ab)

Receiver operating characteristic (ROC) analysis
diagnostic sensitivity of SPA and DPA, spinal osteoporosis, 882(ab)
optimum filter function, SPECT, 643

Receptors
density and binding rate constants, single tracer injection, 863(ab)
pharmacology using non-linear models, variable radioactivities, 822(ab)

Reconstruction algorithms, 3-D, SPECT using cone beam collimator, 1398

Reflex sympathetic dystrophy, hand, bone scanning in, 26

Regional wall motion
assessment of myocardial metabolism and func-

tion, multigated PET, 771(ab)

cardiac abnormalities, expert images, 846(ab)

detection of abnormalities
factor analysis, biplane contrast angiography, 771(ab)
improved probabilistic image, 863(ab)

gated myocardial positron tomography, 828(ab)

interactive digital filtering, gated cardiac studies, cine display, 864(ab)

left ventricular, bull's eye display, cardiac blood pool SPECT, 745(ab)

myocardial perfusion, Tc-99m MIBI vs. Tl-201 perfusion, 950(ab)

phase image triangulation of accessory pathways, catheter ablation, posteroseptal pathways, 744(ab)

prediction of extent of akinesis, acute antimyosin scintigraphy, 851(ab)

significance of metabolic activity, persistent Tl-201 defects, 827(ab)

Relative Values Scales, commentary, N1891

Renal artery
stenosis
abnormal captopril renogram, Tc-99m hippuran analog, 1730
captopril renography and test, 850(ab)
detection, mean parenchymal transit time, 850(ab)
I-123 hippurate renography, angiotensin converting enzyme inhibition, 907(ab)
quantitative captopril radionuclide studies, 908(ab)
quantitative renography, 850(ab)

Renography
absorbed radiation dose, I-123, I-131, and Tc-99m DTPA, 400
captopril
effects, volume depletion, 849(ab)
renal artery stenosis, 850(ab)
diuresis, 2025(ab)
I-123 hippurate and Tc-99m DTPA, renal artery stenosis, ACE inhibition, 908(ab)
saralasin vs. captopril, two-kidney/one-clip hypertension, 849(ab)

186-Re(Sn)-HEDP, initial experience, treatment, painful skeletal metastases, 776(ab)

Restenoses, prediction of, stress Tl-201 imaging post angioplasty, 770(ab)

Rhabdomyosarcoma, tumor imaging using radiolabeled fragments, monoclonal anti-myosin antibody, 791(ab)

Rhenium-185, activable isotopes of, biodegradable radiotherapeutic microspheres, 903(ab)

Rhenium-186, direct radiolabeling, monoclonal antibodies, model studies, 847(ab)

Rhenium-188, W-188/Re-188 gel generator, 923(ab)

Rhenium N₂S₂ antibody, Tc ratio, complexes per antibody Fab fragment, tumor uptake, 815(ab)

Rhodium(III), triamine complexes, labeling of proteins, 814(ab)

Ribose, acceleration of Tl-201 redistribution, coronary artery disease, 953(ab)

Ro15-1788
C-11-labeled, PET studies, benzodiazepine receptors, 931(ab)
quantitative analysis, benzodiazepine receptor, living brain, 809(ab)

RO15-4513, binding to benzodiazepine receptors, 809(ab)

Rubidium-82
distribution behavior, prolonged heart muscle flow physiology, 942(ab)

Tl-201 SPECT and, detection, coronary artery disease, 817(ab)

S

Saline, washing effects, platelet function, 735(ab)
Samarium-153, production of radioimmunoconjugates, 815(ab)
Samarium-153 EDTMP
 bone tumor response, 903(ab)
 dose tolerance in metastatic bone cancer, 775(ab)
 therapy dosimetry and SPECT, disseminated skeletal metastasis, cancer, 762(ab)
Saralasin, vs. captopril renography, two-kidney/one-clip hypertension, 849(ab)
Sarcoidosis, heart disease, magnetic resonance imaging, 891(ab)
Sarcoma
 high dose-delayed Ga-67 scintigraphy, compared with CT and MRI, 749(ab)
 improved imaging, reduced hepatic activity and, 1810
 tumor mass and viability, bone, Tl-201 scintigraphy, 854(ab)
Scatter
 Compton estimation
 Monte Carlo simulation, distributed sources, 865(ab)
 spectral fitting, Monte Carlo simulation, 797(ab)
 direct compensation, photopeak distribution analysis, 797(ab)
 method for correction, energy information, holo-spectral imaging, 864(ab)
 removal by pre- and post-processing techniques, 798(ab)
SCH 23982, radioiodinated, biological distribution, radiation dosimetry, 803(ab)
Schizophrenia, C-11 and C-14 S-methyl-methionine, abnormal oxidation, 784(ab)
Scientific fraud, Congressional investigation, N1469
Scintigraphy
 antimyosin, prediction, extent of akinesia, 851(ab)
 bone, factor analysis, renal osteodystrophy, 883(ab)
 bone marrow, compared to magnetic resonance tomography, plasmacytoma, 891(ab)
 exercise Tl-201
 detection, single vessel disease, 948(ab)
 prognosis assessment, prior myocardial infarction, 951(ab)
 high dose-delayed Ga-67, compared with CT and MRI, sarcoma, 749(ab)
 high resolution, human terminal ileal emptying, 857(ab)
 myocardial sympathetic nerves, ischemia, 840(ab)
 NP-59, accuracy and utility, disease diagnosis, 859(ab)
 pancreas, evaluation, I-123 HIPDM, 826(ab)
 parathyroid, failure, 180 patient studies, 860(ab)
 radioisotope bone images, diagnostic consequences, 884(ab)
 renal, compared to angiographic data, chronic glomerulonephritis, 907(ab)
 renal antegrade perfusion, study, ureteric function, 779(ab)
 Tc-99m MDP, neoadjuvant chemotherapy, osteosarcoma, 882(ab)
 Tc-99m pertechnetate, evaluation, Barrett's esophagus, 886(ab)
 three methods, right ventricular ejection fraction determination, 771(ab)

thyroid, thallium, 860(ab)
 Tl-201, bone and soft tissue sarcoma, 854(ab)
 ultrasound and, assessment, renal transplant pathology, 779(ab)
Scintillation camera
 accumulation of In-111 granulocytes, malignant tumors, 479
 BGO and BaF₂, PET, 338
 cardiac imaging, patient and organ movement in SPECT, 441
 Compton-scatter photons, three boundary detection methods, 203
 design and manufacturing defects, nonisotropic point spread function, 1096
 diagnosis of deep venous thrombophlebitis, 1169
 I-123 HIPDM metabolic lung imaging, pulmonary hypertension, 765(ab)
 I-125 monoclonal antibody, Fisher immunotype 1 *Pseudomonas aeruginosa* infection, 651
 I-131, location of ovarian dysfunction, 1644
 In-111 and I-131, thrombus, 1212
 In-111 lymphocytes and, detection of orthotopic cardiac allograft rejection, 1223
 In-111 WBC, detection of osteomyelitis, 1015
 left ventricular maximum time-varying elastance calculation, 1368
 line resolution pattern, 1856
 modular, status and applications, 760(ab)
 NEMA, count rate curve determination, 538
 position-sensitive bar detector system, multi-slice brain SPECT, 760(ab)
 routine lung perfusion scanning, diffusing capacity and, 1268
 X-ray, bone mineral densitometry, 855(ab)
 Scintitography, Tc-99m HM-PAO, acute cerebral infarction, 843(ab)
Sclerosis, systemic, nifedipine effect, myocardial perfusion, 828(ab)
Selena-25-homocholeic acid, tauro-23, biologic stability of, 1411
Selenium-75, internally-labeled monoclonal antibodies, biodistribution, 889(ab)
Selenium-75 bile acids, biologic stability, 1411
Serotonin
 labeling of uptake sites, 3H-paroxetine, 809(ab)
 synthesis in brain, plasma tryptophan, PET, 784(ab)
Serotonin receptor
 blockade, equilibrium binding kinetic analysis, 809(ab)
 S2 neuroreceptor density measurement, PET, double-injection method, 809(ab)
Serum
in vitro complex formation and clearance, mouse monoclonal antibody, 758(ab)
 TA-4 as marker of squamous cell carcinoma, lung and other organs, 765(ab)
Sex hormones, uptake in mammalian brain, F-18 ligands, PET, 795(ab)
Sex steroids, hormonal relationship of bone density, premenopausal women, 859(ab)
Sickle cell disease, calvarial infarction, radionuclide bone imaging findings, 411
Single-photon absorptiometry (SPA)
 DPA and, diagnostic sensitivity, spinal osteoporosis, 882(ab)
 osteoporosis, eating disorder patients, 882(ab)
Single photon emission computed tomography (SPECT)
 AIDS dementia complex, 1382
 aperture design, 785(ab)
 application of count-dependent Metz filter, bremsstrahlung imaging, 863(ab)
 arterial perfusion, regional chemotherapy, 593

Bayesian reconstruction, in parallel/fan/cone beam geometries, 871(ab)
 bone, hyperplasia, mandibular condyle, 780(ab)
 bone studies of pelvis, digital filtering of the bladder in, 1587
 brain and heart, future directions, 567
 brain tomographic imaging with Tc-99m ECD, stable perfusion agent, 758(ab)
 bremsstrahlung radiation, energy window, collimation, 876(ab)
 cardiac, bull's eye plot, 267(le)
 cardiac data
 computer simulation, 2027(ab)
 evaluation, reconstruction algorithms, 748(ab)
 cardiac image reconstruction, attenuation, detector response correction, 749(ab), 870(ab)
 center of rotation measurement, collimators in, 1393
 clinical studies, optimization, angular sampling frequency, 869(ab)
 Co-57 bleomycin, delivery to brain tumors, 187
 compared to planar imaging, detection, metastatic colorectal cancer, 886(ab)
 comparison of Ga-67 planar images, chest, CT in lymphoma patients, 898(ab)
 comparison of 360° and 180° sections, 868(ab)
 comparison of Tl-201 and Tc-99m RP-30A, cardiac data, 793(ab)
 comparison of three scatter correction techniques, 1971
 compensation for collimator divergence, maximum likelihood reconstruction, 786(ab)
 Compton-scatter correction
 analysis of energy spectra, 195
 spectral fitting, Monte Carlo simulation, 797(ab)
 three boundary detection methods, 203
 cone beam
 collimator, 1398
 maximum-likelihood reconstruction, 869(ab)
 correction for patient and organ movement, Tl-201 cardiac imaging, 441
 cylindrical neuro-SPECT system, imaging characteristics of MUMPI, 832(ab)
 design of simulation system, 871(ab)
 differential diagnosis, non-vascular dementia, 743(ab)
 digital acquisition, radioisotope tomographic images, 870(ab)
 dipyridamole Tl-201 perfusion, exercise, coronary artery disease, 838(ab)
 3D modulation transfer function, stationarity, averaging opposing projections, 749(ab)
 dopamine receptor binding sites, baboon brain, 848(ab)
 dual-energy-window Compton correction, k value object, 797(ab)
 early and late I-123 IMP-labeled, value and limitation, cerebrovascular disease, 844(ab)
 emission and transmission data, three-dimensional display, 786(ab)
 evaluation of hips, bladder artifact correction, 780(ab)
 evaluation of strategies for edge detection, 868(ab)
 exercise Tl-201 imaging
 ischemia assessment, jeopardized myocardium, 943(ab)
 size of perfusion deficit, increased lung uptake, 943(ab)
 "false" positive pyrophosphate tomoscintigrams, 954(ab)
 filtered back-projection reconstructions, factors determining noise character, 870(ab)

- Ga-67, chest, 276(ab)
- Ga-68 deferoxamine-galactosyl-neoglycoalbumin, regional measurement, receptor concentration, 933(ab)
- hepatobiliary, changing radioactivity distribution, 98
- high-resolution 3-headed system, evaluation, cerebral blood flow, 912(ab)
- hip, correction, bladder artifact, 868(ab)
- I-123, thyroid, multinodular goiter, 110
- I-123 estradiol, ER-positive breast cancer detection, 853(ab)
- I-123 HIPDM, carotid artery occlusion, 913(ab)
- I-123 IBZM, D-2 dopamine receptors, 759(ab)
- I-123 IMP
blood flow and redistribution, ischemic CVD, 918(ab)
brain, after cerebral radiation therapy, 914(ab)
brain, auditory hallucination, 917(ab)
brain, Huntington's disease, 916(ab)
brain maturation, human newborns, 893(ab)
clinical application, brain death and coma, 917(ab)
evaluation, major psychosis, 921(ab)
flow and back diffusion rate images, brain, 870(ab)
revascularization prediction, carotid endarterectomy, 844(ab)
- I-123 IMP and Tc-99m HM-PAO, compared to PET, dementia, 916(ab)
- I-123 IMT, brain tumors, 911(ab)
- I-123 ISP, dopamine D-2 receptor imaging, 922(ab)
- I-123 MIBG compared to Tl-201 cardiac imaging, myocardial infarction, 840(ab)
- image data by presentation as stereo pairs, 3D visualization, 810(ab)
- image restoration, singular value decomposition technique, 749(ab)
- imaging using Tc-99m HM-PAO, stroke prognosis, 743(ab)
- imaging with I-123 isopropyl amphetamine, asymptomatic HIV seropositive persons, 742(ab)
- instrumentation, 2026(ab)
- In-111 antimyosin, acute Q-wave infarct size, 942(ab)
- In-111 leukocytes, value in abdominal sepsis, 794(ab)
- interictal, HMPAO, epilepsy in children, 792(ab)
- isopropylamphetamines, comparison, O-15 water cerebral blood flow, 747(ab)
- mapping of human brain benzodiazepine receptors, 759(ab)
- measurement of cerebrovascular reserve, hemodynamic risk patients, 911(ab)
- modular scintillation cameras, status and applications, 760(ab)
- Monte Carlo simulation, Compton scatter, distributed sources, 865(ab)
- multicenter trial of Cedars-Sinai method, quantitative analysis, Tl-201 myocardial tomography, 755(ab)
- multiplane reconstruction, compensation, collimator response, 785(ab)
- multi-slice brain SPECT, position-sensitive bar detector system, 760(ab)
- myocardial imaging, poor predictive values, inferior wall defects, 944(ab)
- myocardial infarction, after attempted reperfusion, 1283
- new method for brain functional study, Tc-99m HM-PAO, 748(ab)
- new methods of examining gamma camera collimators, 676
- new radioiodinated radiopharmaceutical, cerebral amino acid transport studies, 778(ab)
- noise power, 1704
- nonisotropic point spread function, collimator design defects, 1096
- non-uniform attenuation correction, photopeak, Compton spectral windows, 798(ab)
- novel diaminothiol-fatty acid complex, synthesis, myocardial imaging, 935(ab)
- optimum filter function, determination, 643
- phantom, new design, 2030(ab)
- persistent Tl-201 defects, tissue glucose metabolism, myocardium, 827(ab)
- phantom evaluation of distortion, brain, 877(ab)
- planar and transaxial images, Tc-99m sulfur colloid, liver and spleen size, 870(ab)
- quantification, myocardial scar size, 872(ab)
- quantitation, attenuation correction, inhomogeneous media, 797(ab)
- quantitative
bone scintigraphy, 881(ab)
circular harmonic transform algorithm, 868(ab)
empirical threshold method, 879(ab)
imaging, improved method, cerebral perfusion, 869(ab)
radioiodinated glucose derivative, interaction to hexokinase, 928(ab)
- radioiodinated SCH-23982, dopamine D-1 receptors, 929(ab)
- radiopharmaceutical uptake, cerebral blood flow, neocortex, 927(ab)
- radioxenon tomography, cerebral blood flow, 1875(1e)
- rapid sequential study, cerebral vascular diseases, 880(ab)
- reconstructions, predicting noise energy, 748(ab)
- regional cerebral blood flow measurements
maturation, first 20 months of life, 743(ab)
partial epilepsy, childhood, 892(ab)
- relationship to clinical features, Alzheimer's disease, 743(ab)
- RP-30 tomograms, automatic calculation, LV volumes and EF, 805(ab)
- simultaneous acquisition, cerebral blood flow, metabolism, 876(ab)
- skull, comparison with planar scintigraphy, 1341
- SM-153 EDTMP therapy dosimetry, disseminated skeletal metastasis, cancer, 762(ab)
- Sprint II, ring-geometry instrument, brain imaging, 760(ab)
- stress Tl-201 imaging post angioplasty, restenoses, recurrent symptoms, 770(ab)
- stress Tl-201 myocardial emission tomography, assessment, Kawasaki disease, 791(ab)
- Tc-99m anti-melanoma fragments and, clinical experience, 812(ab)
- Tc-99m DISIDA, detection, intrahepatic lithiasis, 826(ab)
- Tc-99m DTPA-HSA, initial experience in man, 922(ab)
- Tc-99m DTPA-HSA and I-123 IMP, assessment, perfusion reserve in CVD, 918(ab)
- Tc-99m ECD, new brain agent, kinetics, 921(ab)
- Tc-99m HM-PAO
Alzheimer's disease, 1507
brain, cerebral perfusion correlation, 914(ab)
brain, cortical peeling and mapping, 914(ab)
brain, post-stroke depression, 918(ab)
evaluation, cerebral perfusion tracer, 843(ab)
flow and rate constants, kinetic model, 917(ab)
glutathione content, brain tumors, 920(ab)
high resolution imaging, SPRINT, 917(ab)
- localization, seizure foci, 913(ab)
- preparation considerations, 928(ab)
- ruptured intracranial aneurysm, 844(ab)
- uptake, primary and metastatic brain tumors, 895(ab)
- Tc-99m HM-PAO compared to Tc-99m ECD, brain perfusion imaging agents, 844(ab)
- Tc-99m HM-PAO compared to I-123 IMP, brain, ischemic lesions, 919(ab)
- Tc-99m MIBI, one and two day protocol, transient ischemia, 851(ab)
- Tc-99m MIBI compared to Tl-201, assessment, coronary disease, 793(ab)
- Tc-99m pyrophosphate and DTPA comparison, ventilation studies, 1761
- Tc-99m PYP, quantitation, skeletal muscle necrosis, 884(ab)
- Tc-99m RP-30, myocardial ischemia and reperfusion, 1539
- Tc-99m sulfur colloid, volume determination in liver and spleen, 1768
- thallium and antimyosin, acute Q-wave myocardial infarction, 806(ab)
- thallium imaging with oral dipyridamole, ambulatory ventricular function monitor, chest pain, 742(ab)
- three-dimensional cone beam reconstruction, iterative maximum likelihood method, 786(ab)
- three-headed system/Prism, initial on-site evaluation, 760(ab)
- Tl-201
abnormal clearance, assessment of coronary artery disease, 948(ab)
"black hole" sign, left ventricular aneurysm, 756(ab)
bull's eye, applying standard deviation, 954(ab)
bull's eye display, 1901
bull's eye display, correcting for patient motion, 91
bull's eye display, ischemia and infarction, 938(ab)
comparison with N-13 ammonia, 1181
coronary artery disease patients, 1479
detection, single vessel disease, 948(ab)
dipyridamole scintigraphy, ECG changes, 945(ab)
effect, early myocardial redistribution, 947(ab)
estimation, left ventricular mass, 945(ab)
evaluation, suspected lung cancer, 895(ab)
exercise, coronary artery disease detection, 755(ab)
exercise/rest, coronary artery disease, 756(ab)
heart, intraobserver variability, 944(ab)
infarct size, myocardial infarction, 951(ab)
inferior attenuation, peritoneal fluid, 941(ab)
interpretation, 272(ab)
late redistribution, myocardial viability, 948(ab)
measurement of myocardial defect size, 1486
patients with LBBB, 279(ab)
peritoneal fluid effects, myocardial imaging in women, 1860
posterolateral myocardial infarction, 954(ab)
predictive value, myocardial infarction, 770(ab)
prone vs. supine position, 953(ab)
quantitation, community hospital, 943(ab)
referrals, subsequent coronary angioplasty, 946(ab)
septal perfusion pattern, discrimination of heart diseases, 942(ab)
simultaneous assessment, leg muscle and myocardial ischemia, 947(ab)

- specificity determinations, coronary artery disease, 946(ab)
- Tc-99m MIBI and angiography, coronary artery disease, 952(ab)
- thyroid cancer, 884(ab)
- Tl-201 cardiac, evaluation, pre-renal transplant patients, 950(ab)
- Tl-201 compared to Rb-82 PET, detection, coronary artery disease, 817(ab)
- Tl-201 myocardial, estimation, right ventricular overloading, 950(ab)
- Tl-201 myocardial imaging, 24-hour delay, revascularization, 769(ab)
- Tl-201 thallous chloride and Tc-99m isonitrite, rest and exercise studies, 944(ab)
- totally digital annular brain camera, 786(ab)
- trapping of I-123 OPPA, myocardium, 851(ab)
- tumor imaging with In-111 synthetic porphyrin, 900(ab)
- use of resampling methods, precision estimation, emission tomography images, 748(ab)
- validation of absolute quantitation, calibration phantom, 871(ab)
- validation of quantitative analysis, exercise thallium tomograms, 871(ab)
- vasoreactivity in cerebral arteriosclerosis, without carotid stenosis, 911(ab)
- workload and sex-related variability, fatty acid utilization, 841(ab)
- Xe-133 and Tc-99m HM-PAO, side localization, temporal lobe epilepsy, 916(ab)
- Xe-133 brain imaging
- developmental childhood dysphasia, 792(ab)
 - error analysis, cerebral blood flow in children, 869(ab)
 - Sturge-Weber cerebral angiomas, 792(ab)
- Skeletal metastases**, absorbed dose, Sr-89, 549
- Smoking**, increased Ga-67 pulmonary activity, HIV-positive persons, 829(ab)
- Sm-117m**, high specific activity, bone cancer therapy, 849(ab)
- Society of Digital Imaging, Management and Communication**, first meeting in June, N10
- Society of Nuclear Medicine—Europe (SNME)**, ENMS and, formation of European Association of Nuclear Medicine, N7
- Society of Nuclear Medicine (SNM)**
- archives seeks material, N1005
 - Board of Trustees, scientific, educational services abroad, N429
 - commentary
 - FDA clarification of policies, N1472
 - FDA/SNM/ACNP recruitment venture, N1477
 - lines from the president
 - a vintage year, N1006
 - getting paid in America-DRGs, RAPs, RVs, N289
 - moving into fall, N1475
 - RVs, regional compacts, and other national issues, N1891
 - need for radioisotope production LINAC, N1758
 - 1988 election results, N1478
 - E&R Foundation approves research grant, N587
 - self-study program, N590
 - SNM annual meeting, San Francisco, N581
 - SNM Education and Research Foundation, student fellowships, N1338
 - SNM 35th Annual meeting, scientific highlights, N1329
 - SNM 7th Annual Winter Meeting, instrumentation and computer seminars, N6
 - structural change, N1014
- technologists offered liability plan, N292
- Sodium**, NMR imaging of acute cardiac rejection, heterotopic heart transplantation, 802(ab)
- SPECTamine**, newly approved agent, N287
- SPECT**. See Single photon emission computed tomography
- Spleen**
- liver size and, Tc-99m sulfur colloid, planar and transaxial SPECT images, 870(ab)
 - pancreas transplantation, graft perfusion, serial radionuclide determinations, 885(ab)
 - planar gamma camera methods, quantitation, radionuclide content, 845(ab)
 - platelet survival in thrombocytopenic children, In-111 oxine, 892(ab)
 - radionuclide imaging, heat denatured Tc-99m RBC, 320
 - volume determination, Tc-99m sulfur colloid SPECT, 1768
- Splenic reticuloendothelial system**, radionuclide imaging, heat denatured Tc-99m RBC, 320
- Splenoportography**, Xe-133, Budd-Chiari syndrome, 423(le)
- Sports medicine**, bone scintigraphy, stress fractures, 1150(le)
- SQ 30217**
- Tc-99m-labeled, dipyridamole tomographic myocardial perfusion, 938(ab)
 - Tl-201 planar myocardial imaging, compared to coronary anatomy, 841(ab)
- Sternal lesions**, scintigraphic, patients with breast cancer, 324
- Sternum**, review of disease on bone scans, 780(ab)
- Stomach**, distal, removal of, gastric emptying, 752(ab)
- Streptavidin**
- conjugated antibody, labeled biotin, tumor localization studies, 762(ab)
 - conjugated monoclonal antibodies, abscess imaging, In-111 biotin, 889(ab)
 - potential tumor imaging agents, 729(le)
 - radiolabeled biotin derivative, facile preparation, 923(ab)
- Stress testing**, thallium scintigraphy and, patient selection, repeat angiography, 770(ab)
- Stroke**, prognosis using Technetium-99m HM-PAO, 743(ab)
- Strontium-89**
- absorbed dose, skeletal metastases, 549
 - marrow toxicity, therapy, osseous metastases, 776(ab)
 - metastatic prostate cancer, palliation, wide field radiotherapy, 775(ab)
- Strontium-89 chloride**, treatment results and kinetics, painful prostate & breast cancer in bone, 763(ab)
- Struma ovarii**, postmenopausal woman, 263
- Sturge-Weber cerebral angiomas**, Xe-133 brain SPECT imaging, 792(ab)
- N-Succinimidyl stannyl benzoates*, meta vs. para substituted, utility, antibody labeling, 834(ab)
- N-Succinimidyl-3-(tri-n-butylstannyl)benzoate*, labeling of monoclonal antibody, iodine and astatine, 835(ab)
- Super-Collider**, superconducting, impact on nuclear medicine, 576(le)
- Swyer-James syndrome**, unilateral hyperlucent lung, ventilation-perfusion scan in, 114
- Sympathetic activity**
- non-neuronal cardiac uptake, I-123 MIBG, humans, 842(ab)
 - response to altitude hypoxia, I-123 MIBG myocardial uptake, 842(ab)
- Sympathetic nerves**, myocardial, scintigraphic assessment, 840(ab)
- Synovitis**, radiation synovectomy, dysprosium-165 ferric hydroxide macroaggregates for, 275(ab)
- T**
- Tachycardia**, ventricular, location of onset, multi-harmonic Fourier mapping, 744(ab)
- Tantalum-178**
- generator system, high volume clinical applications, 1526
 - multiwire gamma camera and, first-pass radionuclide angiography, 293
- Tardive dyskinesia**, PET studies of motor system, 821(ab)
- Technegas**
- initial experience with new ventilation agent, 765(ab)
 - lung ventilation scanning, 765(ab)
- Technetium compounds**, structure-stability relationship, 789(ab)
- Technetium(III)**, neutral tris oxime complexes, chemistry, biodistribution, 800(ab)
- Technetium-99m**
- action of renal agents, sulfur-donating chelates, 801(ab)
 - 10- and 11-membered N2S2 ligands, synthesis, biodistribution, 788(ab)
 - antifibrin antibody
 - imaging, venous thrombi, 745(ab)
 - thrombus model, 746(ab)
 - carbohydrate residue label, tumor xenograft imaging, monoclonal antibodies, 815(ab)
 - comparative study of labeled chicken liver, egg-white as solid markers, gastric emptying, 752(ab)
 - comparison of 360° and 180° sections, SPECT imaging, 868(ab)
 - comparison of MRI and bone scintigraphy, evaluation, osseous spine metastases, 763(ab)
 - complexed with 3 Schiff base/oxime ligands, 936(ab)
 - Compton-scatter estimation, spectral fitting, Monte Carlo simulation, 797(ab)
 - condensing osteitis, clavicle, 1122
 - dioxime complexes, chloro-hydroxy substitution, 800(ab)
 - effect of body position, gastric emptying, 751(ab)
 - effect of caloric content, gastric emptying, 751(ab)
 - enriched uranium embargo risked supply, N1003
 - factors related to parathyroid imaging, 860(ab)
 - fatty acid derivatives of PnAO, tracers, myocardial metabolism, 934(ab)
 - how to avoid complications, intrahepatic arterial infusions, chemotherapeutic agents, 799(ab)
 - I-123 and, comparative imaging, thyroid nodules, 753(ab)
 - instant kit, N586
 - labeled phosphine and isocyanide cationic complexes, protein binding studies, 62
 - labeling of human platelets, improved kit method, 787(ab)
 - measurement of cerebral blood flow, 1464(le)
 - neutral alkyl-DADT-technetium complexes, pulmonary accumulation, 789(ab)
 - noninvasive determination, gastric emptying, antral motility, 862(ab)
 - oxidation state measurement, internal conversion electron microscopy, 789(ab)
 - perfusion of tumor-bearing kidneys, model for scintigraphic screening for monoclonal antibodies, 1078

- radiolabeled paté, esophageal function study, 885(ab)
- tablets, ultrasonic visualization in gastrointestinal tract, 129(le)
- validation of absolute quantitation, SPECT, calibration phantom, 871(ab)
- Technetium-99m D,L-HM-PAO**, stabilization using gentisic acid, 935(ab)
- Technetium-99m albumin**
 - compared to Tc-99m non-specific IgG, other radiolabels, focal sites of infection, 887(ab)
 - labeled leukocytes, evaluation, 903(ab)
- Technetium-99m antibody**
 - labeling with N₃S and N₂S₂ amide mercaptides, 815(ab)
 - Re N₂S₂ complexes per antibody Fab fragment, immunoreactivity, tumor uptake, 815(ab)
- Technetium-99m anti-CEA**, immunoscintigraphy, known and occult colorectal carcinoma, 834(ab)
- Technetium-99m anti-granulocyte antibody**, detection of inflammatory diseases, 829(ab)
- Technetium-99m anti-melanoma**, SPECT and, clinical experience, 812(ab)
- Technetium-99m antimony colloid**, mammary lymphoscintigraphy, 1744(le)
- Technetium-99m anti-SSEA-1**, tracer for human neutrophils, 788(ab)
- Technetium-99m aromatic isocyanides**, potential myocardial imaging agents, 800(ab)
- Technetium-99m carboxylic acids**, α,α -disubstituted, α -hydroxy-, 934(ab)
- Technetium-99m cellulose fiber**, gastrointestinal transit, 857(ab)
- Technetium-99m colloids**, compared to HM-PAO-labeled leukocytes, 813(ab)
- Technetium-99m CPI**, binding characteristics, cultured chick heart cells, 55
- Technetium-99m DADS-amido-fatty acid**, myocardial imaging, 935(ab)
- Technetium-99m diaminodithiol-fatty acid**, synthesis of, myocardial imaging, 935(ab)
- Technetium-99m DISIDA**
 - diagnosis of hepatocellular carcinoma, 1916
 - hepatic duct leak, following liver transplantation, 259
 - hepatobiliary imaging, duodenal-gastric reflux, 17
 - SPECT, detection, intrahepatic lithiasis, 826(ab)
- Technetium-99m dithiosemicarbazone complex**, stable and lipophilic, condensed ring structure, 934(ab)
- Technetium-99m D-MAGAG**, evaluation of diastereomers in primates, 909(ab)
- Technetium-99m DMSA**
 - evaluation of kidney function, extracorporeal shock-wave lithotripsy, 906(ab)
 - pentavalent, medullary cancer of thyroid, 1746(le)
 - pharmacokinetics, cold loading, 908(ab)
 - renal cortical scintigraphy, accuracy of, pyelonephritis, 778(ab)
 - renal handling of, 778(ab)
 - thyroid medullary carcinoma, 33
- Technetium-99m DTPA**
 - absorbed radiation dose, 400
 - aerosol inhalation scans
 - pulmonary embolism, 2029(ab)
 - utility, artificially ventilated patients, 764(ab)
 - aerosolized, normal values, pulmonary clearance, 904(ab)
 - assessment of renal perfusion, insensitive indicator, renal allografts, 779(ab)
 - clearance in healthy non-smokers, gamma camera, 905(ab)
 - comparison with Gd-153 DTPA, biodistribution, 1683
 - effect of saralasin vs. captopril renography, two-kidney/one-clip hypertension, 849(ab)
 - first-pass camera study, renal blood flow, GFR, and filtration fraction, 733(ab)
 - glomerular filtration rate, plasma clearance techniques, 1152(le)
 - I-125 iothalamate plasma clearances, diabetic patients, 816(ab)
 - lack of breakdown, ultrasound nebulization, 905(ab)
 - measurement of differential renal function, 134(le)
 - radioaerosol inhalation, effect of position, ventilation scintigraphy, 764(ab)
 - renography and Tc-99m DMSA renal scintigraphy, renal artery stenosis, ACE inhibition, 908(ab)
 - single-injection, two-sample method, extracellular fluid volume from plasma clearance, 255
- Technetium-99m DTPA-HSA**
 - initial experience in man, 922(ab)
 - SPECT, assessment, perfusion reserve in CVD, 918(ab)
- Technetium-99m ECD**
 - brain perfusion imaging, 788(ab)
 - brain tomographic imaging, stable perfusion agent, 758(ab)
 - compared to Tc-99m HM-PAO, 912(ab)
 - brain perfusion imaging agents, 844(ab)
 - compared to Xe-133, SPECT, cerebral blood flow, 913(ab)
 - compared with Tc-99m HM-PAO, first human results, 747(ab)
 - metabolism in normal volunteers, 747(ab)
 - new brain agent, kinetics and biodistribution, 921(ab)
 - retention in brain, *in vivo* metabolism, 747(ab)
- Technetium-99m erythrocytes**, labeling kit, 902(ab)
- Technetium-99m fatty acid analogs**, myocardial metabolism, 935(ab)
- Technetium-99m galactosyl-neoglycoalbumin**, kinetic sensitivity, 936(ab)
- Technetium-99m gentisic acid**, labeling kit, 902(ab)
- Technetium-99m HDP**, In-111 WBC comparison, occult infection following total joint arthroplasty, 1347
- Technetium-99m HEXAMIBI**
 - quantitative methods, myocardial imaging, 955(ab)
 - synthesis and pharmacokinetics, 934(ab)
- Technetium-99m HM-PAO**
 - accumulation, metastatic hepatocellular carcinoma, 1460(le)
 - D,L and *meso*, single-pass extraction, primate brain, 747(ab)
 - brain SPECT
 - cerebral perfusion, middle cerebral artery velocities, 914(ab)
 - compared to I-123 IMP, ischemic lesions, 919(ab)
 - cortical peeling and mapping, 914(ab)
 - evaluation, post-stroke depression, 918(ab)
 - cerebral perfusion imaging
 - clinical use, pediatric patients, 919(ab)
 - following cerebral trauma, 2028(ab)
 - compared to small colloid, osteomyelitis, 813(ab)
 - compared to Tc-99m ECD, 912(ab)
 - brain perfusion imaging agents, 844(ab)
 - compared with Tc-99m ECD, first human results, 747(ab)
 - decomposition, aqueous media, 1568
 - determination of flow and rate constants, kinetic model, human brain, 917(ab)
 - I-123 IMP SPECT and, compared to PET, dementia, 916(ab)
 - In-111 tropolonate and, kinetics of leukocytes labeled with, 1246
 - labeled leukocytes, reliability, Crohn's disease, 827(ab)
 - linearization of rCBF values, 936(ab)
 - local cerebral blood flow, quantitative measurements, 1387
 - localization of seizure foci, 913(ab)
 - radiochemical purity, 572(le)
 - reverse redistribution, mild cerebral ischemia, 914(ab)
 - scintitomography, acute cerebral infarction, 843(ab)
 - serial radionuclide determinations, graft perfusion, pancreas-spleen transplantation, 885(ab)
- SPECT**
 - cerebral collateral circulation during Matas test, 1724
 - cerebral perfusion tracer, evaluation, 843(ab)
 - high resolution imaging, SPRINT, 917(ab)
 - new method, brain functional study, 748(ab)
 - ruptured intracranial aneurysm, 844(ab)
 - side localization, temporal lobe epilepsy, 916(ab)
 - stereoisomers, interaction with glutathione, 1998
 - stroke prognosis, 743(ab)
 - technical considerations for preparation, assessment, cerebral blood flow, 928(ab)
 - triple mode evaluation, subarachnoid hemorrhage, vasospasm, 743(ab)
 - uptake in brain, primary and metastatic tumors, 895(ab)
- Technetium-99m IDA**, time-activity curves, hepatocyte versus biliary disease, 623
- Technetium-99m IDAS**, hepatocyte uptake, 928(ab)
- Technetium-99m isonitrile**
 - planar exercise imaging, detection, coronary artery disease, 804(ab)
 - reperfusion after thrombolysis, myocardial imaging, 1865
- Tl-201 thallous chloride and, rest and exercise SPECT studies, 944(ab)
- Technetium-99m LDL**
 - I-123 and, human biodistribution, 803(ab)
 - versus radioiodinated LDL preparations, biodistribution studies, 1237
- Technetium-99m leukocytes**, labeling kit, 902(ab)
- Technetium-99m liposomes**, potential of imaging abscesses, 888(ab)
- Technetium-99m MAA**
 - allogenic lymphocytes and, control, allograft rejection, 757(ab)
 - I-123 HIPDM metabolic lung imaging, pulmonary hypertension, 765(ab)
 - Kr-81m ventilation perfusion ratio, inert gas and, weaning, 764(ab)
 - radionuclide venography, evaluation, deep venous thrombosis, 825(ab)
 - sedimentation characteristics, 904(ab)
 - texture analysis of lung scans, 861(ab)
 - ventilation-perfusion scan, unilateral hyperlucent lung patient, 114
- Technetium-99m MAG₃**
 - abnormal captopril renogram, 1730
 - chemistry of, 801(ab)
 - clearance, comparison with I-131 OIH, 1878(le)
 - clearance and biodistribution, altered physiologic state effects, 669
 - clearances after captopril, renovascular hypertension, 905(ab)

- sion, 849(ab)
 compared to I-131 hippuran, dual channel technique, 908(ab)
 compared to I-131 OIH kit formulations, 909(ab)
 comparison with I-131 hippuran, renal imaging, 1189
 effect of urinary pH, 906(ab)
 evaluation of Tc-99m D-MAGAG diastereomers, primates, 909(ab)
 I-123 and I-131 comparison, patients with renal disorders, 147
 kit formulation, renal failure patients, 616
 pharmacokinetics and metabolism, 906(ab)
 probenecid inhibition of uptake, kidney, 908(ab)
 quantitation, renal function, 1931
 renal radiopharmaceutical, 2027(ab)
- Technetium-99m MDP**
 alteration of distribution, systemic aluminum, 856(ab)
 bone formation, metastatic transitional cell carcinoma, 1462(le)
 bone imaging
 adverse reactions, 1302(le)
 symmetric photon deficiency in femoral heads, 266(le)
 bone scanning, trochanteric bursitis, 763(ab)
 detection of infection, delayed/non-union fractures, 813(ab)
 diagnosis and follow-up of neuroblastoma, 750(ab)
 distraction epiphysiolysis, bone healing during, 1259
 early diagnosis of metabolic bone disease, dual tracer method, 780(ab)
 effect on mineralization, ectopic bone, 882(ab)
 factor analysis of bone scintigraphy, renal osteodystrophy, 883(ab)
 failure, acute hematogenous osteomyelitis, animal model, 274(ab)
 lower extremity periostitis, secondary to venous insufficiency, 1279
 metastatic large cell carcinoma of lung, 726(le)
 quantitative bone scintigraphy, 881(ab)
 scintigraphic evaluation, neoadjuvant chemotherapy, osteosarcoma, 882(ab)
 SPECT versus planar scintigraphy, skull, 1341
 three phase bone scan, porous coated hip arthroplasty, prosthetic tip, 780(ab)
 thyroid medullary carcinoma, 33
 toddler's fracture, 2001
- Technetium-99m MIBI**
 amplitude analysis of RP-30A, coronary artery disease assessment, 805(ab)
 assessment of transient ischemia, one and two day protocol, 851(ab)
 compared to Tc-99m MPIN, myocardial imaging in man, 794(ab)
 compared to Tl-201
 detection, coronary artery disease, 793(ab)
 myocardial defect detection, 850(ab)
 compared to Tl-201 SPECT, assessment, coronary disease, 793(ab)
 dosimetry and biodistribution, 874(ab)
 dynamic imaging, determination, left ventricular function, 805(ab)
 effect of ischemia, myocardial uptake, 819(ab)
 effect of metabolic inhibitors, chick heart cells, 820(ab)
 gated tomography, left ventricular volumes assessment, 771(ab)
 lung uptake, extent of coronary artery disease, 952(ab)
 myocardial perfusion imaging, coronary vasodilation, 781(ab)
- quantitative methods, myocardial imaging, 955(ab)
 renal imaging, 2027(ab)
 same-day injections, myocardial tomographic imaging, 804(ab)
 slow infusion, increased myocardial uptake, rest and stress studies, 942(ab)
 Tl-201 and, uptake in thyroid carcinoma, 854(ab)
 Tl-201 SPECT and, coronary angiography, coronary artery disease, 952(ab)
 uptake and release, cultured myocardial cells, 48 vs. Tl-201 perfusion imaging, myocardium, wall motion assessment, 950(ab)
- Technetium-99m microcolloids**, hepatic blood flow, graft rejection and, 1776
- Technetium-99m monoclonal antibodies**
 antiplatelet, diagnosis, mesenteric thrombosis, 886(ab)
 detection of metastatic melanoma, 897(ab)
 kinetics and metabolism, cellular level, 823(ab)
 ocular radioimmunoscintigraphy, 1031
 successful imaging, lung and colon carcinoma, 834(ab)
 targeting of granulocytes, 925(ab)
- Technetium-99m MP-600**, renal imaging, 735(ab)
- Technetium-99m N₂S₂**, Tc-99m antibody labeling, active ester complex, side chain length, 815(ab)
- Technetium-99m N₂S₂ complexes**, stereochemistry, 800(ab)
- Technetium-99m NEP-DADT**, comparison of analogs, potential brain blood flow imaging agents, 73
- Technetium-99m NGA**, test of hepatic functional mass, 790(ab)
- Technetium-99m oxime**, tin-capped compared to boron-capped, 935(ab)
- Technetium-99m PAH analogs**, renal function agents, 937(ab)
- Technetium-99m pertechnetate**
 portal circulation, rectal portal scintigraphy, 460
 pre-rectal portal scintigraphy, 2020(le)
 scintigraphy
 evaluation, Barrett's esophagus, 886(ab)
 torsion of testicular appendages, 892(ab)
 thyroid glands, 274(ab)
 thyroid uptake and imaging, radioiodine study correlation, 753(ab)
 Tl-201 and, evaluation, portal-systemic circulation, 827(ab)
 variability in pharmacokinetics, 864(ab)
- Technetium-99m PPI**, Tl-201 uptake pattern, reperfusion, myocardial infarction, 949(ab)
- Technetium-99m PYP**
 comparison with Tc-99m DTPA, SPECT ventilation lung imaging, 1761
 quantitation of skeletal muscle necrosis, SPECT, canine model, 884(ab)
- Technetium-99m radioaerosol**, radiation pneumonitis, early diagnosis, lung permeability, 894(ab)
- Technetium-99m red blood cells**
 cell labeling efficiency and, red cell surface charge, 1710
 heat denatured, radionuclide imaging of spleen, 320
 heparin, facilitation of bleeding, 725(le)
 venography, deep vein thrombosis, 1498
- Technetium-99m RP-30**
 gated planar studies, quantification, left ventricular function, 818(ab)
 myocardial ischemia and reperfusion, 1539
 myocardial kinetics, flow and work controlled conditions, 792(ab)
- reperfusion effects, myocardial extraction, 819(ab)
- Technetium-99m RP-30A**
 compared to Tl-201, quantitative cardiac SPECT, 793(ab)
 noninvasive delineation of infarct size, vessel patency, 819(ab)
 quantification of infarct size, compared to CPK and LVEF, 946(ab)
 uptake, skeletal muscle, 275(ab)
- Technetium-99m SbSC**, lymphoscintigraphy, cutaneous malignant melanoma, 893(ab)
- Technetium-99m-Sn-pyrophosphate**, localization, neutrophils, 1406
- Technetium-99m SQ 30217**, dipyridamole tomographic myocardial perfusion, 938(ab)
- Technetium-99m stannous fluoride colloid**, preparation of kit, leukocyte labeling, 888(ab)
- Technetium-99m sulfur colloid**
 detection of infected hip arthroplasty, 887(ab)
 fine aerosol distribution, human airway, 1057
 hepatic uptake, microautoradiographic study, 1118
 liver and spleen size, planar and transaxial SPECT images, 870(ab)
 lymphoscintigraphy, surgical management, melanoma, 854(ab)
 radionuclide lymphoscintigraphy, localization of internal mammary lymph nodes, 473
 utility of intraperitoneal scan, continuous ambulatory peritoneal dialysis, 817(ab)
- Technetium-99m sulfur colloid sucralfate**, ulcer avid agent, 936(ab)
- Technetium-99m Technegas**
 initial experience with Technegas, 765(ab)
 lung ventilation scanning, 765(ab)
- Technetium-99m tin colloid**, leukocyte labeling with, 729(le)
- Technetium-99m (V)-DMSA**, Sipple's syndrome, with liver tumors, 1130
- Technetium-99m white blood cells**
 albumin colloid-labeled leukocytes, 903(ab)
 compared to In-111 immunoglobulin G, localizing inflammation, 830(ab)
- Technologist Section**, Reauthorization Action, N1168
- Technologist training**, NRC, medical use of byproduct materials, N1159
- Testes**
 human carcinoma xenograft in athymic mice, radioimmunodetection, 896(ab)
 mouse, cytotoxicity of In-111, 375
 scan, postoperative use, 736(ab)
 torsion of testicular appendages, scintigraphic appearance, 892(ab)
- Tetalman Memorial Award**, Sabah S. Tumeh, N1165
- Thallium**
 dipyridamole, ST segment depression, myocardium, 782(ab)
 intravenous dipyridamole imaging, elderly patients, 953(ab)
 SPECT imaging with oral dipyridamole, ambulatory ventricular function monitor, chest pain, 742(ab)
- Thallium-201**
 analysis of washout, parametric color coded images, 302
 antimyosin and, comparative SPECT imaging, acute Q-wave myocardial infarction, 806(ab)
 blood levels and reversible defects, fasting or eating, 952(ab)
 bull's eye program, 1466(le)
 cardiac imaging

- elliptical versus circular acquisition, 736(ab)
 evaluation, pre-renal transplant patients, 950(ab)
 I-123 MIBG comparison, myocardial infarction, 840(ab)
 patient and organ movement in SPECT, 441
 cardiac stressing, esophageal pacing, 942(ab)
 compared to Rb-82 PET, detection, coronary artery disease, 817(ab)
 compared to Tc-99m MIBI
 assessment, coronary disease, 793(ab)
 detection, coronary artery disease, 793(ab)
 myocardial defect detection, 850(ab)
 compared to Tc-99m RP-30A, quantitative cardiac SPECT, 793(ab)
 computer-simulated cardiac SPECT data, evaluation, reconstruction algorithms, 748(ab)
 dipyridamole and exercise, simultaneous assessment, leg muscle and myocardial ischemia, 947(ab)
 dipyridamole imaging, prediction, in-hospital ischemia, 781(ab)
 dipyridamole perfusion scintigraphy, known or suspected angina, 781(ab)
 dipyridamole tomography, complications predictions, non-cardiac surgery, 838(ab)
 dipyridamole with, serum drug level following, 1662
 distribution behavior, prolonged heart muscle flow physiology, 942(ab)
 distribution of myocardial perfusion, patients surviving sudden death, 769(ab)
 dobutamine imaging, detection, coronary artery disease, 955(ab)
 ECG-gated myocardial perfusion scans, counts-based index, left ventricular "ejection fraction", 947(ab)
 effect of ischemia, myocardial uptake, 819(ab)
 exercise scintigraphy
 benefit from surgery, triple vessel disease, 949(ab)
 extent of coronary disease, unstable angina, 945(ab)
 prognosis assessment, prior myocardial infarction, 951(ab)
 exercise SPECT
 ischemia assessment, jeopardized myocardium, 943(ab)
 size of perfusion deficit, increased lung uptake, 943(ab)
 exercise tomograms, validation, quantitative analysis, 871(ab)
 extent of CAD, 278(ab)
 factors related to parathyroid imaging, 860(ab)
 failure of parathyroid scintigraphy, 860(ab)
 follow-up, differentiated thyroid carcinoma, 1515
 24-hour tomographic myocardial imaging, revascularization, 769(ab)
 human milk, 278(ab)
 hypertrophic obstructive cardiomyopathy
 internal and external radiation dose, nursing child, exposed mother, 874(ab)
 late redistribution imaging, myocardium viability, 948(ab)
 left bundle branch block, coronary artery disease patients, 1479
 lung uptake, dipyridamole, global left ventricular dysfunction, 953(ab)
 mechanism of uptake in tumors, 750(ab)
 microautoradiography localization, human high grade astrocytoma, 854(ab)
 myocardial, diffuse decreased wash-out, quality of stress, 945(ab)
 myocardial defect size, 1486
 myocardial emission assessment, Kawasaki disease, 791(ab)
 myocardial infarction, after attempted reperfusion, 1283
 myocardial perfusion defects, weaning, mechanical ventilator-dependent patients, 947(ab)
 myocardial perfusion imaging, coronary vasodilation, 781(ab)
 myocardial redistribution, ribose effects, 1943
 myocardial scans, reverse redistribution, coronary artery disease marker, 952(ab)
 myocardial SPECT, estimation, right ventricular overloading, 950(ab)
 myocardial tomography, multicenter trial, Cedars-Sinai method, 755(ab)
 noninvasive detection of coronary artery disease, vasospastic angina, 782(ab)
 normal and ischemic myocardium, fatty acid influx, biochemical characteristics, 940(ab)
 perfusion defects, detection and quantification, 273(ab)
 persistent defects
 significance, metabolic activity, 827(ab)
 tissue glucose metabolism, myocardium, 827(ab)
 pharmacokinetics, routine myocardial scintigraphy, 1582
 planar, quantification, degree of reversibility, 861(ab)
 planar myocardial imaging, SQ30217, compared to coronary anatomy, 841(ab)
 planar scintigraphy, myocardial glucose metabolism, 828(ab)
 planar Tc-99m isonitrile exercise imaging
 detection, coronary artery disease, 804(ab)
 new normal database, modified background correction, 804(ab)
 prediction of coronary events in elderly, usefulness, dipyridamole perfusion scintigraphy, 781(ab)
 quantitation of jeopardized myocardium, prediction of coronary events, 770(ab)
 quantitative analysis of scans, thyroid cancer metastases to lung, 895(ab)
 quantitative approaches for imaging, 2024(ab)
 quantitative bullseye display, differentiation, ischemia from infarction, 938(ab)
 quantitative planar and tomographic imaging, detection, single vessel disease, 948(ab)
 rationale for T1 thyroglobulin screening, 753(ab)
 regional left ventricular wall motion assessment, bull's eye display, cardiac blood pool SPECT, 745(ab)
 reinjection after delayed imaging, fill-in to regions with "fixed" defects, 769(ab)
 renal imaging, stress cardiac evaluation, 910(ab)
 reperfusion effects, myocardial extraction, 819(ab)
 resting perfusion abnormalities, coronary stenoses, unstable angina, 768(ab)
 reverse redistribution, acute coronary reperfusion, poor early prognosis, 948(ab)
 reversibility bullseye polar map, myocardial ischemia, 951(ab)
 reversible abnormalities, correlation, severe coronary obstruction, 953(ab)
 reversible rest-redistribution defects, unstable angina, 768(ab)
 ribose acceleration of redistribution, coronary artery disease, 953(ab)
 role in etiologic classification, solitary bone lesions, 814(ab)
 scintigraphy
 bone and soft tissue sarcoma, 854(ab)
 stress testing, patient selection for repeat angiography, 770(ab)
 single-photon emission tomography, exercise, coronary artery disease detection, 755(ab)
 SPECT
 abnormal clearance, assessment of coronary artery disease, 948(ab)
 bullseye, applying standard deviation, 954(ab)
 bull's eye display, 1901
 cardiac studies, intraobserver variability, 944(ab)
 combined with "bullseye" analysis, ischemic coronary disease, 756(ab)
 comparison of bullseye display, 3D surface images, 756(ab)
 dipyridamole, compared to exercise SPECT, coronary artery disease, 838(ab)
 dipyridamole scintigraphy, ECG changes, 945(ab)
 effect, early myocardial redistribution, 947(ab)
 estimation, left ventricular mass, 945(ab)
 evaluation, suspected lung cancer, 895(ab)
 infarct size, myocardial infarction, 951(ab)
 inferior attenuation, peritoneal fluid, 941(ab)
 interpretation, 272(ab)
 myocardial perfusion defect size, 278(ab)
 myocardial perfusion studies, utility, delayed 24-hour redistribution, 769(ab)
 patients with LBBB, 279(ab)
 peritoneal fluid effects, myocardial imaging in women, 1860
 posterolateral myocardial infarction, 954(ab)
 predictive value, myocardial infarction, 770(ab)
 prone vs. supine position, 953(ab)
 quantitation, community hospital, 943(ab)
 referrals, subsequent coronary angioplasty, 946(ab)
 results of exercise/rest, coronary artery disease, 756(ab)
 specificity determinations, coronary artery disease, 946(ab)
 Tc-99m MIBI and angiography, coronary artery disease, 952(ab)
 thyroid cancer, 884(ab)
 value and limitations, 1181
 stress imaging post angioplasty, restenoses, recurrent symptoms, 770(ab)
 stress-redistribution scintigraphy, left bundle branch block, 946(ab)
 suppressed thyroid, after TSH stimulation, 1360
 Tc-99m MIBI and
 quantitative methods, myocardial imaging, 955(ab)
 uptake in thyroid carcinoma, 854(ab)
 Tc-99m pertechnetate and, evaluation, portal-systemic circulation, 827(ab)
 Tc-99m PPI uptake pattern, reperfusion, myocardial infarction, 949(ab)
 thyroid scintigraphy, 860(ab)
 utility of septal perfusion pattern, discrimination, LAD or PDA disease from dual vessel disease, 942(ab)
 vs. Tc-99m MIBI, myocardium, wall motion assessment, 950(ab)
 wash-in and wash-out, redistribution phenomenon, myocardial cells, 939(ab)
Thallium-201 chloride
 detection of intracardiac malignant lymphoma, 1868
 pre-rectal portal scintigraphy, 2020(le)
 uptake and release, cultured myocardial cells, 48
Thallium-201 RP-30, compared to SQ 32014, myocardial uptake and redistribution, 819(ab)

- Thallium-201 SQ 32014**, compared to RP-30, myocardial uptake and redistribution, 819(ab)
- Thallium-201 thallos chloride**, Tc-99m isonitrite and, rest and exercise SPECT studies, 944(ab)
- Therapeutic nuclear medicine**
- application of I-131 lipiodol, massive type hepatocellular carcinoma, 799(ab)
 - biodegradable radiotherapeutic microspheres, activable isotopes, 903(ab)
 - extra-articular leakage, radiation synovectomy, dysprosium-165-FHMA, 873(ab)
 - I-131, parotid oncocyoma, 1126
 - I-131 external exposure rates, guidelines, resuming close contact, 873(ab)
 - I-131 MIBG, metastases of nonsecreting paraganglioma, 2008
 - I-131 uptake in inflammatory lung disease, thyroid carcinoma treatment and, 701
 - internalization of monoclonal 3G5-IgM, tumor cells, 923(ab)
 - lung metastases, differentiated thyroid carcinoma, I-131, 1790
 - lymphoid cell malignancy, In-114m lymphocyte behavior, 485
 - physics protocol for UKCCSG toxicity, I-131 MIBG, resistant neuroblastoma, 798(ab)
 - P-32 therapy, therapy-resistant malignant glioma, 902(ab)
 - radioimmunotherapy, I-131 anti-CEA and anti-AFP antibodies, 846(ab)
 - radioisotopic lobectomy, P-32 resin microspheres, 799(ab)
 - radiorhenium labeling, monoclonal antibodies, model studies, 847(ab)
 - role of PE, thyroid disease treatment, 752(ab)
 - side effects of I-131 MIBG, neural crest tumors, 798(ab)
 - skeletal radiotherapeutic agent, Ga-72 nitrate, 776(ab)
 - Sm-153, production, radioimmunoconjugates, 815(ab)
 - Sr-89 chloride treatment and kinetics, painful bone metastasis, prostate and breast, 763(ab)
 - Sr-89 to palliate metastatic prostate cancer, wide field radiotherapy, 775(ab)
 - theoretical tumor absorbed doses, radioimmunotherapy, radionuclides, 858(ab)
 - therapy of osseous metastases, marrow toxicity, Sr-89, 776(ab)
 - treatment of painful skeletal metastases, initial experience, 186-Re(Sn)-HEDP, 776(ab)
 - value of total body scans, I-131 therapy, thyroid carcinoma, 885(ab)
 - W-188/Re-188 gel generator, 923(ab)
 - Yt-90 anti-tumor antibodies, therapy trials, 846(ab)
 - Yttrium-90 antibodies, intraperitoneal biodistribution, 1428
- Thrombocytopenia**, platelet survival, In-111 oxine, children, 892(ab)
- Thrombolysis**
- In-111 antimyosin Fab scintigraphy, regional asynergy, myocardial infarction, 806(ab)
 - predictive value of thallium SPECT, myocardial infarction, 770(ab)
- Thrombosis**
- antifibrin antibodies, comparison, Tc-99m and In-111, 746(ab)
 - deep venous
 - evaluation, radionuclide venography, 825(ab)
 - In-111 platelet imaging, hip surgery, 787(ab)
 - Tc-99m RBC venography, 1498
 - deep venous phlebitis, In-111 platelet scintigraphy, 1169
- detection of, comparison, monoclonal antifibrin antibodies, 905(ab)
- I-131 fibronectin imaging, 1264
- imaging venous thrombi, In-111 antifibrin monoclonal antibody, 806(ab)
- imaging with radiolabeled Fab' fragments, monoclonal antibody, platelets, 940(ab)
- In-111 and I-131 imaging, 1212
- internal carotid artery, resting and hypercapnic rCBF, 311
- labeling of human platelets, Tc-99m, improved kit method, 787(ab)
- mesenteric, Tc-99m monoclonal antiplatelet antibody, 886(ab)
- radioimmunoimaging using monoclonal antifibrin, antiplatelet antibodies, heparin effect, 825(ab)
- vascular, imaging with In-111 anti-fibrin antibody, 494
- vein, In-111 antifibrin antibodies, 807(ab)
- venous
 - detection, In-111 antifibrin antibody imaging, 825(ab)
 - imaging, Tc-99m antifibrin antibody, 745(ab)
- Thyroid**
- cancer**
- atomic bomb survivors, 268(le)
 - metastatic to lung, quantitative analysis, Tl-201 scans, 895(ab)
 - mortality, 753(ab)
 - Tl-201 SPECT, 804(ab)
- carcinoma**
- differentiated, Tl-201 follow-up, 1515
 - I-131 uptake in inflammatory lung disease and, 701
 - lung metastases from, I-131, 1790
 - Tc-99m MIBI and Tl-201 uptake, 854(ab)
 - total body scans after I-131 therapy dose, 279(ab)
- comparative imaging of nodules, I-123, Tc-99m, 753(ab)
- criteria for ablation of normal tissue, surgery, thyroid cancer, 885(ab)
- disease treatment, role of PET, 752(ab)
- function indices, effect, post dose sampling time, 753(ab)
- hyper- and hypothyroidism, myocardial muscarinic acetylcholine receptor, 808(ab)
- I-131 and I-133 uptake, from Chernobyl, southern Sweden, 1719
- I-131 uptake, after Chernobyl, 1152(le)
- medullary carcinoma**
- pentavalent Tc-99m DMSA imaging, 1746(le)
 - Tc-99m DMSA, Tc-99m MDP, and I-131 MIBG imaging in, 33
- multinodular goiter, I-123 SPECT of, 110
- rational for Tl thyroglobulin screening, Tl-201, I-131, 753(ab)
- scintigraphy, thallium, 860(ab)
- sensitive TSH assay, 766(ab)
- suppressed, Tl-201, 1360
- Tc-99m pertechnetate imaging, 274(ab)
- Tc-99m pertechnetate uptake and imaging, radioiodine study correlation, 753(ab)
- Tin**, -capped Tc-99m oxime, compared to boron-capped, 935(ab)
- Tourette's syndrome**, manic depressive illness and, D-2 dopamine receptors, 820(ab)
- Transfusion**, red blood cell compatibility testing, In-111m tropolone RBC, 684
- Transmission measurements**, PET, rotating source, 1558
- Transplantation**
- See also specific organ*
 - control of allograft rejection, Tc-99m MAA, allogenic lymphocytes, 757(ab)
 - heart: *See Heart*
 - heterotopic heart, acute rejection, sodium NMR imaging, 802(ab)
 - immunosuppressed organ, importance, whole body In-111 leukocyte studies, 795(ab)
 - pregnant patients, renal scans in, 1364
 - renal
 - perfusion after, quantitative measurement of, 1656
 - radionuclide evaluation of, 2024(ab)
 - Tc-99m microcolloid calculation of blood flow, graft rejection, 1776
- Trauma**, toddler's fracture, Tc-99m MDP
- Tryptophan**, brain serotonin synthesis, PET, 784(ab)
- Tumors**
- adrenocortical adenoma, benign, Ga-67 uptake, 1451
 - anti-antibody enhancement of imaging, therapy, radiolabeled antibodies, 890(ab)
 - antigen concentration in tissue sections, quantitative autoradiography, 897(ab)
 - biodegradable radiotherapeutic microspheres, activable isotopes, 903(ab)
 - bone, response to Sm-153 EDTMP therapy, 903(ab)
 - brain
 - FDG-PET and image-guided MR spectroscopy, 785(ab)
 - multi-parameter studies, PET, 853(ab)
 - new imaging agent, F-18 fluorophenylalanine, 919(ab)
 - rat transplant model, glucose transport, 920(ab)
 - SPECT with I-123 IMT, 911(ab)
 - Tc-99m HM-PAO uptake, glutathione content, 920(ab)
 - breast, uptake of Ga-67 with hypothalamic granuloma, 118
 - CEA-producing, radioimmunodetection, I-123 monoclonal antibodies, 898(ab)
 - C-11 malonate platinum, PET studies, 1107
 - colon cancer, imaging, I-131 16-88 monoclonal antibody, 833(ab)
 - colon carcinoma, multicell spheroids, I-131 anti-CEA, 858(ab)
 - comparison of Ga-67 planar and SPECT images, chest, CT in lymphoma patients, 898(ab)
 - comparison of MRI and bone scintigraphy, evaluation, osseous spine metastases, 763(ab)
 - detection
 - esophageal imaging probe, 878(ab)
 - In-111 anti-CEA monoclonal antibody, 833(ab)
 - occult metastatic cancer
 - utility, In-111 monoclonal antibodies, 893(ab)
 - diagnosis of adrenal diseases, NP-59 scintigraphy, accuracy and utility, 859(ab)
 - differentiation, Tc-99m DISIDA in hepatocellular carcinoma, 1916
 - diffuse large-cell lymphoma, Ga-67 citrate therapy, response prediction, 799(ab)
 - digestive system cancer, pancreatic oncofetal antigen/CA19-9/CEA, 906(ab)
 - effect of circulating antigen, monoclonal antibody localization, 762(ab)
 - enhancement of In-111 Fab' utility, radioimmunodetection, 925(ab)
 - ER-positive breast cancer, detection, I-123 estradiol, 853(ab)
 - estimation of absorbed radiation dose, I-131

Tumor-seeking agents

monoclonal antibodies, 900(ab)
evaluation of commercial radioimmunoassay kit, human serum calcitonin, 766(ab)
experimental, Lewis lung carcinoma model, 1252
extremity musculoskeletal, metabolic imaging by PET, 181
fibrosarcoma, paramagnetically-labeled LDL, Ga-67, 890(ab)
Ga-67 accumulation in, 2019(le)
gastrointestinal, In-111 monoclonal antibodies, binding assay, 1436
hepatic perfusion in cancer patients, parameters, 894(ab)
hepatic perfusion index, 1747(le)
hexokinase Michaels-Menten kinetics, 773(ab)
human cancer xenografts, therapy, Y-90 monoclonal antibodies, 901(ab)
hypoxic, new approaches, radiosensitization, 873(ab)
I-123 IMP brain SPECT, after cerebral radiation therapy, 914(ab)
I-125 nucleoside, synthesis and biodistribution, 929(ab)
increased delivery of Ga-67, serum-stable liposomes, 516
In-111 Fab' compared to F(ab)'2 derivative, 812(ab)
internalization of monoclonal 3G5-IgM, 923(ab)
intra-arterial chemotherapy, SPECT evaluation of, 593
liver, Sipple's syndrome, Tc-99m (V)-DMSA and I-131 MIBG, 1130
liver metastases, F-18 uracil accumulation, 776(ab)
localization studies, streptavidin-conjugated antibody, labeled biotin, 762(ab)
lung and colon carcinoma, imaging, Tc-99m monoclonal antibody, 834(ab)
lung uptake, two dose levels, In-111 anti-CEA monoclonal antibody, 825(ab)
malignant
 accumulation of In-111 granulocytes, 479
 localization with radioiodinated recombinant tissue plasminogen activator, 1194
mammary
 chemotherapy, P-31 NMR and 1H-MRI study, 837(ab)
 lymphoscintigraphy, 1744(le)
 mass as determining factor, tissue biodistribution, monoclonal antibodies, 926(ab)
 massive type hepatocellular carcinoma, application, I-131 lipiodol, 799(ab)
 mechanism of Ga-67 accumulation, cell membrane permeability and, 663
 mechanism of Tl-201 uptake, 750(ab)
 melanoma, radioimmunodetection with In-111 monoclonal antibody, 329
 metastatic colon carcinoma, uptake estimation from images, 901(ab)
 metastatic transitional cell carcinoma, bone formation, Tc-99m MDP and, 1462(le)
 neural crest, side effects, I-131 MIBG, 798(ab)
 neuroblastoma imaging, I-131 3F8 and MIBG, 846(ab)
 ocular melanoma, I-123 IMP visualization of, 1448
 optimization of targeting, mixture, monoclonal antibodies, 750(ab)
 parotid concocytoma, I-131 therapy, 1126
 Pb-203 as new antibody label, radioimmunoimaging, 924(ab)
 PET for evaluation, recurrent colorectal tumors, 751(ab)
 physiology, methotrexate effects on N-13 glutamate uptake, 208
 primary and metastatic brain, Tc-99m HM-PAO uptake, 895(ab)
 prostate, localization, monoclonal antibody, 898(ab)
 protein labeling, I-123 PIP conjugate, 929(ab)
 radioimmunodetection of deposits, monoclonal antibody administration, 761(ab)
 radioimmunopharmaceuticals, intact vs. fragments, 893(ab)
 registration of MRI-PET images, procedure, validation, 853(ab)
 review of sternal disease, bone scans, 780(ab)
 squamous cell carcinoma, serum TA-4 as marker, lung and other organs, 765(ab)
 studies using serum from patients, In-111 fab, 895(ab)
 surgical radiation probes, 881(ab)
 surgical staging, dual-detector probe, 1101
 survival and sequestration of In-111 donor platelets, 787(ab)
 thyroid, differentiated, Tl-201 follow-up, 1515
 thyroid carcinoma, Tc-99m MIBI and Tl-201 uptake, 854(ab)
 treatment of painful skeletal metastases, initial experience, 186-Re(Sn)-HEDP, 776(ab)
 uptake
 I-125 IPM compared to I-125 ICI labeling, monoclonal antibodies, 836(ab)
 of I-131 MIBG, gamma camera estimation of, 542
 Yt-90 anti-tumor antibodies, therapy trials, 846(ab)
 Yttrium-90 antibody biodistribution, intraperitoneally, 1428

Tumor-seeking agents

colon cancer, 1022
correlation of radiochemical yield, In-111 antibody-chelator conjugates, 924(ab)
Cu-67 monoclonal antibody, cancer therapy, 217
detection of intracardiac malignant lymphoma, 1868
effect of radiolabeling method, retention of monoclonal antibody, cultured cells, 901(ab)
effects of external beam radiation, tumor uptake, external beam radiation, 926(ab)
estimation of uptake from images, metastatic colon carcinoma, 901(ab)
evaluation of treatment response to radiotherapy, head and neck cancer, 1521
Ga-67, cell membrane permeability and, 663
I-123 IMP
 malignant melanoma detection, 1200
 visualization of ocular melanoma, 1448
I-131 anti-CEA and anti-AFP antibodies, radioimmunotherapy, 846(ab)
imaging of rhabdomyosarcoma, radiolabeled fragments, monoclonal anti-myosin antibody, 791(ab)
imaging with I-131 16-88 monoclonal antibody, colon cancer, 833(ab)
imaging with In-111 synthetic porphyrin, 900(ab)
In-111 anti-CEA monoclonal antibody ZCE 025, detection, colorectal carcinoma, 812(ab)
In-111 bifunctional hapten, pre-targeted immunoscintigraphy, 226
In-111 fab, studies using serum from patients, 895(ab)
In-111 monoclonal antibody, localization, colorectal carcinoma, 898(ab)
influence of antibody catabolism and shed antigen, monoclonal antibody uptake, 823(ab)
influence of chelator denticity, biodistribution, In-111 B72.3 immunoconjugates, 824(ab)

internalization of monoclonal 3G5-IgM, 923(ab)
internally-labeled monoclonal antibodies, biodistribution, 889(ab)
I-125 nucleoside, synthesis and biodistribution, 929(ab)
In-111 ZCE-025 anti-CEA monoclonal Fab' fragments, biodistribution, 896(ab)
location of ovarian dysfunction, 1644
metabolism of In-111 benzyl-EDTA monoclonal antibody, mouse liver, 824(ab)
mucin-like carcinoma-associated antigen, monitoring, breast cancer patients, 894(ab)
optimization of ligand structure, imaging, bifunctional antibody, 835(ab)
radioimmunodetection of human melanoma, 329
radiolabeled, intracavitary use of, 1910
serum-stable liposomes, 516
streptavidin and biotin, 729(le)
synthesis of para-substituted phenyl glyoxals, bromoacetylation, 928(ab)
Tc-99m HM-PAO uptake, primary and metastatic brain tumors, 895(ab)
theoretical tumor absorbed doses, radioimmunotherapy, radionuclides, 858(ab)
tumor-bearing kidneys, model for scintigraphic screening for monoclonal antibodies, 1078
tumor uptake
 as a function of tumor mass, mathematical model, 103
 blood flow and, 1463(le)
 uptake, non-Hodgkin's lymphoma, 1633
 uptake of radiolabel in liver cells, F(ab)'2 fragment, 823(ab)
 value of I-131-MIBG/Tc-99m-MDP/Ga-67-citrate, diagnosis and follow-up, neuroblastoma, 750(ab)

Tungsten-178, generator system, high volume clinical applications, 1526
Tungsten-188, W-188/Re-188 gel generator, 923(ab)
Tyramine-cellobiose antibody
 compared to lactoperoxidase, 835(ab)
 evaluation of, 835(ab)
L-Tyrosine, use of phenylalanine dehydrogenase for synthesis, N-13, 931(ab)

U

Ulcer, Tc-99m sulfur colloid sucalfate, 936(ab)
Ultrasound
 In-111 WBC scintigraphy, febrile ICU patient, 795(ab)
 nebulization, Tc-99m DTPA breakdown, 905(ab)
 scintigraphy and, assessment, renal transplant pathology, 779(ab)
United States Council for Energy Awareness, education plan, N1168
United States Department of Energy (USDOE), Brookhaven National Laboratory contract, N292
Uranium, embargo, supply of Mo-99 and, N1003
Ureter
 renal antegrade perfusion scintigraphy, 779(ab)
 segmental resection of, radionuclides, radiological renal function study, 778(ab)
Urinary tract, obstruction, diuretic renal scan, 133(le)
Urine, single sample, fibrinopeptide-A measurement, 766(ab)
Urology
 factor analysis, dynamic renal studies, 816(ab)
 pediatric, nuclear medicine in, 1287
Uropathy, obstructive, bone scintigraphy, 1781

V

- Valvular regurgitation**, factor analysis, first-pass angiography, 159
- Venography**
 In-111 platelet, diagnosis of deep venous thrombophlebitis, 1169
in vitro evaluation, computer processing algorithms, 862(ab)
 radionuclide
 evaluation, deep venous thrombosis, 825(ab)
 upper extremity and superior vena cava, 737(ab)
 Tc-99m RBC, deep vein thrombosis, 1498
- Venous insufficiency**, lower extremity periostitis secondary to, Tc-99m MDP, 1279
- Ventilation-perfusion**
 routine lung scanning, diffusing capacity and, 1268
 unilateral hyperlucent lung patient, 114
- Ventilation studies**
 effect of position on ventilation scintigraphy, Tc-99m DTPA radioaerosol inhalation, 764(ab)
 initial experience with Technegas, 765(ab)
 Kr-81m/Tc-99m MAA ventilation perfusion ratio, inert gas and, weaning, 764(ab)
 lung scanning, Tc-99m carbon particles, 765(ab)
 parameter estimation gating models, 1842
 Tc-99m DTPA and Tc-99m pyrophosphate aerosols in, 1761
 utility of Tc-99m DTPA aerosol inhalation scans, artificially ventilated patients, 764(ab)
 Xe-133 retention, V/Q pattern, congestive heart failure, 905(ab)
- Ventricular function**
 ambulatory ventricular function monitor
 detection, silent myocardial ischemia, 741(ab)
 validation, exercise left ventricular ejection fraction, 741(ab)
 cine NMR quantification, aortic regurgitation, 802(ab)
 elliptical regions of interest, improved accuracy, myocardial imaging, 944(ab)
 impaired left ventricular filling, ejection fraction response to exercise, hypertension, 772(ab)
- left**
 arterial activity concentrations, PET, 941(ab)
 dispersion evaluation, O-15 water, 867(ab)
 gated planar Tc-99m RP-30, contraction fraction, 818(ab)
 inspiratory reduction, stroke volume, 949(ab)
 lung uptake of Tl-201, 953(ab)
 mass determination, cine vs. gated spin NMR imaging, 891(ab)
 patient outcome, ambulatory radionuclide monitoring, 838(ab)
 radionuclide monitoring, nitroglycerin response in ischemia, 838(ab)
 Tc-99m isonitrile dynamic imaging, 805(ab)
- left ventricular ejection fraction**, exercise response, aortic regurgitation, 744(ab)
- post-prandial changes**, coronary artery disease, ambulatory nuclear monitoring, 742(ab)
- right**
 exercise performance, balloon valvotomy, 945(ab)
 inferior left ventricular infarction, antimyosin, 806(ab)
 pressure overloading, Tl-201 myocardial SPECT, 950(ab)
- Ventricular volume**
 calculation from radionuclide angiography, no blood sampling or distance measurement, 745(ab)
 left, assessment, gated Tc-99m isonitrile tomography, 771(ab)
- Ventriculography**
 exercise-equilibrium-radionuclide, earlier detection, Adriamycin cardiomyopathy, 949(ab)
 multi-probe device, cardiac and central circulatory function, 832(ab)
- radionuclide**
 hemodynamic changes, cardiac transplant rejection, 742(ab)
 location of tachycardia, multiharmonic Fourier mapping, 744(ab)
 removal of Ir-192 from reactor-produced Os-191, 927(ab)
 scintigraphic phase maps, fast CT, 941(ab)
- Verapamil**, 19-iodo-3,3-dimethyl-18-nonadecenoic acid uptake, myocardium, hypertension, 843(ab)
- VEST**: See Ambulatory cardiac monitoring device

W

- Water**, labeled, partition coefficient, grey and white tissue, 773(ab)
- Weaning**, Kr-81m/Tc-99m MAA ventilation perfusion ratio, inert gas and, 764(ab)
- Wiener restoration filter**, alternative formulation, 845(ab)
- World Health Organization (WHO)**, quality control of cardiac imaging, N440

X

- Xenografts**, tumor imaging with monoclonal antibodies, carbohydrate residue label, Tc-99m, 815(ab)
- Xenon-127**

- regional pulmonary ventilation, compartmental modeling, 861(ab)
- texture analysis of lung scans, 861(ab)
- Xenon-133**
 brain SPECT imaging
 developmental childhood dysphasia, 792(ab)
 Sturge-Weber cerebral angiomas, 792(ab)
 cerebral maturation in first 20 months of life, regional cerebral blood flow, SPECT, 743(ab)
 compared to Tc-99m ECD SPECT, cerebral blood flow, 913(ab)
 distribution behavior, prolonged heart muscle flow physiology, 942(ab)
 focal abnormalities, fatty liver, 1050
 radioactivity concentrations of Radon-222, following ingestion, 872(ab)
 radioxenon tomography, validation studies for brain blood flow, 348
 regional cerebral blood flow by SPECT, partial epilepsy, childhood, 892(ab)
 retention, V/Q pattern, congestive heart failure, 905(ab)
- SPECT**
 cerebral blood flow, 1875(le)
 compared to PET, cerebral blood flow, 919(ab)
 error analysis, cerebral blood flow in children, 869(ab)
 side localization, temporal lobe epilepsy, 916(ab)
 splenoportography, Budd-Chiari syndrome, 423(le)
 vasoreactivity in cerebral arteriosclerosis, without carotid stenosis, 911(ab)
- Xenon-133 gas**, SPECT, assessment of dementia, 1621
- X-ray**
 scintillation camera, bone mineral densitometry, 855(ab)
 unique non-invasive method, measurement of calcium and electrolytes, tissues, 883(ab)

Y

Yttrium-90

- absorbed fractions for electrons, beta particles, small spheres, 803(ab)
- anti-tumor antibodies, therapy trials, 846(ab)
- method for estimating organ brake radiation doses, 875(ab)
- monoclonal antibodies, radioimmunotherapy, WR-2721 adjunct, 925(ab)
- monoclonal antibody therapy
 bremsstrahlung dosimetry, 859(ab)
 human cancer xenografts, 901(ab)
 antibodies, biodistribution, intraperitoneally, 1428

Information for Authors

EDITORIAL POLICY

The Journal of Nuclear Medicine publishes original articles pertinent to the field of nuclear medicine in the following categories: clinical and basic sciences, case reports, technical notes, special contributions, editorials, letters to the editor, and news items. Submitted manuscripts, including illustrations and tables, must be original works and not have been published previously. Manuscripts must be submitted solely to the Journal and not concurrently under consideration for publication elsewhere.

The Journal of Nuclear Medicine has agreed to receive manuscripts in accordance with the "Uniform Requirements for Manuscripts Submitted to Biomedical Journals," as cited in the following sources: *Ann Intern Med* (1982; 96:766-770) and *Br Med J* (1982; 284:1766-1770). In preparing manuscripts, authors should follow the "Uniform Requirements for Manuscripts Submitted to Biomedical Journals," and specific author instructions detailed below. Also, helpful guidance in conforming to the "Uniform Requirements" may be found in *Medical Style & Format: An International Manual for Authors, Editors, and Publishers* by Edward J. Huth, M.D. (Philadelphia: ISI Press; 1987).

MANUSCRIPT SUBMISSION

Manuscripts should be submitted to the Editor: Thomas P. Haynie, M.D., *The Journal of Nuclear Medicine*, Office of Special Publications-227, The University of Texas M. D. Anderson Hospital and Tumor Institute, 1515 Holcombe Blvd., Houston, Texas 77030; (713)792-6015. One original and two copies of the manuscript, with three complete sets of *unmounted* glossy illustrations (no smaller than 3½ × 5 in. or larger than 8 × 10 in.), are required for review. See Manuscript Format (below).

REVIEW PROCEDURE

The review procedure is two-tiered: Submitted manuscripts are reviewed for content on the basis of originality, significance, adequacy of documentation, reader interest, and composition. All manuscripts considered suitable for review are evaluated by a minimum of two reviewers. Manuscripts not submitted according to author instructions will be returned to the author for correction prior to review. Revised manuscripts are submitted to impartial referees for judgment of adequacy of response to suggestions and criticisms made on initial review. All accepted manuscripts are subject to editing for scientific accuracy and clarity by the Editor.

MANUSCRIPT FORMAT

Submit one original and two copies of the manuscript and three sets of *unmounted* glossy illustrations. Manuscripts must be written in English.

Type the manuscript on white bond paper, 8½ × 11 in. (21.6 × 27.9 cm), with margins of at least 1½ in. (4 cm). Type on one side of the paper only, double spacing *every* page. Do *not* justify right margins. Begin each of the following sections on separate pages and in the following order: title page, abstract, text, acknowledgments, references, tables (each on a separate page), and legends. Number pages consecutively, beginning with the title page. Type the name of the senior author and page number in the upper right-hand corner of each page. Paragraphs should begin with an indentation of at least five spaces. Handwritten changes are not acceptable.

TITLE PAGE

The title page of the manuscript should include: (1) concise but informative title (strive to eliminate from the title those terms that cannot be readily indexed); (2) short running head or footline of no more than 40 characters (letters and spaces) placed at the bottom of the title page and identified; (3) complete byline, with first name, middle initial, and last name of each author and highest academic degree(s); (4) complete affiliation for each author, with the name of department(s) and institution(s) to which the work should be attributed; (5) disclaimer, if any; (6) name, address, and telephone number of author responsible for correspondence about the manuscript; and (7) name and address of author to whom reprint requests should be directed, or statement that reprints are not available from the author.

ABSTRACT AND KEY WORDS

An abstract of no more than 150 words should state the purpose of the study or investigation, basic procedures (study subjects or experimental animals and observational and analytic methods), major findings (specific data and their statistical significance, if not too lengthy), and the principal conclusions. Emphasize new and important aspects of the study or observations. No abbreviations or reference citations are to be used in the abstract.

TEXT

The text of original scientific and technical articles is usually divided into the following sections: Introduction, Materials and Methods, Results, Discussion, and Summary or Conclusion.

Case Reports should contain a concise description of one to three patients, emphasizing the nuclear medicine aspects and including methodology, data, and correlative studies.

Letters should concern previously published material or matters of general interest and should be brief and to the point. All material is subject to editing and condensation.

Other articles, e.g., reviews, position papers, or editorials, should introduce a problem or question, present evidence, and conclude with an answer. The sequence of topics will be determined by the overall subject.

In general, reference should not be made in the text to institutions or locales except when germane to that particular article. Generic names should be used throughout the text. Identify instruments and radiopharmaceuticals by manufacturer name and address in parentheses and describe procedures in sufficient detail to allow other investigators to reproduce the results.

ACKNOWLEDGMENTS

Acknowledge persons or agencies contributing substantially to the work, including any grant support.

REFERENCES

References should be cited in consecutive numerical order at first mention in the text and designated by the reference number underlined and in parentheses. References appearing in a table or figure should be numbered sequentially with those in the text.

The Reference list must be typed double-spaced and numbered consecutively, as in the text. The Journal follows *Index Medicus* style for references and abbreviates journal names according to the *List of Journals Indexed in Index Medicus*. "Unpublished observations" and "personal communications" should not be used as references, although written—not verbal—communications may be noted as such in the text. References cited as "in press" must have been accepted and not merely in preparation or submitted. The author is responsible for the accuracy of all references and must verify them against the original document.

For journal articles, list all authors when six or less; for seven or more authors, list the first three and et al:

Baumier PL, Krohn KA, Carrasquillo JA, et al. Melanoma localization in nude mice with monoclonal Fab against p97. *J Nucl Med* 1985; 26:1172-1179.

Weissmann HS, Badia J, Sugarman LA, Kluger L, Rosenblatt R, Freeman LM. Spectrum of ^{99m}Tc-IDA cholescintigraphic patterns in acute cholecystitis. *Radiology* 1981; 138:167-175.

For books and book chapters, follow the examples below:

DeGroot LJ. Evaluation of thyroid function and thyroid disease. In: DeGroot LJ, Stanbury JB, eds. *The thyroid and its diseases*. 4th ed. New York: Wiley; 1975:196-248.

Dupont B. Bone marrow transplantation in severe combined immunodeficiency with an unrelated MLC compatible donor. In: White HJ, Smith R, eds. *Proceedings of the third annual meeting of the International Society of Experimental Hematology*. Houston: International Society for Experimental Hematology; 1974:44-46.

TABLES

Type each table double-spaced on a separate page. Do not submit tables as photographs.

Tables should be self-explanatory and should supplement, not duplicate, the text. Each table must be cited in consecutive numerical order in the text. Number the tables consecutively with an arabic number following the word TABLE. The titles should be descriptive, brief, and typed centered in upper- and lower-case letters. Place horizontal rules below the title, column headings, and at the end of the table. *Do not use vertical lines.* Give each column a short or abbreviated heading.

Place explanatory matter in footnotes, not in the heading. Use the following symbols, in this sequence: *, †, ‡, §, ¶, **. Expand in the footnote all nonstandard abbreviations used in each table. For footnotes, identify statistical measures of variations, such as standard deviation and standard error of the mean. If data from another published source are used, obtain written permission from the publisher of the original source and acknowledge fully. If data from an unpublished source are used, obtain permission from the principal investigator, and acknowledge fully.

ILLUSTRATIONS

Illustrations should clarify and augment the text. Because imaging is a major aspect of nuclear medicine, the selection of sharp, high-quality halftone illustrations is of paramount importance. Figures of inferior quality will be returned to the author for correction or replacement.

Submit three complete sets of glossy illustrations, no smaller than $3\frac{1}{2} \times 5$ in. or larger than 8×10 in. *Do not send original artwork.* Glossy photographs of line drawings rendered professionally on white drawing paper in black India ink, with template or typeset lettering, should be submitted. No hand-drawn or typewritten art will be accepted. *High quality* computer-generated art may be accepted if it is professionally done and determined, after review, to be of sufficient reproducible quality. Letters, numbers, and symbols (typeset or template) should be clear and of sufficient size to retain legibility after reduction.

Do not encumber illustrations unnecessarily; titles and detailed explanations should be incorporated into the legend and not placed on the illustration itself. When necessary for clarity, arrows or letter designations may be affixed to the illustration, but they must be of professional artistic quality; handwritten or typewritten designations are not acceptable. All patient information and institutional identifying data must be removed from illustrations.

Each illustration must be numbered and cited in consecutive order in the text. Illustrations should be identified on a gummed label affixed to the back of each illustration with the following information: figure number, part of figure (if more than one), senior author's name, and designation of "top."

Color illustrations will be considered for publication, but the author is responsible for all charges relating to separations and printing. An estimate of these charges will be sent to the author at the time of production. Author approval of charges is required before production will continue. Three complete sets of glossy color photographs (not transparencies) must be submitted for review. Polaroid prints are not acceptable.

All submitted illustrations become the property of The Society of Nuclear Medicine and will not be returned unless the manuscript is rejected.

LEGENDS FOR ILLUSTRATIONS

Type legends double-spaced on a separate page. Each figure should be cited in consecutive numerical order in the text. Number the figures with an arabic number following the word FIGURE. Use letters to designate parts of illustrations (e.g., A, B, C) and describe each part clearly in the legend. Any letter designations or arrows appearing on the illustration should be identified and described fully.

Original (not previously published) illustrations are preferred for publication in the Journal; however, if illustrations have been published previously, authors are responsible for obtaining written permission from the publisher to reprint. The source of the original material must be cited in the references and the following credit line included in the legend: (Reprinted by permission of Ref. X.) All permission releases must be submitted to the Editor at the time of manuscript submission.

UNITS OF MEASUREMENT

The International System of Units (SI) is standard. Measurements of length, height, weight, and volume should be reported in metric units or their decimal multiples. Other measurements should be reported in the units in which they were made. Alternative units (SI or non-SI units) should be added in parentheses by the author if indicated.

ABBREVIATIONS AND SYMBOLS

Use only standard abbreviations and symbols in the text. Avoid using abbreviations in the title and abstract. At first mention, the complete term, followed by the abbreviation in parentheses, should be used in the text. Standard units of measure should not be expanded at first mention. Consult the following sources for approved abbreviations: *CBE Style Manual: A Guide for Authors, Editors, and Publishers in the Biological Sciences*, 5th ed. (Bethesda, MD: Council of Biology Editors; 1983), and "Uniform Requirements for Manuscripts Submitted to Biomedical Journals" (*Ann Intern Med* 1982; 96:766-770).

SUBMISSION OF MANUSCRIPTS

Mail one original and two copies of the manuscript and three complete sets of glossy illustrations in a heavy paper envelope, packed to prevent bending of photographs during mail handling. Manuscripts should be accompanied by a covering letter from the author responsible for correspondence regarding the manuscript. The covering letter should contain the following copyright statement in compliance with the Copyright Revision Act of 1976, effective January 1, 1978.

"Upon acceptance by *The Journal of Nuclear Medicine*, all copyright ownership for the article [complete title of the article in this space] is transferred to The Society of Nuclear Medicine. On behalf of any and all co-authors, I accept the responsibility for release of any part or all of the material contained within the article noted above. The undersigned stipulates that the material submitted to *The Journal of Nuclear Medicine* is original and has not been submitted to another publication for concurrent consideration."

Copyright requirement does not apply to work prepared by United States government employees as part of their official duties.

The letter should also contain a statement that the manuscript has been seen and approved by all authors and should give any additional information helpful to the Editor. If there has been prior publication of any part of the work, this should be acknowledged and appropriate written permission included. If color illustrations are included, a statement that the author(s) is (are) willing to assume the cost of color separation and reproduction is requested.

MANUSCRIPT CHECKLIST

- _____ Original double-spaced typed manuscript and 2 copies.
- _____ Three sets of *unmounted* glossy Figures (no smaller than $3\frac{1}{2} \times 5$ in. or larger than 8×10 in.).
- _____ Copyright transfer.
- _____ Title page with title, authors' names, and complete affiliations; corresponding author, complete address, and telephone number; author for reprint requests and complete address.
- _____ Abstract (maximum, 150 words).
- _____ References in consecutive numerical order. Reference list typed double-spaced.
- _____ Figures and Tables in consecutive numerical order.
- _____ Legends for all Figures; typed double-spaced.
- _____ Consent forms for patient photographs.
- _____ Written permission from the publisher to reprint previously published Figures and Tables.

Index to Advertisers

| Advertiser | Telephone Number | Page Number | Reader Service Number |
|--|------------------|--------------|-----------------------|
| Amersham International Buckshire, England HP7 9LL | 02404 4488 | 29A | 81 |
| Atomic Products, Inc. Shirley, NY | (516)924-9000 | 30A | 29 |
| Capintec, Inc. Ramsey, NJ | (800)631-3826 | 7A | 9 |
| CIS-US Bedford, MA | (800)221-7554 | 33A | 24 |
| Diversified Diagnostic Products, Inc. Houston, TX | (713)955-5323 | 31A | 33 |
| Fuji Medical Stamford, CT | (800)431-1850 | 10A | 7 |
| GE Medical Milwaukee, WI | (800)624-5962 | 17A-18A | 40 |
| Mallinckrodt St. Louis, MO | (314)895-2000 | 11A-12A | 121 |
| Medi-Physics, Inc. Paramus, NJ | (800)451-7732 | IFC, 1A, OBC | 1, 30 |
| NeoRx Seattle, WA | (206)281-7001 | 47A | 50 |
| National Institute of Health Bethesda, MD | (301)496-5675 | 32A | 25 |
| Nuclear Associates Carle Place, NY | (516)741-6360 | 2A | 2 |
| Ohio Imaging Bedford, OH | (216)475-1111 | 19A | 127 |
| Picker International Highland Heights, OH | (800)343-5000 | 14A-15A | 57 |
| Siemens Medical Systems Des Plaines, IL | (312)635-3160 | 8A-9A | 126 |
| Sopha Medical Columbia, MD | (301)740-1100 | 24A | 128 |
| Squibb New Brunswick, NJ | (800)582-5913 | 20A-23A | 17 |
| Syncor International Sylmar, CA | (818)423-5620 | IBC | 10 |
| Toshiba Tustin, CA | (800)421-1968 | 25A-26A | 69 |
| <hr/> | | | |
| SNM Annual Meeting | | 28A | |
| SNM Winter Meeting | | 47A | |
| SNM Publications | | | |
| MIRD | | 50A | |
| Fundamentals of Nuclear Medicine | | 27A | |
| Nuclear Medicine: Self-Study Program I | | 16A | |
| Chromotrography | | 49A | |
| New Titles | | 51A | |